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ABSTRACT
NU:UB compounds are novel spacer-linked amino acid substituted
anthraquinone derivatives; several of these, including an in vivo-active lead
compound NU:UB 31, are cytotoxic in vitro in a range of human and animal
cancer cell lines, with selectivity for melanoma and colon cancers.
Topoisomerase enzymes have proved to be valid targets for anti-cancer
therapeutics. The NU:UB compounds were designed to be inhibitors of DNA
topoisomerase I and II enzymes.
This study has focused on NU:UB 31 (and, in part, on structural analogues) to
investigate the mechanism of action of this compound in vitro. NU:UB 31 was
cytotoxic in the low micro-molar range in human leukaemia, as well as in
colon cancer cell lines, as early as 4h following treatment. NU:UB 31,
exhibited DNA intercalation and minor groove binding properties (that are
thought to facilitate interactions with topoisomerase II and topoisomerase I
respectively). Topoisomerase I-mediated DNA relaxation (of supercoiled
plasmid) was inhibited completely by NU:UB 31 at 50~M. Topoisomerase 110
and 1113 inhibition was achieved by NU:UB 31 concentrations of 25~M and
20~M respectively. NU:UB 31 also induced drug-stabilised topoisomerase I
and II (0 and 13 isoforms) cleavable complex formation in intact HL60 cells
determined by immunoband depletion of the Western blot protein signals.
Therefore, unlike most clinically used chemotherapeutics that act via one type
of topoisomerase, there was evidence to suggest that NU:UB 31 was a dual
topoisomerase inhibitor, which may explain observations that NU:UB 31 can
circumvent drug resistance mediated by altered topoisomerase expression,
levels and functions.
Cellular, morphological and biochemical apoptotic changes were investigated
following NU:UB 31 treatment. In HL60 cells caspase activation, indicative of
apoptosis induction, was recorded after 4h 20~M NU:UB 31 treatment; DNA
fragmentation was evident following 6h NU:UB 31 treatment. Furthermore, the
amount of cells with DNA content less than G1 had more than doubled
following 1h of NU:UB 31 treatment. Additionally, over 20% of HL60 cells
showed apoptotic morphology following 8h NU:UB 31 treatment. Although the
tumour suppressor p53 protein levels were significantly increased following 3h
of NU:UB 31 (at 20 ~M) treatment of p53+ HCT116 cells, there was also
evidence to suggest that p53-independent apoptotic pathways could play a
part in NU:UB cytotoxicity. NU:UB compounds had equipotent Giso values in
NCI p53 wild type and p53 mutant cell lines, suggesting a p53-independent
mechanism together with, or in place of, a p53-dependent mechanism of
action. Confocal microscopic drug accumulation observations revealed a
significant cytosolic (in particular lysosomal) localisation of NU:UB 31. This, in
addition to NCI drug target Compare data suggested that mitochondria may
be an additional NU:UB compound target. Collectively, these findings support
the prediction that molecular events triggered via topoisomerase enzymes
lead to NU:UB 31-induced apoptosis, and further identify mitochondria as a
putative additional molecular target of NU:UB 31.
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PREFACE
Anthraquinone-based compounds, shown to target DNA topoisomerase
enzymes, have been used in the cancer clinic for many years. The clinical use
of these agents is unfortunately, limited due to dose-limiting toxic side effects
associated with non-topoisomerase, secondary mechanisms of action and the
development of drug resistance. In this research programme novel spacer-
linked anthraquinone-amino acid conjugates (code named NU:UB and
represented by the lead compound NU:UB 31, a novel anthraquinone-L-proline
amino acid conjugate), initially developed to exert cytotoxicity by selectively
inhibiting topoisomerase enzymes, were investigated for their mechanism of
action in vitro.
Chapter 1 gives a general introduction to topoisomerases and topoisomerase
inhibition. The problems of toxic side effects and resistance to current drugs is
introduced. Furthermore, drug induced cell cycle disruptions and apoptotic cell
death, as well as apoptotic related proteins including p53 and caspases are
discussed, since these are important determinants of the outcome of
chemotherapeutic treatments and were properties investigated in respect of the
novel agents used in this research programme.
The materials and general methods for the experiments performed in this study
are detailed in Chapter 2; the data obtained and the discussion of the results
are contained within Chapters 3 to 8.
11
Firstly, results from the study of anti-topoisomerase activity, with investigations
of the topoisomerase (I, 110 and 1113) inhibition and poisoning activity of the
NU:UB drugs (focusing on NU:UB 31) are given in Chapter 3.
Chapter 4 goes on to discuss data to establish the cytotoxicity of NU:UB agents
in human cancer cell lines. Following this, cell cycle disruption studies in cell
lines exposed to NU:UB 31 in comparison with known topoisomerase inhibitors
have been presented in Chapter 5.
Chapter 6 presents data of investigations into morphological and biochemical
evidence of induction of apoptotic cell death following NU:UB treatment of
human cancer cells. These apoptotic studies included DNA laddering using
agarose gel electrophoresis, and caspase activation using UV fluorescent
microscopy and flow cytometry.
Alterations in protein levels involved in the regulation of the cell cycle (notably
including p21, p53 and mdm-2) and apoptotic cell death have been investigated
following NU:UB treatments and the results are presented in Chapter 7.
Chapter 8 contains the observations of a confocal microscopic study of the sub-
cellular localisation of NU:UB 31 in cells.
Chapter 9 affords a summary discussion of the collated results (of the separate
studies compiled in Chapters 3 to 8), that highlights the key findings for the
NU:UB agents in the setting of contemporary topoisomerase-targeting drugs
and incorporates conclusions and suggestions for future work with the NU:UB
agents that are identified as important for their continuing pre-clinical
development.
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HYPOTHESIS
Anthraquinone-based compounds have successfully been used in the cancer
clinic for several years; doxorubicin and mitoxantrone are notable examples
that, after their introduction, were shown to target DNA topoisomerase
enzymes as a key component of their cytotoxic action. Clinical application of
these agents is, however, restricted due to acute toxicity and side effects
associated with non-topoisomerase, secondary mechanisms of action and the
development of altered topoisomerase drug resistance and multidrug
resistance. In this research programme, it was hypothesised that lead
compounds from a novel series [code named NU:UB] of spacer-linked
anthraquinone- amino acid conjugates would act as 'clean' inhibitors of DNA
topoisomerase enzymes, and as a consequence, these anti-topoisomerase
properties would, in part, contribute to their mechanism of cytotoxic action.
AIMS
The principal aim of the project was to investigate the biochemical effects of
selected conjugates, focused on the L-proline candidate NU:UB 31, in cancer
cell lines and cell-free systems in vitro to elucidate mechanisms of cytotoxic
action. Specific aims were to establish whether or not the novel agents
inhibited topoisomerase I and II enzymes and affected apoptotic mechanisms
in relation to their pattern of cell kill, in comparison with standard
topoisomerase inhibitors, in order to contribute to the rational design of more
selective drugs to target topoisomerase proteins.
1
CHAPTER 1
GENERAL INTRODUCTION
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1.1 CANCER
It is estimated that one in three people will be diagnosed with cancer during
their lifetime and that one in four people will die from cancer. Much of the
problem in curing cancer lies in the fact that cancer is not just one, but a
whole family of diseases, classified according to tissue type of origin, all with
somewhat different behaviour and prognosis. There are over 200 different
kinds but four types, lung, breast, prostate and colorectal cancers make up
the majority of cancers, together accounting for half of all diagnosed cases.
Table 1.1 displays UK cancer mortality numbers in males and females from
2001 for the four most common cancer types (www.cancerresearchuk.org).
Although there are several types of cancers, they all begin when a single host
cell loses its control mechanisms and starts to grow and divide abnormally.
Eventually the cancerous cells get so numerous that they interfere with the
normal functions of the tissues and organs where the tumour is located. In
addition, tumour cells can also undergo metastasis, which is a mechanism for
the cancer cells to relocate to other sites within the host. If the cancer cannot
be eradicated it will eventually cause the death of the host. The progressive
and uncontrollable growth in cancers is a result of damage to cellular growth
control mechanisms, processes that are governed by our genes to maintain
the correct numbers of cells for homeostasis and proper function. Genetic
damage is accumulated over time and cancers are therefore more often seen
with increasing age (Thibodeau and Patton, 1992; Campell, 1993;
www.cancerresearchuk.org).
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Breast Cancer Mortality Numbers
Male 90
Female 12994
Total 13084
Prostate Cancer
Male 9887
Lung Cancer
Male 20348
Female 13038
Total 33386
Colorectal Cancer
Male 8524
Female 7628
Total 16152
Table 1.1 UK mortality numbers In males and females from 2001. Adapted from www.cancer
researchuk.org
Characteristically, cancer cells have damaged (mutated) genes involved in the
control of the cell cycle and also in the apoptotic pathway(s). Such genes are
often referred to as proto-oncogenes and tumour suppressor genes. Normally
proto-oncogenes regulate cell growth but when damaged (mutated) these
become so-called oncogenes and as a result their gene products (onco
proteins) may stimulate excessive cell growth. Several genes have now been
found to be proto-oncogenes, including genes belonging to the growth factor,
growth factor receptor, transcription factor, cyclin and cyclin dependent kinase
(cdk) families. Tumour suppressor genes usually act to slow cellular growth,
inhibiting cell division making sure each step is completed before growth is
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continued. Damage to tumour suppressor genes will therefore remove the
natural constraints on the cell cycle allowing for continued cell growth
(Thibodeau and Patton, 1992; Campell, 1993). P53 is the most studied
tumour suppressor gene, activating genes that promote cell cycle arrest or
apoptosis.
1.2 DNA-TOPOISOMERASES
Screening against tumour models in animals originally identified the potential
of the majority of clinically used drugs. However, the drug target(s) as well as
the molecular basis of these types of animal models were in many cases
undefined. Enzymes referred to as DNA-topoisomerases have now been
identified as targets of several of the anti-cancer drugs used clinically today
and these enzymes may also provide important and valid targets for new
chemotherapeutic agents. The topoisomerases and the inhibition of these
enzymes are discussed in this section.
DNA supercoiling is an essential feature that enables the long DNA helix to be
stored within the nucleus of the cell. At the same time this presents a problem
when it comes to DNA metabolism, including replication and other processes
that require that the DNA molecule is uncoiled (Wang, 1996; Nitiss, 1998). An
enzyme that was able to alter the topology of superhelical DNA was reported
by Wang (1971). Since then, more of these types of enzymes have been
identified and the name DNA-topoisomerase has been introduced to describe
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this class of enzymes (Wang and Liu, 1979). It is now realised that the
activities of topoisomerase enzymes, to deal with the topological problems
associated with DNA metabolism, are essential in all living cells. One of the
major roles of topoisomerase enzymes is to prevent excessive supercoiling of
DNA. Both positive and negative supercoils may be generated by a number of
processes, including replication and transcription, in which macromolecular
assemblies move along DNA (Gellert, 1981; Nitiss, 1994a; Postow et al.,
1999). Topoisomerase enzymes change the conformation of DNA by a
complex catalytic process involving DNA strand cleavage, strand passage
and finally religation of the DNA strands and can do all this without even
leaving a trace in the DNA. Although these enzymes in themselves are
fascinating, the huge interest and intense studies in this area are more likely
due to the realisation that topoisomerases appear to be the primary targets for
a range of clinically used cytotoxic drugs (Nelson et al., 1984; Tewey et a/.,
1984a; Tewey et al., 1984b; Zunino and Capranico, 1990; Hwang and Hwong,
1991; Chen and Liu, 1994). Since then, these enzymes have also become the
main targets for rational drug design of novel anti-cancer drugs.
The DNA topoisomerases in humans have been divided into three sub-groups
and this classification has been based on their respective protein structures
and on their mechanism to alter DNA topology. These sub-groups are: type IA
enzymes (represented by topoisomerase Ilia and IIIr3), type IB enzymes
(topoisomerase I and mitochondrial topoisomerase I) and finally type II
enzymes (topoisomerase IIa and 11r3) (Wang, 1994; Zhang et al., 2001; Wang
et a/., 2002). Why there are so many kinds of topoisomerase enzymes is not
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known but there must be a requirement for them and these various enzymes
have been discussed by Wang (1991). With continued research into this field
even more topoisomerases may be identified, but so far it is topoisomerase I
and II that have been mostly studied in relation to human cancers.
1.2.1 Topoisomerase I
The gene for topoisomerase I has been mapped to chromosome 20q12-13.2
(Juan et al., 1988). The topoisomerase I gene product is a 100kDa
monomeric protein that requires phosphorylation for full activity (Pommier et
al., 1990). This protein is most abundant in the nucleus but also found in
nucleoplasm and in mitochondria (Fleischmann et al., 1984; Zhang et al.,
2001; Christensen et aI., 2002; Wang et aI., 2002). Characteristic of
topoisomerase I is that it requires no cofactor in its catalysis of DNA strand
breakage and rejoining, the energy for this reaction is instead derived from
that stored in the supercoiled DNA. In the breakage reaction, a hydroxyl group
of an amino acid, tyrosine located in the active site of topoisomerase I, attacks
DNA. This results in the formation of a covalent bond between the
topoisomerase and DNA, where the active site tyrosine of topoisomerase I is
attached to the 3' phosphoryl end of the cleaved DNA molecule and the other
DNA end has a hydroxyl group on its sugar. This cleavage of DNA is however
only a transient arrangement allowing for DNA strand passage, relaxation of
supercoiled DNA, and rejoining of the DNA strand as soon as all this has
been accomplished. When topoisomerase I performs these catalytic reactions
it has been suggested by Berger (1998) to look like a hand holding on to, and
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entirely enclosing DNA. In this 'hand', DNA lies between the fingers
(topoisomerase I subdomains I and II) and the palm (III and the C-terminal
domain). The thumb is made up of the linker domain and has not much
contact with DNA, it instead helps in its rotation. DNA is cleaved when it is
locked between the fingers and the palm, and the rotation of DNA to relax it
may occur by slightly loosening the grip (Berger, 1998; Stewart et a/., 1998).
For an illustration of the topoisomerase I mediated cleavage reaction see Fig.
1.1.
1.2.2 Topoisomerase II
Topoisomerase II is, in some capacity, thought to be involved in chromosome
condensation and decondensation and is found to play an important part in
chromosome structure. It is believed that topoisomerase II partly makes up
the chromosome scaffold and the nuclear matrix. The chromosome scaffold is
the protein structure that remains after DNA and histones have been removed
from chromosomes in mitotic cells, and the nuclear matrix is a similar
preparation from cells in interphase (Berezney and Coffey, 1974; Adolphs et
a/., 1977; Nitiss, 1998). Two isoforms of the topoisomerase II enzyme have
been identified; these are 170 and 180kDa in size and have been referred to
as topoisomerase 110 and topoisomerase 1Ir3 respectively (Drake et a/., 1987;
Stacey et aI., 2000). The topoisomerase 110 gene is located on chromosome
17q21-22 and the topoisomerase 1Ir3 gene on the 3p24 chromosome (Tan et
a/., 1992). These two gene product isoenzymes have different localisation and
expression patterns, which would imply that they differ in their cellular
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functions (Stacey et a/., 2000). Topoisomerase 110 is localised in the
nucleoplasm, while topoisomerase 1IJ3 is found in the nucleolus (Cummings
and Smyth 1993; Zini et aI., 1992). Drake et a/. (1989) compared biochemical
and pharmacological properties between the two topoisomerase II isoforms
and found that while there were some similarities between these, they had
also many unique biochemical properties and differential pharmacological
sensitivities to several drugs.
In contrast to topoisomerase I catalysed reactions, topoisomerase II cuts both
strands of DNA, passing an intact helix through this double stranded cut and
reseals the cut. To do so, topoisomerase II utilises ATP. While topoisomerase
I was likened to a hand holding onto and cleaving one strand of DNA,
topoisomerase II has been thought of as a pair of closable jaws coupled by a
set of hinges. For an illustration of this see Fig. 1.2, adapted from Berger
(1998). In this arrangement, one set of jaws is responsible for gripping and
cleaving a DNA duplex. A second DNA duplex and ATP also bind to the
enzyme, this will result in closure of the jaws, trapping of the second DNA
strand (sometimes desribed as the closed-clamp conformation), and cleavage
of the first DNA strand allowing the second to pass through the break in the
first one (Lindsley and Wang, 1991; Roca and Wang, 1992). In common with
topoisomerase I, it is a tyrosine in the cleavage site of topoisomerase II that is
important as the nucleophile in attacking the DNA strand, but the enzyme
becomes attached to DNA through a 5'-phosphotyrosine linkage rather than
through 3'-linkage, which is the case following topoisomerase I cleavage
(Berger, 1998). In addition to the function of topoisomerase II in relaxing DNA
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(functions that can also be performed by topoisomerase I), topoisomerase II is
the only enzyme capable of separating interlocked double stranded daughter
chromosomes that are formed during replication, a process referred to as
decatenation (Chen and Liu, 1994). In summary, while there are some
features of topoisomerase I and II that are shared; for example, both types
relax positive and negative supercoils and form covalent links to DNA,
topoisomerase I attaches to the 3' end of DNA whereas topoisomerase II links
to the 5' end. Topoisomerase II but not topoisomerase I, requires ATP and is
able to catenate and decatenate DNA (Cummings and Smyth, 1993).
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Fig. 1.1 Schematic illustration of the topoisomerase I mediated cleavage reaction.
Topoisomerase I binds DNA (1). One of the DNA strands is cleaved by topoisomerase I and
following cleavage the topoisomerase I-DNA interaction is loosened slightly allowing for one end
of the DNA to rotate (2). Figure adapted from Berger, 1998.
1St DNA
ATPas
1
Topoisomerase II
Fig. 1.2 Representation of the topoisomerase II catalysed cleavage reaction. Topoisomerase II
binds first to DNA (1). A second DNA duplex and ATP bind to topoisomerase II (2,3). Cleavage of
the first DNA duplex and transport of the second one through the break (4,5). Religation of the
cleaved DNA duplex and release of DNA(6). Figure adapted from Berger, 1998.
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1.3 INHIBITION OF TOPOISOMERASES
Since tumour cells in many cases are highly proliferative cells and
topoisomerases are involved in replication and proliferation processes, the
levels of these enzymes are often increased in growing cancer cells
compared to normal cells. Several tumours have been shown to have
increased levels of topoisomerases promoting further DNA separation and
growth. For example, colorectal tumours show a 5 to 35-fold increase in
topoisomerase I compared to normal colon tissue (Larsen and Skladanowski,
1998). Furthermore, overexpression of topoisomerase II has been noted in
human cervix, lung and colon cancers (McLeod et aI., 1994). If
topoisomerases in tumour cells could be inhibited, then unwinding, strand
separation and reproduction of DNA would be prevented. For drugs
selectively targeting the topoisomerase enzymes, the increased levels found
in many tumours could provide some degree of tumour cell selectivity that
would hopefully decrease the DNA damage to normal tissue and thereby
reduce side effects.
1.3.1 Inhibitors And Poisons
Drugs are thought to work as anti-topoisomerase agents mainly by two
mechanisms. They can act as pure catalytic inhibitors of topoisomerases or
as topoisomerase poisons (although the name topoisomerase inhibitors often
in the literature refers to both types). Topoisomerase inhibitors either bind to
topoisomerases directly or bind to DNA, changing its structure so that it can
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no longer be recognised by the topoisomerases. Drugs trapping
topoisomerases in what is referred to as cleavable complexes (drug-stabilised
intermediates) are called topoisomerase poisons. Topoisomerase poisons
normally do not inhibit the catalytic activity of topoisomerases; these agents
instead take advantage of the DNA cleavage reaction by topoisomerases and
increase the concentrations of the drug-stabilised cleavable complexes to
levels that cells can no longer tolerate (Froelich-Ammon and Osheroff, 1995).
When DNA is to be replicated, there are a lot of cleavable complexes formed
and this process is likely to be the main cellular process that drives the
conversion of transient cleavable complexes into lethal lesions following
treatment with for example the topoisomerase I poison camptothecin. Cellular
processes other than replication may however also be of importance for the
cell kill mechanism of these types of drugs. For the pure inhibitors of
topoisomerase II, mitosis may be the cellular process whereby the damage is
instigated; proceeding through this stage of the cell cycle when
topoisomerase II is inhibited can result in aneuploidy and chromosomal
breakage (Wang, 1994). Whereas for topoisomerase poisons, the sensitivity
to these drugs increases with over-expression of the topoisomerase enzymes,
thus increasing the level of cleavable complexes that can be formed per cell
(Nitiss et al., 1992; Wang, 1994), for pure topoisomerase inhibitors sensitivity
should be the other way around.
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1.3.2 DNA Binding Mode
Several of the agents acting as poisons are known to be DNA binders and
these can be further subdivided into intercalators, groove binders and mixed-
modal binding agents (with features of both intercalators and groove binders).
Thus, anti-tumour agents may be classified not only as poisons or inhibitors,
or according to which topoisomerase enzyme they act on, but also according
to their DNA binding mode. The binding mode of anthracyclines (e.g.
doxorubicin, daunorubicin and idarubicin) and anthracenediones (e.g.
mitoxantrone) has largely been considered to be by pure intercalation. Studies
of intercalators have however revealed that many of these have a side chain
that allows for a direct contact with the topoisomerase protein, and thus a
groove-binding moiety may also be important for their topoisomerase
poisoning activity (Capranico et aI., 1997; Capranico and Binaschi, 1998).
Camptothecin and etoposide are examples of topoisomerase poisons that are
not believed to be intercalators or DNA binders, but instead bind only to the
DNA-topoisomerase cleavage complex and interfere with the religation steps
(Hertzberg et al., 1990; Hwang and Hwong, 1991). Anthracenediones
generally have a high affinity constant of DNA binding, which alone may be
responsible for conferring catalytic inhibitory properties (in addition to
poisoning actions). Whereas at low drug concentrations these may stimulate
DNA cleavage, at high enough concentrations these could inhibit the catalytic
activity without stimulating cleavage. This type of behaviour will generate a
bell shaped dose-response curve of DNA cleavage stimulation (Capranico et
al., 1997; Capranico and Binaschi, 1998). Properties of this type have been
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observed amongst members of the NU:UB compound series (Mincher D.J.
personal communications). However, strong DNA binders can also induce
adverse toxicity as these may non-selectively inhibit the activity of other DNA
dependent enzymes.
1.3.3 Anti-topoisomerase Drugs And Their Side Effects
Chemotherapy and radiation therapies have for some cancers been very
successful, with the survival figures for certain types of cancers having greatly
improved over the years. Despite this, the treatment of the most common
forms of cancers such as lung, breast and bowel carcinomas is still
troublesome, since these types of cancers in many cases are more or less
resistant to current therapies. In addition, the effectiveness of the currently
used chemotherapy regimens has also been limited by the side effects of
these drugs.
Camptothecin and its more soluble derivatives target topoisomerase I.
Several camptothecin analogues, including 9-aminocamptothecin, topotecan
and irinotecan (CPT-11) have been developed and put through clinical trials
(Takimoto and Thomas, 2000; Kohn and Pommier, 2000). In addition, the
homocamptothecin (hCPT) derivative BN80915, containing a seven-
membered (instead of the conventional six-membered) lactone ring, is a
potent topoisomerase I compound. This agent has reached phase I clinical
trials and appears to be a promising addition to the camptothecin drug family
(Lansiaux et al., 2001). While licensed topoisomerase I poisons so far only
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include the camptothecin derivatives, there are several topoisomerase II
poisons available. Topoisomerase II anti-cancer agents are among the most
effective drugs available for cancer treatment. Agents found to interfere with
topoisomerase II include doxorubicin (adriamycin), daunorubicin and
idarubicin, as well as mitoxantrone. Etoposide (VP-16) was the first cancer
drug to be demonstrated to work through inhibition of topoisomerase II and
teniposide (VM-26) belongs to the same family as etoposide (Hande, 1998).
The chemical structures for some of the anti-topoisomerase drugs and other
types of drugs available and referred to in this project have been collated in
Appendix 1.
The side effects from the camptothecins, irinotecan and topotecan are of a
similar nature and comprise nausea, hairloss, bone marrow toxicities and
diarrhoea. While irinotecan is used for the treatment of bowel cancers,
topotecan is most commonly used when treating ovarian cancers, but also in
the treatment of small cell lung cancer and acute myeloid leukaemia. The
primary use for doxorubicin is in the treatment of lymphomas, breast cancer,
sarcomas, ovarian and bladder cancer. Side effects of doxorubicin include
suppression of white blood cells, inflammation of mucus membranes, hair loss
and more severely, heart damage. Daunorubicin and idarubicin are used in
treating leukaemias and their toxicities are similar to those of doxorubicin.
Mitoxantrone is mainly used for the treatment of breast cancer, prostate
cancer, leukaemia and lymphoma. Mitoxantrone has perhaps overall slightly
less antitumour activity compared to doxorubicin, but although of a similar
nature, the side effects from mitoxantrone are less severe than following
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doxorubicin treatment. Etoposide is active against several cancers including
lung, testicular and stomach cancers, leukaemias, KS, non-Hodgkin's
lymphomas, neuroblastoma and sarcomas. Toxicities include bone marrow
suppression, nausea and hair loss (www.cancerreserachuk.org; Hande,
1998).
Many of the currently used topoisomerase agents have not been specifically
designed to target topoisomerases and it has been realised that they are not
'clean' topoisomerase inhibitors. For example doxorubicin, in addition to
targeting topoiomerase II, is also known to generate free radicals in its
mechanisms of action, contributing to its high degree of host toxicity. The
mechanisms involved in doxorubicin-mediated toxicities including free radical
formation, have recently been reviewed by Jung and Reszka (2001). Many
topoisomerase II drugs may also induce sister chromatid exchange and
illegitimate recombinations and these effects are thought to reflect the
capacity of topoisomerase II to induce double strand breaks (Chen and Liu,
1994). It is important to understand this, and the extent of genetic
rearrangements induced by drugs targeting topoisomerases, since agents that
stabilise cleavable DNA-topoisomerase complexes such as etoposide and
doxorubicin may increase the risk of secondary malignancies (Morgan and
Rubin, 1998; Turner et al., 2001).
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1.4 DRUG RESISTANCE
In addition to the side effects from chemotherapeutics, the effectiveness of
current agents is also hampered by resistance, a major problem and cause of
treatment failure. Natural resistance is resistance present prior to treatment,
whereas acquired drug resistance is developed as a result of drug treatment.
Both natural and aquired resistance restrict the clinical efficacy of
chemotherapy. Larsen and Skladanowski (1998) stated that the same
molecular mechanisms are nearly always involved in natural and acquired
resistance, and these mechanisms are also always multi-factorial in nature.
The molecular mechanisms involved in resistance, from drug uptake to cell
death were reviewed here and divided into: pre-target events (including drug
accumulation, distribution and metabolism), drug-target interactions
(chromatin structure, topoisomerase levels, activity, localisation and
mutations), and post-target events (macromolecular synthesis, mechanisms
involved in the regulation of DNA repair/recombination, cell cycle progression
and of cell death). Additionally, in an article by Hannun (1997), the
mechanisms involved in chemotherapy induced cell death, and in resistance
to chemotherapeutics have been outlined in relation to apoptosis.
1.4.1 Multi Drug Resistance And Transporter Proteins
There are many and complex factors involved in the development of resistant
cells, including pre-target events where increased drug efflux results in less
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drug-target interactions since many agents are substrates for the protein
transporters associated with multi drug resistance (MDR).
MDR defines a resistance phenotype where cells, even though they have
been selected for resistance to a single agent are also cross-resistant to a
range of agents with different structures and molecular targets. A gene
product, making up a 170kDa glycoprotein transporter responsible for MDR
has been described. This transporter has been given the names, P-
glycoprotein (P-gp), P-170 or MDR-associated glycoprotein. Transfection
experiments with drug sensitive cells have shown that P-gp expression could
result in a MDR phenotype (Gros et al.,1986; Ueda et al., 1987). In addition to
P-gp, another protein transporter associated with resistance has also been
identified, the multidrug resistance protein (MRP) (Cole et al., 1992). MRP is a
190kDa protein that has several substrates in common with P-gp and the
simultaneous activity of these is thought to be important in resistant cells
(Legrand et al., 1999). These types of resistance transporters can be
expressed on the plasma membrane and also on vesicular membranes (Feller
et aI., 1995; Flens et al., 1996) with decreased intracellular drug levels as a
result of their actions. However, to establish the combined importance of the
expression of MDR-related transporters in chemotherapy failure, more studies
of P-gp and MRP expression in tumour samples from patients undergoing
chemotherapy will be required (Legrand et al., 1999).
In summary, there are a range of mechanisms such as, increased drug efflux,
altered intracellular drug distribution, diminished drug-target interaction,
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altered cell cycle regulation, and uncoupling of the pathways linking cellular
damage with apoptosis involved in resistance (Larsen and Skladanowski,
1998). These resistance mechanisms are still major obstacles for today's anti-
topoisomerase based cancer treatments and provide a valid reason for the
development of new and more effective topoisomerase targeting drugs. In
addition to the limitations linked to resistance, there are also other reasons as
to why there is a need for research into the development of more anti-
topoisomerase agents. Topoisomerases are the targets of the most active
cancer drugs currently used in clinics. The fact that new topoisomerase
enzymes have recently been discovered, which could possibly be explored as
therapeutic targets, makes a strong case for topoisomerases still being valid
targets even though there is already a range of anti-topoisomerase drugs
available in the clinics. Arguments for the need for more topoisomerase drugs
have been outlined by Pommier (1999).
1.5 NU:UB COMPOUNDS
The NU:UB compounds have been synthesised and developed so that via
selective topoisomerase inhibition they will act as improved anti-cancer
agents. Computerised molecular modelling and structure activity
investigations are beginning to reveal the molecular requirements for
formation of cleavable complexes between drug, DNA and protein. For this
kind of cleavable complex formation a polycyclic ring system is thought
necessary for the drug to intercalate into DNA. To interact with the protein, a
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hydroxy or amino moiety is thought to be required to reach out from the site of
intercalation into the grooves of DNA (Cummings et al., 1996). For the design
of the NU:UB compounds an anthraquinone was the ring system of choice to
potentially confer DNA intercalation properties. To the anthraquinone, a
spacer arm was linked, to which amino acids were added, providing the amino
moiety that was thought to be required for enzyme interaction. The type of
spacer, as well as the composition and sequence of the amino acids, was
then altered to achieve different modes of interactions with the target proteins,
and to provide chemical diversity in the attempts to design efficient anti-
topoisomerase agents. Compounds of this type were thought to have a low
affinity for DNA, yet they still appear to possess anti-topoisomerase activity.
The low level of DNA interaction of these types of compounds was hoped to
limit the overall level of DNA damage, which would hopefully result in fewer
side effects than with conventional anti-cancer drugs. In addition these types
of compounds in vivo are highly unlikely to undergo bioreduction and induce
toxicity through formation of free radicals (Mincher D.J., personal
communications) due to unfavourable quinone one-electron reduction
potentials.
Six NU:UB compounds, numbered NU:UB 31, 43, 51, 73, 80 and 81 have
recently been in focus when studying cytotoxicity and anti-topoisomerase
activity of the NU:UB agents. These agents represent a novel class of anti-
topoisomerase agents that are believed to act through either cleavable
complex formation, or through pure topoisomerase inhibition. NU:UB 31 was
chosen as the lead compound for the investigations in this project. The
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chemical structures of each of the NU:UB compounds mentioned above can
be found in Appendix 1. Fig. 1.3a represents a general structure of the NU:UB
compounds and Fig. 1.3b represents NU:UB 31. Table 1.2 summarises the
spacer and peptide motifs of the NU:UB compounds referred to in this thesis.
(OHJi o
Spacer-X
Amide or esterlinkage
H(OH)
Fig.1.3a General structure of the NU:UB compounds
o
o
»<: »<: D\t)8
NH.... ............... 'NHCO ~ OOCCFJ
NU:UB31
Fig. 1.3b Structure of NU:UB 31.
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Compound Spacer Descriptor Spacer Structure Peptide Motif
NU:UB 31 Propyl NH~NH L-Pro
NU:UB 43 Butyl ~NH L-Pro
NH
NU:UB 51 Propyl (AQ4,8 di-OH) NH~NH Gly
NU:UB 73 Butoxy NH~O L-Ala
NU:UB 80 Butyl ~NH D-Val
NH
NU:UB 81 Butyl ~NH L-Val
NH
NU:UB 150 1,4-diaminocyclohexyl NH-Q-NH L-Phe
Table. 1.2 Spacer and peptide motifs of NU:UB compounds.
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1.6 THE CELL CYCLE
1.6.1 Cell Cycle Phases And Checkpoints
The period following one cell division, mitotic phase (M-phase) to the next
division is referred to as the cell cycle. The cell cycle can be divided into
different phases called M, G1, Sand G2 phases. In addition, a quiescent cell
that is not involved in division is in a GO state. Most studies have been
performed on immortalised cells in culture and for cultured mammalian cells
the cycle typically lasts about 18-24 hours. If division is triggered, the cell first
enters the G1 phase, during which RNA and certain proteins essential for
DNA replication are made. When the cell starts to make new DNA it has
entered the S-phase of the cycle. During this phase the DNA content of the
cell increases until it has doubled. At this point DNA synthesis ceases and the
cell is in the G2 phase, where the cell cycle can be arrested if DNA is
damaged, to allow time for repair before M-phase. Finally the cell will enter M-
phase and divide thereby returning to G1 if cell division is to be sustained, or
to GO. In the M-phase two main processes take place, nuclear division (called
mitosis) and subsequent division of the cytoplasm. If growing cells are starved
of nutrients they will arrest in G1, and this leads to the identification of a point
of no return in the late G1-phase. This point has been referred to as a
restriction point and cells that pass this point are obliged to divide. Two other
check points also exist: one at the G2-phase and another within the M-phase
(Becker et al., 1996; Tannock and Hill, 1998). With regard to DNA content,
cells in G2 and M phases of the cell cycle have double the DNA content of
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those in GO and G1, and cells in S phase have a DNA content somewhere in
between. If the DNA content of cells is to be measured, using for example a
flow cytometer and a DNA binding probe, a histogram of the number of cells
against DNA content can be plotted reflecting the cell cycle state of the cell
population (Fig. 1.4).
1.6.2 Cell Cycle Regulation
The molecular basis of cell cycle regulation has been heavily researched and
an understanding of this will hopefully give an insight into how cancer cells
manage to escape normal control mechanisms. The cell cycle regulation is
very likely to involve complex protein cascades and although these cascades
are yet to be clearly defined, the regulation of the cycle appears to rely on
specific cyclin and kinase complexes (Becker et al., 1996). The cell cycle and
its regulation via various cyclins and kinases is a complicated issue indeed,
discussed in detail by Sherr et al. (1993). Briefly, cyclins and cyclin dependent
kinases (cdks) are key regulators of the cell cycle, and what governs the
correct progression of cells through the cycle appears to be the activation and
subsequent inactivation of cyclin-cdk complexes. During the course of the cell
cycle, the level of various cyclins acting as positive regulatory subunits for a
series of cdks, increase and subsequently decrease in a defined order. The
increase and decrease of cyclins is striking since most proteins like cdks have
relatively constant levels in cells, but this will confer substrate and thereby
also cell cycle specificity upon the cdks. The various types of cdks and cyclins
act in different combinations and at different stages of the cell cycle controlling
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the G1/S and G2/M transitions (Lee and Fukushima, 1998; Tannock and Hill,
1998; Chetly, 2002). For an illustration of the cdks in the cell cycle see
Fig.1.5.
In addition to the positive regulation of the cell cycle by activation of cyclin-cdk
complexes, negative regulation also occurs at the cell cycle checkpoints.
Feedback mechanisms act here to prevent cells from entering the next stage
of the cell cycle, before the molecular events required for such a transition
have been completed and the cell is ready for the next phase. If proper control
is not maintained, the cell cycle progression may become insensitive to DNA
damage. The negative regulators include tumour suppressor proteins such as
Rb and p53 as well as the cyclin dependent kinase inhibitors (CKls) including
p21 (Lee and Fukushima, 1998; Tannock and Hill, 1998). P21 and p53 will be
discussed in more detail in sections 1.8 and 1.9 respectively.
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Fig. 1.4 Diagram representing the cell cycle phases (a). Histogram of DNA content
measured with flow cytometry analysis of propidium iodide (PI) fluorescence (b). Cells are
stained with PI that intercalates into DNA to give a linear relationship between red
fluorescence and cellular DNA content. The fluorescence i.e. the DNA content of each cell is
measured and reflects the cell cycle position. Figure represents a normal population of cells.
The G1-phase is the period between the previous nuclear division and the beginning of DNA
synthesis. S-phase, DNA synthesis phase during which chromosomal DNA replicates.G2-
phase represent the time between DNA replication and nuclear division a nd finally the M-
phase (mitosis) which is the nuclear division phase where two daughter cells are produced.
Cells in G2/M phase have double the amount of DNA compared to cells in GO/G1 phase and
S-phase cells have intermediate DNA content. The diagram of the cell cycle and a DNA
histogram were adapted from Ormerod, 2000.
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1.6.3 The Cell Cycle And Topoisomerases
It has been suggested that the action of some anti-cancer drugs in part is cell
cycle dependent, such that there could be a link between the efficiencies of
these drugs and the cell cycle phase of the cells being targeted. This may
partly be due to variations in topoisomerase enzyme activity between different
phases of the cell cycle. In a study by Heck et al. (1988), immunoblotting was
performed for the examination of topoisomerase (I and II) levels in cells. It
was found that while there were no differences in stability of topoisomerase I
in normal compared to transformed cells, for topoisomerase II the half-life was
shorter in normal than in transformed cells. Topoisomerase I and
topoisomerase II also appeared to have distinct functions in the cell cycle
process. Whereas topoisomerase I expression levels appeared stable,
topoisomerase II levels underwent cell cycle dependent fluctuations, reaching
higher levels in proliferating cells, with topoisomerase II peaking at G2. Thus,
topoisomerase II might have a regulatory role during the G2-phase of the cell
cycle. Furthermore, there are also different expression patterns between the
two isoforms of topoisomerase II. Whereas the topoisomerase 1113 isoform is
present in GO cells and expressed at constant levels throughout the cell cycle,
topoisomerase lIa expression levels fluctuate over the course of the cell cycle.
Topoisomerase lIa proteins do not appear to be present in GO cells and cells
in exponential growth have more topoisomerase lIa protein, whereas cells
having reached a growth plateau phase have higher levels of the 1113 protein
(Woessner et aI., 1991; Hwang and Hwong, 1991; Cummings and Smyth,
1993; Poot et al., 1995; Valkov et aI., 2000).
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1.7 APOPTOSIS
Apoptosis can be defined as a form of cell death in which the cell is destroyed
from within (Kerr et al., 1972; Wyllie et al., 1980). The word 'apoptosis' stems
from the classical Greek 'apo' that means apart and 'ptosis' meaning falling.
Apoptosis is a morphological descriptor of cell death that was first described
in the 1970s by Kerr et al. (1972). Apoptotic cell death is continually taking
place in both slowly and rapidly proliferating tissues. While past research has
identified regulation of cell proliferation as a key element in tumour growth and
spread, it is now thought that improper regulation of growth arrest and
apoptosis are implicated in the development of cancers, and that apoptotic
cell kill is also considered important in the treatment of cancers (Kerr et al.,
1994). Evidence in the past few years has revealed that many
chemotherapeutics kill cells in vitro and in vivo through apoptosis. An
understanding of how apoptosis is engaged following treatment with
chemotherapeutic agents and why it fails to get engaged in some cases, may
offer novel approaches to overcoming the clinical problem of drug resistance
(Makin and Hickman, 2000).
Apoptosis is different from the other major form of cell death, necrosis. These
two types of cell death can be induced by different stimuli, although it has also
been realised that the same stimulus may induce apoptosis or necrosis in a
cell depending on the dose of a given agent used to induce cell death. Thus,
whereas mild injury might induce apoptosis, exposure to high doses inducing
severe damage leads directly to cell death by necrosis (Anselmi et al., 2002).
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The situation is however, more complicated, a process starting with very
specific changes may end non-specifically when the cell loses the ability to
maintain homeostasis. This will complicate the identification of apoptotic cells
since apoptosis quite often ends in secondary necrosis, at least in vitro, where
the removal of apoptotic cells is inefficient or nonexistent (Squir et al., 1995).
Some of the most characteristic features of apoptotic cell death will be
outlined below.
1.7.1 Characteristic Features Of Apoptotic Cells
Whereas necrotic cell death appears to be accidental, apoptosis is a
genetically programmed mechanism of cell death that can be triggered by a
variety of external and internal stimuli (Tortora and Grabowski, 2000). For
apoptotic changes to occur, new gene expression is in many cases needed.
Apoptosis is thereby an active process in which synthesis of proteins is likely
to take place (this is however, not the case in all cell lines e.g. HL60). Many
morphological and biochemical changes triggered during apoptosis appear to
be similar.
1.7.1a Morphological Changes
Characteristic apoptotic events at the cellular level include both morphological
and biochemical changes. Morphologically, nuclear size is reduced and there
is typically shrinkage of total cell volume. In early apoptosis there are plasma
membrane changes that shift phospholipid distribution between the inner and
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outer leaflets and this may also contribute to the plasma membrane blebbing.
There is also e vidence that exposure of phospholipids, phosphatidylserines
(PS) on the surface of apoptotic cells may lead to their specific recognition by
macrophages. This is a mechanism that appears to happen early in vivo, and
when using vital dyes, cells appear to be phagocytosed whilst still viable.
Other morphological features include dilation of the endoplasmic reticulum,
chromatin condensation, increase in cell density, nuclear fragmentation, and
constriction of both the nucleus and the cytoplasm into multiple, small,
membrane-bound apoptotic bodies (Cohen, 1993; Kerr et al ., 1994 ;
Studzinski, 1995; Squir, 1995; Cima and Brunner, 2003). Fig. 1.6 shows
typical morphological features of cells undergoing apoptosis.
Fig. 1.6 Morphological changes in Jurkat cells undergoing apoptosis following UV irradiation.
Normal cells (A). Membrane blebbing in early apoptotic cells (8). Apoptotic bodies (C).
Cellular and nuclear condensation (D). Nuclear fragmentation (E). Figure adapted from Cima
and Brunner, 2003.
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1.7.1b Biochemical Changes
An established hallmark of apoptotic cell death is internucleosomal DNA
cleavage, generating a characteristic ladder formation on agarose gels
following electrophoresis. This process is thought to proceed in two steps:
there is first an infrequent DNA cutting that results in the generation of
fragments of 300-50 kilo base pairs. The enzymes responsible for this have
not yet been clearly identified. Secondly, in some (but not all) cell types, the
DNA degradation proceeds with more specific DNA scission, producing
fragments of DNA that are multiples of 180-200 base pairs. This is the length
of DNA wrapped around histones in a nucleosome, which indicates that the
chromatin is being cleaved at the linker DNA between nucleosomes (Wyllie,
1980). However, the cleavage occasionally may be delayed or absent in cell
death that appears by other criteria to be apoptotic (Cohen et al., 1992; Ucker
et al., 1992; Falcieri et al., 1993; Pandey et al., 1994; Sieiman, 1998).
Although DNA fragmentation is an indicator of apoptosis, many researchers
prefer to investigate caspase-3 activation, which is considered to be a reliable
hallmark of apoptosis. So far it is not fully understood how the caspases
cleave their cellular protein targets and thereby induce cell death, but three
mechanisms have been suggested; inactivation of proteins that protect cells
from apoptosis; destruction of nuclear lamina and other vital cell structures;
and indirect cleavage of proteins involved in cytoskeleton regulation
(Thornberry and Lazebnik, 1998).
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1.7.2 Necrosis
There are some features that distinguish necrosis from apoptosis. Cell death
by necrosis is a passive process that can be sustained by hyperthermia,
severe physical or chemical trauma. The early event of necrosis is a change
in mitochondrial shape and function and the cell rapidly becomes unable to
maintain homeostasis. The plasma membrane may however be the major site
of damage (Majno and Joris, 1995), no longer maintaining the proper
regulation of osmotic pressure. This results in swelling of the cell, and rupture
with spilled cell contents provoking inflammation. An inflammatory response
following extensive injury can be beneficial, efficiently clearing away debris so
that the repair process can begin. An inflammatory response may however
not be desirable following in vivo chemotherapy treatments as this can result
in severe side effects, and thus an apoptotic response with no inflammation is
more desirable. Furthermore, the nuclear morphology of necrotic cells never
separates into discrete membrane enclosed fragments that in apoptotic cell
death are referred to as apoptotic bodies (Kerr et al., 1994). Whereas there is
DNA fragmentation in apoptosis, the DNA degradation in necrosis does not
occur to the same extent. During the necrotic process Iysosomes may rupture
and with the escape of lysosomal enzymes, DNA and other cellular
components get digested. DNA is then cleaved into fragments that are
heterogeneous in size and therefore do not form discrete bands, but rather
smears, upon agarose gel electrophoresis. The release of these lysosomal
hydrolases is further thought to rapidly accelerate the cellular disintegration in
late necrosis (Schwartzmann and Cidlowski, 1993). The above characteristics
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distinguish necrotic cells from apoptotic ones, but there are sometimes
similarities between these two types of cell death so conclusive evidence of
apoptosis therefore has to include more than one morphological or
biochemical criterion (Studzinski, 1995).
1.7.3 Apoptosis And Therapeutics
Dysregulation of apoptotic cell death has been suggested to playa role in the
pathogenesis of a variety of human diseases. Defects in genes that control
apoptosis can result in too little apoptosis and the survival of cells that under
normal conditions would be destroyed; this can promote cancer development
(Tannock and Hill, 1998). Hence, a way to stimulate apoptosis in malignant
cells would be therapeutically valuable. The observation that apoptosis is a
programmed process in which gene transcription may be required is
encouraging, so it may be possible to control this process by developing
drugs to act against the molecular components in the apoptotic pathway. A
wide range of agents are thought to induce apoptosis (Shellhaas and
Zuckerman, 1995; Kaufmann and Earnshaw, 2000), a summary of anti-cancer
treatments that induce apoptosis in vitro has been given by Kaufmann and
Earnshaw (2000). This list includes the intercalating agents, doxorubicin and
mitoxantrone, the topoisomerase I poisons, camptothecin and topotecan as
well as the topoisomerase II poisons etoposide and teniposide. Etoposide,
camptothecin, doxorubicin and several other agents have been found to
induce DNA fragmentation (Kaufmann, 1989; Onishi et aI., 1993). It has also
been proposed that apoptosis might proceed through mechanisms that vary
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according to cell type or apoptotic inducer. The topoisomerase inhibitors,
camptothecin and etoposide that were potent apoptotic inducers in HL60
cells, induced only a weak apoptotic response in Syrian hamster embryo
(SHE) cells. In both cell lines condensation of chromatin and DNA
fragmentation were observed, but whereas caspase-3 was activated and
poly(ADP-ribose)polymerase (PARP) cleaved in HL60 cells, caspase-3
activation was not observed in SHE cells. SHE cells did however show
increased p53 levels following topoisomerase inhibitor treatments, which
would indicate that DNA damage is induced, but despite this there were no
massive apoptotic responses (Alexandre et al., 2000). The way in which
various anticancer drugs induce apoptosis has not been fully established, but
apoptosis is likely to be an important part for chemotherapy to be successful.
Cellular transformations that decrease the ability to activate the apoptotic
machinery might play a role in the resistance observed with many drugs
(Kaufmann and Earnshaw, 2000).
1.8 P21
There are various reasons for thinking of apoptosis as a cell cycle
phenomenon, and some of these have been discussed by Meikrantz and
Schlegel (1995). In brief, apoptosis is mainly found in proliferating tissues.
Depending on the point of arrest, the manipulation of the cell cycle can either
prevent or potentiate apoptosis. By premature activation of cdks it is possible
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to induce apoptosis, but also premature mitosis, often referred to as mitotic
catastrophe.
P21 is a cell cycle regulation protein and this cdk inhibitor has, following its
identification in the early 1990's, also been given several other names as it
has been cloned independently by different routes. Cip1 (cdk-interacting
protein) (Harper et aI., 1993), was identified with a screen for human proteins
that interact with cdk2. Sdi1 (senescent cell derived inhibitor) (Noda et al.,
1994) was identified in a search for expression to prevent growing cells from
entering S-phase. In addition, WAF1 (wild-type p53 activated fragment) (EI-
Deiry et al., 1993), was discovered in identifying genes stimulated by wild-type
p53 but not mutant p53. Pic1 (p53-regulated inhibitor of cdks) is another
acronym that has been suggested by Xiong et al. (1992) and Zhang et al.
(1993) that is based on the p53-mediated induction of WAF1 as well as the
ability of cip1 to inhibit cdk-cyclin activity. Localisation studies of p21 proteins
have revealed that these proteins formed quaternary complexes with cyclins
(A, B, D or E), cdks (cdk2 or cdk4) and proliferating cell nuclear antigen
(peNA), a protein important in DNA replication and DNA repair (Xiong et al.,
1992; Zhang et aI., 1993; Waga et al., 1994). The fact that p21 associates
with PCNA makes it different from other cdk inhibitors. The interaction of p21
with cdk-cyclin complexes is thought to result in arrest of the cell cycle in G1,
whereas the effects on cell cycle progression from interactions of p21 with
PCNA have not been clearly defined. The p21-PCNA interaction possibly
plays a part in both G1 and G2 arrest (Cayrol et al. 1998). More detailed
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information about the identification of p21 and inhibition of cyclin-cdk
complexes in cell cycle control can be found in a review by Hunter (1993). An
overview of p21 functions and its relation to malignancies has been given by
Harada and Ogden (2000).
1.8.1 P21 In Cell Cycle Arrest And Apoptosis
Cells may respond to DNA damage by either arresting the cell cycle (G1 and
G2 arrest) or by instructing the cell to die. The p21 protein is thought to
mediate some of the effects of p53, mainly the G1 cell cycle arrest in
response to DNA damage, but a role of the p21 protein in G2 arrest has also
been suggested (Cayrol et a/. 1998; Rigberg et a/., 1999). Since p21 appears
to be directly activated by p53, and a major part of p53 mediated growth
arrest is thought to proceed through the induction of this cdk inhibitor, its
identification was considered to provide a direct link between growth
suppression by p53 and cell cycle regulation by cdks (Hunter, 1993; Evan and
Littlewood, 1998). However, there appear to be at least two separate
pathways of p21 induction: a p53-dependent pathway activated by DNA
damage that leads to cell cycle arrest, and a p53-independent pathway
associated with cell growth that is activated by growth factors at the entry into
the cell cycle.
Whereas growth arrest is elicited in some cells following p21 expression (Di
Leonardo et a/., 1994) apoptosis may occur in others (EI-Deiry et a/., 1994). It
is further suggested that if sufficient levels of p21 are not expressed, the cell
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cycle arrest may be converted into apoptotic cell death and this protein may
thereby be a critical checkpoint protein for both cell cycle arrest and apoptosis
in response to DNA damage (Waldmann et al., 1996). The role of p21 in
apoptosis is, however, controversial and p21 induction might take place under
different physiological situations. Gamma radiation that induced p21 via p53 in
p53 positive cells did not induce p21 expression in HL60 cells, as these are
p53 negative (Serrano et al., 1993). However Steinman et al. (1994) showed
that p21 upregulation was evident in HL60 cells that were induced to
differentiate, but when HL60 cells were induced to undergo apoptosis there
was (as in the study above) no p21 increase in this cell line. Therefore it
appears that expression of p21 is neither necessary nor sufficient for
apoptosis in p53 negative cells. Using urothelial carcinoma cells, it was
proposed that while p21 inhibits proliferation by p53-dependent or p53-
independent mechanisms, p21 does not mediate p53-induced apoptosis in
these cells. The results in this study therefore suggested that the function of
p21 in p53 mutant urothelial carcinoma cells appears to be restricted to the
regulation of cell proliferation (Makri et al., 1998). Furthermore, p53-
dependent apoptosis does occur in cells lacking p21 following DNA damage
(Waldmann et al., 1996). In different experiments performed by EI-Deiry et al
(1994), p21 was up-regulated in cells undergoing p53 associated G1 arrest
and apoptosis but not in cells induced to arrest or undergo apoptosis by p53
independent mechanisms. This suggests that p53 is required for p21 to be
induced following DNA damage and this is supported by studies of wild type
and mutant p53 containing cells, where p21 was only induced in the wild type
p53 cell line upon DNA damage. To summarise the findings from the above
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mentioned studies, it seems that while p21 mediates the growth inhibitory
effects of p53 in response to DNA damage, it is not clear what role, if any, it
plays in p53-mediated apoptosis. Data exist supporting both pro- and anti-
apoptotic functions, and p21 involvement in apoptosis may vary depending on
cell type and physiological situation.
1.9 P53
Despite the large number of different cancers and the heterogeneity among
malignant diseases affecting different tissues, there seem to be alterations in
a certain protein, involved directly or indirectly in many of these, suggesting
that that there might be one pathway for controlling abnormal growth
(Vogelstein and Kinzler, 1992). P53 is a likely candidate considering that this
protein has tumour suppressive activity and that loss of wild type p53 function
takes place in almost all human cancers (Hollstein et al., 1991). It is now well
established that p53 plays a highly important role in preventing cancer
development by arresting or killing potential tumour cells, and impaired p53
function has been associated with loss of normal cell cycle control and
diminished apoptosis, as well as genomic instability.
P53 was originally identified towards the end of the 1970s in co-
immunoprecipitations with the SV40 T antigen (Linzer and Levine, 1979; Lane
and Crawford, 1979) and was initially thought to have dominant oncogenic
activity. However, later studies demonstrated that it is mutant p53 that has
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dominant oncogenic activity, and wild type p53 is instead a tumour suppressor
(Lane and Benchimol, 1990). To highlight this, the rate of spontaneous
tumours in p53 deficient mice (Donehower et al., 1992) is increased and these
high rates may partially result from a lack of p53-induced apoptosis.
P53 proteins are capable of integrating a variety of stress signals and
following these, bind to specific DNA sequences. The binding of p53 to DNA
will activate corresponding genes and via these gene products the cells are
hopefully enabled to respond to the signals accordingly (Hall et al., 1996; Hall,
1998). In normal cells p53 monitors the integrity of the genome and responses
initiated via the p53 pathway may lead to cell growth inhibition by arresting
proliferation and allowing time for repair, or to apoptosis if the damage is
extensive (Lane, 1992). These responses thereby prevent the propagation of
cells that may be undergoing malignant transformation. The favoured
response will however depend on factors such as cell type and environment
(Vousden, 2000; 2002). In contrast to cell cycle arrest, the pathway of p53-
mediated apoptosis is less well defined, with the induction of many specific
target genes (Sabbatini et al., 1995; Attardi et al., 1996) that appear to differ
from those applied in growth arrest (Friedlander et al., 1996a). Studies have
revealed proteins with which p53 may interact, but in many cases the
functional consequences of such interactions are yet to be established. Genes
with p53-responsive elements include p21, mdm2 and many others. Mdm2
was the first p53 partner to be identified (Oliner et al., 1992). It has been
found that overexpression of this protein may affect cells in a similar manner
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as mutations of the p53 gene, and the realisation that mdm2 could be an
important oncogene stepped up the search for other p53 associating proteins.
1.9.1 Cell Cycle Arrest Or Apoptosis?
It is not clear how a cell makes the choice between arrest and apoptosis
following damage-induced p53 expression. It is also uncertain whether or not
p53 mediates apoptosis by separate mechanisms from which it regulates cell
cycle arrests. It has been suggested that p53 inhibits progression of the cell
cycle, but in certain contexts such as over expression of oncogenes,
simultaneous inhibition and stimulatory signals may clash and result in
apoptosis (Shiamura and Fisher, 1996). On the other hand it is likely that cell
cycle arrest and apoptosis are different separable functions of p53; that p53
differentially controls cell cycle arrest and apoptosis depending on which
target genes it activates (Rowan et al., 1996; Chen et aI., 1996; Ryan and
Vousden 1998). Furthermore, the extent of DNA damage and possibly the
level of p53 may affect the choice between cell cycle arrest and apoptosis
(Chen et al., 1996). However, to contradict this, the basal levels of p53 in
some cells are higher than the stimulated levels reached in others following
DNA damage (O'Connor et al., 1997). These observations thereby suggest
that whether or not apoptosis occurs depends more on the cellular context
such as cell type, cellular environment or whether the cell has sustained other
oncogenic alterations, than on the level of p53 (Fojo, 2002; Vousden, 2002).
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1.9.2 P53 In Cell Cycle Arrest
Cells containing functional p53 are, after DNA damage, likely to undergo cell
cycle arrest. Following such damage there is a rapid increase in p53 protein
levels. This rapid increase is thought to be due to post-translational changes
in p53 stability and leads to transcriptional activation of certain target genes.
P53 mediated cell cycle arrest is thought to proceed via the cdk inhibitor p21
and also via Gadd45 and 14-3-30. The p21 upregulation prevents cells from
entering S-phase by arresting in G1, and p21 is also thought to bind PCNA
and via this interaction prevents DNA replication (Pines, 1994). While p21 is
predominantly implicated in G1 arrest, Gadd45 is one of the mediators
thought to be involved in the G2/M-phases (Kastan et al., 1992; EI-Deiry et al.,
1993). Gadd45 is induced by p53 following DNA damage, at which point it
binds PCNA and this is thought to stimulate DNA damage repair, indicating
that p53 may be involved in controlling the DNA repair machinery (Smith et
al., 1994). Therefore p53 mediated induction of both p21 and Gadd45 may
make it possible for p53 to inhibit DNA replication and simultaneously
propagate DNA repair.
1.9.3 P53 In Apoptosis
Apoptosis plays an important part in normal cellular homeostasis, and early
studies restoring p53 function to p53 deficient cells resulting in rapid
apoptosis, provided evidence that p53 may control apoptosis (Yonish-Rouach
et al., 1991). The occurrence of tumour cells with deficient p53 functions
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possibly reflects a growth advantage and damaged apoptotic responses,
compared to normal wild type p53 containing cells. It has also been shown
that lack of p53 is linked to resistance, whereas wild type p53 cells are more
sensitive. Initially it may seem strange that cells containing no p53 and
therefore incapable of properly repairing damaged DNA, would be more
resistant. However, p53 can also affect a cell's susceptibility to apoptotic cell
death and this would provide an explanation for this phenomenon. It has been
shown that the absence of proper p53 function confers chemotherapy
resistance (Lowe et al., 1993a; Blandino et al., 1999). The cellular effect of
p53 disruptions may however vary between cell lines and this could possibly
be explained by differences in the apoptotic regulatory signals. Adverse
alterations in other proteins along the p53 mediated pathway(s), either before
or after p53 tumour suppressor activity, can potentially be equivalent to
inactivation of p53 itself. This could disrupt all, or part of the p53 pathway, and
lead to disruptions in cell cycle check points, genomic instability and possibly
tumourigenesis as a result (Agarwal et al., 1998). Various anti-cancer agents
are known to induce DNA damage, resulting in apoptosis. P53 may, however,
also modulate apoptosis from other stresses that do not induce DNA damage,
and the variety of stimuli that are able to induce apoptosis via the p53
pathway, indicate that p53 activation might be a general stress response
(Wagner et al., 1994; Hermeking and Eick, 1995).
DNA damage induces p53 and apoptosis, but the pathway whereby p53 leads
to execution of apoptosis is not well characterised. It was initially thought that
pro-apoptotic bax was the main effector of p53 in apoptosis. The p53-bax
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pathway involves translocation of bax from the cytosol to mitochondrial
membranes. The resulting release of cytochrome c from mitochondria
activates initiator caspase-9, setting off the caspase cascade. However, these
days it is thought that there must be effector proteins other than bax involved
in p53-mediated apoptosis and several apoptosis related genes that are
transcriptionally regulated by p53 have now been identified (Miyashita and
Reed, 1995; Oda et al., 2000; Nakano and Vousden, 2001; Polyak et al.,
1997).
P53-responding caspases include caspase-9, caspase-3 and caspase-8,
which suggest that the p53-mediated apoptotic pathway(s) converge on
initiator as well as effector caspase activation (Fischer et al., 2003). Capase-3
is a general executioner that is involved in many apoptotic pathways. It has
been proposed that the p53-mediated cellular destruction in apoptosis could
be carried out via activation of caspase-3 (Cregan et al., 1999; Hietanen et al.,
2000; Schuler 2000). However, the mechanism by which p53 activates the
caspases and if these are required in p53-mediated apoptosis is still to be
deduced.
While a crucial role for the p53 tumour suppressor gene in the execution of
some forms of apoptosis has been demonstrated, other studies have reported
that not all forms of apoptosis require p53 and data have been gathered
showing evidence of p53-independent apoptosis (Lowe et al., 1993b; Clarke
et aI., 1993; Liu et al., 2002). HL60 cells containing no p53 are indeed capable
of dying by apoptosis independently of p53-mediated transcription, and DNA
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damage may also kill cells with mutant p53 proteins, unable to trans-activate
target genes. Thus cells that sustain sufficient damage may undergo
apoptosis regardless of their p53 status. In addition, apoptosis that continually
occurs during development appears to take place in p53 knockouts (Lowe et
aI., 1993b).
1.9.4 P53 Mutations
To date several tumour suppressor genes and oncogenes that are in mutated
form in human cancers have been identified, with cancers being derived from
some combination of these mutant genes. P53 is a nuclear phosphoprotein
and the core of p53 can fold to form a domain that can bind to double
stranded DNA in a sequence specific manner (Kern et al., 1991; Bargonetti et
al., 1991; Hall, 1998). Crystal structures of this DNA binding configuration
have indeed revealed a highly folded and conformationally complex
architecture (Cho et al., 1994). The complexity of the interaction(s) between
p53 and DNA is likely to make this protein sensitive to mutations, and a
number of these have been reported (Halevy et al., 1990; Blandino et al.,
1999; Fojo, 2002). In fact, p53 is the single most common molecular
abnormality in human cancers. Overall it is estimated that as many as 40-50%
of all cancers have p53 mutations, and whereas only 10-20% of prostate
cancers and leukaemias have mutated p53, as many as 60-70% of head and
neck, colon and lung carcinomas express mutant p53 (Fojo et al., 2002). The
problem in tumour cells with mutated p53 is that these are not capable of
proper cell cycle arrest. Due to this, these cells are often genetically unstable
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and therefore readily accumulate mutations and abnormal chromosomal
rearrangements resulting in malignancies. Studies of mice containing no p53
confirm this. These mice developed normally, but did indeed have an
increased incidence of tumours (Donehower et a/., 1992). Cells undergoing
p53 mutation or loss would therefore have a selective advantage during
tumour progression, but it is not only the increased incidence of mutations and
the occurrence of tumours that will be a problem associated with mutant p53;
as mentioned above, loss of p53 activity may also be related to resistance.
Tumour cells may acquire drug resistance through p53 mutations disrupting
the apoptotic pathway. Thus, the presence of p53 may in some cases be
required for efficient activation of apoptosis following chemotherapy, whereas
the absence of p53 confers resistance (Lowe et et., 1993a; Blandino et a/.,
1999).
1.9.5 P53 Interactions With Topoisomerases
It is not clear how the cell allocates all the topoisomerase tasks involved in
DNA metabolism between different cellular topoisomerases. More answers as
to how a cell divides up the tasks to the different types of topoisomerases,
possibly lie in the identification of other proteins such as chromosomal
proteins or transcription factors with which the topoisomerases interact. P53 is
an example of a tumour suppressor with which topoisomerases are thought to
interact. Both topoisomerase I and topoisomerase II have been found in
complexes with p53 and it has been reported that p53 stimulates the enzyme
activity of topoisomerase I in vitro (Gobert et aI., 1996; Albor et a/., 1998). It
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was suggested by Cowell et al. (2000) that topoisomerase II generates a
background level of DNA strand breaks that can be tolerated in cells if
repaired. Further, an interaction between topoisomerase II and p53 may be
required for these breaks to be realised and repaired. Thus, this interaction
between topoisomerase II and p53 may be important in providing cells a
surveillance mechanism for topoisomerase II mediated genomic damage. This
group also found that both topoisomerase 110 and topoisomerase II~ interact
with p53 in vitro in plasmids and in vivo using human mammary carcinoma
(MCF7) cells. Overexpression of topoisomerase II is common in many
cancers and topoisomerase II binding to p53 may be involved in inhibiting p53
mediated apoptosis in cells. Faults in this regulation could possibly help to
explain the early stages of carcinogenesis when p53 mutations are rare
(Yuwen et al., 1997).
1.9.6 P53 And Therapeutics
The cellular targets for many anti-cancer drugs have been identified, but less
is known about the mechanisms leading to cell death of cancer cells (Dive
and Hickman, 1991). A major goal is to identify features unique to tumour
cells that can act as targets for new drug discovery. A number of genes, and
in particular p53, are thought to be important for efficient induction of
apoptosis. Many anti-cancer agents are thought to activate a so called
"intrinsic" apoptotic pathway (Fuchs et al., 1997; Sun et al., 1999). The events
before mitochondrial cytochrome c release and caspase activation in this
intrinsic pathway are not well understood, but are thought to involve bax. It
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could be that p53 increases bax transcription, or p53 may induce
conformational changes and mitochondrial targeting of bax, or this pathway
may go via different so far unidentified mediators (Schuler et al., 2000). When
the p53 pathway(s) and the relationship between p53 status and therapeutic
response to chemotherapy have been completely deduced, analysis of p53
protein may provide some prediction of therapeutic responses, or p53 could
provide a target for more tailored cancer treatments (Lowe et al., 1993a).
Several mechanisms are now being explored with regard to the knowledge of
p53 and p53-mediated pathways in an attempt to kill tumour cells (Vogelstein
and Kinzler, 2001). For example it may be beneficial to stimulate p53
functions in cells that retain their wild type p53, but are defective in their ability
to activate this protein, or to re-introduce wild type p53 into p53 mutant
tumours. This could reverse the malignant phenotype, or enhance cellular
sensitivity to the drugs used in treatment. A number of researchers have
claimed to be able to regain at least some wild type functions from mutant p53
proteins, and in vitro data do suggest that this may be possible. Different
strategies have recently been developed in an attempt to kill cancer cells with
deficiencies in their p53 pathways, for example, the transfer of wild type p53
into cancer cells with gene replacement therapy using adenovirus vectors (Liu
et al., 1994; Gomez-Manzano et aI., 1996; Hitt et al., 1997). Another virus-
based approach uses a mutant human adenovirus that has been designed for
viral replication in p53 mutant cells but not in wild type containing cells. Thus,
normal cells will be resistant to cytolysis whereas the virus replicates and kills
tumour cells with mutant p53. Additionally, destroyed cells will release more
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viruses capable of infecting other p53-mutant containing tumour cells
(Bischoff et al., 1996).
Targeting other p53 interacting/controlling proteins is also being investigated.
For example mdm2 proteins play an essential part in normalising p53 levels
following its activation and this interaction could in theory make a target
(Bottger et aI., 1997). In wild type p53-containing tumours inactivated by faulty
mdm2 proteins, restoration of p53 activity can be achieved by anti-sense
approaches decreasing levels or blocking undesired interactions.
Another approach (that may be relevant to the NU:UB category of compounds
studied in this research project, discussed in Chapter 7) is the identification
and design of small molecules with therapeutic, stabilising potential against
mutant p53, restoring their wild type activities in cancer cells (Foster et aI.,
1999). For example, compared to approaches using viral delivery systems
that have disadvantages such as inefficiency of gene transfer and risk of
toxicity and immunoresponses to viral antigens, the use of synthetic
compounds provides low toxicity upon administration and ease of entry into
tumour cells due to small size.
In summary, various therpapeutic strategies have been attempted to restore
p53 function to cancereous cells. The above-mentioned therapies and others
have recently been described by Willis and Chen (2002), and by Lane and
Lain (2002).
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1.10 MDM2
It is essential for the organism that apoptosis is properly regulated, being
initiated when required but not otherwise. The understanding of how
apoptosis is regulated will have great implications in the cancer area, as well
as in other areas. From the above information it is clear that p53 is implicated
in both cell growth and apoptosis, so the regulation of p53 activity is therefore
critical to allow for both normal cell division and tumour suppression. Thus,
p53 function must be dampened sufficiently to allow normal growth and
development, while retaining the capacity for rapid induction in response to
stresses associated with tumourigenesis. P53 is subject to a diverse range of
regulatory mechanisms which keep it in check until needed and, in addition to
synthesis and degradation of p53, other mechanisms are also involved. For
example: protein-protein interactions, post-translational modifications as well
as regulation of the subcellular localisation of p53 (Levine, 1997; Agarwal et
al., 1998; Vousden, 2002).
With regard to regulation of p53 degradation, this process is mainly initiated
by mdm2. Mdm2 is the abbreviation for murine double minute 2 and the
human analogue of this gene is named hdm2 accordingly. The human mdm2
can be found on 12q13-q14 where it encodes a 90kDa, 491 amino acid
nuclear phosphoprotein and this protein has further been identified as a
dominant transforming oncogene (Fakharzadeh et al., 1991). Activation of p53
requires post-transcriptional modifications of the protein by, for example
phosphorylations and acetylations. These modifications contribute to the
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dramatic increase in the half-life of p53 and the fine-tuning of its
transcriptional activities, and mdm2 appears to be of importance in these
aspects of p53 regulation. Thus, the relationship between mdm2 and p53 is
thought to be carefully controlled by complex post-translational modifications,
determining the stability and activity of p53 and mdm2. In normal unstressed
cells mdm2 maintains low levels of inactive wild type p53. However, in
response to various stimuli p53 accumulates inducing cell cycle arrest and/or
apoptosis (Levine, 1997). Stress dissociates mdm2 from p53 and this
stabilises p53 and increases transcription of p53 target genes. Fig. 1.7
schematically shows how DNA damage causes disruption in the mdm2-p53
interaction and stabilisation of the p53 protein (Colman et aI., 2000). The
mdm2 gene itself is a transcriptional target of p53, and accumulation of mdm2
protein could be important for cellular recovery once the cell damage has
been repaired (Daujat et al., 2001; Vousden, 2002). The interval between p53
activation and consequent mdm2 accumulation defines the time window
during which p53 exerts its effects. During recovery from DNA damage,
maximal mdm2 induction coincides with rapid p53 loss. Results by Haupt et
al. (1997) showed that mdm2 could significantly reduce p53 levels and that
binding of mdm2 to p53 is important for this effect. In their study, p53 peaked
within 1h of radiation then decreased over the next 2h, whereas mdm2
peaked 1.5-2h post irradiation coinciding with the subsequent p53 loss.
Furthermore, earlier research had also determined that whereas p53
stimulates synthesis of mdm2 proteins, mdm2 can in turn inhibit p53 activation
by binding to the transcriptional domain of p53, so in this way p53 and mdm2
form an interrelationship (Chen et al., 1993; Picksley and Lane, 1993,
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Vousden 2002). The complex interrelationship between mdm2 and p53 is
thought to involve mdm2 binding to the transcriptional N-terminal region of
p53. Thus mdm2 counteracts p53 activity not only by mediating its
degradation (acting as a shuttling protein, inducing nuclear export of p53 for
ubiquitination and degradation), but mdm2 also interferes with the
transactivation of p53 by blocking its transcriptional activation domain (Haupt
et al., 1997; Kubbutat et al., 1997; reviewed by Vousden 2002).
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Fig 1.7 Activation of p53-mediated gene expression in response to DNA damage. Various types
of DNA damage trigger the phosphorylation of the p53 N-terminus, which stabilised the p53
protein via disruption of the mdm2-p53 interaction. Activation of the latent DNA-binding activity of
p53 is facilitated through the phosphorylation-acetylation cascade at the p53 C-terminus.
Integration of signals by p53 culminates in growth arrest, apoptosis, or adaptation to DNA
damage. Figure adapted from Colman et al., 2000.
54
1.11 CASPASES
Activation of a family of proteases is thought to be central to the apoptotic
pathway. These types of proteases, now named caspases appear to be
responsible for many of the characteristics of apoptotic cell death. The name
caspase was based on two catalytic properties of these enzymes. The 'c'
refers to a cysteine present in the active site of these proteases, and 'aspase'
refers to their most distinctive catalytic feature, t.e. to cleave substrates after
aspartic acids (Caspases=Cysteine-Aspartate Proteases). The caspases are
first synthesised as pro-enzymes and these inactive precursors are named
pro-caspase-1, pro-enzyme-3 accordingly (Alnemri et al., 1996). The
mammalian caspase family is growing and currently contains 14 members.
Most of the so far identified caspases participate either in the activation of pro-
inflammatory cytokine pathways, or in the promotion of apoptotic cell death
pathways (Salvesen and Dixit, 1997). Caspase -2, -3, -6, -7, -8, -9 and -10 are
involved in apoptosis, while caspase -1, -4, -5 and -11 are mainly involved in
cytokine processing. Not much is known about the latter caspase group,
involved in cytokine processing, and in addition caspase -12, -13, and 14
have been identified but not yet characterised.
1.11.1 Caspases In Apoptosis
In this project we investigated apoptotic caspase activation in cancer cells in
response to NU:UB compound exposure. Goyal (2001) compared the
apoptotic dismantling of cells with the implosion of a building that depends on
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the precise detonation of explosives where the explosives would be
represented by the caspases in an apoptotic cell. The caspase enzymes
make up a so called, caspase cascade that is triggered in response to pro-
apoptotic signals and culminates in cleavage of proteins that result in the
disassembly of the cell. Caspases involved in mediating apoptotic cell death
have been subdivided into upstream signalling initiator caspases and
downstream effector caspases. This was mainly based on their structure and
length of their respective pro-domain. Long pro-domain caspases include
caspase-2, -8, -9 and -10. These are typically recruited into membrane
complexes by adaptor proteins, initiating the caspase cascade and thereby
activating other caspases. The effector caspases, caspase-3, -6 and -7 have
short pro-domains and are presumed to dismantle the cell. This model of
initiating and effector type caspases gives an understanding of the caspase
cascade, but the cellular situation is often more complex, as caspases further
down the cascade can amplify the response by feeding back on caspases
further up. An example of this is caspase-3; following its activation by an
initiator, caspase-9, this effector caspase-3 can feed back on caspase-9
thereby amplifying the cascade (Slee et al., 1996). Inactive pro-caspases can
be activated by proteolytic cleavage and are usually activated at conserved
Asp residues, therefore, most activated caspases can process their own (auto
catalysis triggered by e.g. cofactor binding) as well as other caspase
precursors (Salvesen, 1997). Furthermore, large amounts of pro-enzymes can
be made and accumulated in advance and then activated when required
(Thornberry and Lazebnik, 1998).
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While many caspases are localised in the cytosol, many of their substrates
are contained within the nucleus or other cellular compartments and there is
therefore likely to be some delay between caspase activation and the
proteolytic attack of the target (Slee et aI., 1996). Caspase activity is however
thought to be an early event, possibly preceeding phospholipid (PS)
externalisation. PS externalisation observed in response to several agents is
thought to be one of the earliest indications of apoptosis, preceeding nuclear
changes associated with apoptotic cell death. Studies of caspase inhibition
however blocked the externalisation of membrane PS, which would indicate
that the loss of membrane phospholipid asymmetry is a downstream event of
caspase activation (Pervaiz et aI., 1998).
Caspases participate in apoptotic control on several levels, as triggers of the
death machinery, as regulatory elements within it and also as effectors of the
machinery itself. The cellular death programme can be divided into different
phases: initiation, commitment, amplification and demolition. These phases
have been depicted in Fig. 1.8 (Slee et al., 1996).
1.11.1 a Initiation
In the initiation phase the cell receives signals and these may result in the
activation of cell death. The initiators can be further divided into three
categories: death receptor signals, contents of cytotoxic T and NK cell
granules and stimuli such as cytotoxic drugs and radiation that provoke
generalised cellular damage.
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1.11.1b Commitment
The commitment phase is the point at which the death signals become
irreversible and here the mitochondria appear to be an important sensor of
cellular damage. Several pro-apoptotic stimuli provoke changes in the
permeability of the outer membrane of the mitochondria permitting the escape
of proteins such as AIF and cytochrome c. These can be released in a
caspase dependent or a caspase independent manner (via unknown
effectors). Which it is, most likely depends on the nature of the pro-apoptotic
stimulus. AIF exerts its effects in a caspase independent manner by
translocating to the nucleus and triggering chromatin collapse and
fragmentation into high molecular weight fragments that is commonly
observed during apoptosis. When cytochrome c is released from mitochondria
it regulates activities of Apaf-1 and the so called apoptosome is formed. The
apoptosome is a large protein complex of approximately 700-1400 kDa that is
composed of several Apaf-1 molecules, that each has a bound caspase-9
molecule and dATP is also involved (Cain et a/., 2002). The apoptosome
recruits and activates caspase-9 that drives the next, amplification phase of
the caspase cascade.
1.11.1c Amplification
In the amplification phase, multiple caspases are activated in a cascade to
cooperate in the destruction of the cell. The caspase activation events driven
by caspase-9 appear to be simultaneously the activation of caspase-3 and -7.
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Caspase-3 then drives the activation of caspases-2 and caspase-6 followed
by activation of caspase-8 and caspase-1 O.
1.11.1d Demolition
Finally, when the caspases that are necessary for proper execution of the
death programme are activated, the final demolition phase begins. In the
demolition phase, caspases destroy cellular structures and inactivate various
proteins directly, or via the activation (or inactivation) of other enzymes (Slee
et al., 1996). Thus, caspases are thought to be involved in all the phases of
cell death and play a central role in the complex demolition process of
apoptosis. Caspases are for example involved in reorganising the
cytoskeleton, disrupting the nuclear structure, shutting down DNA replication
and repair, interrupting splicing and disintegrating the cell into apoptotic
bodies (Salvesen, 1997; Thornberry and Lazebnik, 1998; Cima and Brunner,
2003).
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Fig 1.8 Representation of the routes to caspase activation. Figure adapted from Slee et a/.,
1999.
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1.11.2 Caspase-3
It is predominantly caspase-3 which has been in focus in apoptotic studies.
This enzyme exists in the cytosol as a 33kD inactive pro-enzyme that is
cleaved and activated in apoptotic cells. Caspase-3 cleaves PARP and is
activated in HL60 cells by a number of agents. For example a study by Zhu et
al. (2002) showed that squamocin induced apoptosis in HL60 cells. In their
studies, a caspase-3 activation assay and Western blotting of caspase-3
(using time points from 2-6h) were performed. The results showed that
caspase-3 was involved in the apoptosis induction since caspase-3 inhibitors
prevented apoptosis. Furthermore, caspase-3 activation appears to be
initiated by the release of cytochrome c from mitochondria (Martins et aI.,
1997). However, it has been proved that apoptotic cell death does not require
caspase-3, so although caspase-3 is considered to be important in the
apoptotic cascade, MCF-7 human breast cancer cells that do not express
caspase-3 can be made to undergo apoptosis after treatment with a variety of
stimuli. Therefore, that MCF-7 cells, without caspase-3 undergo
morphological and physiological apoptosis, suggests that they have an
alternative pathway. With the use of caspase inhibitors, enzyme specific
chromogenic substrates and antibodies it was determined that apoptosis in
these cells proceeds via caspase-9, caspase-7 and caspase-6 (Liang et aI.,
2001).
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1.11.3 Apoptosis In Resistant Cells Via Caspase Activation
The major challenge in treating cancer is to kill cells that have become
resistant to available chemotherapy. Failure to undergo apoptosis is
associated with drug resistance, and different rational strategies have been
identified during the last decade to re-sensitise resistant tumours. In
particular, restoration of p53 has been an attractive target (discussed
previously in 1.9). However, mutations of the p53 downstream effectors such
as caspases might undermine such p53-targeted efforts (Pruschy et al.,
2001). Therefore direct activation of caspases in cancer cells may be an
effective strategy to kill resistant cells (Salvesen and Dixit, 1997). When
apoptotic signals in cells are uncoupled from caspase activation, the
transformed cells survive. If these signals could be re-coupled to caspase
activation this might provide an opportunity to selectively kill transformed cells.
One possibility may be to activate death receptor complexes directly linked to
initiator caspases but this should only happen in cancer cells and not in
normal cells (Thornberry and Lazebnik, 1998). Furthermore, caspase-
independent activation of apoptosis may be another way to induce apoptosis
in cells with defects in their caspase cascade, and agents with caspase
independent pathways may be useful for treatment of cancers resistant to
usual chemotherapy. Though many anti-cancer drugs are known to induce
apoptosis in tumour cells, few are reported to be independent of caspases.
The means of caspase independent induction of apoptosis is so far uncertain,
but a mitochondrial protein AIF could be connected to this pathway (Kawagoe
et al., 2002).
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1.12 MITOCHONDRIA
Mitochondria are indeed important organelles in cells and are involved in the
regulation of several aspects of cell biology, including energy production,
molecular metabolism e.g. fatty acid oxidation and purine and pyrimidine
metabolism, redox status, calcium signalling and apoptosis. With so many and
important functions, the estimation that 75-100 human disorders have
improper mitochondrial function implicated at some point in their pathogenesis
comes as no surprise. A recent area of research is the role of mitochondrial
function in cancers and in the treatment of cancers. Gathered information of
cancer drugs and their mechanism(s) of action have now revealed that
several agents may have significant mitochondrial effects, even though these
agents were not originally developed to act on mitochondrial targets (Howell
et al., 2003).
1.12.1 Mitochondrial Structure
The mitochondria are approximately 1IJm in diameter, elongated, thread like,
differing in length and make up approximately 15% of the total cellular protein.
The mitochondria are thought to have originated from protobacteria that have
been taken up by nucleated cells. It is therefore possible that the inner
mitochondrial membrane (IMM) originally stems from bacteria, whereas the
outer mitochondrial membrane (OMM) is derived from a nucleated cell.
Mitochondria can be divided into four parts, each with different compositions
and functions: the OMM which is fairly porous, the IMM which is a highly
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convoluted structure containing the enzymes of oxidative phosphorylation and
a range of metabolite carrier proteins. Whereas the OMM is relatively
permeable, the IMM is more impermeable and there is therefore a complex
machinery involved to transport molecules across this membrane. The space
in between these two membranes (OMM and IMM) is referred to as the
intermembrane space and contains a number of specialised proteins. In the
centre of mitochondria, enclosed by the IMM, is the mitochondrial matrix, this
compartment contains mitochondrial DNA, ribosomes and enzymes used for
many different pathways (e.g. for the urea cycle, the citric acid cycle and for
fatty acid oxidation). Mitochondria contain their own DNA and all but 13
proteins (compartments of the respiratory chain or ATP synthase) of the
hundreds of mitochondrial proteins, are encoded by nuclear DNA. This
confirms that mitochondria do require nucleated encoded proteins for proper
function (reviewed by Alberts et al., 1998; Preston et al., 2001; Murphy and
Smith, 2000).
1.12.2 Mitochondrial Function
1.12.2a AlP Production
One of the main functions of mitochondria is to generate energy in the form of
ATP, a process also referred to as respiration. To accommodate the enzyme
complexes required for this ATP production a large surface area is required
which is why the IMM has to be highly folded. One of the proteins in
mitochondria involved in the production of energy is cytochrome c, which
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transfers electrons in the electron transport chain. As electrons are
transported along the chain, protons are pumped out of the matrix. This
creates a negative potential called mitochondrial transmembrane potential
wherein ATP synthase converts ADP to ATP (Waterhouse et al., 2002;
Custido et al., 2001).
In the conversion of oxygen to energy (ATP) in mitochondrial respiration,
reactive oxygen species (ROS, e.g. superoxide Oi·, hydrogen peroxide H202 ,
hydroxyl radical OH) are generated and mitochondria are therefore
continuously exposed to ROS, which can have damaging consequences to
the cell (Ames et aI., 1993; Shigenaga et al., 1994; Wallace, 1999). For
protection of cellular components, cells have developed antioxidant
mechanisms for example glutathione GSH and superoxide dismutase SOD
(Oberley and Oberley, 1997).
1.12.2b Mitochondria And Calcium
In addition to the major function of mitochondria, to provide ATP by oxidative
phosphorylation, mitochondria have also a role in the modulation of
intracellular calcium concentrations. If there is disruption of mitochondria
calcium metabolism this may both interfere with cellular calcium signalling and
make cells in danger of calcium overload and necrosis. Mitochondria may
thus act as a safeguard to increased cytosolic calcium levels, in a mechanism
to protect cells. The responses to high calcium levels in mitochondria depends
on the duration of the calcium signal (Cano-Abad et al., 2001) and on cell type
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(Andreyev and Fiskum, 1999). Increased cellular calcium levels can be the
result of exposure to chemicals; calcium accumulation in mitochondria may
increase ROS production, cytochrome c release and result in cell death. Thus,
calcium regulation by mitochondria seems to playa part in apoptotic cell
death and therefore, adjusting the amount of calcium in mitochondria and the
cytosol may inhibit or induce apoptosis (Parone et al., 2002).
1.12.2c Mitochondria And Apoptosis
Mitochondria are thought to regulate apoptosis in cells since they store a
range of apoptogenic proteins. These include Smac/Diablo (Du et al., 2000;
Verhagen et al., 2000), AIF (apoptosis inducing factor, that is not thought to
activate caspases directly but instead moves to and induces apoptosis via the
nucleus) (Daugas et al., 2000; Joza et al., 2001), several caspases [pro-(2, 3,
8 and 9)] and cytochrome c. Cytochrome c appears to playa dual role in cells,
it is a trigger of apoptosis but also in viable cells as mentioned above, a vital
component of the respiratory chain.
In apoptosis, mitochondria may be integrating a range of apoptotic
downstream signalling cascades. Several factors may be capable of
transmitting death signals from e.g. DNA damage, radiation or oxidative stress
to the mitochondria. For example bcl-2 and bax are found to translocate from
the cytosol to mitochondria when exposed to apoptotic stimuli. Bid, another
bcl-2 family member, is thought to mediate the death response from cell
surface death receptors (via caspase-8) (Desagher et al., 1999; Luo et al.,
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1998). In response to nuclear DNA damage P53 is thought to be able to
directly insert into mitochondria, activating caspases without causing release
of cytochrome c. Furthermore, PUMA or Noxa (Nakano and Vousden, 2001;
Oda et al., 2000) have also been found to be involved in the p53-dependent
death response to DNA damage, moving to mitochondria, and via Bcl-2 sub-
families inducing the release of apoptogenic factors such as cytochrome c
and other apoptotic proteins, for example pro-caspases and AIF. Thus, the
mitochondria indeed seem to playa key role in the apoptotic processes linking
the apoptotic mediators (e.g. bcl-2 proteins) with the effector molecules
(caspases) (Parone et al., 2002). In addition to apoptotic cell death,
mitochondria also seem to be a factor in necrosis. Apoptotic cell death
requires ATP, whereas extensive mitochondrial damage following ATP
depletion and calcium overload results in uncontrolled necrotic cell death.
Furthermore, if the ATP level falls below a critical threshold after initiation of
the apoptotic pathway, this is aborted and the cell dies by necrosis (Leist and
Nicotera, 1997; 1998).
Thus, mitochondria have been proposed to have a role(s) in cell death.
However, the role(s) is controversial where several aspects of mitochondrial
functions including generation of ROS, calcium overload and permeability
transition and others have been implied. This area of research has recently
been reviewed by Newmeyer and Ferguson-Miller (2003).
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1.12.3 Mitochondria As A Potential Drug Target
Due to the fact that mitochondrial damage contributes to a range of human
diseases, and because mitochondrial function is important in apoptosis, this
organelle is potentially a promising intracellular target for drug delivery. The
mitochondrial DNA is surrounded by the IMM where the electron transport
chain generates ROS and these ROS species cause significant mitochondrial
DNA damage, which is more common than nuclear DNA damage (Yakes and
Vanhouten, 1997). The lack of introns in mitochondrial DNA further increases
the probability that any mutation will be damaging to the mitochondrial DNA
and this, together with the limited capacity for repair (Singh and Maniccia-
Bozzo, 1990; Driggers et al., 1996), makes mitochondria sensitive targets. In
addition, the lack of histones makes mitochondrial DNA more susceptible to
covalent binding by alkylating agents than nuclear DNA (Allen and Coombs,
1980). Mitochondria are thought to have a large membrane potential and
lipophilic cations would therefore readily accumulate within mitochondria.
Some cancer cells have been found to have elevated mitochondrial
transmembrane potentials; therefore, if critical differences between the
mitochondrial permeability transition pore of certain cancer cells and
untransformed cells can be identified and targeted, this may provide a feasible
target to enhance tumour destruction. Improved understanding of
mitochondrial permeability transition pore agents and their functions may
therefore prove useful for treatments. Additionally, therapeutics to prevent
mitochondrial damage from free radicals, from mitochondrial DNA mutations,
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or to genetically correct mutated mitochondrial DNA could possibly be useful
in the future (reviewed by Murphy and Smith, 2000; Preston et aI., 2001).
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CHAPTER 2
MATERIALS AND GENERAL METHODS
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2.1 MATERIALS AND GENERAL METHODS
2.1.1 Anti-cancer Agents
A series of NU:UB compounds including NU:UB 31, 51, 43, 80, 81, and 150
were available in the host laboratory. Camptothecin (36,563-7, Aldrich);
Doxorubicin (86036-0, Aldrich); Etoposide (E1383, Sigma); m-AMSA (A9809,
Sigma).
The NU:UB compounds were dissolved in DMSO to make a stock solution of
10mM. From each stock, serial dilutions were made in suitable cell culture
medium, making sure that DMSO concentration in cell treatments did not
exceed 0.1%.
2.1.2a Materials For Cell Culture
RPMI 1640 (without L-glutamine), McCoy's 5a, penicillin-streptomycin, foetal
bovine serum (FBS), Hanks balanced salt solution (HBSS), trypsin,
trypsin/EDTA (prepared by diluting 10x solution in sterile saline, the resulting
1x solution stored at -20°C) all obtained from Sigma. L-glutamine 2mM
(Gibco); freezing medium (8% DMSO in FBS, filter sterilised and stored at -
20°C); HL60 cells (human Caucasian promyelocytic leukaemia cells, ECACC,
85011431); HCT116 (human colon carcinoma cells, obtained from Bradford
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University); HT29 (human colon adenocarcinoma cells, from Napier
University); inverted light microscope, Axiovert 25 (Zeiss).
2.1.2b Methods For Cell Culture
HL60 cells were grown in suspension and were kept in RPMI 1640 medium
supplemented with 2mM L-glutamine, 1% penicillin-streptomycin and 10%
heat inactivated FBS.
The HCT116 and HT29 cells were both epithelial, adherent cell lines. HCT116
and HT29 were maintained in McCoy's 5a with the addition of 2mM glutamine,
1% penicillin-streptomycin and 10% heat inactivated FBS. These cell lines
were passaged by trypsinisation.
All cell cultures were kept in a humidified incubator at 37°C with 95% air and
5% C02. The cell lines were regularly examined under an inverted light
microscope, Axiovert 25 (Zeiss).
2.1.3 Materials For Cytotoxicity Assays
Dimethyl Sulphoxide (DMSO), MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide), Nigrosin (Sigma); Dynatech MRX microplate
reader (Dynex Technologies).
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2.1.4 Materials For DNA Mobility Assays (Topoisomerase
Relaxation And Cleavage Assays)
Ethidium bromide, agarose, proteinase K, SOS, TBE buffer (10x, running
buffer) (Sigma); plasmid pBR322 ONA (BOH); topoisomerase I (Amersham);
topoisomerase 110 and topoisomerase II~ (provided by Or Caroline Austin,
University of Newcastle upon Tyne); 10x running buffer (Tris Borate 0.89M,
EOTA 0.02M); Proteinase K (5mg/ml); 10x topoisomerase I buffer (used for
topoisomerase I relaxation and cleavage assay, 100mM Tris-HCI pH 7.9,
500mM KCI, 1mM EOTA, 50mM MgClz, 150 IJg/ml BSA); 10x topoisomerase
II buffer [used for (0 and ~) relaxation and cleavage assay, 100mM Tris-HCI
pH 7.9, 500mM NaCI, 500mM KCI, 1mM EOTA, 50mM MgCIz, 150 IJg/ml
BSA, 10mM ATP]; loading buffer (SOS 5%, Bromophenol Blue 0.25mg/ml,
Glycerol 25%); mini horizontal submarine unit HE 33 (Hoefer).
2.1.5a Materials For Lysing Cells
Complete mini protease inhibitor cocktail tablets (1836170, Roche); lysing
buffer (0.5% NP40 in PBS); 1% SOS lysis buffer in PBS (Boege et al., 1996);
4M deionized urea (2.4g), 2% SOS (0.2g), 62.5mM Tris-HCI pH 6.8 (0.0985g),
1mM EOTA (3.7mg) in 10ml dHzO (Kaufman and Svingen, 1999).
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2.1.5b Methods For Lysing Cells With Protease Inhibitors
Each protease inhibitor tablet was diluted in 1.5ml PBS to make up a 10x
stock, which was aliquoted and stored at -80°C. For use, each aliquot was
diluted 1:10 in lysing buffer and put on ice. Cells were washed twice in ice
cold PBS, pelleted by centrifugation at 500 x g for 5 mins at 4°C. Cells were
immediately lysed with protease inhibitor lysing solution for 30 mins on ice,
and centrifuged at 15 000 x g for 20 mins at 4°C. Following centrifugation the
supernatants were aliquoted and either stored at -80°C until required, or
protein content determined with the bicinchoninic protein assay and samples
used immediately.
2.1.6a Materials For Bicinchoninic Acid Protein Assay
Protein (Bovine serum albumin) standard (P-014), bicinchoninic acid, copper
(II) sulphate (Sigma); BCA working reagent [copper (II) sulphate 4%(v/v)
solution was added to bicinchoninic acid solution in the ratio 1:50 immediately
prior to use].
2.1.6b Method For Bicinchoninic Acid Protein Assay
Total protein concentration in each sample was determined by the
bicinchoninic acid protein (BCA) assay according to Smith et al. (1985). A
serial doubling dilution of BSA standard 1mg/ml in PBS was prepared ranging
from 1mg/ml to 7.8J,Jg/ml. These were stored at -80°C and defrosted when
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needed. 101J1 of each sample and BSA standard were added to individual
wells on a 96 well microtitre plate and 1901J1 working reagent was added. This
was carried out in duplicate for standards and triplicates for samples. Blank
wells, containing 1901J1 of working reagent and 101J1 diluent were included in
each analysis. The plate was covered and incubated at 37°C for 30 mins,
after which the absorbance was measured at 570nm in a Oynatech MRX
microplate reader. Using blank corrected mean absorbance values over the
range of BSA standards, concentrations in the unknown samples were
determined.
2.1.7a Materials For Western Blotting And Immunostaining
PBS tablets, TEMEO, ammonium persulphate, colour markers, SOS (Sigma);
acrylamide mix 30% (BioRad); biotinylated markers (BioRad); 0.5M Tris pH
6.8 (30.4g Trizma base was dissolved in 400ml dH20, pH was adjusted to 6.8
and the volume was made up to 500ml); 1.5M Tris pH 8.8 (91.2g Trizma base
was dissolved in 400ml dH20, the pH was adjusted to 8.8 and the volume
made up to 500ml); 10% ammonium persulphate (50mg ammonium
persulphate was dissolved in 5001J1 dH20); 10% SOS (50g SOS was dissolved
in 400ml dH20 and made up to 500 ml); separating gel (see table 2.2);
stacking gel (see table 2.3); sample buffer (prepared by mixing 4.0ml dH20,
1.0ml Trizma base 0.5M pH 6.8, 0.8ml glycerol, 1.6ml SOS (10%), 0.2ml
bromophenol blue 0.05%); on 1M (1.54g on dissolved in 10ml dH20 to
make a 10x stock, stored frozen. For use, OTT was diluted 1:10 in sample
buffer); electrophoresis buffer (A 10x stock solution of electrophoresis buffer
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was prepared by dissolving 30.3g Trizma base, 144.4g glycine and 10g SDS
in dH20 , the volume was made up to 1L. For use 10x stock solution was
made up to 1x in dH20 ); transfer buffer (30.3g Trizma base and 144g glycine
was dissolved in 4l of water, 2l of methanol was added and the volume was
made up to 10l, pH 8.1-8,3, buffer stored at room temperature); blocking
buffer (Marvel non-fat milk powder 5% was dissolved in 0.05% Tween, 0.1%
NP-40 PBS solution); wash buffer (0.25% Tween, 0.1% NP-40 in PBS);
nitrocellulose Protan (SlS); enhanced chemiluminescence reagents, Eel
(Amersham Pharmacia); hyperfilm (Amersham Pharmacia); developing
solution and fixer (HA West); mighty small electrophoresis apparatus (Hoefer);
mini Trans Blot transfer apparatus (BioRad); Scotts Tapwater (potassium
hydrogen carbonate, 2g, magnesium sulphate 7-hydrate, 20g and sodium
azide, 1g were added to 1l tapwater).
% Polyacrylamide Protein size (kDa)
15 12-43
10 16-68
8 36-94
6 57-212
Table 2.1 Polyacrylamide concentration (protein separation range) in relation to protein size
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For 10ml separating gel solution the following were added (volumes in ml):
6% 8% 10% 12% 15%
dH20 5.3 4.6 4.0 3.3 2.3
30% acrylamide mix 2.0 2.7 3.3 4.0 5.0
1.5M Tris (pH 8.8) 2.5 2.5 2.5 2.5 2.5
10% SOS 0.1 0.1 0.1 0.1 0.1
10% APS 0.1 0.1 0.1 0.1 0.1
TEMEO 0.008 0.006 0.004 0.004 0.004
Table 2.2 Components for the making of SDS-polyacrylamlde separating gel solutions
APS and TEMED were added to the separating gel solution immediately prior
to the gel being made up.
For 10ml stacking gel solution the following were added (volumes in ml):
dH20 6.8
30% acrylamide mix 1.7
0.5M Tris (pH 6.8) 1.25
10% SOS 0.1
10% APS 0.1
TEMEO 0.01
Table 2.3 Components for the making of SDS-polyacrylamide stacking gel solutions
APS and TEMED were added to the stacking gel solution immediately prior to
the gel being made up.
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2.1.7b Antibodies And Probes
Human polyclonal anti-topo I antibody (2012, 1:10 000 dilution) from
TopoGEN; monoclonal anti-topo 110 (1 :75 dilution); monoclonal anti-topo 1113
antibody (1:100 dilution), monoclonal anti-p53 antibody (NCLp53D01, 1:1000
dilution), vectastain ABC mouse IgG (PK6102) all from Novo Castra;
monoclonal anti-WAF1 (p21) antibody (Ab-4, OP76, 1:100 dilution) Oncogene
Research Products; monoclonal anti-mdm2 antibody (Sc965, 1:500 dilution),
monoclonal anti-caspase-3 antibody (Sc7272, 1:200 dilution) from Santa Cruz
(Autogen Bioclear); DAB (SK-41 00, Vector); biotinylated anti-mouse IgG
(1 :250 dilution), biotinylated anti-human IgG (1 :250 dilution), streptavidin
horseradish peroxidase (1 :250 dilution) were purchased from Amersham
Pharmacia; lysoTracker green DND-26 (L-7526, Molecular Probes);
MitoTracker green FM (M-7514, Molecular Probes).
2.1.7c Methods For Western Blotting
SDS-polyacrylamide gels were prepared with a separating gel of the
appropriate concentration and a 10 well stacking gel. The separating gel was
allowed to polymerise for 1h before adding the stacking gel, which was
polymerised for at least 30 mins at room temperature. The use of a stacking
gel, which is of low acrylamide concentration, allows relatively large samples
to be concentrated before reaching the separating gel, increasing resolution of
the bands. The samples were diluted in sample buffer so that the total volume
(301-'1 sample + buffer) contained 30l-'g of total protein. Each sample was then
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boiled for 3 mins and immediately cooled on ice. Molecular weight markers
(rainbow markers and biotinylated markers), in sample buffer (total volume of
301J1) were also included on each gel and were treated in the same way as the
samples. The proteins in each sample and markers were separated at 40mA
for approximately 40 mins on an electrophoresis apparatus until the blue dye
front reached the bottom of the gel. The proteins were transferred onto
membranes for 1h at 1OOV with cooling using a transfer apparatus.
Membranes were immersed in blocking buffer for 1h at room temperature with
shaking or left in the fridge overnight. The immunostaining was performed at
constant shaking. Membranes were stained with primary antibody for 1-2h at
room temperature. Residues were washed off by wash buffer 2 x 5 mins and
the primary antibodies were bound by secondary biotinylated antibody for 30
mins. Membranes were washed 2 x 5 mins and Streptavidin horseradish
peroxidase was added to the membranes for 30 mins. After the final washing
steps (2 x 5 mins wash buffer, 1 x 5 mins PBS), the membranes were
incubated in Eel according to the manufacturer's instructions and the
topoisomerase proteins visualised on Hyperfilm.
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2.1.7d Dot Blot Assay For Determining The Primary Antibody
Concentration To Be Used In The Western Blotting Experiments
Nitrocellulose membrane was cut into pieces. Sample, 21J1 at the protein
concentration to be used in the Western blot experiment was blotted onto the
membrane pieces in duplicate. The membranes were air dried and blocked in
marvel solution. The primary antibody was diluted in blocking buffer in a range
of concentrations (1/10 000, .... 1/100). Each membrane was labelled with one
of these concentrations, and was then immersed in corresponding primary
antibody concentration. The blotted membranes were incubated with primary
antibody for 1h. Primary antibody residues were washed off with wash buffer
(2 x 5 mins) and the membranes were incubated for 30 mins with the
secondary biotinylated antibody at the concentration to be used in Western
blot experiments. Following washing the membranes (2 x 5 mins), these were
incubated 30 mins in streptavidin horseradish peroxidase. The membranes
were finally washed in wash buffer (2 x 5 mins), and in PBS (1 x 5 mins), and
a photograph was taken using the ECl technique.
2.1.7e Stripping Solution For Western Blot Membranes
Glycine, 1.5g (0.2M) and SDS, 1g (1 %) were dissolved in 100ml dH20 . HCI
was used to adjust the pH to 2.5. To strip the Western blot membranes from
antibodies, the membranes were soaked in stripping solution for 45 mins, on a
shaker, at room temperature. After this the strip solution was poured off and
membranes were washed in wash buffer 2 x 5 mins. Membranes could then
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be re-used immediately, or were wrapped in cling film and foil, and stored in
air-tight containers kept in the fridge.
2.1.8 Materials For Apoptotic Investigations
ApoTarget Quick Apoptotic DNA ladder detection kit (KH01 021, BioSource);
RAPI-DIFF stain pack for rapid Romanowsky staining (Raymond A Lamb
Limited); CaspaTag™Fluorescein Caspase Assay kit (VA0 , S7300, Intergen);
CaspaTag™Fluorescein Caspase-3 Assay kit (DEVD, S7301, Intergen);
MitoCapture kit (K250-25-100, BioVision); Sorensens buffered water (KH2P04
9.1 gIL (solution A) and NaHP04 9.5g/L (solution B) were made up separately.
To make a 10x buffer, 50.8ml of solution A was mixed with 49.2ml of solution
B. 1x Sorensens buffered water was obtained by adding 50ml stock to 950ml
dH20).
2.1.9 Equipment
Fluorescence spectrophotometer (Perkin Elmer LF50B); mini horizontal
submarine unit HE 33 (Hoefer); SynGene Digital Imager (SynGene); mighty
small electrophoresis apparatus (Hoefer); Dynatech MRX microplate reader
(Dynex Technologies); mini Trans Blot transfer apparatus (BioRad); Cytospin3
(Shandon); light microscope, Axioskop (Zeiss); inverted light microscope,
Axiovert 25 (Zeiss); FACSCalibur flow cytometer, equipped with a 15mW
argon-ion air-cooled laser with excitation wavelength 488nm (Becton
Dickinson Immunocytometry Systems, BOIS); UV fluorescent microscope,
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fitted with JVC colour video camera (KY-F55B) (Leica DMRB); Confocal
microscope(NikonEclipseTE2000-U).
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CHAPTER 3
ANTI-TOPOISOMERASE ACTIVITY
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3.1 ANTI-TOPOISOMERASE ACTIVITY
Rational drug design typically starts with a molecule that has some degree of
pharmacological activity, perhaps a lead compound, or less commonly a
biochemical target, usually an enzyme or receptor with known molecular
architecture. The chemistry of the lead molecule is then optimised to fit a
potential target (e.g. the topoisomerase-DNA cleavable complex), whilst
retaining the pharmacological potential of the molecule (Monks et aI., 1997).
The NU:UB agents were rationally designed to selectively target DNA
topoisomerase enzymes; the anti-topoisomerase activities of these
compounds have been investigated in this research programme and
presented within this chapter. The focus was put on the lead compound
NU:UB 31, to determine whether or not it bound to DNA and whether or not it
interfered with the DNA cleavage and relaxation activities of topoisomerase
enzymes in vitro. Although the focus has been on NU:UB 31, other NU:UB
compounds have also been included in some of the assays. The
topoisomerase I and topoisomerase II poisons camptothecin and etoposide
(respectively) have further been included for comparison.
NU:UB31
As tumour cells in many cases are highly proliferative cells and
topoisomerases are involved in the processes of DNA metabolism, the levels
84
and activities of these types of enzymes are often increased in proliferating
tumour cells compared to normal cells. If topoisomerases in tumour cells
could be inhibited, then unwinding, strand separation and reproduction of
DNA would be prevented. With the discovery that several, currently used
chemotherapeutics act on topoisomerases, these enzymes have become
popular and validated targets for therapeutic intervention. The increased
topoisomerase levels found in many tumours would then provide some
degree of tumour cell specificity for these topoisomerase-targeting agents that
should hopefully limit the side effects. Drugs can work as anti-topoisomerase
agents mainly by two mechanisms. They can act as pure catalytic inhibitors of
topoisomerases or as topoisomerase poisons. Pure topoisomerase inhibitors
either bind to topoisomerases directly or bind to DNA, changing its structure
so that it can no longer be recognised by the topoisomerases. Drugs trapping
topoisomerases in what is referred to as cleavable complexes are called
topoisomerase poisons. Topoisomerase poisons do not inhibit the catalytic
activity of these enzymes, but instead take advantage of the DNA cleavage by
topoisomerases, increasing the concentration of the ternary drug-stabilised
cleavable complexes to levels which a cell can no longer tolerate. Agents that
are able to form stable, relatively long-lived complexes with DNA and
topoisomerase may confer yet improved cytotoxicity.
The ability of the NU:UB compounds to inhibit topoisomerase enzymes, and
possibly form cleavable complexes was investigated. We chose to study drug
inhibition of topoisomerase I and topoisomerase II-mediated DNA relaxation
using a supercoiled (pBR322) plasmid DNA. NU:UB compounds were also
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found to stabilize topoisomerase-DNA cleavable complexes in cell free assays
using plasmid DNA with purified enzymes. Furthermore, we wanted to find out
whether or not NU:UB compounds were able to form such cleavable
complexes in living cells, which we achieved using topoisomerase
immunoband depletion assays after incubation of intact tumour cells with a
given drug. The topoisomerase inhibition and cleavable complex formation
investigations were performed using DNA gel mobility assays, on agarose
gels for the relaxation experiments (Keller, 1975) and cleavable complex
formation assays (Boege et al. 1996), and on SDS polyacrylamide gels
according to Boege et al. (1996) for the topoisomerase immunoband depletion
investigations. The principle of these techniques relies on the fact that
compact nucleic acid structures move faster through a gel than more open
conformations. Thus, supercoiled DNA generally migrates faster through an
agarose gel compared to DNA with a more open and relaxed conformation.
Topoisomerase (lor II) protein moves more readily through a SDS
polyacrylamide gel compared to topoisomerase that has been trapped by drug
(topoisomerase poison) in a ternary DNA-topoisomerase-drug cleavable
complex forming the basis of the immunoband depletion assay. Hence, the
topoisomerase relaxation assay provided an indication of whether or not
compounds were pure catalytic topoisomerase inhibitors, binding directly to
topoisomerase (or DNA) preventing topoisomerase from relaxing the
supercoiled plasmid DNA. The topoisomerase immunoband depletion assays
like the topoisomerase cleavage assay provided information on whether or not
compounds acted as topoisomerase poisons, by the mechanism of stabilising
cleavable complexes with DNA and topoisomerases in the cell.
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3.2 METHODS
3.2.1 DNA Binding Mode Of NU:UB 31 In Relation To The
Comparative Intercalator, Mitoxantrone And The Minor
Groove binder, Netropsin
The displacement of known DNA binders was detected by measuring the
fluorescence of a fluorescent DNA-bound reporter molecule complex. The
reporter molecules, ethidium bromide and Hoechst dye 33258 strongly
intercalate or bind to the minor groove of DNA respectively. Stock solutions of
these dyes were prepared at 601JM, reaching a final concentration of 2IJM
once added to the 3ml standard quartz cuvette. For this assay calf thymus
DNA (molar extinction coefficient 6600, 260nm) was used. A DNA solution at
20IJM was prepared in buffer (10mM Tris-HCI, pH7.5) and water was added to
the assay to make up a total volume of 3m!. Once ethidium bromide or
Hoechst stain had been added, the fluorescence of the DNA-bound complex
was measured using a fluorescence spectrometer (Perkin Elmer LF50B) and
recorded as the maximum fluorescence for ethidium bromide (E) or Hoechst
dye (H).
In this study, the DNA binding characteristics of NU:UB 31 were related to
mitoxantrone and netropsin using these as comparator molecules for
intercalation and groove-binding, respectively. The methods used were
essentially adaptations of the procedures according to Bailly et al. (1989).
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Each test compound was prepared for assay by making up a stock solution of
60IJM concentration. Subsequent dilutions were made to obtain a range of
concentrations for the total volume of 3ml to be analysed using a standard
cuvette in the spectrometer. The addition of NU:UB 31 or comparator drug to
the DNA-dye (ethidium bromide or Hoechst stain) solution displaced the dye
depending on the strength and mode of DNA binding (intercalation or groove
binding) and thus reduced the fluorescence accordingly of the fluorescent
DNA-bound dye complex.
3.2.1a Treatment Of Results
The mode of DNA binding by NU:UB 31 (or comparative agent) was
quantified by determining the reduction in fluorescence of the reporter
fluorophore upon treatment with a given concentration of the analysed
compound. A competitive displacement graph for each drug (mitoxantrone,
netropsin and NU:UB 31) with each dye was plotted from the mean
fluorescence intensity values at each drug concentration of 3 separate
experiments ± SO. The measure of the ability to bind to DNA was then
expressed as Q50 values: the concentration required to reduce the
fluorescence intensity of the DNA-bound ethidium bromide (QE50) or Hoechst
stain (QH50) complexes by 50%.
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3.2.2 Topoisomerase I And Topoisomerase II (a And (3)
Relaxation Assays
Stock solution, 100IJM and 1000IJM of NU:UB compound was made up in
DMSO/dH20 . Plasmid pBR322 DNA, was diluted in dH20 to 40ng/1l1. To make
up a total volume of 201J1, buffer, DNA, dH20 and compound solution were
added to eppendorf tubes as follows.
DNA Topoisomerase 10flM 25flM 50flM
Control Control Compound Compound Compound
Buffer (lor II) 2 2 2 2 2
DNA 10 10 10 10 10
dH20 8 7.8 5.8 2.8 6.8
Topoisomerase - 0.2 0.2 0.2 0.2
(I, 110 or liP)
Table 3.1 Topoisornerase I and II relaxation assay components (volumes In Ill)
Finally, topoisomerase I (2 units) was added and the contents of the tubes
were mixed. Samples were incubated for 30 mins in a waterbath at 37°C. The
reaction was terminated by addition of 4111 loading buffer. The plasmid
samples were separated on an agarose gel (0.8%) by 1 x TBE at 50V for 2h,
or overnight at 16V. DNA was stained in ethidium bromide (1Ilg/ml in 1 x TBE)
for 1h and was then destained in dH20 water for another hour to reduce
background fluorescence. The gel was viewed in UV light and photographed.
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The topoisomerase II relaxation assay protocol was the same as the above
topoisomerase I relaxation assay protocol, but the topoisomerase I buffer was
exchanged for the topoisomerase II buffer and topoisomerase II (0 or ~, 2
units) replaced topoisomerase I.
3.2.3 Topoisomerase I and Topoisomerase II (0 And J3)
Cleavage Assays
NU:UB compound stock solutions were prepared. Plasmid pBR322 DNA was
prepared at 40nghtl. Buffer, DNA, dH20 and compound were added to an
eppendorf as depicted in Table 3.2.
DNA Topoisomerase 10~M 50~M 100~M
Control Control Compound Compound Compound
Buffer (lor II) 2 2 2 2 2
DNA 10 10 10 10 10
dH20 8 4 2 3 2
Compound - - 2 (at 100IJM) 1 (at 1000IJM) 2 (at 1000IJM)
Topoisomerase - 4 4 4 4
(I, 110 or 11(3)
Table 3.2 Topoisomerase I and II cleavage assay components (volumes in ~I)
Topoisomerase I (50 units) was added and samples were left in a waterbath
at 37°C for 45mins. SDS (10%), (2.2~I) was added and samples left for 30
sec. Proteinase K (5mg/ml), (2.4IJI) was added and the samples were
incubated in the waterbath, at 37°C for 1h. Loading buffer, 4~1 was added to
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each sample. Samples were loaded onto an agarose gel (0.8%). The gel was
electrophoresed in 1 x TBE buffer with ethidium bromide, 0.5IJg/ml at 50V for
2h or overnight at 16V. The gel was de-stained in dH20 for 1h in darkness,
viewed in UV light and photographed.
The topoisomerase II (0 and ~) cleavage assay was performed by a similar
procedure to the topoisomerase I cleavage assay. The topoisomerase II
buffer was used and suitable topoisomerase II enzyme. Furthermore,
following the addition of SDS, the tubes were left for 30 seconds followed by
the addition of 1.51J1 of 250mM Na2EDTA. Proteinase K, 21J1 was then added
at 0.8mg/ml and the tubes were incubated for 1h at 45° C. Loading buffer, 4~1
was added to each sample to terminate the reaction. The samples were then
separated on an agarose gel as described above. The electrophoresis was
performed in the absence of ethidium bromide and, under these conditions,
evidence of cleavable complex formation was detected by the formation of a
band of linear DNA that has previously been shown to run between the
supercoiled plasmid and the retarded nickedlrelaxed DNA bands. The
methods were adapted from Austin et a/. (1995).
3.2.4 Topoisomerase I and IIlmmunoband Depletion Assays
The samples were lysed under denaturing conditions without being washed to
prevent reversion of the cleavable complexes formed. Therefore, to avoid
contamination with serum proteins from the culture medium, cells were
resuspended in serum-free medium prior to the start of the assay. HL60 cells
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were recovered from culture, washed and resuspended in FBS free, RPMI
1640 HEPES medium at a density of 20 x 104 cells/ml. Cells were untreated
(solvent only), or treated with NU:UB compounds, or standard drugs. The
topoisomerase immunoband depletion assay requires the formation of large
numbers of topoisomerase-ONA complexes to produce band depletion,
whereas cytotoxicity can result from a small number of cleavable complexes
being converted into permanent cytotoxic lesions. Thus for these assays, high
drug concentrations, 100-1OOO-foid higher than those used to produce
cytotoxicity have been suggested. Camptothecin was recommended to be
used at 50~M, and etoposide at up to 700~M was reported to partially deplete
topoisomerase II (0 and ~). The drug incubation time suggested for
topoisomerase immunoband depletion assays was 30-60 mins (Kaufman and
Svingen, 1999), but longer incubation times have been used. Boege et al.
(1996) used a 2h incubation time in their topoisomerase I depletion study of
f1avones. In our assays NU:UB compounds were used over a concentration
range of 50~M, 1OO~M, 200~M, 300~M and up to 400~M. As a positive
topoisomerase I depletion control camptothecin was used at 50~M. Etoposide
was used at 100-700~M. Cells were treated with agents for 45 mins.
Following this exposure time, cells were counted, cell density adjusted to 1 x
106 cells/ml and the samples were then pelleted by centrifugation at 500 x g
for 5 mins at 4°C. To prevent lysosomal proteases from degrading the
topoisomerase enzymes, cell lysis was performed rapidly. The cells were
lysed in a SOS containing buffer according to Boege et al. (1996). Further
improvements to the topoisomerase immunoband depletion assay and the
sample preparation for this assay have been suggested by Kaufman and
92
Svingen (1999). Lysate samples were aliquoted and used immediately, or
stored at -80°C until analysis could be performed.
The lysate samples were loaded onto a SOS polyacrylamide gel and the
proteins separated by electrophoresis. When large proteins, such as
topoisomerase 110 and topoisomerase II~ were transferred, a greater transfer
was achieved by the addition of SOS (0.02%) to the transfer buffer. Western
blotting using human anti-human topoisomerase I antibody, mouse
monoclonal anti-topoisomerase lIa or mouse monoclonal anti-topoisomerase
II~ were performed and topoisomerase bands photographed and identified.
For the detailed Western blot protocol see materials and general methods
section in Chapter 2.
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3.3 RESULTS
3.3.1 DNA Binding Mode Of NU:UB 31 In Relation To
Comparative Drugs (Mitoxantrone And Netropsin)
DNA interacting studies were performed using calf thymus DNA. Mitoxantrone
is a molecule which is known to be a good intercalator, and NU:UB 31 was
therefore compared to mitoxantrone in order to determine if it was a DNA
intercalating compound. Fig. 3.1a shows mitoxantrone displacement of
ethidium bromide. The ethidium bromide fluorescence decreased with
increased mitoxantrone concentration. Mitoxantrone had a QEso value of
approximately 0.5~M, which is the concentration where ethidium bromide
fluorescence had dropped 50%. Netropsin is a potent minor groove binder
and for this reason, netropsin was used as a comparator compound. NU:UB
31 was compared to netropsin, in order to determine if it was able to bind
to DNA by a groove-binding mechanism. Fig. 3.1b displays Hoechst dye
fluorescence versus netropsin concentration. Netropsin had a QHso value
of 0.67~M. The same measurements were performed with NU:UB 31,
replacing mitoxantrone and netropsin. Fig 3.1c and Fig. 3.1 d shows
ethidium bromide fluorescence against NU:UB 31 concentration and
Hoechst dye against NU:UB 31 concentration respectively. NU:UB 31 gave
a QEso value of 0.791JM and a QHso value of 0.42IJM. The QEso and QHso
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values of mitoxantrone, netropsin and NU:UB 31 have been summarised in
Table 3.3.
3.3.2 Topoisomerase Relaxation Assays
3.3.2a Topoisomerase I Relaxation Assays
These experiments assessed the capacity of NU:UB compounds to inhibit
topoisomerase I-mediated relaxation of DNA. When the plasmid DNA was
treated with topoisomerase I enzyme, supercoils were removed, resulting in a
more relaxed (conformationally flexible) structure, which was retarded on the
gel compared to the supercoiled DNA. Fig. 3.2a shows a relaxation assay of
plasmid by NU:UB 31. In lane 1 (DNA) the main band is the supercoiled
plasmid DNA. In lane 2 (DNA + topoisomerase I) relaxed DNA bands
appeared, and the supercoiled DNA band disappeared. This meant that
topoisomerase I had converted the previously supercoiled DNA into relaxed
topoisomers, which were retarded to various degrees on the agarose gel.
Treatment with 10IJM or 25IJM NU:UB 31 resulted in partial inhibition of the
topoisomerase I mediated DNA relaxation (lane 3 and 4). At a concentration
of 50IJM NU:UB 31, complete inhibition of topoisomerase I-mediated
relaxation was observed (lane 5). Relaxation assays of the close analogues
NU:UB 80 and NU:UB 81 can be seen in Fig. 3.2b and Fig. 3.2c. The
topoisomerase I relaxation assay results have been summarised in table 3.3
(p109), and suggest that NU:UB 31 and to some degree NU:UB 80 inhibited
topoisomerase I mediated DNA relaxation, possibly by binding directly to
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topoisomerase I, or to DNA changing the conformation of DNA so that it is no
longer recognised (nor consequently cut) by topoisomerase I. The latter is a
more likely process since NU:UB 31 has been shown to bind to DNA. In
contrast, NU:UB 81 did not appear to inhibit topoisomerase I mediated DNA
relaxation despite having a broadly similar chromophore (cationically-charged
and hydrophobic) and comparable antitumour potency and selectivity (anti-
melanoma and colon sub-panel selectivity) in the cytotoxicity data from NCI
(see Appendix 2).
3.3.2b Topoisomerase II Relaxation Assays
In an analogous manner to the action of topoisomerase I, the individual
isoforms (a and P) of human topoisomerase II are capable of converting
supercoiled plasmid DNA into relaxed topoisomers. Inhibition of
topoisomerase lIa or topoisomerase II~ mediated relaxation of supercoiled
plasmid DNA was investigated following NU:UB 31 treatments. Fig 3.3 is
representative of the topoisomerase lIa relaxation assays of plasmid DNA by
NU:UB 31. A NU:UB 31 concentration of 1O~M was sufficient to partially
inhibit topoisomerase lIa-mediated DNA relaxation (lane 5). At the higher
concentrations 25~M and 50~M, complete inhibition of topoisomerase lIa was
evident (lane 6-7). Similarly to topoisomerase lIa, inhibition of topoisomerase
II~-mediated DNA relaxation was also observed following 10~M NU:UB 31
treatment (lane 4), with the higher NU:UB 31 concentrations resulting in
complete inhibition (lane 5-7) of topoisomerase II~ catalytic activity (Fig. 3.4).
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3.3.3 Topoisomerase Cleavage Assays
3.3.3a Topoisomerase I Cleavage Assays
The formation of drug-stabilised topoisomerase I-DNA cleavable complexes
were investigated with the topoisomerase I cleavage assay. Fig 3.5 shows a
topoisomerase I cleavage assay of NU:UB 31 using camptothecin as a
positive control. Upon visualisation supercoiled plasmid DNA appeared as
one band, travelling far down the gel due to its compact size (lane 1). For this
assay more topoisomerase was used than in the relaxation assay in order to
induce a high degree of cleavable complex formation. In contrast to relaxation
gels, the conditions for running the DNA gels under cleavage conditions
required the use of ethidium bromide in the gel matrix in addition to the
running buffer; in this way, the fully relaxed plasmid topoisomers migrated as
a single band ahead of the supercoiled band, thereby allowing resolution of
the retarded nicked plasmid from relaxed forms. Topoisomerase I-DNA
complexes are trapped and stabilized by anti-topoisomerase drugs, including
the anti-topoisomerase I standard agent camptothecin. Treatment with
camptothecin resulted in increased levels of cleavable complex formation,
resulting in open-circular (or nicked) DNA plasmids that were severely
retarded on the gel (lane 3). The cleavage induced by camptothecin and
NU:UB were observed as an increase in the intensity of the open-circular
band compared to the background cleavage with topoisomerase I treated
DNA. At low concentrations (O.1IJM, 1IJM, 5IJM and 101JM) NU:UB 31 showed
stimulation of topoisomerase I induced cleavage, whereas the high
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concentration (100JJM) NU:UB 31 appeared to antagonise its own cleavage
reaction (self-inhibition). In contrast to camptothecin (lane 3, apparently
complete disappearance of supercoiled plasmid), only partial cleavable
complex formation by NU:UB 31 was produced at a concentration of 5f.!M.
Nevertheless, the cleavage assay results indicated that NU:UB compounds,
like camptothecin, to some degree stabilise ternary topoisomerase I-DNA-
drug complexes in cell-free in vitro systems.
3.3.3b Topoisomerase II Cleavage Assays
The ability of NU:UB 31 to stabilise DNA-topoisomerase cleavable complexes
was investigated by comparision of the individual isoforms of (recombinant)
human topoisomerase II, with the topoisomerase II poison, m-AMSA. A range
of experiments was performed to find the optimum levels of cleavage by the
test and comparator compound; a representative gel is shown in Fig. 3.6.
When the enzymes were used at levels of 50 units (considerably higher than
those required to effect relaxation), m-AMSA at 100JJM gave largely nicked
plasmid (lane 1); a concentration of 50JJM was found to reproducibly induce
the formation of a band corresponding to linear DNA (shown in lane 2).
Comparable levels of linear DNA formation were obtained with the P-isoform
at the same concentration (data not shown); earlier studies (Marsh et a/.,
1996) had demonstrated that m-AMSA promoted drug-stabilised cleavable
complex formation equally well with P and a-isoforms of topoisomerase II.
NU:UB 31, at an optimal concentration of 25JJM, produced comparable linear
DNA band formation to m-AMSA at 50JJM with each of the a- and P-isoforms
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of topoisomerase II (Fig. 3.6, lane 3 and Fig. 3.7, lane 4), representing drug-
stabilised cleavable complex formation compared to drug-free enzyme-only
controls wherein supercoiled plasmid was notably converted to some of the
nicked form at the high concentrations of enzyme used.
3.3.4 Topoisomerase Immunoband Depletion Assays
3.3.4a Topoisomerase I Immunoband Depletion Assays
The inhibition of the religation step during the processing of DNA
topoisomerases is believed to be the molecular basis of the anti-tumour
activity of topoisomerase I poisons including camptothecin and its derivatives
irinotecan (CPT 11) and topotecan. Inhibition of religation can be detected in
drug treated cells by immunoband depletion assays. Whereas topoisomerase
will migrate at the molecular weight of the topoisomerase molecule on SDS-
polyacrylamide gels, the covalent topoisomerase-DNA complexes are larger
in size and will exhibit a lower mobility. In untreated cells, there are few and
probably short-lived covalent topoisomerase-DNA complexes. Drug treatment
of cells may however increase the number of covalent topoisomerase-DNA
complexes. Thus, the degree of topoisomerase I immunoband depletion will
reflect the drugs' capacity to stabilise topoisomerase I-DNA cleavable
complexes by depleting the Western blot topoisomerase I signal. HL60 cells
were treated with 501JM, 100IJM, 200IJM and 300IJM NU:UB compound for 45
mins. In the topoisomerase I band depletion assay, 50IJM camptothecin
treatment resulted in a weaker topoisomerase I signal because the
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topoisomerase I enzymes became covalently trapped by the drug. The NU:UB
compounds, except NU:UB 80 and NU:UB 81 (Fig. 3.8b) also induced
topoisomerase I immunoband depletion, albeit at higher concentrations than
were used for camptothecin. The topoisomerase I signal was not depleted by
50IJM of any of the NU:UB compounds. For NU:UB 31, the topoisomerase I
band intensity was notably diminished at 100IJM (Fig. 3.8a). Treatment with
the more hydrophobic and conformationally restricted analogue NU:UB 150 at
200IJM also resulted in partial depletion of the topoisomerase I bands (Fig.
3.8c). The topoisomerase I immunoband depletion results have been
summarised in Table 3.4.
3.3.4b Topoisomerase II Immunoband Depletion Assays
To investigate whether or not NU:UB compounds bind and form cleavable
topoisomerase II complexes in HL60 cells, topoisomerase II immunoband
depletion assays were performed using isoform-specific antibodies. The
topoisomerase II depletion assays used the same principle as the above
topoisomerase I depletion assay. The electrophoretic properties of the human
topoisomerase lIa and topoisomerase liP, migrating as proteins of 170kOa
and 180kOa respectively on SOS-polyacrylamide gels were studied. The
degree of topoisomerase II (a and/or P) immunoband depletion reflects the
capacity of the NU:UB compound to stabilise cleavable complexes with DNA
and topoisomerase ll« and/or topoisomerase liP, trapping the proteins and
thus decreasing the topoisomerase II (a and/or P) Western blot signal. HL60
cells were treated with NU:UB 31. Following 200IJM, no band depletion was
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observed but the topoisomerase lIa signal was weakened at 300lJM (Fig.
3.9a). At 200lJM partial depletion of the topoisomerase II~ signal was evident
when compared to the control (Table 3.4, p110). The signal was also depleted
following 300lJM and 400lJM NU:UB 31 treatment (Fig. 3.9b). It has to be
noted that problems were encountered in getting the positive etoposide
control to work in these assays. However, using camptothecin (topoisomerase
I poison) as a negative control it was confirmed that camptothecin did not, as
expected, deplete the topoisomerase II signal.
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Fig. 3.1 Graphs of DNA/binder fluorescence versus drug concentration reflecting the DNA
intercalating capacity of mitoxantrone (a), minor groove binding capacity of netropsin (b) and the
intercalation and groove binding capacities of NU:UB 31 (c and d). QE50 and QH50 representing
the concentration of compound that has displaced 50% of fluorescence of ethidium bromide and
Hoechst stain respectively, The graphs represents mean intensity ± SD where n=3,
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Fig. 3.2a Topoisomerase I relaxation assay of NU:UB 31. DNA (lane 1), DNA +
Topoisomerase I (lane 2), DNA + Topoisomerase I + NU:UB 31 at 101JM, 25IJM
and 50IJM (lane 3, 4 and 5). Fig. is representative of a series of separate
experiments.
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Fig. 3.2b Representative figure of the NU:UB 80 topoisomerase I relaxation
assay. DNA (lane 1), DNA + topoisomerase I (lane 2), DNA + topoisomerase I +
NU:UB 80 at 51JM, 101JM, 251JM, 50IJM and 100IJM (lane 3-7).
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Fig. 3.2c Representative figure of the NU:UB 81 topoisomerase I relaxation
assay. DNA (lane 1), DNA + topoisomerase I (lane 2), DNA + topoisomerase I
+ NU :UB 81 at 51JM, 101JM, 25IJM and 50IJM (lane 3-6).
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Fig. 3.3 Topoisomerase lin relaxation assay of NU:UB 31. DNA (lane 1), DNA + topoisomerase
lin (lane 2), DNA + topo isomerase lin + NU:UB 31 at 1IJM, 5IJM, 10IJM, 25IJM and 50IJM (lane
3-7) , DNA + NU:UB 31 at 50IJM (lane 8). The figure is representative of a series of separate
experiments.
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Fig. 3.4 Topoisomerase II~ relaxation assay of NU:UB 31. DNA (lane 1), DNA + topoisomerase
II~ (lane 2), DNA + topoisomerase II~ + NU:UB 31 at 5IJM, 10IJM, 15IJM, 20IJM and 50IJM (lane
3-7). The figure is representative of a series of separate experiments.
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Fig. 3.5 Topoisomerase I cleavage assay of NU:UB 31. DNA (lane 1), DNA +
topoisomerase I (lane 2), DNA + topoisomerase I + camptothecin 10IJM (lane 3), DNA +
topoisomerase I + NU:UB 31, O.1IJM, 1IJM, 51JM, 10IJM and 100IJM (lane 4-8). The figure is
representative of a series of separate experiments.
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Fig. 3.6 Topoisomerase llu cleavage assay of NU:UB 31. DNA + m-AMSA (100IlM) +
topoisomerase llo (lane 1), DNA + m-AMSA (50IlM) + topoisomerase llu (lane 2), DNA +
NU:UB 31 (25IlM) + topoisomerase llu (lane 3), DNA (lane 4), relaxed DNA (lane 5), DNA +
topoisomerase lln (lane 6). The figure is representative of a series of separate experiments.
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Fig. 3.7 Topo isomerase liP cleavage assay of NU:UB 31. DNA (lane 1), relaxed DNA (lane
2), DNA + topoisomerase liP (lane 3), DNA + NU:UB 31 (25IlM) + topoisomerase liP (lane
4), DNA + mAMSA (100IlM) + topoisomerase liP (lane 5). The figure is representative of a
series of separate experiments.
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Fig. 3.8a Topoisomerase I immunodepletion assay of NU:UB 31 and NU:UB 51.
Camptothecin 5011M (lane 1), Biotinylated marker (lane 2), empty (lane 3). NU:UB 51
300llM (lane 4). NU:UB 51 20011M (lane 5). NU:UB 31 300llM (lane 6), NU:UB 31
100llM (lane 7). solvent control (lane 8). The figure is representative 0 f a series of
separate experiments.
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Fig. 3.8b Topoisomerase I immunodepletion assay of NU:UB 81 - No topoisomerase I
immunoband depletion. Camptothecin 5011M (lane 1). solvent control (lane 2), NU:UB 81
300llM (lane 3). NU:UB 81 20011M (lane 4). NU:UB 81 100llM (lane 5), NU:UB 81 50llM
(lane 6). empty (lane 7), solvent control (lane 8). The figure is representative of a series
of separate experiments.
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Fig. 3.8e Topoisomerase I immunodepletion assay of NU:UB 150. Camptothecin 50llM
(lane 1). Camptothecin 50llM (lane 2). N U:UB 1 503 0011M (lane 3). N U:UB 1 502 OOIlM
(lane 4). NU:UB 150 100llM (lane 5), NU:UB 150 50llM (lane 6). solvent control (lane 7).
control (lane 8). The figure is representative of a series of separate experiments.
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Fig. 3.9a Topoisomerase llo immunoband depletion assay of NU:UB 31. Solvent
control (lane1), Etoposide 500llM (lane 2), NU:UB 31 200llM (lane 3), NU:UB 31
300llM (lane 4), solvent control (lane 5), Etoposide 500llM (lane 6). The figure is
representative of a series of separate experiments.
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Fig. 3.9b Topoisomerase II~ immunoband depletion assay of NU:UB 31. Solvent
control (lane 1), Camptothecin 50llM (lane 2), NU:UB 31 200llM (lane 3), NU:UB 31
300llM (lane 4), Etoposide 700llM (lane 5). The figure is representative of a series
of separate experiments.
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Treatment Type Of Assay
DNA Binding Assay
Mitoxantrone QEso value - 0.5OIJM
Netropsin QHso value - 0.671JM
NU:UB 31 QEso value - 0.791JM
NU:UB 31 QHso value - 0.421JM
Topoisomerase I Relaxation
NU:UB 31 Partial at 10-251JM, Complete at 50IJM
NU:UB 80 Partial at 25IJM (n=2)
NU:UB 81 No inhibition
Topoisomerase 110 Relaxation
NU:UB 31 Partial at 10IJM, Complete at 25IJM
Topoisomerase 1113 Relaxation
NU:UB 31 Partial at 101JM, Complete at 15IJM
Topoisomerase I Cleavage
NU:UB 31 Optimum at 5IJM
Topoisomerase 110 Cleavage
NU:UB 31 Optimum at 25IJM
Topoisomerase 1113 Cleavage
NU:UB 31 Optimum at 25IJM
Table 3.3 Summary of DNA binding, topoisomerase relaxation and topoisomerase cleavage
assay results. Concentration of mitoxantrone, netropsin and NU:UB 31 where ethidium
bromide (QEso) and Hoechst dye (QHso) fluorescence have diminished by 50%.
Concentrations at which NU:UB compounds inhibited topoisomerase I or topoisomerase 11-
mediated DNA relaxation or cleavage. Results were obtained from 3 or more separate
experiments if not otherwise stated.
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Treatment Type Of Assay
Topoisomerase I Immunoband Depletion
NU:UB 31 100IJM
NU:UB 43 200IJM
NU:UB 51 200IJM
NU:UB 80 No depletion
NU:UB 81 No depletion (n=2)
NU:UB 150 200IJM (n=2)
Camptothecin 50IJM
Topoisomerase 110 Immunoband Depletion
NU:UB 31 300IJM
Topoisomerase liP Immunoband Depletion
NU:UB 31 200IJM
Table 3.4 Toposiomerase immunoband depletion results. Drug concentration at which NU:UB
compounds partially stabilised topoisomerase I-DNA or topoisomerase II-DNA cleavable
complexes. Results were obtained from 3 separate experiments if not otherwise stated.
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3.4 DISCUSSION
The DNA-binding properties of drug molecules are important factors that can
contribute to cytotoxic potency, mutagenicity, or the ability to interact with
DNA-processing enzymes including topoisomerases. Indeed, direct targeting
of DNA or DNA-associated proteins have received great attention in the past
and still figure prominently as viable approaches in cancer therapy stratergies
(Hurley, 2002). Reversible drug interactions with DNA take place in three
primary ways (Neidle, 2002):
1. Non-specific interactions, involving electrostatic binding along the exterior
of the helix.
2. Specific groove binding, involving interactions with the edges of base pairs
in the major or minor grooves.
3. DNA intercalation that relies on insertion of a planar or approximately
planar (aromatic) ring system between base pairs.
Strong correlations exist between chemical structure and DNA-binding
properties. Groove binding molecules are generally crescent-shaped and
incorporate an aromatic ring such as benzene, or heteroaromatic ring such as
pyrrole, that is able to twist into the helical curve of the groove, with the
displacement of water. Netropsin (Fig. 3.10) and Hoechst 33258 (Fig. 3.11)
are typical minor groove binding molecules.
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Fig. 3.10 Chemical structure of the minor groove binder netropsin.
Fig. 3.11 Chemical structure of the minor groove binder Hoechst 33258.
DNA intercalation typically displays an aromatic ring system that is planar and
has the same thickness as the base pairs of DNA. Nucleic acid conformation
is changed when intercalation takes place, which favours insertion of the flat
molecules into DNA. Mitoxantrone (Fig. 3.12) and ethidium bromide (Fig.
3.13) are typical intercalating molecules.
OH 0 NH~NH~OH
Fig. 3.12 Chemical structure of the DNA intercalator mitoxantrone.
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Fig. 3.13 Chemical structure of the DNA intercalator ethidium bromide.
Competitive DNA-ethidium (or Hoechst dye) fluorescence quenching is a well
established technique that has been applied to structurally diverse DNA
binding ligands to give a measure of the relative strengths of binding of small
molecules to DNA (McConnaughie and Jenkins, 1996). The
aminoanthraquinone and topoisomerase inhibitor mitoxantrone was used as a
comparator agent in order to probe the potential intercalative properties of
NU:UB 31 by ethidium displacement. It is generally accepted that Qso values
> 1 indicates poor intercalative capacity; mitoxantrone was determined to
have a mean QEso value of O.5~M, whereas NU:UB 31 was found to have a
mean value of O.79~M, confirming that an intercalative component contributed
to the process of DNA-binding by NU:UB 31; although it does not bind so
tightly as the comparator compound. This observation is consistent with
NU:UB 31 possessing a single cationic charge in contrast to the double
cationic mitoxantrone, which through its two side chains has additional
stabilisation of the intercalated complex. It is proposed that NU:UB 31 has a
mixed-modal (part intercalative, part groove-binding) mechanism of binding to
DNA, given the potent groove binding properties shown by the low mean QHso
value of 0.42~M compared to the groove-binding comparator netropsin which
had a mean QHso value of O.67~M. Molecules with a planar chromophore
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(that can insert into the hydrophobic space between base pairs in DNA)
combined with positively charged side chains of appropriate length and
conformation have been shown to have groove-binding contributions to the
DNA-bound intercalation complex in which the charges act as anchor points
to the negatively charged phosphodiester backbone in the nucleic acid,
effectively slowing the dissociation kinetics and tethering the molecule firmly
to DNA. Empirical observations have noted that intercalating compounds,
including the anthracyclines and mitoxantrone, generally favour interaction
with DNA topoisomerase II and often function as poisons, whereas crescent-
shaped, groove binding molecules, including the camptothecins and Hoechst
33258 (pibenzimol), interact with topoisomerase I, also usually functioning as
enzyme poisons. The mixed-modal DNA binding behaviour of NU:UB 31 is
thus consistent with its proposed dual action on each of topoisomerase I and
topoisomerase II.
Most clinically used anti-topoisomerase agents work via the formation of
cleavable topoisomerase-DNA-drug complexes (the effect termed 'poisoning')
rather than by inhibiting the catalytic activity of these enzymes. Drug-
stabilised cleavable complexes commonly induce permanent damage to the
structural integrity of DNA; the DNA lesions are considered to then trigger
apoptotic mechanisms, leading to cell death. Resistance to topoisomerase
inhibitors is still problematic in treating cancers and can be the result of
various factors including disruptions in the interactions between drug, DNA
and topoisomerase so that proper stabilisation of cleavable complexes by the
drug is not achieved. Down-regulation of topoisomerases, or (compensating)
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up-regulation of a topoisomerase enzyme that is not targeted by the drug, are
mechanisms with implications for the efficacy of topoisomerase inhibitors
(Larsen and Skladonovski, 1998; Pommier et a/., 1999). For example,
alterations in topoisomerase I, due either to decreases in levels or qualitative
changes of this enzyme which affect the interactions between topoisomerase I
and camptothecins have been observed in cell lines resistant to camptothecin
(Madelaine et al., 1993; Chang et al., 1992; Sorensen et al., 1997). In
experiments performed by Murren et al. (1996) camptothecin resistance was
related to the down regulation of topoisomerase I. Enzyme concentrations
were here determined in human nasopharyngeal (KB) cells by
immunoblotting. The total amount of topoisomerase I in resistant KB cells was
reduced compared to the parental KB cells and furthermore, in the resistant
cells this topoisomerase I reduction was further associated with increased
topoisomerase II levels (not related to proliferation differences). In cells made
resistant to etoposide, the opposite was found; lower topoisomerase II and an
increased amount of topoisomerase I enzyme. Thus, the reduction of one
topoisomerase enzyme was associated with an increase in the other, but no
collateral sensitivity to drugs (etoposide and camptothecin respectively)
directed against this topoisomerase was observed.
Mutations in the topoisomerase enzyme targeted by the drug is yet another
problem that can have implications for efficacy of drug regimens.
Topoisomerase II mutations often make cells cross-resistant towards several
of the topoisomerase II drugs. Moreover, alterations in topoisomerase
localisation may be involved in development of resistance and treatment of
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cells with topoisomerase inhibitors has been found to affect the localisation of
these enzymes. Camptothecin treatment of human KB cells resulted in
translocation of topoisomerase I from the nucleolus to other sites.
Immunolocalisation of topoisomerase I by confocal microscopy revealed less
intra-nuclear staining in camptothecin resistant cells and these observations
further suggested a greater cytosolic topoisomerase I distribution in the
resistant cells compared to the parental cell line (Murren et al., 1996). How
relevant this translocation is for the toxicity of camptothecin derivatives was
however not established. Boege et al. (1993) reported on the existence of two
types of topoisomerase 110 enzymes and the possibility that cells may become
more resistant by altering the levels of these. Mitoxantrone resistant HL60
cells expressed the nuclear 170 000 Mr, and also a cytoplasmic 160 000 Mr
form of topoisomerase 110 (Harker et al., 1995). This shift of topoisomerases
from the nucleus into cytoplasm may possibly be a way for cells to diminish
the formation of drug-induced cleavable complexes (i.e. limiting DNA
damage).
The drug-target mechanisms discussed above may confer resistance to a
variety of drugs. However, a high level of resistance is likely to be associated
with several of these target enzyme modifications as well as other pre- and
post- target resistance mechanisms. In cases where resistance associated
with topoisomerase levels/functions is a problem, treatment with new potent
drugs with dual topoisomerase I and topoisomerase II inhibition capacity may
be beneficial in circumventing these resistance mechanisms. Anthraquinone-
based amino acid substituted drugs (NU/ICRF 600, 601 and 602) have been
116
investigated by Meikle et al. (1995) and were found to be dual inhibitors of the
catalytic activity of topoisomerase I and topoisomerase II. Some of the NU:UB
compounds investigated here and elsewhere also appeared to be dual
topoisomerase I and II inhibitors (poisons). The mechanistic studies with
topoisomerase I performed in this project included assays for the
determination of drug-induced effects on topoisomerase I-mediated relaxation
(topoisomerase I inhibition) of supercoiled DNA as well as cleavable complex
formation studies, by in vitro topoisomerase I cleavage assays and
topisomerase I immunoband depletion assays in intact cells. The
topoisomerase I inhibition studies of the NU:UB compounds showed that
NU:UB 81 did not inhibit topoisomerase I activity in relaxation assays,
whereas, inhibition of topoisomerase I-mediated relaxation of pBR322 plasmid
was however evident in assays using NU:UB 31 and NU:UB 80 (the unnatural
D-isomer of NU:UB 81).
In topoisomerase I cleavage assays using supercoiled plasmid DNA, NU:UB
31 was found to stabilize cleavable complexes. Additionally, NU:UB 31,43, 51
and NU:UB 150, but not NU:UB 80 nor NU:UB 81, were active in the
topoisomerase I immunoband depletion experiments confirming that these
agents stabilised topoisomerase I-DNA complexes in whole HL60 cells.
NU:UB 31 showed band depletion at 100~M but higher NU:UB 31
concentrations appeared to antagonise topoisomerase I band depletion (a
phenomenon also reported at high NU:UB 31 concentrations in the
topoisomerase I cleavage assay using plasmid DNA). The observation that
NU:UB 31 antagonised its own topoisomerase I cleavage reaction (i.e. 'self
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inhibition') with increased concentrations may be consistent with its properties
of being a catalytic inhibitor and poison vested in the same molecule.
Precedent exists for this type of behaviour and has notably been observed for
the dual topoisomerase inhibitor, DACA that like NU:UB 31 possesses a
planar (acridine) chromophore with a single, positively charged aminoalkyl
side chain substituent (Bridewell et a/., 1999). Additionally, it is known that
pure catalytic inihbitors can nullify the effects of known topoisomerase
poisons. The poisoning activity of many topoisomerase inhibitors is known to
be antagonised by co-incubation with pure catalytic inhibitors with consequent
reduced levels of cleavable complex formation. Camptothecin was used as a
positive control in these topoisomerase I immunoband depletion assays and
efficiently depleted the topoisomerase I signal at 501JM. Although the NU:UB
agents were less potent than camptothecin in forming cleavable complexes,
NU:UB 31 and some of the other NU:UB compounds were also inhibitors of
toposiomerase I mediated DNA relaxation. It should be noted that the
cleavable complexes induced by camptothecin are in vivo highly reversible
upon drug removal so if NU:UB compounds induce less cleavage complexes
but these have longer half lives and they also act to inhibit topoisomerase I
directly this may be beneficial for cytotoxicity in vivo.
The same experimental principles as for the topoisomerase I studies were
used in the topoisomerase II studies, but instead of topoisomerase I,
topoisomerase lIa and topoisomerase II~ enzymes and antibodies were being
used. Work involving topoisomerase II plasmid DNA relaxation assays
suggested that NU:UB 31 was an inhibitor of topoisomerase Iia and
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topoisomerase II~ enzyme catalytic activities. Topoisomerase 110 and
topoisomerase II~ cleavage assays in cell-free purified enzyme systems
indicated that NU:UB 31 effected approximately equivalent levels of linear
DNA formation indicative of the formation of drug-stabilised cleavable
complexes with either the 0- or ~-isoforms. This result parallels the behaviour
of m-AMSA, which has been shown not to discriminate between
topoisomerase II isoforms (Marsh, 1996). These results supported the data
from topoisomerase 110 and topoisomerase II~ immunoband depletion assays
in which NU:UB 31 was shown to cause topoisomerase II depletion. The
topoisomerase II immunoband depletion experiments were however not
conclusive as the positive control recommended for these assays, etoposide,
was not successful in depleting topoisomerase II. Insolubility could have been
a problem as concentrations of up to 700~M were recommended.
In summary, the DNA binding studies showed that NU:UB 31 bound DNA, via
intercalation as well as through groove binding. The anti-topoisomerase
investigations in this project together with earlier work implied that NU:UB
compounds were active in topoisomerase assays using plasmid DNA as well
as whole cells. For NU:UB 31 both topoisomerase I relaxation and cleavage
complex formation were observed. Additionally anti-topoisomerase II (0 and
~) activities were also revealed. Thus, there is evidence to suggest that
NU:UB 31 (and possibly other NU:UB compounds, Mincher D.J., personal
communications) may have dual topoisomerase I and II activities and that
NU:UB 31 could work via direct inhibition of enzyme function as well as acting
as a topoisomerase poison. This may mean that the NU:UB 31 mechanism of
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action is less specific than the action of a drug that only acts by poisoning
topoisomerases. However, dual mechanisms may well prove to be beneficial
in vivo considering reports of resistance where alterations in topoisomerase
levels and functions are contributory factors.
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CHAPTER 4
CYTOTOXICITY
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4.1 CYTOTOXICITY
The cytotoxicity of NU:UB compounds, previously found to exert anti-
topoisomerase activity (anti-topoisomerase data presented in Chapter 3) was
investigated during this research programme. Standard anti-topoisomerase I
and II drugs were also included in these studies for comparison.
The cytotoxic potency of an anti-cancer agent is an important consideration
(not least from an in vivo perspective). Before we can expose cells to
compounds for apoptotic, cell cycle and related studies, the cytotoxicities of
these agents need to be established. The cytotoxicity induced over short and
long drug exposure times in the cell lines that would be used in future
experiments was assessed. This would further give an indication of stability of
the NU:UB compounds over time in vitro. The cytotoxicity of the NU:UB
compounds was studied with the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MIT) assay, which is a colorimetric-based
assay for quantification of cell growth and viability. With this assay,
cytotoxicity is expressed as IC50 values. This is a measure representing the
drug concentration at which 50% of the cells have survived the course of the
treatment. The MIT assay was originally developed by Mosmann (1983) and
has, in cancer research, become a tool for quantification of in vitro
chemosensitivity in tumour cells. Denizot and Lang (1986) suggested
modifications to the MIT assay to further improve reliability and sensitivity.
Early studies suggested that MTT is reduced in mitochondria (at the
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ubiquinone and cytochrome band c sites of the mitochondrial electron
transport system) (Slater et a/., 1963). Cleavage of MIT is thought to take
place only in active, living cells and therefore the amount of formazan, and
thus the intensity of blue colour produced should be proportional to the
number of cells present (as well as the mitochondrial activity per cell) (Vistica
et a/., 1991). In this MTT cytotoxicity study, three human cell lines were used;
firstly, a leukaemia cell line, HL60 that was used for the immunoband
depletion experiments (Chapter 3), and also for investigations of apoptosis
(Chapter 6). The two other cell types chosen were the colon cell lines HCT116
and HT29, that have been reported to contain wild type and mutant p53
respectively (Chapter 7). The cytotoxicity at three time points, 4h, 24h and
96h was assessed. Cytotoxicity following 4h and 24h treatments was
investigated since we wanted to determine whether or not the NU:UB agents
had effect at short exposure times. If this was the case, the 4h and 24h time
points would hopefully be suitable for the apoptotic investigations. A time point
at 96h was also used since this is a standard time point used in the host
laboratory and by collaborators at the Cancer Research Unit, Bradford
University.
Cytotoxicity was also assessed by a second method, nigrosin exclusion cell
counts. Nigrosin is a blue dye that is excluded from viable cells with intact
membranes, but that can enter cells with compromised membranes and
thereby distinguish between viable and dead cells. For this study HL60 cells
were used and these were counted at various time points. NU:UB 31 was
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used for this experiment, and known topoisomerase inhibitors (camptothecin
and etoposide) were also included.
In addition, NU:UB compounds have been screened in vitro by NCI in a 60
cell line screen with the sulforhodamine B cytotoxicity assay, using 48h
endpoints. The results from this screen are presented, in part, in mean graphs
that can be found in Appendix 2. The activity of NU:UB agents (NU:UB 31 and
NU:UB 51) in vivo, has also been investigated in NMRI mice bearing
subcutaneous MAC 15A (murine adenocarcinoma) tumours. This work was
performed by collaborators at the Cancer Research Unit, Bradford University
and the results are presented in Appendix 3.
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4.2 METHODS
4.2.1 Growth Curve Of HL60 Cells
HL60 cells were recovered from culture and washed. 1801-11 per well, of a cell
suspension at 1 x 104 cells/ml, was seeded into 96 well plates in all columns
except column 1 (A1 to H1). Column 1 was used as a blank and contained
medium only. For a 10 day growth curve, 10 plates were used and the plates
were kept at 37°C, 5% CO2. Each day 201-11 MTI (5mg/ml) was added and left
to incubate for 4h. The optical density (00) was measured at 540nm in a
MRX Microplate Reader (Oynex Technologies).
4.2.2 Cytotoxicity Investigations With The MTT Assay,
Preparation And Treatment Of Cells With Anti-Cancer Agents
The cell solution was transferred to a sterile universal and centrifuged at 500 x
9 for 5 mins at 4°C. The supernatant was discarded and the cell pellet
resuspended in fresh culture medium. Cell counts were performed using a
haemocytometer. Cells were diluted to a density of 1 x 104 cells/ml with
culture medium for 96h MTI assay. The cell suspension was seeded into a 96
well plate (180~1 cell solution per well) in all wells except A1 to H1 in column
1. Column 1 represented the blank, and medium only (1801-11 per well) was
added to these wells. The plate was left to recover overnight, before being
treated with NU:UB compounds or standard agents.
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For each compound, serial dilutions were made in suitable culture medium
from the 10mM stock solution. Drug solution, 201J1, was added per well from
drug dilutions of 0.1 to 1000IJM into columns 3 to 7. Thereby, the final
concentrations ranged from 0.01 to 100IJM with a total volume of 2001J1 per
well. Columns 8 to 12 were used for a second compound in the same
concentration range. Column 1 was left as a blank, and column 2 contained
control cells, to which 201J1 of medium was added. Treatments were carried
out at 37°C, 5% CO2, for 96h.
4.2.3 Addition Of MTT
Following treatments, 20111 MTT (5mg/ml in PBS) was added to each well of
the 96 well plate, and the plate was then incubated at 37°C for 4 hours. When
using non-adherent cells (HL60), the plates were centrifuged at 500 x g for 5
mins before removing the supernatant. Supernatants were removed and the
purple formazan crystals were dissolved in 150111 of OMSO. 00 was
measured at 540nm in an MRX Microplate Reader (Oynex Technologies).
4.2.3a Treatment Of Results
The mean 00 value of each column was obtained. The mean blank value, for
medium only from column 1, was subtracted from all the other mean 00
values. The results were expressed as percentage of survival, where any
decrease from the control, 100% cell viability, would indicate cytotoxicity. The
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concentration at which 50% of the cells had survived following treatment,
relative to the control, was referred to as the IC50 value. For each treatment
the results have been expressed as the mean IC50 value ± SEM.
4.2.4 Cytotoxicity Investigations With Nigrosin Exclusion Cell
Counts
HL60 cells were recovered from suspension by centrifugation, 500 x g for 5
mins at 4°C, cells were washed, resuspended in fresh medium at 10 x 104
cells/ml in 10ml per sample and left overnight. Cells were treated with NU:UB
31 (5IJM, 20IJM, or 30IJM), camptothecin (0.1IJM or 51JM), etoposide (5IJM) or
with solvent (control). Cell viability was investigated over a time course of 4h,
8h, 24h and 48h treatments. Following treatments, cells were spun down at
500 x g for 5 mins at 4°C and were resuspended in 1ml medium. An aliqout of
each sample was mixed 1:1 with 0.1% nigrosin and counted in a
haemocytometer.
4.2.4a Treatment of Results
The experiment was performed in triplicate and the nigrosin negative
(viable) cell counts were expressed as a percentage of total number of
viable cells ± SEM. Tukey's one-way analysis of variance was used to
evaluate significant differences between treated cells and control cells at
each time point.
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4.3 RESULTS
4.3.1 Growth Curve Of HL60 Cells
A growth curve of HL60 cells grown in 96 well plates, such as would be used
for the MTT assay, was performed to make sure that the MTI assay
conditions were suitable for this cell line. From this growth curve it was
realised that a seeding density of 1 x 104 cells/ml was suitable, and that cells
grew exponentially from day 1-8 (Fig. 4.1). Thus, throughout the MTI assay,
when cells will be seeded, left overnight and treated for 96h, the HL60 cells
should grow exponentially.
4.3.2 MTT Cytotoxicity Assay Of NU:UB And Standard Drugs
Using HL60, HCT116 And HT29 Cells
Cells were exposed to NU:UB compounds or to standard anti-topoisomerase
drugs (camptothecin, doxorubicin, etoposide) for 4h, 24h and 96h. After the
exposure times the cell survival relative to the control was determined by
addition of MTT. The cytotoxic potencies of the compounds at each time point
expressed as IC5c values are shown in Table 4.1.
At the 4h time point, for all three cell lines, NU:UB compounds had IC5c values
of less than 391JM. At the 24h time point the IC5c mean values ranged from
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1.7-26.5IJM, where NU:UB 51 was the most cytotoxic of the NU:UB agents in
all three cell lines. Additional hydroxy groups in the nucleus of the
anthraquinone might be predicted to confer greater cytotoxic properties; in
1A-bis-substituted (aminoalkylamino)anthraquinones, activity is greatly
enhanced by inclusion of hydroxy groups at the 5- and 8- positions. Removal,
for example, of the 5- and 8-hydroxy groups from mitoxantrone to afford
ametantrone reduces activity 10-fold. The enhanced potency of hydroxylated
aminoanthraquinones is believed to be due to their increased DNA-binding
capacity (by intercalation) and to their increased propensity to result in free
radical (ultimately hydroxy radical) formation (Cheng and Zee-Cheng, 1983).
The ICso values of the NU:UB compounds did not differ greatly over the 4h
and 24h time points for these cell lines. This was not the case for the standard
drugs, where camptothecin and doxorubicin had ICso values above 100IJM
(except camptothecin, 1.91JM in HL60 cells) in the 4h MIT assays. However in
the 24h MIT assays, the standard drugs were more cytotoxic with ICsovalues
between O.02IJM and 15.7IJM. Thus, there were overall larger differences in
the ICso values between the 4h to 24h time points for the standard drugs in
HL60 and colon cells. For NU:UB compounds there were no differences or
only up to 6-fold differences in the ICso values between the 4h and 24h time
points. For the 96h time point the ICso values of the NU:UB compounds
ranged from O.3-4.2IJM. In contrast, the ICso values of the known
topoisomerase inhibitors were considerably lower for all cell lines, ranging
from <O.01-0.4IJM. Clearly for the NU:UB agents maximum cell death occurs
early despite the lower intrinsic cytotoxic potency when compared to standard
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agents. Cell death and the relationship to onset of apoptosis are discussed in
Chapter 5 and 6.
4.3.3 Nigrosin Exclusion Assay Of NU:UB And Standard
Drugs Using HL60 Cells
The effect of NU:UB 31 on growth and viability was assayed by nigrosin
exclusion cell counts. This assay distinguished viable and dead cells on the
basis of cell membrane permeability of the nigrosin dye. NU:UB 31 was used
in a concentration range of 51JM, 20IJM and 30IJM, camptothecin and
etoposide were also included for comparison. Cell counts were carried out
following 4h, 8h, 24h and 48h treatment. Nigrosin negative cells were
considered to be viable in this experiment; negatively-stained and blue
nigrosin positive (dead) cells were counted. Nigrosin negative (viable) cell
were visualized by light microscopy. Whereas the cell numbers in the controls
increased over the time course, 5IJM NU:UB 31 resulted in growth inhibition
compared to the control, however, there did not appear to be any significant
cell kill with this concentration. At a concentration of 20J-LM there was some
cell kill after 8h treatment, and cell growth was inhibited at the 24h and the
48h time points. Following 30J-LM NU:UB 31 treatment there were less viable
cells at all time points compared to controls, including the first, 4h time point.
In Fig 4.2 the nigrosin results have been expressed as percentages of viable
cells in relation to total cell numbers. For the control, viability remained above
85% throughout the course of the experiment, confirming a healthy cell
population. Fig. 4.2a indicates that the majority (>90%), of the cells were
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viable, excluding the nigrosin dye at the 4h time point for all treatments.
Following 8h, camptothecin (5IJM) resulted in decreased viability (Fig. 4.2b).
Fig. 4.2c shows that the control cells had >90% viability. NU:UB 31 at 20llM
had effect on viability after 24h. Following NU:UB 31 (at 30IlM), etoposide
(5IlM) and camptothecin (0.1IlM and 51lM) treatment for 24h, significant
differences from the control were reached. At 48h highly significant
differences were reached compared to the control after NU:UB 31 (30IJM),
etoposide and camptothecin treatments (p<0.001) (Fig. 4.2d).
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Fig. 4.1 Growth curve of HL60 cells grown in 96 well plates. HL60 cells seeded at a density of
1 x 104 cells/ml at day O. Following addition of MTT the optical density in each well was
measured at 540nm.
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HL60 4h 24h 96h
NU:UB 31 27.5 ± 2.0 4.9 ± 0.5 3.1 ± 0.3
NU:UB 43 - - 3.2 ± 0.2
NU:UB 51 4.0 ± 0.3 1.7 ± 0.2 0.3 ± 0.02
NU:UB 80 6.7 ± 0.6 2.9 ± 0.1 2.9 ± 0.3
NU:UB 81 - - 4 (n=2)
Camptothecin 1.9 ± 0.2 0.02 ± 0.002 <0.01
Doxorubicin > 100 0.3 ± 0.03 -
Etoposide 41.7±1.7 1.0±0.1 0.035 ± 0.005
HCT116 4h 24h 96h
NU:UB 31 30.0±1.7 26.3 ± 2.4 2.8 ± 0.2
NU:UB 51 15.3±1.5 3.8 ± 0.5 1.0 ± 0.07
NU:UB 80 38.5 ± 3.1 19.3 ± 1.8 2.9 ± 0.3
Camptothecin > 100 0.1 ± 0.01 <0.01
Doxorubicin > 100 0.9 ± 0.0 0.03 ± 0.003
Etoposide - - 0.4 ± 0.04
HT29 4h 24h 96h
NU:UB 31 33.5 ± 1.7 26.5 ± 1.9 4.2 ± 0.3
NU:UB 51 0.6 ± 0.1 2.2 ± 0.2 2.9 ± 0.3
NU:UB 80 29.5 ± 0.7 5.4 ± 0.5 2.6 ± 0.2
Camptothecin > 100 15.7 ± 1.8 < 0.01
Doxorubicin > 100 15.0 ± 4.5 0.06 ± 0.003
Etoposide - - 0.9 ± 0.09
Table 4.1 IGso values (IJM) in cells exposed to standard drugs or NU:UB compounds for 4h,
24h, or 96h. Results are the mean IGso values ± SEM of 3 or more MTT assays.
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Fig. 4.2 (a and b). Nigrosin exclusion counts of HL60 cells following NU:UB 31, camptothecin (cmt)
or etoposide (etp) treatment carried out for 4h (a) and 8h (b). Nigrosin negative (viable) cells
expressed as a percentage of total (nigrosin negative + nigrosin positive) HL60 cells. Results are the
mean of 3 separate experiments ± SEM (except for the 8h time point (b) where n=2).
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Fig. 4.2 (c and d). Nigrosin exclusion counts of HL60 cells following NU:UB 31, camptothecin (cmt)
or etoposide (etp) treatment carried out for 4h 24h (c) and 48h (d). Nigrosin negative (viable) cells
expressed as a percentage of total (nigrosin negative + nigrosin positive) HL60 cells. Results are the
mean of 3 separate experiments ± SEM. Asterisks denote significant differences from the control
(* p<0.05, ** p<0.01, *** p<0.001).
135
4.4 DISCUSSION
Toxicity of the standard agents, camptothecin, doxorubicin and etoposide is
well documented in a range of cell lines and these known topoisomerase
inhibitors were used as positive cytotoxicity controls. NU:UB 31, 43, 80 and 81
have previously, in a 60 cell line 48h sulforhodamine B cytotoxicity screen
performed by NCI, shown exceptional profiles against refractory human colon
carcinomas and malignant melanomas. Based on this, these compounds
have therefore been chosen by NCI for complete biological evaluation as part
of progression to clinical trials. In the NCI cell screen, different drugs are
screened against a number of cell lines and to be able to compare these
drugs, 'mean graphs' can be plotted. Mean graphs of the NU:UB agents can
be found in Appendix 2. The NCI data include GI50 (mean concentration of
drug which inhibits cell growth by 50%), TGI (mean concentration of drug
which inhibits cell growth by 100%) and LC50 (mean concentration of drug
which decreases protein stain absorbance by 50%) values, which are an
effective indicator of cell kill, rather than growth inhibition. The effect of a
compound on a specific cell line (or type of cell line, e.g. melanoma) can in
these mean graphs be related to the mean effect on all screened cell lines,
since these graphs display the mean of each cell line as a deflection from the
overall calculated mean value. If the GI50 values of a cell line is to the right of
the mean value, these cells are sensitive to the drug (G15ovalues < the mean,
sensitivity), whereas cells that are more resistant will be to the left (G15ovalues
> the mean, resistant). Screening drugs in this manner may be very useful
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since a growth inhibitory response of a single cell line might give relatively
little information about a particular drug, whereas a pattern of response by
several cell lines (and groups of cell lines) can make up a "molecular
fingerprint" that could aid in categorising drugs according to their
mechanism(s) of action (Monks et al., 1997).
In this study, a series of NU:UB compounds (NU:UB 31, 51 and 80) were
screened with 96h MIT assays in the human HL60, HCT116 and HT29 cell
lines. ICso values for these NU:UB agents ranged for the 96h time point from
0.3-4.0IJM in HL60 cells, 1.0-2.9IJM in HCT116 cells and 2.6-4.2IJM in HT29
cells. Additionally, NU:UB 31 and NU:UB 80 have also been screened by NCI,
and showed cytotoxicity. The MIT results together with the NCI data,
indicated that the NU:UB compounds were cytotoxic at low, IJM
concentrations. The standard drugs camptothecin, doxorubicin and etoposide
were (in the MIT assay) more cytotoxic at 96h than any of the NU:UB
compounds. This was not the case at the short, 4h time point where NU:UB
compounds were more potent than the standard drugs with ICsovalues at IJM
levels, compared to the standard drugs which had ICso values above 100IJM
in the colon cell lines. Thus the MIT data in the cell lines used, together
showed that the NU:UB compounds were cytotoxic at low, IJM concentrations
at both long and short exposure times over a range of cell lines. Furthermore,
the NU:UB ICso values did not decrease very much between the 4h and 24h
time points, which was the case for standard drugs. From the MTT data it
appeared that the NU:UB compounds were taken up by the cells and acted
within the 4h exposure time. One major contributor to low potency of cytotoxic
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agents is drug resistance commonly manifested through the expression of the
MDR1 gene product, P-gp (classical multidrug resistance phenotypes);
furthermore, many standard topoisomerase inhibitors are susceptible to P-gp-
or the related MRP-mediated protein efflux mechanisms (Larsen and
Skladanowski, 1998). The anthraquinone NU:UB 31 has, however, shown
activity in a number of cell lines that are classically resistant to topoisomerase
inhibitors; in the NCI screen, for example, NU:UB 31 showed only 1.3-fold
resistance in the (doxorubicin-resistant) high P-gp-expressing NCI/ADR-res
cell line when compared to the wild type MCF7 counterpart, whereas the
anthraquinones, doxorubicin and mitoxantrone were 630- and 1ODD-fold
resistant, respectively. NU:UB 31 was also found to be only 4.8-fold resistant
in the P-gp-expressing, doxorubicin-resistant A2780/ADR human ovarian
carcinoma cell line, in contrast to doxorubicin (150-fold resistant) when
resistance levels were compared to the wild-type A2780 parent cell line.
Furthermore, in studies from this laboratory, NU:UB 31 has been found to
show 2.7-fold hypersensitivity in a highly P-gp-expressing, mutated Chinese
Hamster Ovarian cell line, CHO/ADR-r (14-fold resistant to doxorubicin) when
compared to the wild-type CHO- K1 parent (P-gp-expression was measured
by flow cytometry as the percentage of cells staining positive with MRK-16
anti-P-gp antibody (21 % and 91 % for wild-type and resistant variant,
respectively) (Gilmour P.S. and Mincher D.J., unpublished data). The data
may suggest that NU:UB 31 is a poor substrate for the P-gp protein efflux
pump and given its hydrophobic cationic properties may facilitate early
mechanisms of cell death induction, in contrast to anthracyclines like
doxorubicin. Additionally, the hypersensitivity observed with NU:UB 31 may
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be correlated to the topoisomerase protein expression in the CHO/ADR cell
line. When CHO/ADR was compared with the wild -type it was characterised
as having a two-fold decrease in topo Iia levels and concomitant increases
(2.5-fold and 2-fold, respectively) in topoisomerase II~ and topoisomerase I
proteins. NU:UB 31 has here been shown to inhibit all three topoisomerases
(at least in vitro) whereas anti-topoisomerase II agents including doxorubicin
have been considered largely to target the alpha isoform, that is down-
regulated in this and other resistant cell lines.
Camptothecin has been reported to be dependent on the cell cycle for its
cytotoxic action. In this study, the MTT IC50 values at 24h were lower than
following 4h exposure in the three cell lines and even more so at the 96h time
point. This was also the case for doxorubicin and etoposide. Fewer cells had
survived at the 24h time point than at the 4h time point. This may be a
reflection that the standard drugs were stable, and did not break down during
the course of the MTT assay. The NU:UB compounds had however, at the 4h
and 24h time points, similar values in these assays. This suggests that the
drug action of the NU:UB compounds took place fairly rapidly, and possibly
following this, the NU:UB compound may have been inactivated, broken
down. However, previous pharmacokinetic work performed at the Cancer
Research Unit at Bradford University assessing the stability of NU:UB 31 gave
in vitro t1/2 values of >100h in plasma, 75.1 h in tissue culture medium and
25.7h in whole blood, which would indicate that this agent is relatively stable
in vitro. Additionally, an in vivo pharmacokinetic analysis of NU:UB 31 was
also performed over an 8h period in MAC15A tumour-bearing mice where
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NU:UB 31 was administered i.p. at the maximum tolerated dose (MTD,
100mg/kg). It was demonstrated that NU:UB 31 concentration peaked in
plasma after 30 minutes with a t1l2 value of 2.2h. Peak tumour concentrations
exceeded the concentration in plasma by approximately 3-fold, peaking at 2h
with a t1/2 value of 6h (see Appendix 4). That NU:UB 31 had a fairly long half-
life in MAC15A tumours in vivo may in part explain the anti-tumour activity
seen against these tumours, refractory to several known anti-topoisomerase
drugs. Furthermore in vivo work in NMRI mice bearing subcutaneous MAC
15A tumours has indeed shown reduced tumour growth following
administration of NU:UB 31. Treatment with NU:UB 31 (MTD, 100mg/kg) led
to a significant delay in tumour growth (P<0.01) and administration of doses
below the MTD also resulted in delayed tumour growth. NU:UB 31,
administered to the NMRI mice i.p, at single doses of 67mg/kg and 33mg/kg
resulted in a growth delay of 4.3 and 3.2 days respectively. In both cases,
treatment resulted in a statistically significant delay in tumour growth (p<0.01)
compared to controls. In vivo results of comparative studies of NU:UB 31,
NU:UB 51, camptothecin, doxorubicin and mitoxantrone can be viewed in
Appendix 3.
In addition to the MTT assay, cytotoxicity following NU:UB 31, camptothecin
and etoposide treatment was studied with nigrosin exclusion cell counts using
HL60 cells. This experiment identified viable and dead cells on the basis of
cell membrane permeability of the nigrosin dye. Following 4h exposure, the
majority of the cells in all treatments were viable, excluding the blue nigrosin
dye. Following 24h and 48h exposures NU:UB 31 (30~M), camptothecin
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(0.1 f.lM and 5f.lM) and etoposide (5f.lM) all resulted in significantly decreased
cell viability as measured with nigrosin exclusion.
Hence, the two cytotoxicity assays used in this study (the MIT assay and the
nigrosin exclusion assay) implied that the compounds were cytotoxic in vitro.
However, the effect appeared to be greater measured by the MIT assay than
when measured with nigrosin exclusion cell counts. This may be explained by
the fact that the two assays rely on different mechanisms. The MIT assay
uses mitochondrial function in distinguishing viable and dead cells, whereas,
dead cells are distinguished from viable cells by membrane permeability in the
nigrosin exclusion assay. Thus mitochondrial function seemed to be disrupted
in cells before the cell membranes became permeable to the nigrosin dye.
This may be significant in the light of sub-cellular localisation of NU:UB
compound.
In summary, NU:UB compounds were cytotoxic in the cell lines used. NU:UB
compounds were, at shorter exposure times, but not at the longer exposure
times, more cytotoxic than standard agents. Thus, the NU:UB agents
appeared to have a fairly rapid mechanism of action. The IC50 values of the
NU:UB compounds did not differ as much between the time points as the IC50
values for the standard agents. This may indicate that the NU:UB compounds
broke down in cell culture over time, and/or the cells could, following drug
uptake, have had mechanisms of excluding (efflux) these agents, and/or
repair mechanisms that repaired drug damaged cells and thereby allowed for
continued growth. The nigrosin exclusion cell count experiment further
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confirmed that NU:UB 31 was cytotoxic. From the these investigations it was
demonstrated that NU:UB exposure times of 4h and 24h were sufficient to
have an impact on cell survival, making these time points suitable for
apoptotic studies. Considering the topoisomerase assays conducted earlier
and described in the previous chapter (Chapter 3) along with the in vitro
cytotoxicity studies (Chapter 4 and Appendix 2) and in vivo data of NU:UB 31
and NU:UB 51 (Appendix 3), it appears that both these NU:UB agents act via
topoisomerases and both agents have been reported to shrink tumours in
previous mice studies. NU:UB 51 was however, particularly at the shorter
exposure times, the more cytotoxic compound in vitro. There might be other
targets/mechanisms involved in the way by which these compounds kill cells.
That NU:UB 51 was more cytotoxic in vitro is likely to be due to OH groups in
its anthraquinone chromophore, making this agent more open to free radical
formation that could playa part in its cytotoxicity. Although, NU:UB 51 was
slightly more potent in vitro at the shorter exposure times, NU:UB 31 and
NU:UB 51 both had similar cytotoxic potency at longer exposure times, acted
via topoisomerases and both shrank tumours in vivo. With this in mind,
NU:UB 31, rather than NU:UB 51, was chosen as the lead compound, since
NU:UB 31 does not contain OH groups and was therefore considered to be
less likely to be a source of free radical formation that could potentially
increase the probability of non-specific adverse toxic effects in vivo.
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CHAPTER 5
INVESTIGATION OF CELL CYCLE
DISTURBANCES FOLLOWING NU:UB TREATMENT
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5.1 INVESTIGATION OF CELL CYCLE DISTURBANCES
This part of the research programme investigated whether or not treatment
with NU:UB compounds affected cell cycle progression in HL60 cells. The
focus was on NU:UB 31, but for comparision, NU:UB 51 as well as classical
anti-topoisomerase agents were also used.
It was hoped that studying the cell cycle effects, and the cell cycle phase
specificity of anti-cancer agents would help in the understanding of their
mechanisms of action. Furthermore, such studies were also hoped to aid in
the development of new agents and, in particular, clinical drug regimens,
since factors such as simultaneous administration of agents may playa part in
resistance, limiting the effectiveness of drugs (Larsen and Skladonowki,
1998). Various anti-topoisomerase agents have been found to affect the cell
cycle and/or induce apoptosis in cells, so the reason for arrest in a particular
phase of the cell cycle following treatment with anti-cancer drugs may partly
be linked to the topoisomerase (I and II) activities in relation to the cell cycle,
and how these drugs affect the respective topoisomerase enzymes. Cell cycle
arrest can occur in either G1 or G2 phases, but cells may also be inhibited in
S-phase. It has been suggested that topoisomerase I is important in all
phases of the cell cycle and that topoisomerase II may be required to enter S-
phase and to complete G2 phase (Poot et al., 1995).
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Two anti-topoisomerase drugs were included in this cell cycle study for
comparison, camptothecin and etoposide, since they are reported to act via
topoisomerase I, and II respectively. Previously, in Chapter 3 the findings from
anti-topoisomerase activity studies of some of the NU:UB compounds were
presented and it was found that the NU:UB agents interfered with these
enzymes. Therefore if NU:UB agents cause arrest in a particular phase of the
cell cycle, similar to the known anti-topoisomerase drugs used for
comparison, this may confirm their mechanism of action as anti-
topoisomerase I or II inhibitors. This study of cell cycle was facilitated by the
use of flow cytometry by measuring emission from the DNA intercalator,
propidium iodide. In addition to the cell cycle measurements, analysis of
apoptotic cells was also performed. In ethanol fixed and rehydrated apoptotic
cells, some of the lower molecular weight DNA fragments may diffuse out,
and this lowers the DNA content in apoptotic cells. These cells are
quantifiable in a DNA histogram belonging to the so called sub G1 material.
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5.2 METHODS
5.2.1 Growth Curve Of HL60 Cells
HL60 cells were seeded in culture flasks at concentrations of 1 x 104, 2 x 104
and 5 x 104 cells/ml at day O. To monitor the growth of this cell line, cells were
counted each day over a time course of 8 days. The growth curves were
performed in triplicate, and the cells were counted using a haemocytometer.
5.2.2 Analysis Of The Cell Cycle Using Flow Cytometry
One of the most commonly used flow cytometric methods to study how
treatment with drugs affects the cell cycle progression, relies on analysis of
the DNA distribution of a cell population. DNA content measurements use
fluorescent probes with a high degree of specificity for DNA; in this project
propidium iodide (PI) was used. The PI probe intercalates into DNA, is excited
by the appropriate wavelength, and the fluorescence emission is collected
and displayed using flow cytometry. The fluorescence intensity in this method
is accepted to be proportional to the amount of bound dye and thereby the
fluorescence intensity of the individual cell will be proportional to its DNA
content. From each sample, the DNA content of cells was measured and a
histogram of the number of cells against DNA content was plotted reflecting
the state of the cell cycle. This histogram was further divided into different
phases with regard to DNA content (fluorescence). Cells in G1 can be
146
considered to have a DNA index of 1.0. When the cells start to make new
DNA they enter the DNA synthesizing S-phase of the cycle and have a DNA
index between 1.0 and 2.0. Cells in the G2/M phase have a DNA content of
2.0. Thereby cells in G2 and M phases of the cell cycle have double the DNA
content of those in G1 (and GO), and cells in S phase have DNA content
somewhere in between these extremes. Treatment of cells with agents that
affect the progression of cells through the cell cycle will result in changes in
the DNA distribution, altering the proportion of cells in the individual cell cycle
phases.
Various treatments of HL60 cells with NU:UB compounds or standard drugs
were performed. HL60 cells were seeded at 5 x 104 cells/ml and left to
recover overnight. Cells were transferred to universals and pelleted by
centrifugation at 500 x g for 5 mins. The cell pellets were resuspended in 10ml
drug solution or medium with solvent (control) and incubated at 37°C for 1 or
4h. Following treatment, cells were washed in HBSS, resuspended in fresh
medium and left in the incubator to recover for Oh, 4h or 24h. Cells were
pelleted at 500 x g for 5 mins, resuspended in 0.1 ml PBS and transferred to
Eppendorf tubes. Ice cold 70% ethanol (0.9ml), was added and the cells left to
fix in the freezer. Cells were harvested by centrifugation at 500 x g for 5 mins,
and were rehydrated in OAml PBS. RNAse was added, 501J1 (1 mg/ml in PBS)
and samples were incubated at 37°C for 30 mins. PI, 501J1 (OAmg/ml in water)
was added and the samples were left to incubate for another 10 mins in the
dark. Cells were recovered at 500 x g for 5 mins, resuspended in 1ml PBS
and stored on ice in the dark until analysed.
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The DNA content of each cell was analysed using a FACSCalibur flow
cytometer (Becton Dickinson Immunocytometry Systems, BOIS) equipped
with a 15mW argon-ion air-cooled laser with excitation wavelength 488nm,
measuring light scatter and red fluorescence.
5.2.2a Treatment Of Results
Cellular DNA content following PI staining was measured and a cell cycle
histogram of 10 000 events (cells) was obtained from each sample. Pulse
height signals of forward and side light scatter (SSC) were collected for the
discrimination of debris. Each fluorescence histogram was analysed with
Cellquest software (BOIS) that allowed for estimation of the percentage of
cells in G1, Sand G2/M phase of the cycle. Each sample was analysed in
triplicate (or duplicate), and a mean ± SO of the percentage of fluorescence
for each cell cycle phase was calculated and plotted in a histogram.
5.2.3 Analysis of Apoptosis Using Flow Cytometry
The above method of analysing DNA content of individual PI stained cells
using flow cytometry can also be a tool for identifying apoptotic cells in a cell
population. In apoptotic cells, the DNA content is thought to be less than in
viable cells. Therefore, cells with DNA content below that of G1 cells were
considered to be apoptotic and appeared as a sub G1 peak in the cell cycle
histograms. In samples with high cell turn over, rapid cell growth or cell kill,
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there was however also likely to be a lot of cell debris present in the sub G1
region and information about cell size and granularity was obtained from
analysing scattered light as the cells pass through the laser beam.
5.2.3a Treatment Of Results
Cells with DNA content below G1 were gated out in each of the above cell
cycle histograms, and measured. The sub G1 populations in controls were
compared to sub G1 material in treated cells. The result was calculated as the
mean value from two or three separate experiments.
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5.3 RESULTS
5.3.1 Growth Curve Of HL60 Cells
Fig. 5.1 shows the growth curves of HL60 cells seeded at 1 x 104, 2 x 104 and
5 x 104 cells/ml. Following a brief lag phase, the cells grew exponentially until
day 6 for cells seeded at 5 x 104 cells/ml, and until day 7 for cell cultures
seeded at 1 x 104 and 2 x 104 cells/ml.
5.3.2 Cell Cycle Analysis
The cells were harvested following 1h or 4h treatment, and at Oh, 4h or 24h
recovery, fixed in ethanol, stained and measured by flow cytometry.
5.3.2a Cell Cycle Analysis Of HL60 Cells Following 1h Treatment
With NU:UB 31 Or Standard Drugs
Cells were treated with NU:UB 31 (and NU:UB 51 1h + 4h), or standard drugs
for 1h and recovered for 4h or 24h. Representative cell cycle histograms of
these treatments can be seen in Figs. 5.2a-f and Figs. 5.3a-f. Control cells, 1
+ 4h and 1 + 24h can be seen in Fig. 5.2a and 5.3a respectively. Both these
controls showed sharp major G1 peaks and minor G2/M peaks located at
approximatively 200 and 400nm, indicating that these control cell populations
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were healthy and normal. Treatments with camptothecin and etoposide
resulted in cell cycle disturbances. Particularly after 1h treatment followed by
24h recovery, the normal cell cycle distribution was greatly distorted with a
build up in S-phase and G2/M phase respectively (Fig. 5.3b, Fig. 5.3c). For
NU:UB 31, slight cell cycle disturbances compared to control were observed
following 1h treatment with 4h recovery. However, following 24h recovery the
cell cycle histograms for these treatments were again normally distributed and
hence no permanent cell cycle block appeared to occur once the cells had
been washed and left for 24h. The percentages of each cell cycle phase were
calculated for each cell cycle distribution histogram. The mean cell cycle
phase values from each treatment and time point were plotted in summary
histograms. Histograms to summarise the 1h + 4h and the 1h + 24h
experiments can be found in Fig. 5.2g and Fig. 5.3g respectively. Following 1h
treatment (and 4h recovery) with the anti-topoisomerase I agent,
camptothecin (21..1M and 51..1M) there was an increase, compared to the control,
in the number of cells in the G1 phase; the G2/M phase remained the same,
but there was a decrease in the S phase population (Fig. 5.2g). When the
camptothecin (2I..1M) treated cells were left to recover for 24h there was a
decrease in both G1 and G2/M cells and there seemed to be an accumulation
of cells in S phase. Thus camptothecin caused an accumulation of cells in
early S phase, which presented as a shift in distribution with a concomitant
decrease in G1 and G2 phase cells. Following 1h treatment (and 4h recovery)
with the anti-topoisomerase II drug, etoposide (5I..1M), there was also at first an
increased number of G1 phase cells, but over time with 24h recovery this
resulted in a G2/M block. NU:UB 31 (201..1M, 301..1M, 40I..lM and 50I..lM) and
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NU:UB 51 (O.5IJM and 11JM) 1h exposure with 4h recovery showed different
histograms compared to the standard drugs, there was a decrease in G1, a
slight increase in G2/M and S phases. However, when the cells had been left
to recover for 24h, cell cycle distributions were similar in NU:UB 31 treated
and untreated control samples (Fig. 5.3g).
5.3.2b Cell Cycle Analysis Of HL60 Cells Following 4h Treatment
With NU:UB 31
Figs. 5.4a-c show cell cycle histograms representative of the 4h treatments
with no recovery, Figs. 5.4d-f represent 4h treatments with 4h recovery, and
Figs. 5.4g-h are the 4h treatments followed by 24h recovery. The untreated
HL60 controls for these time points did, as expected, appear to have normal
and healthy cell cycle distribution with very little material in the sub G1 region
(the region in FL2-A below 200nm) (Fig. 5.4a, Fig. 5.4d, Fig. 5.4h). There was
a slight decrease in the number of G1 cells, and increase in S phase cells
following 4h 30IJM NU:UB 31 treatment without recovery (Fig. 5.4b). No
apparent changes in the different phases were seen following the 50IJM
NU:UB 31 treatment at this time point. At this concentration there was rather
an increase in the sub G1 material with no cell cycle distribution alterations
(Fig. 5.4c). With 4h recovery there was a similar finding; the lower NU:UB 31
concentrations, but not 501JM, gave slight cell cycle distribution changes with
what appeared to be a block in the Sand G2/M phases (Fig. 5.4e and Fig.
5.4t). At this time point there was also more cell kill, more sub G1 material
than in the treatments without recovery. However, when the cells had been
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treated with NU:UB 31 at 30IJM for 4h and had been allowed to recover for
24h, there was no blockage in the cell cycle and these histograms showed a
normal distribution of cells through the cycle (Fig. 5.4h). In addition, at this
time point, following 30IJM NU:UB 31 treatment, there was only a slight
increase in sub G1 material. In contrast, no viable cells were present following
50IJM NU:UB 31 treatment for 4h with 24h recovery. Histograms that
summarise the mean values of the 4h treatments with Oh, 4h or 24h recovery
can be found in Fig. 5.4L
5.3.3 Analysis Of The Sub G1 Population
For each cell cycle histogram, the cell population (cell material) in the sub G1
region was gated out and measured. Some of this material was likely to be
cell debris (late apoptotic and necrotic cells). However, upon analysing light
scattering properties of the cells, along with PI in FL2-A, cells with lower
(below 200nm) PI staining (less DNA content), but which retained the same
degree of side scatter (granularity) were considered to be apoptotic. Cells and
cell material with lower PI staining, as well as less granularity, below 200nm
were considered to be debris. The levels of debris and apoptotic cells were
low in control samples (Fig. 5.2a, Fig. 5.3a, Fig. 5.4a). However, following
camptothecin, etoposide and NU:UB 31 treatments the apoptotic population in
these samples increased dramatically (Figs. 5.2b-f, Figs. 5.3b-c, Fig. 5.4c, e, f
and h). In addition to the increased apoptotic population, the level of debris
was also increased in samples treated with camptothecin, etoposide and high
(50IJM) NU:UB 31 concentration due to the high degree of cell kill induced by
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these treatments (Figs. 5.2b-c and f, Figs. 5.3b-c, Fig. 5.4c and f). Figs. 5.5-
5.7 summarise the mean values of sub G1 material for each treatment and
time point obtained from the cell cycle histograms. Following camptothecin
treatment there was a drastic increase in the level of cells located in the sub
G1 region following 1h treatment and 4h recovery, and an even higher
increase after 24h recovery. Etoposide treatment also induced apoptotic cell
death, evident by a massive increase in cell number in the sub G1 region.
After 1h NU:UB 31 treatment with 4h recovery there was a slight increase in
sub G1 cells compared to control, but not as high as for camptothecin and
etoposide. Following 24h recovery, NU:UB 31 treated cells appeared normal
with sub G1 levels that were comparable to the control (Fig. 5.5, Fig. 5.6).
For all 4h 20IJM and 30IJM NU:UB 31 treatments there was an increase in the
number of cells in the sub G1 region. However, following 4h recovery the sub
G1 levels were higher than following 24h recovery. At the NU:UB 31 50IJM
concentration there was a massive increase in sub G1 levels after 4h
treatment, which after 4h recovery increased to levels comparable to the
amount of cell kill induced by standard drugs. Upon examination, the 50IJM
NU:UB 31 treated cell cultures that had been left to recover for 24h contained
no viable cells. The amount of DNA leached out of cells, and hence the
position of the apoptotic peak in the sub G1 region of the DNA histogram may
depend on the cell type. For some of the HL60 cell histograms presented
within this chapter there was a lot of sub G1 material, but not a defined sub
G1 peak. Inclusion of a high molarity phosphate-citric acid buffer to the rinsing
solution is thought to enhance the extraction of the degraded DNA, improving
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resolution with a sharper sub G1 peak following drug treatment (Gong et al.,
1994). In addition to the light scattering properties, to confirm that the material
in the sub G1 region was indeed apoptotic cells, a sample with high levels of
sub G1 material was viewed under the confocal microscope. These cells
appeared to be apoptotic and Fig.5.8 shows cells treated with camptothecin at
2~M for 1h with 24h recovery, two pictures were taken of each cell and the
picture of PI stained DNA has been fused with the white light picture. This
revealed condensed DNA within the apoptotic sub G1 cells.
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Fig. 5.2a-c Representative histograms and respective cytograms of the cell cycle distribution in
HL60 cells, measured with flow cytometry. Cells were treated for 1h, were left to recover for 4h,
and were then stained in PI. Control (a), camptothecin 2IJM (b) and etoposide 5IJM (c).
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Fig. 5.2d-f Representative histograms and respective cytograms of the cell cycle distribution in
HL60 cells, measured with flow cytometry. Cells were treated for 1h, were left to recover for 4h,
and were then stained in PI. NU:UB 31 30IJM (d), NU:UB 31 40IJM (e) and NU:UB 31 50IJM (f).
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Fig. 5.2g Summary histogram of the cell cycle phase distribution in treated and untreated HL60
cells. Cells were treated for 1h, left to recover for 4h and stained in PI. Mean values of each cell
cycle phase ± SD were calculated.
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Fig. 5.3d·f Representative histograms and respective cytograms of the cell cycle distribution in
HL60 cells, measured with flow cytometry. Cells were treated for 1h, were left to recover for 24h,
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Fig. 5.3g Summary histogram of the cell cycle phase distribution in treated and untreated HL60
cells. Cells were treated for 1h, were left to recover for 24h, and were then stained in PI. Mean
values of each cell cycle phase ± SD were calculated.
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Fig. 5.4i Summary of flow cytometry analysis of cell cycle in HL60 cells . Cells were treated for 4h, left
to recover for 0, 4 or 24h and stained in PI. Mean values of each cell cycle phase ± SO were
calculated .
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Fig. 5.5 Summary of flow cytometry analysis of sub G1 material in HL60 cell samples. Cells were
treated for 1h, left to recover for 4h and stained in PI. Mean sub G1 values were calculated and
plotted,
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Fig. 5.6 Summary of flow cytometry analysis of sub G1 material in HL60 cell samples. Cells were
treated for 1h, left to recover for 24h and stained in PI. Mean sub G1 values were calculated and
plotted.
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Fig. 5.7 Summary of flow cytometry analysis of sub G1 material in HL60 cell samples. Cells were
treated for 4h, left to recover for Oh, 4h or 24h and stained in PI. Mean sub G1 values were calculated
and plotted.
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Fig. 5.8 Representative image of cells from the sub-G1 fraction of HL60 samples treated 1h with 2IJM
camptothecin and left to recover 24h. White light image merged with fluorescent image to visualise
condensed DNA in apoptotic HL60 cells. Cells were viewed at 60x magnification (a) or 60x
magnification and zoomed 4 times (b).
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5.4 DISCUSSION
In order to overcome the resistance problems with current agents, more than
one drug is in most cases used to treat a cancer. Drugs used in these
combination therapies generally have different cellular targets to avoid
development of drug resistant tumour cells. Treatments that synergistically
combine both topoisomerase I and topoisomerase II drugs can be used. For
example, a study by Kim et al. (1992) using human xenografts showed that
treatment that increased topoisomerase II levels (in this case pre-treatment
with the topoisomerase I drug irinotecan for 24 hours) augmented the activity
of topoisomerase II agents. However, combining different types of drugs must
be done with care since co-administration of topoisomerase I and II agents
may produce antagonism (Kaufman, 1991). In addition, understanding the cell
cycle and the possible cell cycle phase specificity of anti-cancer drugs will be
helpful in developing clinical protocols. Robles et al. (1999) investigated
whether anti-cancer drugs were capable of inducing permanent cell cycle
arrest in human fibroblasts. This group of researchers used etoposide and
camptothecin to induce DNA strand breaks in human fibroblasts. It was found
that camptothecin merely transiently arrested the cells, whereas etoposide on
the other hand induced a permanent cell cycle arrest in these cells. One
reason why a transient versus permanent cell cycle arrest was observed in
these cells was suggested to be due to differences in the drug mechanism of
inducing DNA breaks. Etoposide directly induces both single strand and
double strand DNA breaks. Camptothecin on the other hand first induces
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reversible single stranded breaks that have to be converted into irreversible
double strand breaks during replication fork movements. The transient arrest
following camptothecin treatment observed by Robles and co-workers (1999)
could therefore be due to mechanisms repairing the single strand breaks
before DNA replication took place.
Chemotherapy drugs may be subdivided into agents that primarily target non-
cycling cells or cycling cells, and also according to whether or not they target
a particular phase of the cell cycle. Flow cytometry investigations of HL60
cells revealed that different stresses could indeed affect the cells in different
phases of the cell cycle. For example, nitrogen mustard primarily affected G1-
phase cells, S-phase cells were susceptible to camptothecin, whereas G2/M
phase cells were most sensitive to radiation (Gorczyca et a/., 1993).
Additionally, etoposide was more potent when added to cells in late Sand
G2/M phases than when added to cells in the G1 phase (Stacey et a/., 2000).
Considering that arrest can occur in either the G1 or the G2 phase of the cell
cycle, and that cells may be inhibited in S-phase, it is feasible to ask, why do
some agents mainly arrest cells in G1 whereas others arrest cells
predominantly in G2 or in S-phase? The S-phase of the cell cycle, during
which DNA replication takes place is especially a target of anti-cancer drugs.
Studies by Darzynkiewicz et a/. (1996) have highlighted the cell cycle phase
specificity of camptothecin and it is here and elsewhere reported that
camptothecin induced cell death in a S-phase specific manner, arresting cells
in the S-phase (Gallo et a/., 1971; Horowitz and Horowitz, 1973; Malonne and
Atassi, 1997). Other studies using human lymphoid cells showed that long-
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term camptothecin exposure instead accumulated cells in all compartments of
the cell cycle, whereas m-AMSA previously reported to trap topoisomerase II
(Liu, 1989) retained cells in the G2 and GO/G1 phases. These findings have
been linked to topoisomerase (I and II) activities in relation to the cell cycle.
Topoisomerase I being important and expressed at relatively constant levels
in all phases of the cell cycle, and topoisomerase II possibly required to enter
S-phase and to complete G2 phase. Topoisomerase lIa expression levels
fluctuate over the course of the cell cycle, its levels increase in S-phase, peak
in G2/M phases and then decline as cells approach G1 (Poot et al., 1995).
Most of the cells in an asynchronously growing population will, however, be in
the G1 phase in the cell cycle. It may therefore be surprising that the majority
of cells are not arrested in G1 accordingly. Although p53 and p21 were up-
regulated, cells were not primarily arrested in G1 following doxorubicin
treatment. However, in a study by Siu et al. (1999) it was found that
doxorubicin, in addition to arresting cells in G2, was also capable of inducing
G1 arrest in Swiss3T3 cells. The basis of the G1 versus G2 cell cycle arrest
following doxorubicin treatment was examined. It was found that the G1 arrest
was, in contrast to the G2 arrest, relatively transient, and it was suggested
that the cells that initially arrested in G1 might eventually accumulate in the
G2 phase over long-term exposure.
Other agents may directly induce apoptosis with little or no cell cycle
specificity. NU/ICRF 505 is an example to illustrate this. This compound is an
agent, structurally related to the NU:UB series, that in previous studies has
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been reported to have a mechanism operating via topoisomerase I (Meikle et
al., 1995a; Cummings et al., 1996). In a study by Macpherson et al. (1997) the
cell cycle effect of NU/ICRF 505 was investigated in Chinese hamster ovary
(CHO) cell lines. It was here found that NU/ICRF 505 had little effect on the
cell cycle distribution in these cells. Also in these CHO cells, camptothecin
treatment was proven not to block cells in G2, and since these cells were
capable of arresting in G2 following etoposide treatment, the lack of G2 arrest
following NU/ICRF 505 treatment was here considered to be consistent with
the cellular response of CHO cells to an anti-topoisomerase I agent.
From the results of cell cycle studies presented within this chapter it seemed
that the standard drugs, camptothecin and etoposide induced cell cycle
arrests, while camptothecin accumulated the cells in S-phase, etoposide
blocked the cells in the G2/M phase. The 1h drug treatments with 4h recovery
induced high levels of apoptosis, which were even more evident after 24h
recovery. This was in agreement with earlier studies that have reported that
death induced by camptothecin is selective to cells in S-phase (Darzynkiewicz
et al., 1996), and etoposide arrests cells in G2/M (Sleiman et al., 1998; Stacey
et al., 2000). Following NU:UB 31 treatments, there were slight changes in the
cell cycle histograms, with decreases in the G1 peak and some cell kill
evident, but upon recovery for 24h the cell cycle histograms reverted to
normal. Thus, these results suggested that either the cell cycle arrest induced
by 1h NU:UB 31 treatment was not sufficient to initiate irreversible changes
and cells continued cycling once the drug was removed, or perhaps not all
cells were affected by the NU:UB 31 compound. However, in the study of
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NU/ICRF 505 in CHO cells mentioned above, the lack of G2 arrest following
treatment was considered to be consistent with the cellular response to a
topoisomerase I inhibitor (Macpherson et al., 1997). When cells were treated
with NU:UB 31 at 20IJM or 30IJM for 4h more cell kill was seen, but the pattern
was similar in that there was no definite cell cycle arrest, the cells that
survived the drug impact recovered once drug was removed and the cell cycle
profile was looking normal once cells had recovered for 24h. When NU:UB 31
concentration was increased to 50IJM, a lot more cells were killed and there
was permanent cell damage since after 24h recovery there were no viable
cells present in the culture.
Following 1h camptothecin or etoposide treatment the cycle was blocked even
when these drugs had been washed off and the cells were left to recover for 4
and 24h. Thus, the DNA damage was permanent and there was a lot of cell
kill over time. In contrast, NU:UB 31 seemed to have a more immediate, short
term effect. After NU:UB 31 treatment it appeared that once the compound
was washed off, NU:UB 31 20IJM and 30IJM treatments had no long term
effect and those cells that did not die fairly quickly would recover. If the
concentration was increased to 50IJM the damage was made permanent and
there was no recovery. Overall, NU:UB 31 did not seem to induce a specific
cell phase block in HL60 cells, rather cells might die from all phases of the
cycle, and the cells that survived the impact of NU:UB 31 might have been
allowed back into cell cycle upon removal of the compound unless the
concentration was very high (50IJM).
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It has been suggested that apoptosis is a premature, abortive mitosis and that
apoptosis can be thought of as a cell cycle phenomenon (Meikrantz and
Schlegel, 1995). Cell death by mitotic catastrophe is morphologically very
similar indeed to apoptosis since one of the most prominent apoptotic
morphological feature, chromatin condensation, may also be seen in mitosis
(Lazebnik et al., 1993; Rubin et al., 1993). It has further been reported that
agents may be capable of inducing both types of cell death, depending on cell
type and the cell's position in the cell cycle. This should be taken into
consideration when investigating apoptotic cell death. The sub G1 material
was here measured for each sample to give an additional indication of the
level of apoptosis in drug treated and untreated HL60 cells. There was an
increase in sub G1 material compared to control following NU:UB 31
treatments, but after 24h recovery from NU:UB 31 treatment (1 h or 4h) the
cell cycle appeared normal and there were low levels of sub G1 material in
these samples. This might suggest that drug damaged cells that survived the
impact of the treatment had recovered and returned back into the cell cycle
and thus the drug had no further effect on these cells. A further increased
recovery time is, therefore, not likely to kill more cells, but instead allow for
continued growth of the cells that survived the impact of the drug. Following
4h 50IJM the drug treatment appeared to be high enough to damage all cells
in the sample, and thus no recovery was possible with no remaining viable
cells following 4h 50IJM NU:UB 31 treatment with 24h recovery.
In summary, in contrast to the standard drugs, NU:UB 31 did not appear to
cause any specific and permanent arrest of the cell cycle. The cells instead
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appeared to die from all phases of the cell cycle following treatment with a
high enough dose of NU:UB 31. Following NU:UB 31 and standard anti-
topoisomerase inhibitor treatment the cells appeared to become apoptotic,
confirmed by flow cytometry investigations of accumulated sub G1 material.
The evidence for apoptosis induction by this method was consistent with
confocal microscope imaging observations.
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CHAPTER 6
INVESTIGATION OF APOPTOTIC CELL DEATH
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6.1 INVESTIGATION OF APOPTOTIC CELL DEATH
It was established that NU:UB compounds were cytotoxic in vitro (data
presented in Chapter 4). Furthermore, it was found that there was an increase
in the number of cells with a sub G1 DNA content following NU:UB treatment,
suggesting that these cells were apoptotic (data presented in Chapter 5).
Further in-depth investigations of apoptosis have been presented within this
chapter and were obtained by studying the morphological and biochemical
changes in vitro, in NU:UB treated cells. The focus has been on NU:UB 31,
with supporting studies on NU:UB 51 and NU:UB 80; camptothecin and
etoposide were also included as positive apoptotic controls.
Viable apoptosis pathways in tumour cells are thought important for
chemotherapy to be successful. Many of the morphological and biochemical
changes triggered during apoptosis appear to be of a similar nature in
different cell types. It is generally believed that apoptotic events at the cellular
level include morphological changes such as: reduction in nuclear size,
shrinkage of total cell volume, chromatin condensation, increase in cell
density, nuclear fragmentation, membrane blebbing and constriction of both
the nucleus and the cytoplasm into multiple, small, membrane-bound
apoptotic bodies. During the apoptotic response, cellular proteins are thought
to be degraded by caspase enzyme activities. Furthermore, DNA is cleaved,
degraded by endonucleases, which generates a characteristic ladder on
agarose gels (Studzinski 1995; Cohen 1993).
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Necrosis is another type of cell death and cell death by necrosis is different
from apoptosis in that it is a passive process where the cell swells and
ruptures. In necrotic cell death, DNA is also degraded, but not to the same
extent as in apoptotic DNA fragmentation. The necrotic DNA products are
heterogeneous in size, and therefore do not form discrete bands upon
agarose gel electrophoresis. However, although there are differences
between these two forms of cell death, there are also similarities that
frequently overlap. In addition, these two mentioned types of cell death may
not account for all forms of cell death. Conclusive evidence of apoptosis will
therefore have to include more than one morphological or biochemical
criterion (Studzinski 1995).
It has been demonstrated by Nelson and Kastan (1994) that DNA strand
breaks, but not other DNA lesions were capable of inducing p53, and it is
thought that p53 serves as a sensor of DNA strand breaks in cells. Although it
has been suggested that p53 plays a crucial role in apoptosis as a response
to chemotherapeutics, a functional p53-dependent pathway is not the only
mechanism for apoptosis to be induced, as p53-independent pathways may
playa role. In a study by Shellhaas and Zuckerman (1995), HL60 cells
(containing no p53) were used to investigate the capacity of various stimuli in
promoting apoptosis. The results of these experiments demonstrated that
HL60 offers a well-characterized in vitro system for investigating apoptosis in
drug treated cells. Earlier studies have also demonstrated that the HL60 cell
line showed DNA fragmentation in response to several topoisomerase
inhibitors and would thus provide a suitable cell line to use in DNA ladder
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assays (Kaufman 1989; Solary et al., 1993). In the apoptotic studies reported
within this Chapter, HL60 was the cell line of choice. Studies were performed
by treating HL60 cells with camptothecin, etoposide or NU:UB compound for
the identification of apoptotic cells. The first aim was to identify apoptotic
morphology following NU:UB treatment. In addition to the morphological
studies, biochemical changes following NU:UB treatment were also
investigated. The second aim in this study was to examine DNA fragmentation
as evidence of DNA damage and apoptosis. The third aim was to investigate
whether or not NU:UB compounds, in killing cells, activate caspases and for
this purpose fluorescein-labelled caspase inhibitors have been used.
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6.2 METHODS
6.2.1 Morphology Studies In HL60 Cells Following Treatment
With NU:UB Compounds
HL60 cells were seeded in 24 well plates at 20 x 104 cells/ml. Cells were
treated with NU:UB compounds, standard drugs or with solvent alone (control)
for a selected length of time. Cells in the solvent controls were exposed to the
same concentration of solvent as used for the drug treated cells. Following
treatment, cells were centrifuged at 500 x g for 5 mins and were washed twice
in PBS. Cytospin (Cytospin3, Shandon) preparations were made up in
triplicate with 1 x 105 cells per slide. Following cytospin centrifugation at 1000
rpm, 5 mins cells were fixed for 5 mins in methanol and stained using the Diff
Quick rapid staining set. The slides were soaked in acid dye for 10-20 sees,
and subsequently soaked in basic dye for 10-20 sees. Following staining, the
residues were washed off in S6rensens buffered water. The cells were
dehydrated, mounted in DPX and viewed in a light microscope (Axioskop,
Zeiss) at 40x magnification.
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6.2.1 a Treatment Of Results
For each treatment, >1000 cells were counted on three different slide
preparations. Cells with apoptotic appearance were identified, counted and
expressed as a percentage of the total number of counted cells.
6.2.2 Additional Experiments
HL60 cells were stained with Hoechst 33342 stain (1/100 dilution of a
1OO~g/ml stock) to visualise the nuclear morphology. Hoechst 33342 is a cell
permeable adenine-thymidine specific fluorescent dye that is widely used to
stain DNA for evaluating apoptosis. The HL60 cells were treated as above
and were then stained in Hoechst stain for 5 mins. Cells were put onto glass
slides and were viewed in a UV fluorescent microscope (Leica DMRB) fitted
with a JVC colour video camera (KY-F55B) using AcQuis Bio software to
obtain images.
6.2.3 DNA Laddering Studies Following Treatment With
NU:UB Compounds
The detection of DNA fragments in cells is one of the methods available to
identify cells undergoing apoptosis. For this study the ApoTarget Quick
Apoptotic DNA ladder detection kit (BioSource) was used. DNA and DNA
fragments were extracted from cells and the level of DNA fragmentation
visualised by ethidium bromide gel electrophoresis. The time points and
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standard drug concentrations chosen were based on the instructions in the
DNA ladder kit and the IC50 values obtained for the NU:UB compounds.
HL60 or Jurkat cells, 150 x 104 cells per sample were treated with NU:UB
compounds, standard drugs or solvent (control). Cells were transferred to
universals and centrifuged at 500g for 5 mins at 4°C. Cell pellets were
washed in PBS, transferred to Eppendorf tubes and pelleted by another
centrifugation step at 500 x g for 5 mins at 4°C. Supernatants were discarded
and the cells resuspended in 201-11 TE lysis buffer by careful pipetting. Enzyme
A, 51-11 was added to each sample and the tubes were gently vortexed and
incubated in a 37°C waterbath for 10 mins. Enzyme B, 51-11 was added and
samples were incubated until the cell Iysates were clear (approximately 30
mins). Ammonium acetate, 5111 and ice-cold absolute ethanol, (1001-11) was
added to each lysate. The samples were vortexed and left in a freezer to
precipitate for 15 mins or longer. The samples were centrifuged at 14 000 x g
for 10 mins at 4°C to collect the precipitated DNA. The supernatants were
discarded and the DNA was washed in 70% ice-cold ethanol and centrifuged
at 14 000 x g for 10 mins at 4°C. The ethanol was discarded and the DNA
pellets were left to air dry at room temperature. DNA suspension buffer, 301-11
was added to each sample to dissolve the DNA. A horizontal mini gel
electrophoresis apparatus (HE 33 Hoefer) was used and the samples were
loaded onto an agarose gel (1 %) containing ethidium bromide (0.5I-1g/ml) in
both gel (1g agarose was boiled in 100ml 1x TBE, and when cooled 51-11
ethidium bromide (1mg/ml) was added), and running buffer [250ml 1x TBE
with 12.51-11 ethidium bromide (1 mg/ml)]. The electrophoresis was run at 50V
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(5V/cm) for 1.5-2h and the gel was visualized in a UV light and photographed
with the SynGene Imager using the GeneSnap and GeneTool software.
6.2.4 Caspase Activation Studies Following Treatment With
NU:UB Compounds
To study general caspase activation, the CaspaTag Fluorescein caspase
(VAD) kit (Intergen) was used. Caspase-3 activation was investigated with the
CaspaTag caspase-3 (DEVD) activity kit (Intergen). These kits detect active
caspases in living cells through the use of a carboxyfluorescein labelled
caspase inhibitor, where inhibitor irreversibly binds to active caspases. FAM-
VAD-FMK is a derivative of benzyloxycarbonylvalylalanyl aspartic acid
fluoromethyl ketone (zVAD-FMK), which is a potent general inhibitor of
caspase activity. FAM-DEVD-FMK is a derivative of
benzyloxycarbonylaspartylglutamylvalylaspartic acid fluoromethyl ketone
(zDEVD-FMK), which is a potent inhibitor of caspase-3. Cells that contained
bound inhibitor were analysed with a flow cytometer (FACSCalibur, Becton
Dickinson Immunocytometry Systems) equipped with a 15mW argon ion air-
cooled laser with excitation wavelength 488nm and with UV fluorescent
microscope (Leica DMRB).
Cells were diluted to 5 x 104 cells/ml with culture medium and left to recover
overnight. The manual provided by Intergen recommended HL60 cells to be
treated with 4lJg/ml (11.5IJM) camptothecin for 4 hours as a positive control
for apoptosis. Treatments were carried out at 37°C, 5% CO2 , for 4 and 24h.
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Prior to use, caspase inhibitor solution, 150x was diluted 1:5 in PBS and used
as soon as possible. The wash buffer was placed in a 37°C incubator for 30
mins to dissolve precipitated protein and buffer salts. The buffer was then
diluted 1:10 in dH20 and ready for use. Following drug treatment, cells were
pelleted at 400 x g for 5 mins, counted and resuspended at 106 cells/ml.
Aliquots of 3001J1 from each treatments were transferred into Eppendorf tubes.
FAM-VAD-FMK, 101J1 was added to each tube and the samples were then left
to incubate in dark for 1h at 37°C under 5% C02. Wash buffer was added to
the samples and cells were pelleted by centrifugation at 400x g for 5 mins.
After a second wash step, cells were pelleted and finally resuspended in
4001J1 wash buffer and kept on ice until analysed. If cells could not be
analysed immediately, they were fixed by adding 401J1 fixative solution to the
4001J1 cell suspension. Fixed cells could last up to 24h in the dark before
analysis. Fluorescein emission intensity was measured on the FL1 channel
and log FL1 (X-axis) versus number of cells (Y-axis) was generated into a
histogram. On the histogram two cell populations represented by two peaks
appeared for caspase positive cell populations. The majority of the caspase
negative cells appeared within the first log decade whereas caspase positive
cells appeared in a separate peak or as a shoulder of the first peak with
increased fluorescence intensity.
For cells that were to be analysed with fluorescence microscopy, the same
procedure was followed but after the 1h FAM-VAD-FMK staining, cells were
also stained in Hoechst Stain (provided with the kit), adding 1.51J1 and
incubating for another 5 mins. The same washing procedure was followed but
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cells were resuspended in 1001-11 instead of 4001-11 to get a higher cell density.
One drop of cell suspension was put onto a microscope slide and covered
with a coverslip. Cells were observed under UV fluorescence microscope
(Leica DMRB) and images were obtained with a fitted JVC colour video
camera (KY-F55B).
Caspase-3 activation was investigated with the CaspaTag caspase-3 (DEVD)
activity kit, and the protocol for this assay was identical to the above
CaspaTag caspase (VAD) activity kit protocol.
6.2.4a Treatment Of Results
Caspase-positive cells appeared in the second log phase on the FL-1, x-axis
of the cell histogram, and were expressed as a percentage of the total number
of cells analysed. Experiments were performed in duplicate or triplicate,
resulting in a mean value of caspase positive cells for every treatment.
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6.3 RESULTS
6.3.1 Morphology Studies In HL60 Cells Following Treatment
With NU:UB Compounds, Camptothecin Or Etoposide
For morphology studies, HL60 cells were exposed to solvent (control), NU:UB
compounds, camptothecin or etoposide for 8h and 24h. Cells were fixed onto
glass slides, stained and viewed in a light microscope at 40x magnification.
The standard drugs, camptothecin and etoposide induced high levels of
apoptosis in HL60 cells following 8h exposure (Fig. 6.1b; Fig 6.1c; Fig. 6.1j;
Fig. 6.2a). The morphology data indicated that HL60 cells also showed
apoptotic morphology following NU:UB 31 [Fig. 6.1d (10IJM, 8h); Fig. 6.1e
(20IJM, 8h); Fig. 6.1 k (20IJM, 24h); Fig. 6.2b] and NU:UB 51 [Fig. 6.1 g (5IJM,
8h); Fig. 6.1 h (10IJM, 8h); Fig. 6.11 (1IJM, 24h); Fig. 6.1 m (5IJM, 24h)]
treatments. Using Diff Quick staining, apoptotic morphology following NU:UB
treatment was evident at the 8h time point, but not to the levels induced by the
standard drugs, camptothecin and etoposide. There was in addition to
apoptotic morphology also a lot of cells that seemed to have a necrotic (or
secondary necrotic) appearance present at the high NU:UB 31, 30IJM
concentration (Fig.6.1f).
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6.3.2 Hoechst Staining Of HL60 Cells
HL60 cells were stained in Hoechst Stain 33342 to visualise nuclei following
4h and 24h treatment with solvent (control), camptothecin or NU:UB
compounds (Fig. 6.3). When viewed in a UV fluorescence microscope the
nucleus in normal control cells appeared rounded. Treated Hoechst stained
HL60 cells seemed to have apoptotic nuclear morphology with apoptotic
bodies and intensely stained, condensed and thus smaller nuclei compared to
control cells. HL60 cells were exposed to the following treatments:
camptothecin [Fig. 6.3b (10IJM, 4h); Fig. 6.3f (O.5IJM, 24h)], NU:UB 31 [Fig.
6.3c (20IJM, 4h); Fig. 6.3g (10IJM, 24h)] and NU:UB 51 [Fig. 6.3d (10IJM, 4h);
Fig. 6.3h (51JM, 24h)], and the highest levels of apoptotic cells were observed
following camptothecin treatment.
6.3.3 DNA Laddering Studies Following Treatment With
NU:UB Compounds Or Camptothecin
To obtain a positive DNA ladder control, the standard topoisomerase
inhibitors camptothecin, and etoposide, both inducers of apoptosis, were
investigated in jurkat cells as this cell line was used in the kit protocol. On the
basis of these results, camptothecin was chosen as a positive control as this
drug clearly induced DNA fragmentation, resulting in a typical apoptotic DNA
ladder (Fig. 6.4a). Etoposide did not show as clear laddering as camptothecin,
but DNA was damaged followed etoposide treatment (Fig. 6.4b). Although
etoposide induced apoptosis (observed morphologically), no DNA ladders
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were seen here and longer exposure time, and/or other etoposide
concentrations might be required. However, studies do suggest that DNA
laddering may not be essential for apoptosis, that apoptosis can take place
without the typical DNA fragmentation (Cohen et al., 1992; Ucker et al., 1992;
Falcieri et al., 1993; Pandey et al., 1994; Sieiman, 1998).
For this study, HL60 rather than Jurkat cells were used since we had
previously found morphological evidence of apoptosis following NU:UB
treatment in this cell line. Furthermore, the HL60 cell line is routinely used for
investigating apoptosis. HL60 cells were treated with camptothecin to find out
whether or not this cell line was suitable for the DNA ladder assay. Following
6h and 24h there was, as expected, no DNA laddering and fragmentation in
the solvent control. Treatment with camptothecin revealed substantial DNA
fragmentation at the 6h time point, presented as a DNA ladder. Following 24h
exposure to camptothecin, DNA appeared as a smear on the gel possibly
indicating a 24h exposure time at a 1O~M concentration was too long in this
cell line. The 6h time point was also sufficient for NU:UB 31 (20IJM) to induce
DNA damage. At the longer, 24h exposure time, NU:UB 31 at 10IJM or 20IJM
did not result in more laddering (Fig. 6.5). Following NU:UB 51 and NU:UB 80,
at 5IJM and 15IJM respectively there was also DNA laddering, but for the
lower concentrations (1IJM and 5IJM respectively) of these compounds, there
was no apparent DNA laddering present (Fig. 6.6).
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6.3.4 Caspase Activation Studies Following Treatment With
NU:UB Compounds Or Camptothecin Using Flow Cytometry
General caspase activation and caspase-3 activation were studied in HL60
and HCT116 cells by flow cytometry. Two exposure times were chosen (4 and
24h), 4h was the exposure time suggested in the caspase assay protocol
using HL60 cells treated with camptothecin. HL60 cells (Fig. 6.7; Fig. 6.8a;
Fig. 6.8b) and HCT116 cells (Fig. 6.9a; Fig. 6.9b) were treated with
compounds for 4h and 24h, and were then stained with the general caspase
inhibitor. These experiments suggested that there was caspase activation
following 4h NU:UB 31 at 20IJM and NU:UB 51 at 10IJM treatment, but not so
much at the lower concentrations of these agents. Camptothecin 10IJM
treatment for 4h only resulted in a slight increase in caspase activation
compared to the control (Fig. 6.8a), but following 24h of O.05IJM camptothecin
there was a higher increase in caspase activation (Fig. 6.8b). Camptothecin
and NU:UB 31 were also assayed in HCT116 cells. At the 4h time point there
was no increase in caspase activation following 10IJM camptothecin
treatment, but at the 24h time point caspase activation was evident. NU:UB
31 at 40IJM resulted in caspase activation after 4h, and at the 24h time point
25IJM NU:UB 31 showed significant (p<O.05) caspase activation compared to
control (Fig. 6.9a; Fig. 6.9b). Thus, NU:UB 31 and NU:UB 51 appeared to
activate caspases in HL60 cells as early as 4h. Caspase activation was
slightly increased by 4h and was further increased following 24h of
camptothecin treatment. In HCT116 cells NU:UB 31 induced caspases at the
4h time point. There was however no caspase activation at 4h following
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camptothecin treatment, but following 24h camptothecin treatment, caspase
activation was observed.
In addition to investigating general caspase activation, the effector caspase,
caspase-3 was studied specifically. The results from this study have been
graphed in Fig. 6.10 and show caspase-3 activation following 4h and 24h
treatment with camptothecin, NU:UB 31 and NU:UB 51. Following 4h
camptothecin treatment there was no increase compared to control. NU:UB
31 at 20IJM, on the other hand, showed a slight increase in caspase-3
activation and NU:UB 51 at 15IJM showed a significant increase (p<O.01)
compared to the control following 4h treatment (Fig. 6.10a). After 24h
treatment, O.5IJM camptothecin induced a caspase-3 response, and there was
also increased caspase-3 activation compared to control following 24h NU:UB
31 or NU:UB 51 compound treatment (Fig. 6.10b). Thus NU:UB 31 and
NU:UB 51 induced caspase-3 in HL60 cells at the 4h time point. There was,
however, no caspase-3 activation following 4h camptothecin treatment, but
after 24h the response was greatly increased.
6.3.5 Caspase Activation Studies Following Treatment With
NU:UB Compounds Or Camptothecin Using UV Fluorescence
Microscopy
To confirm caspase and caspase-3 staining observed in the above flow
cytometry studies, HL60 cells were also viewed under UV fluorescence
microscope. The cells were double stained in Hoechst stain (blue) and the
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general caspase, and caspase-3 inhibitors resulted in green fluorescence.
Figs. 6.11-6.18 show HL60 cells treated with solvent (control), camptothecin,
NU:UB 31 or NU:UB 51. These cells have been stained with Hoechst stain to
visualise the nucleus (a), and with the general caspase inhibitor binding to
active caspases with in the apoptotic cells (b). This series of images revealed
that there was caspase activation in cells following camptothecin, NU:UB 31
and NU:UB 51 treatments, many of the cells had condensed nuclei, and
apoptotic bodies were also revealed with the blue Hoechst stain.
Caspase-3 stained HL60 cells were captured in Figs. 6.19-6.27. Cells were
treated with solvent (control), camptothecin, NU:UB 31 or NU:UB 51.
Following staining with Hoechst stain (a), and with caspase-3 inhibitor (b), the
cells were viewed under UV fluorescent microscope.
In for example Fig. 6.13b, Fig. 6.17b and Fig. 6.21b the cells were treated with
NU:UB 31, which has a bright red intrinsic fluorescence. The bright red colour
from NU:UB 31 and from NU:UB 51 was found to strongly interfere with
propidium iodide (PI), and thus PI could unfortunately not be used as a
measure to separate out the necrotic population from the apoptotic cells in the
flow cytometer experiments and this is why we resorted to one colour staining
in the flow cytometer studies.
193
Fig. 6.1a Control 8h
Fig. 6.1b Camptothec in 51..lM 8h
Fig. 6.1a-b HL60 cells treated with solvent (control) or camptothecin (511M) for 8h.
Following treatment, the cells have been visualized by D iff Quick staining and viewed
under light microscope at 40x magnification.
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Fig. 6.1c Etoposide 5IJM 8h
Fig. 6.1d NU:UB 31 5IJM 8h
Fig. 6.1c-d HL60 cells treated with etoposide (5IJM) or NU:UB 31 (5~M) for 8h. Following
treatment, the cells were visualized by Diff Quick staining and viewed under light microscope
at 40x magnification .
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Fig . 6.1e NU:UB 31 20IJM 8h
Fig. 6.1f NU:UB 31 30IJM 8h
Fig. 6.1e-f HL60 cells treated with NU:UB 31 (30llM or 20IlM) for 8h. HL60 cells have been
visualized by Diff Quick staining and viewed under light microscope at 40x magnification.
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Fig. 6.1g NU:UB 51 5IJM 8h
Fig. 6.1h NU:UB 51 10IJM 8h
Fig. 6.1g-h HL60 cells treated with NU:UB 51 (10~M or 5~M) for 8h. Following treatment, the
cells were visualized by Diff Quick staining and viewed under light microscope at 40x
magnification.
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Fig. 6.1i Control24h
Fig. 6.1j Camptothecin O.5IJM 24h
Fig. 6.1i-j HL60 cells treated with solven t (control) or camptothecin (O.5IlM) for 24h.
Following treatment, HL60 cells were visualized by Diff Quick staining and viewed under light
microscope at 40x magnification.
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Fig. 6.1k NU:UB 31 20IJM 24h
Fig . 6.11 NU:UB 51 1IJM 24h
Fig. 6.1k-I HL60 cells treated with NU:UB 31 (20IlM) or NU:UB 51 (111M) for 24h. Following
treatment , the cells were visualized by Diff Quick staining and viewed under light microscope
at 40x magnification.
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Fig. 6.1m NU:UB 51 5IJM 24h
Fig. 6.1m HL60 cells treated with NU:UB 51 (5l!M) for 24h. HL60 cells have been visualized
by Diff Quick staining and viewed under light microscope at 40x magnification .
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Fig. 6.2 HL60 cells exposed to camptothecin (cmt, O.5IJM or 51JM) or etoposide (etp, 51JM) for
8 and 24h (a). HL60 cells exposed to NU:UB 31 (5IJM, 20IJM or 301JM) for 8,24 and 48h (b).
Cells were counted and a percentage of cells with apoptotic morphology established for each
treatment. Results are the mean percentages of cells counted (>1000) from three slide
preparations of one experiment.
201
Fig. 6.3a HL60 control 4h
Fig. 6.3b Camptothecin 1O~M 4h
Fig. 6.3a-b HL60 cells treated with solvent (control) or camptothecin (1O~M) for 4h.
Following treatment, HL60 cells were stained in Hoechst stain to visualise their nucleus
and were then viewed under UV fluorescent microscope at 60x magnification.
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Fig. 6.3c NU:UB 31 2011M 4h
Fig . 6.3d NU:UB 51 1011M 4h
Fig. e.ae-e HL60 cells treated with NU:UB 31 (2011M) or NU:UB 51 (1011M) for 4h.
Following treatment, HL60 cells were stained in Hoechst stain to visualise their nucleus
and were then viewed under UV fluorescent microscope at 60x magnification.
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Fig. 6.3e Control 24h
Fig. 6.3f Camptothecin O.5~M 24h
Fig. 6.3e-f HL60 cells treated with solvent (control) or camptothecin (O .5~M) for 24h.
Following treatment, HL60 cells were stained in Hoechst stain to visualise their nucleus
and were then viewed under UV fluorescent microscope at 60x magnification.
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Fig. 6.3g NU:UB 31 10JlM 24h
Fig. 6.3h NU:UB 51 5JlM 24h
Fig. 6.3g-h HL60 cells treated with NU:UB 31 (10JlM) or NU:UB 51 (5JlM) for 24h.
Following treatment, HL60 cells were stained in Hoechst stain to visualise their nucleus
and were then viewed under UV fluorescent microscope.
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Fig 6.4 (a)
Fig 6.4 (b)
Fig. 6.4 Jurkat cells 6h exposure. Solvent control (lane 1), camptothecin 3IJM (lane 2),
camptothecin 10IJM (lane 3) (a). Jurkat cells 6h exposure. Solvent control (lane 1),
camptothecin 10IJM (lane 2), etoposide 5IJM (lane 3) (b).
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Fig. 6.5 HL60 cells 6h and 24h exposure . Control 6h (lane 1), camptothecin 10IJM 6h (lane
2), NU:UB 31 20IJM 6h (lane 3), control 24h (lane 4), camptothecin 10IJM 24h (lane 5),
NU:UB 31 10IJM24h (lane 6), NU:UB 31 20IJM 24h (lane 7).
Fig. 6.6 HL60 cells 6h exposure. Control (lane 1), camptothecin 10IJM (lane 2), NU:UB
31 20IJM (lane 3), NU:UB 51 1IJM(lane 4), NU:UB 51 5IJM (lane 5), NU:UB 80 5IJM (lane
6), NU:UB 80 151JM.
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Fig. 6.7a-c Flow cytometer cytograms and corresponding histograms of caspase activation in
HL60 cells. 4h Control (a), camptothecin 10IJM (b) and NU:UB 31 20IJM (c).
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Fig. 6.7d-f Flow cytometer cytograms and corresponding histograms of caspase activation in
HL60 cells. 24h Control (d), camptothecin O.05IJM (e) or NU:UB 31 10IJM (f).
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Fig. 6.8a-b General caspase activation expressed as a percentage in HL60 cells, Cells exposed
4h (a) or 24h (b) to solvent (control), camptothecin (cmt), NU:UB 31 or NU:UB 51,
210
Fig. 6.9 (a)
80
!!l.
Q)
o 70
CD
.....
..... 60I-
o
:c 50c
c
0 40:;::;
ro
>:;::; 30o
«
(I)
20(/)ro
0-
(/)
ro 10o
~0 0
C3' f ~ ~
-s ~ ~ Ilrs f' "- "-o '? '?o $J $J:::;. :::;.
~ ~
Fig. 6.9 (b)
60
sa
Qi
<.) 50<0
......
~
<.) 40:::c
.E
c:
~ 30
~ 20
Q)
f/)
<II
0-
f/) 10<II
<.)
:::,g
0
0
C3'
"sso
*
Fig. 6.9a-b General caspase activation in HCT116 cells, expressed as a percentage of the total
number of cells. Cells exposed 4h (a) and 24h (b) to solvent (control), camptothecin (cmt) or
NU:UB 31.
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Fig. 6.10a-b Caspase-3 activation in HL60 cells, expressed as a percentage of total cells. Cells
exposed 4h (a) and 24h (b) to solvent (control), camptothecin (cmt), NU:UB 31 or NU:UB 51
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Fig. 6.11a Control4h, Hoechst stain
Fig. 6.12a Camptothecin 10JlM 4h
Fig. 6.13a NU:UB 31 20JlM 4h
Fig. 6.11b Control4h, General caspase stain
Fig. 6.12b Camptothecin 10JlM 4h
Fig. 6.13b NU:UB 31 20JlM4h
Fig. 6.11-6.13 HL60 cells treated with solvent (control), camptothecin or NU:UB 31 for4h. Following
treatment, cells were stained with Hoechst stain and general caspase inhibitor. The cells were
viewed under UV fluorescent microscope at 60x magnification, two pictures were taken of the same
field of cells to visualise the blue Hoechst stain (a) and the green caspase stain (b).
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Fig. 6.14a NU:UB 51 10llM 4h
Fig. 6.15a Control24h
Fig. 6.16a Camptothecin O.5IlM 24h
Fig. 6.14b NU:UB 51 10llM 4h
Fig. 6.15b Control 24h
Fig. 6.16b Camptothecin O.5IlM 24h
Fig. 6.14-6.16 HL60 cells treated with solvent (control), camptothecin or NU:UB 51 for 4h and 24h.
Following treatment, cells were stained with Hoechst stain and genaral caspase inhibitor. The cells
were viewed under UV fluorescent microscope at 60x magnification, two pictures were taken of the
same field of cells to visualise the blue Hoechst stain (a) and the green caspase stain (b).
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Fig. 6.17a NU:UB 31 10~M 24h
Fig. 6.18a NU:UB 51 5~M 24h
Fig. 6.17b NU:UB 31 10~M 24h
Fig. 6.18b NU:UB 51 5~M 24h
Fig. 6.17-6.18 HL60 cells treated with NU:UB 31 or NU:UB 51 for 24h. Following treatment, cells
were stained with Hoechst stain and genaral c aspase inhibitor. The cells were viewed under UV
fluorescent microscope at 60x magnification, two pictures were taken of the same field of cells to
visualise the blue Hoechst stain (a) and the green caspase stain (b).
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Fig. 6.19a Control4h, Hoechst stain
Fig. 6.20a Camptothecin 10llM 4h
Fig. 6.21a NU:UB 31 20llM 4h
Fig. 6.19b Control4h, Caspase-3 stain
Fig. 6.20b Camptothecin 10llM 4h
Fig . 6.21b NU:UB 31 20llM 4h
Fig. 6.19-6.21 HL60 cells treated with solvent (control), camptothecin or NU:UB 31 for 4h. Following
treatment, cells were stained with Hoechst stain and caspase-3 inhibitor. The cells were viewed
under UV fluorescent microscope at 60x magnification, two pictures were taken of the same field of
cells to visualise the blue Hoechst stain (a) and the green caspase-3 stain (b).
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Fig. 6.22a NU:UB 51 15~M 4h
Fig. 6.23a Control 24h
Fig . 6.24a Camptothecin O.05~M 24h
Fig . 6.22b NU:UB 51 15~M 4h
Fig. 6.23b Control 24h
Fig . 6.24b Camptothecin O.05~M 24h
Fig. 6.22-6.24 HL60 cells treated with solvent (control) , camptothecin, NU:UB 51 for 4h and 24h.
Following treatment, cells were stained with Hoechst stain and caspase-3 inhibitor. The cells were
viewed under UV fluorescent microscope at 60x magnification, two pictures were taken of the same
field of cells to visualise the blue Hoechst stain (a) and the green caspase-3 stain (b).
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Fig. 6.25a NU:UB 31 10flM 24h
Fig. 6.26a NU:UB 31 15flM 24h
Fig. 6.27a NU:UB 51 5flM 24h
Fig. 6.25b NU:UB 31 10flM 24h
Fig. 6.26b NU:UB 31 15flM 24h
Fig. 6.27b NU:UB 51 5flM 24h
Fig. 6.25-6.27 HL60 cells treated with NU:UB 31 or NU:UB 51 for 24h. Following treatment, cells
were stained with Hoechst stain and caspase-3 inhibitor. The cells were viewed in fluorescent
microscope. two pictures were taken of the same field of cells to visualise the blue Hoechst stain (a)
and the green caspase-3 stain (b).
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6.4 DISCUSSION
In this part of the research programme, apoptotic studies, including light and
UV fluorescent microscopy observations, DNA fragmentation studies and flow
cytometry investigations are presented to provide evidence that apoptosis
was induced following treatments with NU:UB compounds and classical
topoisomerase inhibitors. Etoposide and camptothecin were used as positive
apoptotic controls in these studies. Etoposide has in the literature been
reported to induce apoptosis in cell lines, including the HL60 cell line (Onishi
et al., 1993; Alexandre et aI., 2000). The mechanism of cytotoxic action of
etoposide and induction of apoptosis, are thought to be related to its
interaction with topoisomerase II as this drug has been found to target both
topoisomerase lIa and topoisomerase II~ (Willmore et al., 1998).
Camptothecin is reported to induce apoptosis in several human cancer cell
lines; the exact pathway(s) is not fully understood, but thought to be linked to
DNA strand breaks produced by camptothecin through stabilization of the
topoisomerase I-DNA cleavable complexes (Covey et al., 1989; Gong et al.,
1993; Onishi et al., 1993; Johnson et al., 1997; Alexandre et aI., 2000). A
previous study with camptothecin showed that changes in cell morphology as
well as DNA laddering by camptothecin treatment can be seen as early as 3h
in HL60 cells (Gong et al., 1994). Other studies used longer exposure times
for investigating apoptotic DNA laddering following camptothecin exposure.
For example, Goossens et al. (2000) exposed HL60 cells to 1-201JM for 15h,
or to 10-501JM for 5h and found that short incubation times at higher drug
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concentrations, or longer incubation times with low drug concentrations gave
rise to similar results. In agreement with the above mentioned publications,
the apoptotic investigations of camptothecin in this study showed DNA
fragmentation and morphological changes of HL60 cells. The DNA
fragmentation patterns visualized on agarose gels showed that the DNA
fragmentations as a result of NU:UB 31, NU:UB 51 and NU:UB 80 treatments
appeared similar to DNA fragments extracted from camptothecin-treated
HL60 cells. This indicated preferential hydrolysis of DNA at the
internucleosomal linker sections. This pattern is characteristic (but not a
necessary criterion) for apoptosis.
Observations of cells by microscopy after staining provided evidence of
apoptotic morphology. The cell morphology in general appeared similar
regardless of treatment by camptothecin, etoposide or NU:UB compounds,
both nuclear and cytoplasmic shrinkage were observed. In non-apoptotic
HL60 cells, chromatins are generally not well stained, whereas HL60 cells
engaged in the apoptotic pathway often present several clumps of condensed
chromatin and these features were observed here. In addition to apoptosis
there are at least two other types of cell death in vivo; necrosis and premature
mitosis, also referred to as mitotic catastrophe. These cell deaths are though
to be based on different molecular mechanisms and show distinct
morphological characteristics, but in spite of this they are often hard to
characterise since both biochemical and morphological features may change
over time. Further, the mechanism of cell death seems to depend on drug
dose, exposure time and cell type as well as expression of certain oncogenes
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and tumour suppressor genes. For example, whereas apoptosis can be
induced in sensitive cells, more resistant cells may instead die by premature
mitosis (mitotic catastrophe) (Larsen and Skladanowski, 1998). Although
apoptosis in many ways is similar to premature mitosis with one of the most
prominent morphological features of apoptosis, condensation of chromatins,
also found in mitosis, there are differences between these types of cell
deaths. Similarities and differences between apoptosis and premature mitosis
have been outlined by Meikrantz and Schlegel (1995). Thus, the original
definition of apoptosis as a form of cell death distinct from necrosis may not
be adequate to describe all forms of cell death. In addition, Speranido et a/.
(2000) recently described a form of cell death called 'paraptosis' (para=next to
or related to) that they said was morphologically and biochemically distinct
from apoptosis. They further suggested that paraptosis in some previous
cases may have been assumed to be necrosis due to its morphological
features of cytoplasmic vacuolation and mitochondrial swelling and since
caspase inhibitors did not appear to have effect. The basis for this alternative
form of cell death is yet unknown, but understanding the mechanism behind
this may be beneficial in the understanding of the mechanisms of several
cancer therapeutics.
Activation of caspases as a strategy in cancer therapy has gained much
interest during the past decade, particularly for inducing cell death in tumours
and determining the efficacy of chemotherapeutic agents. A reason for failure
of current chemotherapeutics in resistant tumours is the possibly of mutations
disrupting apoptotic pathways. A strategy to induce apoptosis in cells may be
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to design treatments that activate caspases directly. Flow cytometry and UV
fluorescent microscopy experiments were performed using general caspase
and caspase-3 inhibitors labelled with a green fluorescent probe. These
studies indicated that caspases were activated following 4h and 24h NU:UB
31 and NU:UB 51 treatment in HL60 and HCT116 cells. Caspases have been
reported to be a marker of apoptotic cell death, so these experiments would
thus further imply that cells become apoptotic following NU:UB compound
treatment. However, although caspases appeared to be activated following
NU:UB treatment it has been reported that apoptosis can take place
independently of caspase activation. It was recently suggested by Kawagoe et
al. (2002) that valproic acid (VPA, a member of the short chain fatty acids)
killed cells by both caspase-dependent and caspase-indepenedent apoptosis.
Whereas the caspase-dependent pathways were suggested to mediate
nuclear apoptotic changes, the caspase-independent pathways mediated PS
events (phosphatidylserine exposure) on the cell membrane; the exact
mechanism however of the latter caspase-independent apoptotic cell death is
still to be determined. With this in mind, caspase-independent pathways may
also be triggered by NU:UB compounds resulting in apoptosis.
In summary, we have used several methods to identify apoptotic cells, and
found that known anti-topoisomerase drugs and NU:UB compounds induced
apoptosis in HL60 and HCT116 cells when assessed by the above assays.
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CHAPTER 7
PROTEIN STUDIES
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7.1 PROTEIN STUDIES
Proteins involved in arresting the cell cycle and in the apoptotic process have
been investigated in this research project and the data presented within this
chapter. This study included p53 with its down-stream mediators, mdm2 and
p21. In addition, the dependency of drug cytotoxicity on p53 status (wild type
or mutated p53) in a range of cell lines have been investigated by NCI to give
an indication of the importance of this protein for mechanism of action. To
confirm the apoptotic caspase-3 activation findings (presented in Chapter 6),
procaspase-3 cleavage following NU:UB treatment was investigated.
The information available so far on how certain genes, implicated in tumour
formation (oncogenes and/or tumour suppressor genes) have a role in the
response to anti-tumour drugs is realised but not clear. For example, the
importance of p53 in drug-induced apoptosis is contradictory. Drug research
indicates that the DNA damage induced by several chemotherapeutics,
including camptothecin, etoposide and doxorubicin can function as a signal to
trigger p53-mediated apoptosis, but experiments have also shown that
apoptosis can be induced in HL60 cells (which do not contain p53), following
treatment with these drugs. Other studies have also reported that apoptosis
can take place through p53-independent pathways (Clarke et a/., 1993; Lowe
et a/., 1993a; Lowe et a/., 1993b; Liu and Zhang, 1998; Alexandre et a/.,
2000). Larsen and Skladanowski (1998) gave one explanation to the p53
controversy, suggesting that p53 is a protein involved in several pathways
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including apoptosis, DNA repair and in cell cycle regulation. Thus, the
interplay between the pathways affecting DNA repair, cell cycle progression
and cell death, which again depends on which gene products are expressed
in a given cell type, all appear to be important factors for cellular responses
and outcome following drug treatment. In healthy cells the p53 tumour
suppressor gene function is dampened to allow for normal growth, but it can
rapidly be induced upon DNA damage. The cellular responses to p53
activation include both growth arrest and apoptotic cell death. Since p53 is an
element of the DNA damage response pathway, this protein was here
investigated to get a better understanding of what takes place within cells
when treating with experimental (NU:UB) anti-cancer agents.
Tight regulation of p53 is critical for normal cell growth and one mechanism by
which p53 is controlled is via mdm2. Mdm2 is a transcriptional target of p53
and enhanced mdm2 expression prevents p53 from acting as a tumour
suppressor. Under normal conditions mdm2 binds p53 and shuttles p53 from
the nucleus to be degraded in the cytoplasm, maintaining low p53 levels. DNA
damage leads to phosphorylation and as a result, stabilisation of the p53
protein and accumulation of p53 in the nucleus (Haupt et aI., 1997; Kubbutat
et aI., 1997; Shieh et al., 1997; Colman et al., 2000). During recovery from
DNA damage, maximal mdm2 induction coincides with rapid p53 loss. Thus,
mechanisms regulating mdm2-induced degradation of p53 should playa role
in controlling the extent and duration of the p53 response. As expected, the
cellular effect of inhibitors of the p53-mdm2 interaction is p53 accumulation
since these inhibitors should prevent the mdm2 interaction and thereby p53
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degradation. P21 provides a link between cell cycle regulation and growth
suppression by p53. The p21 gene is thought to be activated directly by p53,
and p21 protein induction is suggested to playa part in p53-mediated growth
arrest (Evan and Littlewood, 1998). P21 is a reversible cell cycle inhibitor and
irreversible G1 or G2 arrest may lead to apoptosis. The exact role(s) of p21 in
apoptosis has however been disputed, while p21 has been reported to be up-
regulated in p53-mediated apoptosis by some researchers (EI-Deiry et al.,
1994), this protein was not thought to be required in apoptosis by others
(Makri et al., 1998). Cell line variations could again be the reason for these
differences.
The p53-mediated apoptotic pathway(s) are thought to converge on caspase
activation. However, the mechanism by which p53 activates the caspases,
and if these are always required in p53-mediated apoptosis, are still to be
deduced. One of the caspases identified, caspase-3, has been implicated in
the execution phase of apoptosis and it has been proposed that the p53-
mediated cellular destruction in apoptosis could be carried out via activation of
caspase-3 (Cregan et al., 1999; Hietanen et al., 2000; Schuler et al., 2000).
Caspase-3 activation was earlier investigated by flow cytometry using a
fluorescent caspase-3 inhibitor that bound to activated caspase-3 (presented
in Chapter 6). In this part of the project procaspase-3 protein cleavage was
studied by Western blotting to support (or otherwise) our earlier findings.
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7.2 METHODS
7.2.1 Investigation Of The P53 Protein Content In HCT116,
HT29 And HL60 Cells.
Natural p53 protein levels are usually kept low, whereas in mutant cells p53
proteins may be present at much higher concentrations than in cells
containing wild type p53. P53 levels were investigated by Western blotting in
the three human cell lines that were previously used in our cytotoxicity
studies. A mouse monoclonal anti-p53 (DO-1) antibody (Novo Castra),
recognising both wild type and mutant p53 was used in these experiments. A
high level of p53 in untreated cells would thus suggest that the cell line under
investigation contains mutant p53 and low levels would imply wild type p53.
The cells were transferred to a sterile universal and centrifuged at 500 x g for
5 mins at 4°C. The supernatants were discarded and the cell pellets re-
suspended in fresh culture medium. Cell counts were performed using a
haemocytometer. HL60, HCT116 and HT29 cells were seeded at 1Ox1 04
cells/ml and were left to adhere (HCT116 and HT29). All cell treatments were
carried out under cell culturing conditions, 37°C, 5% CO2. Cells were treated
with doxorubicin (1 ~M) or with solvent (control) for 24h. Following treatments,
cell solutions (HL60), supernatants and trypsinised cells (HCT116 and HT29)
were transferred to universals and were centrifuged at 500 x g for 5 mins at
4°C. Cells were lysed with protease inhibitors on ice. Following lysis, the
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amount of protein in each sample was determined using the bicinchoninic acid
protein assay. Equal amounts of proteins for each sample were separated on
an SOS polyacrylamide gel, immunoblotted and stained with the mouse
monoclonal anti-p53 (00-1) antibody. For detailed protocols of these
procedures see materials and general methods, Chapter 2.
7.2.2 Investigation Of P53 Protein Levels In HCT116 Cells
Treated With NU:UB Compounds Or Doxorubicin
HCT116 cells were seeded at 10 x 104 cells/ml and were left to adhere. Cells
were treated with NU:UB 31 (20IJM), NU:UB 51 (10IJM), doxorubicin (0.1IJM,
1IJM and 10IJM), or with solvent (control) over a 24h time course, using Oh,
0.5h, 1h, 2h, 3h, 4h, 6h, 8h and 24h time points. Following treatment,
supernatants and trypsinised cells were transferred to universals, pelleted and
subsequently lysed with protease inhibitors. Total protein concentration in
each sample was determined with the bicinchoninic acid assay. Each sample
was separated on an SOS polyacrylamide gel, immunoblotled and stained
with mouse monoclonal anti-p53 (00-1) antibody (for detailed procedures,
see materials and general methods, Chapter 2).
7.2.2a Treatment of Results
Experiments were performed in triplicate or more, and each Western blot
image was analysed using a digital Syngene imager with the GeneSnap and
GeneTool software. The p53 protein band densities of the controls were
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aliquoted to 100%, to which the band densities of the treated cells were
compared. Mean ± SEM was obtained and Tukey's one-way analysis of
variance was used to evaluate significant differences between control p53
protein levels and the effects of the various treatments and time points.
7.2.3 P53 Protein Immunostaining Of HCT116 Cells Treated
With NU:UB Compounds Or Doxorubicin
Round coverslips (Raymond Lamb) were soaked in 70% ethanol, left to dry
and placed in 24 well plates. HCT116 cells were washed and seeded (20 x
104 cells/ml) in the wells. The plates were left in an incubator for the cells to
adhere to the coverslips. Once sufficient confluence was reached, the cells
were either left untreated (solvent only), or treated with NU:UB 31, NU:UB 51
or doxorubicin. Following treatment, the cells were washed briefly in PBS,
fixed, and had their membranes permeabilized by soaking in ice-cold acetone
for 10 mins on ice. The acetone was washed off with PBS, and the well plates
were put into a humidified chamber to prevent drying out. The immunostaining
was performed using a Vectastain ABC mouse IgG kit (Novo Castra) with the
components diluted according to manufacturer's recommendations. Cells
were blocked in normal serum (1 :20 dilution) for 30 mins. Excess serum was
removed, and each cover slip was carefully removed from the wells, for them
to be stained with primary antibody. This was done by placing a drop of
mouse anti-p53 (DO-1) antibody, diluted 1:1000 in PBS, on a sheet of
parafilm stretched over a 24 well plate. Each coverslip was placed with the
cell side down onto the drop of primary antibody solution and the plates were
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left in the humidified chamber for 2h. Following staining, the cover slips were
put back into their respective wells and were washed in PBS. The biotinylated
secondary antibody (ABC kit) was added (1 :10 dilution) and left for 40 mins.
Following a PBS wash step, streptavidin-horseradish peroxidase (ABC kit)
was added (1 :25 dilution) and the plate was left to incubate for 40 mins. Cells
were washed in PBS and were then incubated with peroxidase substrate kit
DAB (Vector) for 2.5 mins. The cover slips were washed in distilled H20 and
counterstained in Haematoxylin (1 :40 dilution in tap water) for 30 sec. The
cover slips were soaked in Scotts tap water for 1 min, and were then removed
from their wells and dehydrated. After dehydration the cells were mounted in
OPX and were viewed in a light microscope (Zeiss Axioskop) at 40x
magnification.
7.2.4 Investigation Of Mdm2 Protein Levels In HCT116 Cells
Treated With NU:UB Compounds Or Doxorubicin
HCT116 cells were seeded (10 x 104 cells/ml) and were left to adhere. Cells
were treated with NU:UB 31 (20IJM), NU:UB 51 (10IJM), doxorubicin (0.1IJM,
1IJM and 101JM) or with solvent (control) over a 24h time course, using 1h, 2h,
4h, 6h, 8h and 24h time points. Following treatment, supernatants and
trypsinised cells were collected and lysed with protease inhibitors, and total
protein levels determined with the bicinchoninic acid protein assay. The
proteins in each sample were separated on an SOS-polyacrylamide gel,
immunoblotted and stained with the mouse monoclonal anti-mdm2 antibody
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(Autogen Bioclear) (for detailed procedures, see materials and general
methods, Chapter 2).
7.2.4a Treatment Of Results
Experiments were performed in triplicate or more and each Western blot
image was analysed in the Syngene imager using the GeneSnap and
GeneTool software. The mdm2 protein band densities of the controls were
aliquoted to 100%, to which the band densities of the treated cells were
compared. Mean ± SEM was obtained.
7.2.5 Investigation Of P21 Levels In HCT116 Cells Treated
With NU:UB 31 Or Doxorubicin
HCT116 cells were seeded and left to adhere. Cells were treated with NU:UB
31 (20IJM), NU:UB 51 (10IJM), doxorubicin or with solvent (control). Following
treatment, supernatants and trypsinised cells were transferred to universals,
cells were lysed using protease inhibitors, and the total protein levels
determined with the bicinchoninic acid assay. The proteins in each sample
were separated on an SOS polyacrylamide gel, immunoblotted and stained
with the anti-p21 (WAF1) antibody (Oncogene) (for detailed procedures, see
materials and general methods, Chapter 2).
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7.2.6 Investigation Of Procaspase-3 Levels In HL60 And
HCT116 Cells Treated With NU:UB Compounds, Doxorubicin
Or Camptothecin
HCT116 and HL60 cells were seeded at 10 x 104 cells/ml and were left to
recover and adhere (HCT116). HCT116 cells were treated with NU:UB 31
(20J.,JM), NU:UB 51 (1 OJ.,JM) , doxorubicin (1 J.,JM or 1OJ.,JM) , or with solvent
(control). HL60 cells were treated with NU:UB 31 (20J.,JM or 10J.,JM), NU:UB 51
(5J.,JM), camptothecin (0.5J.,JM), or with solvent (control). Following treatment,
cell solutions (HL60), supernatants and trypsinised cells (HCT116) were
transferred to universals, which were centrifuged at 500 x g for 5 mins at 4°C.
Cell pellets were immediately lysed with protease inhibitors. The total protein
levels in each sample were detected with the bicinchoninic acid assay. The
samples were separated on an SOS polyacrylamide gel and the proteins
transferred onto membranes. The immunostaining was performed using the
primary mouse monoclonal anti-procaspase-3 antibody (Autogen Bioclear)
(for detailed procedures, see materials and general methods, Chapter 2).
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7.3 RESULTS
7.3.1 P53 Protein
7.3.1a P53 Protein Contents In HL60, HCT116 And HT29 Cells
P53 levels were analysed in HL60, HCT116 and HT29 cells following a 24h
treatment with doxorubicin (1IJM) as this would provide a positive control for
p53 induction. Fig. 7.1 shows one of three similar Western blot results. P53
protein levels are normally kept at low levels whereas in mutant cells, p53
may be present at much higher concentrations than in cells with wild type p53.
A p53 antibody recognising both wild type and mutant p53 was used in these
experiments. A high level of p53 in untreated cells would suggest that the cell
line contained mutant p53. HL60 cells were used as a negative control as this
cell line has been shown to contain no p53. These results confirmed that there
was no p53 protein present in either untreated or treated HL60 cells. In
contrast, HCT116 cells had low levels of p53 in untreated cells, and upon
doxorubicin treatment there was a great increase in p53 protein levels. The
HT29 cell line contained high levels in both untreated and doxorubicin treated
cells. This suggested that the HCT116 cell line contained wild type p53, that
accumulated in the cells upon DNA damage whereas HT29 contained
mutated p53. It was realised from this experiment that the HCT116 would be a
suitable cell line to use in studying p53 upregulation.
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7.3.1b Time Course Of P53 Protein Levels In HCT116 Cells
Western blots of p53 in HCT116 cells showed that NU:UB treatment induced
p53 protein upregulation (Fig. 7.2). The data shown in Fig. 7.3a, Fig. 7.3b and
Fig. 7.3c represents the p53 protein levels in HCT116 cells as measured by
Western blotting over a period of time. P53 levels in the control remained low
throughout the 24h exposure time. Doxorubicin was used as a positive
control; 24h exposure to doxorubicin resulted in significantly increased p53
levels. NU:UB 31 also to some degree increased p53 levels in HCT116 cells
and p53 levels peaked at 2-8h exposure. For NU:UB 51 a similar response
was seen. After 24h of NU:UB 31 or NU:UB 51 treatment the p53 protein
content had dropped. Thus, for NU:UB 31 and NU:UB 51 it seemed that the
highest p53 levels were detected as early as 2-8h. However, these levels
were not as progressively increased as with 24h doxorubicin exposure. For
doxorubicin, the 24h treatment elicited higher p53 levels than a shorter
doxorubicin exposure (p<O.001).
7.3.1c Immunostaining Of HCT116 Cells Treated With NU:UB 31,
NU:UB 51 Or Doxorubicin
In addition to the Western blotting experiments, p53 immunostainings were
performed, and images are presented in Fig 7.4. These images confirmed p53
upregulation in HCT116 cells. Following doxorubicin treatment the cell nuclei
were strongly positively stained (brown) compared to the control where there
234
was no or only low levels of staining (Fig. 7.4a, Fig. 7.4b). NU:UB 31 and
NU:UB 51 treated cells were also positively stained (Fig. 7.4c, Fig. 7.4d).
7.3.1d Relationship Between Drug Sensitivity And P53 Status In
NCI Cell Lines
NU:UB 31, NU:UB 43, NU:UB 80, NU:UB 81 and the standard drug,
doxorubicin, have been screened by NCI in a range of wild type p53 versus
mutant p53 containing cell lines. Giso values for each compound were
obtained by NCI (Fig. 7.5). These values were plotted in scattergrams of Giso
versus p53 status. For each compound two median Giso values were
provided, one from the p53 wild type cell lines and another from the p53
mutant cell lines. The scattergram of doxorubicin gave an average wild type
Giso of 0.0881JM versus a mutant Giso of 0.171JM (Fig. 7.5a). The difference
between wild type and mutant Giso was thus above 1.9-fold for doxorubicin.
The NU:UB compounds were overall less potent than doxorubicin, the
average NU:UB Glso values were higher in both the wild type and the mutant
cell lines (NU:UB 31 wild type 3.981JM versus mutant 5.75IJM, Fig. 7.5b;
NU:UB 43 wild type 3.081JM versus mutant 4.06IJM, Fig. 7.5c; NU:UB 80 wild
type 2.651JM versus mutant 3.16IJM, Fig. 7.5d; NU:UB 81 wild type 2.371JM
versus mutant 3.09IJM, Fig. 7.5e). The difference between wild type and
mutant median Giso values for the NU:UB compounds ranged from 1.2 to 1.4-
fold, thus less than for doxorubicin.
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7.3.2 Mdm2 Protein
7.3.2a Time Course Of Mdm2 Protein Levels In HCT116 Cells
Western blot images of mdm2 protein levels in HCT116 cells following NU:UB
treatment are given in Fig. 7.6a and Fig. 7.6b. Time course experiments were
performed and increased mdm2 levels were evident following 4-8h of NU:UB
31 (Fig. 7.7a) or NU:UB 51 (Fig. 7.7b) treatment. At the 24h time points of
NU:UB treatment, mdm2 levels had dropped and were comparable to the
mdm2 protein levels in controls. Following doxorubicin treatment there was no
increase in mdm2 levels (Fig. 7.7a, Fig. 7.7b).
7.3.3 P21 Protein
7.3.3a P21 Levels In HCT116 Cells Treated With NU:UB
Compound Or Doxorubicin
The HCT116 cell line, which was shown to express wild type p53 in previous
studies, was used in these p21 experiments. Doxorubicin was used as a
positive control as this drug (at O.35I..1M, 14h and 28h) had been shown to
cause p21 upregulation in previous research using HCT116 cells (EI-Deiry et
al., 1994). Contrary to this earlier study, there was in our experiments a high
basal level of p21 in HCT116 control cells. There was further no significant
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increase in p21 protein levels following doxorubicin or NU:UB 31 (20IJM)
treatment (Fig. 7.8a).
7.3.3b HCT116 Cells Grown In Culture Medium Supplemented
With 10/0, 5% Or 100/0 FBS Concentrations
In some cell lines FBS can be involved in inducing proteins. We therefore
cultured the HCT116 cells in 1%, 5%, or 10 % FBS supplemented culture
medium before drug treatment to investigate whether or not FBS had an effect
on p21 levels in these cells. Fig. 7.8b shows a Western blot image of
untreated cells, or cells treated with NU:UB 31 or doxorubicin. From these
experiments it was shown that FBS did not cause p21 induction, as the levels
of p21 were similar in cells grown in 1%, 5%, and 10% FBS supplemented
medium.
7.3.3c Time Course Of P21 Levels In HCT116 Cells
P53 levels were increased following 3-4h NU:UB treatment in HCT116 cells
and decreased after 24h treatment. It may be that p21 levels had peaked prior
to the 24h time point. Therefore, p21 protein levels were measured following
shorter treatment times. Time course experiments of p21 protein levels were
performed and these are represented in Fig 7.8c and Fig. 7.8d. It was
discovered that there was no increase in p21 compared to control in this cell
line following NU:UB 31 or NU:UB 51 treatment at either of the time points
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used. Thus it seemed that NU:UB treatment did not induce p21 in our
HCT116 cells.
7.3.4 Procaspase-3 Cleavage In HCT116 And HL60 Cells
Caspase-3 is synthesised as a 33kDa inactive proenzyme that requires
proteolytic activation. Two smaller subunits, derived from this caspase-3
proenzyme have been reported following cleavage activation. These active
species have been detected as early as 3h in HL60 cells with etoposide
treatment (Martins et a/., 1997). Western blotting experiments revealed that
high levels of inactive, procaspase-3 were present as a band of approximately
32-34kDa in control cells of both cell lines used. Cleaved procaspase-3
(activated caspase-3) proteins were represented by bands of low molecular
weight, below the procaspase-3 bands. There were only low, or no levels of
active caspase-3 in the controls for both cell lines used. In HCT116 cells,
caspase-3 activation was evident following 24h doxorubicin treatment, but not
at the 1h doxorubicin time point. Following NU:UB 31 or NU:UB 51 treatment,
cleaved caspase-3 bands appeared at the 8h and 24h time points in HCT116
cells (Fig. 7.9a, Fig.7.9b). While active caspase-3 was not observed in the
HL60 controls, NU:UB 31 and NU:UB 51 treatments resulted in a slight
increase in the caspase-3 band density at the 4h, 8h and 24h time points.
There was however no evident decrease in the level of procaspase-3 band
density. In contrast, following 24h camptothecin treatment there was no longer
any inactive procaspase-3 present, but instead a high level of active caspase-
3 (Fig. 7.9c).
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Fig 7.1 Western blot of p53 contents in untreated HL60, HCT116 and HT29 cells, or following 24h
treatment with doxorubicin (1I.lM). HL60 cells, untreated (lane 1), HL60 cells, doxorubicin treated
(lane 2), HCT116 cells, untreated (lane 3), HCT116 cells, doxorubicin treated (lane 4), HT29 cells,
untreated (lane 5), HT29 cells, doxorubicin treated (lane 6). Figure is representative of three
separate experiments.
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Fig 7.2a Time course. Western blot of p53 levels in HCT116 following NU:UB 31 or doxorubicin
treatment. Control 1h (lane 1), doxorubicin 10I.lM 1h (lane 2), NU:UB 31 20I.lM 1h (lane 3), NU:UB
31 20I.lM 4h (lane 4), NU:UB 31 20I.lM 8h (lane 5) NU:UB 31 20I.lM 24h (lane 6), Control 24h
(lane 7), Doxorub icin 11.lM 24h (lane 8). Figure is representative of three separate experiments.
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Fig 7.2b Time course. Western blot of p53 levels in HCT116 following NU:UB 51 or doxorubicin
treatment. Control 1h (lane 1), doxorubicin 10I.lM 1h (lane 2), NU:UB 51 10IJM 1h (lane 3), NU:UB
51 10I.lM 4h (lane 4), NU:UB 51 10I.lM 8h (lane 5) NU:UB 51 10IJM 24h (lane 6), Control 24h
(lane 7), doxorubicin 11.lM 24h (lane 8). Figure is representative of three separate experiments.
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Fig 7.3a Time course of p53 levels in HCT116 cells treated with NU:UB 31 (20flM) or
doxorubicin (Dox) (10flM 1hand 2h, 1flM 24h). Results are the mean of three or more
separate Western blot experiments ± SEM (with the exception of doxorubicin 10IJM 1h
(n=2)). Asterisks denote significant differences from the control (* p<O.05, ** p<O.01, ***
p<O.001 ).
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Fig 7.3b Time course ofp53 levels in HCT116 cells treated with NU:UB 51 (10!!M) or
doxorubicin (Dox) (10!!M 1hand 2h, 1!!M 24h). Results are the mean of three or more
separate Western blot experiments ± SEM (with the exception of NU:UB 51 Oh, O.5h and
3h (n=2)). Asterisks denote significant differences from the control (* p<O.05, *** p<O.001).
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Fig 7.3c Time course of p53 levels in HCT116 cells treated with doxorubicin (Dox) (10J,!M
for Oh, 1h, 2h and 3h or, 0.1 and 1J,!M for 24h). Results are the mean of three or more
separate Western blot experiments ± SEM (with the exception of Oh and 3h where n=1and
2 respectively). Asterisks denote significant differences from the control 24h (*** p<0.001).
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Fig.7.4a Control
Fig. 7.4c NU:UB 31
Fig. 7.4b Doxorubicin
Fig. 7.4d NU:UB 51
Fig. 7.4a-d P53 immunostaining of HCT116 cells treated for 24h with solvent (control) , doxorubicin
(1IJM), NU:UB 31 (5IJM) or NU:UB 51 (5IJM). The immunostaining has been performed in duplicate .
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Fig. 7.5a Relationship between NCI cell line sensitivity to doxorubicin and expression of
wild type or mutated p53
244
-4.5
-4.6
-4.7
~ -4.8 •
Eo--
•~\F1 • •Z -4.9 •~ •\F1 • •\F1 -5.0 •\F1 • •~ • •~ •
-5.1
• •
• 5.75~
0 -5.2 • -514--1 • •l£l • •~e
•eo -5.3 •0 • 3.98~ • •~ • • • -5.40 •
-5.4 • • • •• • • •~ • • •~ -5.5 • •Eo-- •~ • •\F1 -5.6Z
~ • •00 -5.7~ • •
0
-5.8~
-5.9
-6.0
WILD-lYPE p53 MUfANTp53
Fig. 7.5b Relationship between NCI cell line sensitivity to NU:UB 31and expression of wild
type or mutated p53
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Fig. 7.5c Relationship between NCI cell line sensitivity to NU:UB 43 and expression of
wild type or mutated p53
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Fig.7.5d Relationship between NCI cell line sensitivity to NU:UB 80 and expression of
wild type or mutated p53
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Fig . 7.5e Relationship between NCI cell line sensitivity to NU:UB 81 and expression of
wild type or mutated p53
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Fig 7.6b Time course . Western blot of mdm2 levels in HCT116 cells following NU:UB 51 or
doxorubicin treatment. Control1h (lane 1), doxorub icin 10IJM 1h (lane 2), NU:UB 51 10IJM
1h (lane 3), NU:UB 51 10IJM4h (lane 4), NU:UB 51 10IJM 8h (lane 5). NU:UB 51 10IJM 24h
(lane 6), Control 24h (lane 7), doxorubicin 1IJM 24h (lane 8). The figure is representative of
three separate experiments.
Fig 7.6a Time course. Western blot of mdm2 levels in HCT116 cells following NU:UB 31 or
doxorubicin treatment. Control 1h (lane 1), doxorubicin 10IJM 1h (lane 2). NU:UB 31 20IJM 1h
(lane 3), NU:UB 31 20IJM 4h (lane 4), NU:UB 31 20IJM 8h (lane 5), NU:UB 31 20IJM 24h (lane
6), Control 24h (lane 7). doxorubicin 1IJM 24h (lane 8). The figure is representative of three
separate experiments.
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Fig 7.7a Time course of mdm2 levels in HCT116 cells treated with NU:UB 31 (20IlM) or
doxorubicin (Dox) (0.1IlM or 111M for 24h). Results are the mean of three or more separate
Western blot experiments ± SEM (with the exception of NU:UB 31 1hand doxorubicin 0.11JM 24h
where n=2, and NU:UB 31 6h where n=1).
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Fig 7.7b Time course of mdm2 levels in HCT116 cells treated with NU:UB 51 (10!!M) or
doxorubicin (Dox) (10!!M for 2h, or 1!!M for 24h). Results are the mean of three or more separate
Western blot experiments ± SEM (with the exception of NU:UB 51 8h and doxorubicin 10!!M 2h
where n=2).
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Fig. 7.8a 24h exposure. Western blot of p21 levels in HCT116 cells following NU:UB 31 or
doxorubicin treatment. Doxorubicin (lane 1), NU:UB 31 20~M (lane 2), Control (lane 3),
Doxorubicin 0.35~M (lane 4), NU:UB 31 20~M (lane 5), Control (lane 6). The figure is
representative of three separate experiments.
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Fig. 7.8b 24h exposure. Western blot of p21 levels in HCT116 cells following NU:UB 31 or
doxorubicin treatment. Cells grown in 1%, 5% or 10% FBS. Doxorubicin 0.35IJM, 5% FBS
(lane 1), NU:UB 31 20~M 5% FBS (lane 2), Control 5% FBS (lane 3), Doxorubicin 0.35~M
10% FBS (lane 4), NU:UB 31 20~M 10% FBS (lane 5), Control 10% FBS (lane 6), Control
1% FBS (lane 7), Biotinylated marker (lane 8). The figure is representative of two separate
experiments.
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Fig 7.8e Time course. Western blot of p21 levels in HCT116 cells following NU:UB 31
treatment. Control 4h (lane 1), NU:UB 31 20IJM 4h (lane 2), NU:UB 31 20IJM 8h (lane 3),
NU:UB 31 20IJM 12h (lane 4), NU:UB 31 20IJM 24h (lane 5), Control 24h (lane 6). The figure
is representative of three separate experiments.
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Fig 7.8d Time course. Western blot of p21 levels in HCT116 cells following NU:UB 51
treatment. Control 4h (lane 1), NU:UB 51 10IJM 4h (lane 2), NU:UB 51 10IJM 8h (lane 3),
NU:UB 51 10IJM 12h (lane 4), NU:UB 51 10IJM 24h (lane 5), NU:UB 51 5IJM 24h (lane 6).
The figure is representative of three separate experiments.
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Fig. 7.9a Time course . Western blot of procaspase-3 levels in HCT116 following NU:UB 31 or
doxorub icin treatment. Biotinylated marker (lane 1), colour marker (lane 2), control 1h (lane 3),
doxorubicin 10IJM 1h (lane 4), NU:UB 31 20IJM 1h (lane 5), NU:UB 31 20IJM 4h (lane 6),
NU:UB31 20IJM 8h (lane 7), NU:UB 31 20IJM 24h (lane 8), contro l 24h (lane 9), doxorub icin
1IJM 24h (lane 10). The figure is representat ive of three separate experiments .
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Fig. 7.9b Time course . Western blot of procaspase-3 levels in HCT116 following NU:UB 51 or
doxorubicin treatment. Biotinylated marker (lane 1), colour marker (lane 2), control 1h (lane 3),
doxorubicin 10IJM 1h (lane 4), NU:UB 51 10IJM 1h (lane 5), NU:UB 51 10IJM 4h (lane 6),
NU:UB 51 10IJM 8h (lane 7), NU:UB 51 10IJM 24h (lane 8), control 24h (lane 9), doxorubicin
1IJM 24h (lane 10). The figure is representative of three separate experiments .
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Fig. 7.9c Time course. Western blot of procaspase-3 levels in HL60 cells following
NU:UB 31, NU:UB 51 or camptothecin treatment. Biotinylated marker (lane 1), colour
marker (lane 2), NU:UB 31 20IJM 4h (lane 3), NU:UB 31 20IJM 8h (lane 4), NU:UB 31
10IJM 24h (lane 5), control 24h (lane 6), NU:UB 51 5IJM 4h (lane 7), NU:UB 51 5IJM 8h
(lane 8), NU:UB 51 5IJM 24h (lane 9), camptothecin 0.51JM 24h (lane 10). The figure is
representative of three separate experiments.
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7.4 DISCUSSION
Apoptosis and cell cycle arrest have been investigated in cells exposed to
NU:UB compounds and these investigations have been presented within this
thesis. The morphological and biochemical investigations performed implied
that cells exposed to NU:UB agents died by apoptosis (Chapter 6). In this part
of the project, apoptotic cell death was further investigated by examining what
happens in cells on a protein level when exposed to NU:UB compounds. P53
was one of the proteins studied to determine, whether or not p53 was induced
by NU:UB compounds, and if so, how rapidly this induction was detected. For
the cancer therapeutic area, the role of p53 in apoptosis is probably more
important than its role in arresting the cell cycle. It has been suggested that
p53 plays a crucial role in apoptotic cell death in the response to
chemotherapeutics, but the p53-dependent pathway is not the only
mechanism of apoptosis, since p53-independent pathways may also play
meaningful roles. Evidence that apoptosis can be induced in cells regardless
of p53 status was obtained in our earlier apoptotic studies where HL60 cells
containing no p53 were used. P53 protein levels were studied in HCT116 cells
following treatment with NU:UB 31, NU:UB 51 and known topoisomerase
inhibitors. In our untreated HCT116 cells there was none, or very low levels of
p53 that were increased upon doxorubicin treatment. This indicated that these
cells contained wild type p53, which was also in agreement with previous
research by O'Connor et al. (1997). In contrast, the untreated as well as the
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doxorubicin treated HT29 cells had high p53 levels and were therefore
thought to contain mutant p53.
Time course Western blot experiments measuring p53 protein levels over 24h
were performed. This revealed that p53 protein levels in HCT116 cells
exposed to NU:UB 31 or NU:UB 51 increased, compared to controls following
2-8h treatment. After the p53 peak at 2-8h the levels dropped, and were
similar to control levels at the 24h time point. Thus, following treatment with
NU:UB compound, the p53 concentration increased, reached a maximum,
and then decreased. This decrease in p53 concentration could however be a
consequence of degradation of the NU:UB compound. To evaluate this
possibility in future work, the medium containing the NU:UB agent could be
removed and replaced, for example every 4h with medium containing fresh
NU:UB compound. By doing this, the p53 levels may not decrease but instead
remain high. It may also be feasible that the NU:UB compound was effluxed
from cells via resistance mechanisms, and/or repair mechanisms might
operate allowing cells to recover from drug damage and thereby decrease the
p53 expression. P53 levels following doxorubicin treatment were not
increased much following 2h, but reached significantly higher levels after 24h
treatment, which was not the case following NU:UB treatment. The highest
level of p53 following NU:UB treatment was still lower than the levels induced
by 24h doxorubicin exposure. It might be that for NU:UB compounds, the
mechanism of action does not only involve the p53 pathway.
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The relationship between the cytotoxicity of these compounds in vitro and the
p53 status of the cell lines used has also been examined by NCI. From
screening commonly used clinical anticancer agents in the NCI in vitro screen
for p53 gene status, it was determined that most of these agents appeared to
rely on intact p53 function for optimum potential (Monks et al., 1997;
Weinstein et al., 1997). The relationship between cell line sensitivity to the
NU:UB compounds (NU:UB 31, NU:UB 43, NU:UB 80 and NU:UB 81) and
expression of wild type or mutated p53 was examined in a range of NCI cell
lines (p244-248). The topoisomerase inhibitor, doxorubicin was also included
in this cell screen. The Giso value for each cell line was plotted as a
scattergram of drug cytotoxicity versus mutant or wild type p53. From each
drug scattergram two median Giso values were deduced, a wild type and a
mutant median Giso and the difference in these values were compared for
each drug. The study showed that the standard drug was overall more potent
than the NU:UB compounds, with lower Glee values. Moreover, doxorubicin
sensitivity in wild type cell lines was far greater, compared to mutant cell lines.
This was not the case for any of the NU:UB compounds, the sensitivity to the
NU:UB compounds being similar in wild type and mutant cell lines, suggesting
that these compounds may be able to circumvent p53-reliant cell death
pathways.
Current research of different strategies, exploiting the p53 pathway in cancer
treatment has recently been summarised by Lane and Lain (2002). The
identification of molecules able to restore the function of mutant p53 should be
an interesting approach due to the high number of cancers with mutated p53
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protein. It was found that several of the mutations of p53 reduce its stability
(Bullock et a/., 1997), causing it to misfold and mutant p53 lacks the stable
conformation required for proper DNA binding (Friedlander et a/., 1996b).
Bykov et al. (2002) hypothesised that reactivation of p53 in tumours with
mutant p53 would trigger massive apoptosis, eliminating the tumour cells, and
that normal cells expressing low levels of p53 should not be affected. To
prevent incorrect p53 folding, Foster et a/. (1999) identified several small
compounds with the following features in common; a hydrophobic part, a
linker in-between and a positively charged cationic part that would fit into and
stabilise faulty p53. Among these molecules, CP-31398 rescued mutant p53
by stabilizing the active conformation of newly synthesised mutant p53 and as
a result, the p53 protein was allowed to regain its tumour supressive function.
In a study by Luu et a/. (2002) using CP-31398, it was demonstrated that this
p53-stabilizing molecule induced apoptosis via bax upregulation,
mitochondrial membrane potential alterations and caspase-9 and caspase-3
activation in wild type p53 containing HCT116 cells. In contrast, HCT116 cells
devoid of p53 were more or less resistant to CP-31398 induced apoptosis,
further supporting the p53-mediated effects of this agent. (It remains to be
determined, however, whether or not this agent induces apoptosis in mutant
p53 containing cancer cells). Another low molecular weight compound,
PRIMA-1 (p53 Reactivation and Induction of Massive Apoptosis), that
restored the active p53 conformation, reactivating mutant p53 has also been
identified. This compound restored p53-dependent apoptosis in cells
containing mutant p53. Growth of cells expressing mutant p53 was inhibited,
but there was only a slight effect on cells without mutant p53. Additionally, the
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two target genes, p21 and mdm2 were induced exclusively in the presence of
mutant p53 but not in HCT116 cells containing wild type p53. However,
whereas in vitro PRIMA-1 treatment resulted in apoptosis, evidence of growth
suppression was seen in vivo. Likewise, following in vivo CP-31398
administration, induction of p21 was reported. Thus, it may be that growth
arrest rather than apoptosis occurs following the in vivo administration of
these compounds, and it may be more beneficial in vivo also to induce pro-
apoptotic genes in addition to p21 (Fojo, 2002).
The above research may be of relevance to our study of NU:UB agents, since
the NU:UB compounds have a broadly similar structure to some of the
molecules identified by Foster et a/. (1999) in terms of the component parts
which may constitute a generalisation pharmacophore. However, whether
NU:UB agents act via a similar mechanism, reactivating mutant p53 needs to
be further investigated. Our cytotoxic screen of HL60 (p53 null), HCT116 (p53
wild type) and HT29 (p53 mutant) cells did not show striking evidence that the
HT29 cells containing mutant p53 were significantly more sensitive to NU:UB
31, 51 nor 80 than the other cells (see Chapter 4). Rather the sensitivity to the
NU:UB compounds appeared similar in the wild type and the mutant cell line,
which was also reflected in the NCI GI50 data (see Appendix 2).
Overexpression of mdm2 leads to inhibition of the tumour suppressor activity
of p53. Inhibitors of the p53-mdm2 interaction might therefore be attractive
agents for the treatment of tumours that overexpress mdm2 but contain
functional wild type p53. The aim of a p53-mdm2 inhibitor approach would
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thus be to find compounds that could be used as drugs to release wild type
p53 from the p53-mdm2 complex. This should then be beneficial for treating
certain cancers in which an mdm2 related pathway of p53 inactivation is in
operation. The subsequent inhibition of p53 degradation should induce p53
accumulation and possibly cell death by apoptosis. Different groups of
researchers have successfully used this approach. For example Chene et al.
(2000) used an octamer synthetic peptide, referred to as AP peptide in their
studies, showing that this small peptide inhibited the p53-mdm2 interaction in
vitro. When assayed in HCT116 cells this peptide was further found to induce
p53 accumulation, as well as accumulation of the two p53 gene products p21
and mdm2. Cells overexpressing mdm2 are good targets for inhibitors of the
p53-mdm2 interaction, and the AP peptide was also found to induce apoptosis
as measured by caspase-3 activation, in tumour cells that over expressed
mdm2. The AP peptide was also compared to the standard agent cisplatin,
and the data obtained suggested that AP might activate p53 differently from
DNA damaging agents, as measured by p53 phosphorylation on serine 15.
Zhao et al. (2002) utilized computer aided design to develop a small non-
peptidic compound that in tumour cell lines inhibited the p53-mdm2
interaction, activating the p53 pathway which leads to caspase-3 induction
and apoptosis. Mdm2 was reported to be induced by p53 (Barak et al., 1993).
Since NU:UB compounds induced p53 accumulation, we were interested to
see if there was induction of mdm2. By investigating up-regulation of down
stream mediators of p53 (mdm2 and p21) we also hoped to confirm the p53
induction observed. As for p53, mdm2 protein levels were investigated in the
HCT116 cell line. The data showed that following 4h treatment, mdm2 started
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to accumulate, and that maximum accumulation was achieved after 4-8h
treatment of HCT116 cells following a single dose of NU:UB compound.
These studies suggested that the increased mdm2 levels at 4-8h, were
sequential to decreased p53 levels. In future studies it may be of interest to
use cells that overexpress mdm2 (and contain wild type p53) to see if p53 and
other proteins involved in apoptotic pathways are increased following
treatment, since tumours overexpressing mdm2 are good targets for inhibitors
of the p53-mdm2 interaction. For doxorubicin there was no significant
increase in mdm2 despite high p53 levels after 24h treatment. Thus, it may be
that doxorubicin remains active and stable during the course of the
experiment and the p53 levels remain high, and the mdm2 levels low. A
longer time course may be required to detect mdm2 upregulation following
doxorubicin treatment.
Like mdm2, p21 is also a transcriptional target of p53. The major role of p21 is
in cell cycle arrest, preventing the progress of a cell through the G1
checkpoint, hence cell growth is inhibited with the over expression of p21 (EI-
Deiry et al., 1993). It is generally believed that wild type p53 is required for
DNA damaging chemotherapeutics to induce p21. The level of p21 protein
was investigated in HCT116 cells following drug treatments. In the HCT116
cells used here there were basal levels of p21 present in controls, but in
comparison there was no significant increase in p21 levels in HCT116 cells
following 24h drug treatment. The reason for this could be that either p21 was
induced and cell cycle arrested in all cells, including control cells; or that the
drug concentration and/or exposure time were not optimum for this cell line to
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see p21 upregulation; or that in contrast these drugs do not work by inducing
p21, and arresting the cell cycle in this cell line. Since the p53 upregulation
following NU:UB treatments was fairly rapid and brief, shorter exposure times
were attempted for our p21 studies. However, no significant p21 induction
was seen with these HCT116 cells at any of the time points used, following
NU:UB compound treatment. That NU:UB 31 may not act by arresting the cell
cycle was also suggested in our earlier cell cycle analysis investigations
(Chapter 5), where there was no evidence of a permanent cell cycle block
following NU:UB treatment.
P53-responding caspases include caspase-3, and it has been suggested that
p53-mediated apoptosis could involve caspase-3. To confirm the findings from
our apoptotic caspase-3 study (recorded in Chapter 6) we investigated
procaspase-3 cleavage using Western blotting. Using HL60 and HCT116
cells, we found that there were active caspase-3 protein bands present
following NU:UB 31 and NU:UB 51 treatments, at 4h and 8h respectively in
the two cell lines. Although an increase in caspase-3 protein levels following
NU:UB treatment was observed, there was not much of a decrease in the
density of the inactive procaspase-3 bands. This has, however, previously
been reported by Li et al. (1999). This group found that p53 mediated
apoptosis involved activation of caspases, but procaspase-3 detected by
Western blotting was not cleaved although caspase-3 activity could be
detected.
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In summary, p53, mdm2 and caspase-3, but not p21 protein levels were
increased as measured by Western blotting in HCT116 cells following NU:UB
treatment. The level of p53 protein increased early and briefly by NU:UB
treatments. The p53 increase was then followed by an increase in the level of
mdm2 protein. Following doxorubicin exposure (24h) the p53 levels were
higher than at any point throughout the time course of NU:UB compound
treatment, and no mdm2 up-regulation was observed. That the p53 induction
following NU:UB treatment was brief suggests that the compound might be
degraded and/or effluxed from the cells.
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CHAPTER 8
INTRACELLULAR DRUG ACCUMULATION STUDIES
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8.1 INTRACELLULAR DRUG ACCUMULATION STUDIES
Several of the NU:UB compounds have a red colour, and also showed a
strong red fluorescence when viewed under the UV fluorescent and the
confocal microscopes. This allowed us to directly observe where the NU:UB
agents were located in cells following treatment. In this chapter, the results of
drug localisation studies have been presented, in an attempt to deduce in
which cellular compartment(s) these NU:UB agents accumulate. For this
purpose, cells were also stained with Hoechst stain and with fluorescent
probes labelling mitochondria and Iysosomes. We further intended to study
mitochondrial disruptions following NU:UB treatments with the MitoCapture
kit, a mitochondrial membrane potential indicator. We have focused on NU:UB
31, but NU:UB 80 and doxorubicin were also used for intracellular drug
distribution observations, and betulinic acid was used in mitochondrial
disruption investigations.
It was originally thought that mitochondria were not involved in apoptosis
since the morphology of these organelles remained intact, and cells lacking
mitochondrial DNA can undergo apoptosis. However, mitochondria are these
days thought to play an important part in apoptosis and it is now realised that
major alterations in mitochondrial membrane functions do take place during
the apoptotic process. Drugs can affect the mitochondrial function in many
ways. For example, by inhibiting the electron transport chain, or by uncoupling
of oxidative phosphorylation, which means that there is no production of ATP
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or by oxidative damage to mitochondrial DNA. Opening of mega-channels in
the inner mitochondrial membrane (IMM) that lead to swelling and collapse of
the mitochondrial transmembrane potential is another feasible mechanism for
drug toxicity (Krahenbuhl, 2001). Mitochondrial changes are early events
(Metivier et al., 1998; Castedo et al., 2002), likely to take place in cells that
still retain normal light scattering characteristics (side/forward scatter) before
they have shrunk and formed apoptotic bodies. Hence, preceding the
appearance of the characteristic morphologically apoptotic features it has
been reported that there are disruptions in the mitochondrial transmembrane
potential of the cells, and partial disruption of mitochondria along with release
of cytochrome c are thought to be early signs of apoptosis. Thus,
mitochondrial disruption may be, although not necessarily, a sign of a drug
targeting mitochondria, but could also be an early general indication of
apoptosis.
Apoptosis may be induced by different classes of anti-cancer agents by acting
on different cellular targets and by activating distinct signalling pathways. If a
compound accumulates in cellular mitochondria, targeting components of this
organelle, this is likely to cause disruptions in mitochondria. There are
compounds that are thought to directly act on the mitochondria, inducing
apoptosis and betulinic acid is an example of such an agent and has been
included in the present study. Betulinic acid is a triterpene of natural origin
isolated from tropical plants. This compound has shown anti-cancer activities
but its clinical activity is yet to be established. By directly targeting
mitochondria, betulinic acid might be able to bypass the requirement for
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upstream signalling, and may therefore still be effective against tumour cells
that have a defect in upstream apoptosis pathways and therefore do not
respond to classical drugs. Furthermore, growth inhibition following betulinic
acid treatment has been reported to be independent of p53 status (Zuco et el.,
2002; Fulda et al., 1997; Fulda et al., 1998). In this light, mitochondria may
potentially be promising intracellular targets for drug delivery in cases where,
for example, the classical topoisomerase inhibitors targeting nuclear enzymes
fail to induce a response in cells with defects in their nuclear-originating
apoptotic pathway(s). Mitochondria have long been known to contain their
own DNA and this has been highlighted as a possible drug target in
conjunction with its associated nuclear enzymes that are now known to
include a non-nuclear type I topoisomerase (Zhang et ai, 2001).
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8.2 METHODS
8.2.1 NU:UB And Doxorubicin Distribution In HL60 Cells
Throughout the experiments described in this chapter, HL60 cells were
seeded at a density of 10 x 104 cells/ml and left to recover overnight before
being used.
Cells were left untreated (control) or treated with NU:UB 31 or NU:UB 80 for
Oh, 1h, 2h, 4h and 24h. A concentration of 10IJM was chosen for NU:UB 31 to
give a bright red fluorescence, and to be suitable for the time course. NU:UB
80 was also used at 101JM, and doxorubicin at 10IJM and 1IJM for Oh and 24h
respectively. Following treatments the cells were washed in HBSS, then
resuspended in a total volume of 501J1 to get a high cell density. Each sample
was then put onto glass slides and viewed using the confocal microscope
(Nikon Eclipse TE 2000-U) at 60x oil immersion.
8.2.2 Localisation Of The Nucleus In HL60 Cells Treated With
NU:UB 31 Or Doxorubicin
To localise the nucleus, the cells were stained with Hoechst 33342 Stain.
Cells were treated with NU:UB 31 (10IJM) or doxorubicin (1OIJM) for 1h. Drugs
were washed off and cells were stained in Hoechst stain (1001Jg/ml stock
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diluted 1/100) for 5 mins and were then viewed under the confocal
microscope at 60x oil immersion.
8.2.3 MitoTracker Green And Hoechst Staining Of NU:UB 31
Treated HL60 Cells
We set out here to investigate if NU:UB 31 enters mitochondria. The
mitochondria in HL60 cells were labelled with MitoTracker green FM
(Molecular Probes). MitoTracker probes exist in several colours and green
was chosen to be able to distinguish this green colour from the red NU:UB
fluorescence. Cells were probed with MitoTracker according to manufacturers
instructions. Briefly, MitoTracker green was dissolved in DMSO to a stock of
1mM. For the MitoTracker green probe a concentration range was suggested
of 20-200nM and an incubation time of 15-45 mins. We chose an incubation
time of 30 mins, made a series of dilutions of the MitoTracker probe and found
that 50nM was sufficient to visualise the mitochondria in HL60 cells. Treated
(NU:UB 31, 1h at 101JM) and untreated cells (solvent) were washed in pre-
warmed HBSS, pelleted by centrifugation 500 x g, 5 mins and resuspended in
fresh pre-warmed 37°C HBSS (or medium) containing the MitoTracker at
50nM. Cells were incubated for 30 mins in the dark at 37°C. To visualise the
nucleus, cells were centrifuged 500 x g, 5 mins and resuspended in Hoechst
stain (100IJg/ml stock diluted 1/100) for an additional 5 mins. There was no
wash step included in this protocol since the MitoTracker probe only becomes
fluorescent once accumulated in the lipid environment of mitochondria and
there is therefore no problem with background fluorescence. Following
269
Hoechst staining, cells were pelleted and resuspended in 501J1 of pre-warmed
HBSS. The green MitoTracker was not suitable for fixing so the cells were
viewed immediately in the confocal microscope (Ex 490 nm, Em 516 nm).
8.2.4 Investigation Of Mitochondrial Disruption In HL60 Cells
With A MitoCapture Kit Using Flow Cytometry
Mitochondrial function can be measured with JC-1, a lipophilic cationic
fluorescent probe that was used in the MitoCapture assay. When JC-1 is in its
monomic form it emits green fluorescence. On the contrary, at a high
mitochondria transmembrane potential that can be achieved in functioning
mitochondrial, JC-1 forms multimers (J-aggregates), which upon excitation
emits red/orange fluorescence. Upon mitochondrial disruption there is a
resulting decrease in red J-aggregate fluorescence and this decrease is likely
mirrored by an increase in green JC-1 monomers (Cossarizza et al., 1993;
Bradbury et a/., 2000). Betulinic acid is an agent that is thought to target the
mitochondria directly and thereby induce apoptosis. We sought to investigate
whether or not NU:UB 31 directly targets mitochondria, disrupting the
mitochondrial membrane potential as a possible mechanism of inducing cell
kill. For this purpose a mitochondrial membrane potential indicator, a
MitoCapture kit was used (BioVision). Since we wanted to study if NU:UB 31
had an immediate effect on mitochondria, short exposure times were used. A
recent study of mitochondrial disruption in osteosarcoma cells using JC-1
reported that there was a loss in mitochondrial transmembrane potential after
1h treatment with staurosporine (1IJM), and further that this loss was over the
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same time course as caspase-3 activation (Jiang et a/., 1999). We had
previously seen caspase-3 activation following 4h treatments, and therefore a
4h exposure time was used in this MitoCapture study, as well as a shorter
exposure time of 1h. Thus, cells were left untreated (solvent), treated for 1h,
or treated for 4h with NU:UB 31 or betulinic acid. NU:UB 31 was used at
201JM, 30IJM or 401JM, based on previous ICso results for the HL60 cell line.
Betulinic acid was included for comparison in these experiments and was
used at 20IJM (10IJg/ml) or 40IJM (20IJg/ml). For the MitoCapture assay the
manufacturers instructions were followed. Briefly, untreated (solvent), NU:UB
31 and betulinic acid treated HL60 cells (1 x 106 cells per sample) were
washed and resuspended in 1ml fresh MitoCapture containing pre-warmed
incubation buffer (provided with the kit, 11J1 MitoCapture/ml buffer). The
samples were allowed to incubate with the MitoCapture stain in the dark for
1h at 37°C. Following staining the cells were washed in the provided
MitoCapture wash buffer, resuspended in pre-warmed incubation buffer and
immediately analysed in flow cytometry. The MitoCapture stain is red or green
depending on its localisation. In normal, viable cells the MitoCapture stain
enters, remains in mitochondria and shows red fluorescence. Upon
mitochondrial disruption the stain enters cytoplasm and fluoresces green. It
was anticipated that if NU:UB 31 caused mitochondrial disruptions, an
increase in green fluorescence and a decrease in the red fluorescent signal
would be observed. Green monomer versus red aggregate fluorescence was
measured on the FL1 (Ex 488nm, Em 530nm) and FL2 (Ex 488nm, Em
590nm) channels respectively.
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8.2.5 LysoTracker Green And Hoechst Staining Of NU:UB 31
Treated HL60 Cells
We sought to investigate if NU:UB 31 accumulated in Iysosomes using
LysoTracker green DND-26 (Molecular Probes) to visualise these acidic
organelles. Weak bases are though to selectively accumulate in cellular
compartments with low internal pH e.g. lysosomes. LysoTracker green
consists of a fluorophore linked to a weak base that can freely penetrate cell
membranes and concentrate and thereby labelling the acidic organelles in
living cells. LysoTracker green was used according to manufacturers
instructions. Briefly, the LysoTracker was provided in vials of 1mM in DMSO
and was further diluted to in pre-warmed culture medium. A 45 mins
incubation time was chosen, a series of LysoTracker dilutions was made and
50nM was found sufficient in this assay. Untreated (solvent) and treated
(NU:UB 31 1h at 10 IJM) HL60 cells were washed in pre-warmed HBSS,
resuspended in 1ml pre-warmed HBSS containing 50nM LysoTracker green
and incubated for 45 mins in the dark at 37°C. Cells were resuspended in
Hoechst stain (1001Jg/ml stock diluted 1/100) for 5 mins. Following
centrifugation, 500 x g, 5 mins, each sample was resuspended in 501J1 pre-
warmed HBSS and was then viewed in the confocal microscope (Abs 504nm,
Em 511nm).
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8.3 RESULTS
8.3.1 Time Course Of NU:UB 31, NU:UB 80 Or Doxorubicin
Treated HL60 Cells
Confocal microscope images over a time course ranging from 0 to 24h of drug
accumulation (NU:UB 31 and NU:UB 80) are given in Fig. 8.1 and Fig. 8.2.
This study indicated that the NU:UB compounds, which have a bright red
colour (white in Fig. 8.1 and Fig. 8.2), seem to enter the cellular cytosol
immediately following treatment. NU:UB localisation looked similar at all time
points, but these NU:UB agents did not seem to enter all areas of the cells (a
black space in cells was observed). Cells treated with doxorubicin show that
this drug is also readily taken up, but its localisation patterns differ from that of
NU:UB agents (Fig. 8.3). Considering that NU:UB 31 accumulation appeared
to remain the same throughout the time course, we chose a 1h exposure time
in further localisation experiments.
8.3.2 Hoechst Staining Of NU:UB 31 Treated HL60 Cells To
Visualise The Nucleus
To identify drug localisation in relation to the nucleus in NU:UB 31 treated
cells Hoechst 33342 stain was used. Fig 8.4 shows that the black space with
no red NU:UB 31 fluorescence present is the nucleus of the cell. Thus, there
273
was no fluorescence from NU:UB 31 in this area of the cell, the red
fluorescence was instead seen in the cytosol. This appeared to be the case
throughout the 24h exposure time. Doxorubicin did however appear to reach,
and accumulate in the nucleus instantly and remained here at the 24h time
point (Fig. 8.3).
8.3.3 MitoTracker And Hoechst Staining Of NU:UB 31 Treated
Cells
Next we sought to identify organelles in the cytosol in which NU:UB 31
accumulated. The mitochondria were the first organelles to be studied, NU:UB
compounds were synthesised to intercalate and groove bind into DNA,
interacting with DNA topoisomerases, and mitochondria contain their own
DNA (and are thought to have topoisomerase activity). To visualise
mitochondria in the cells, MitoTracker green was used. Fig. 8.5 shows green
mitochondria in untreated HL60 cells, the nucleus was stained blue with
Hoechst stain. In Fig. 8.6 NU:UB 31 treated HL60 cells were observed.
NU:UB 31 was bright red (a), the blue Hoechst stain located the nucleus (b)
and the green MitoTracker revealed the localisation of mitochondria (c). Fig.
8.6d is a merged picture of the three above and from this as well as the
zoomed image in Fig. 8.7, it seems that the main concentration of NU:UB 31
did not accumulate in the mitochondria. However, this does not exclude the
possibility that NU:UB 31 reached the mitochondria, as there seems to be
lower levels of NU:UB 31 within these organelles and throughout the cytosol.
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8.3.4 Investigation Of Mitochondrial Disruption In HL60 Cells
With A MitoCapture Kit
An attempt to investigate if NU:UB 31 targets mitochondria directly was made
using the MitoCapture kit. Betulinic acid was used as a positive control in
these experiments as this agent is has been found to work primarily on
mitochondria in its mechanism of action. Untreated and treated cells were
stained in MitoCapture stain and analysed by flow cytometer. Untreated cells
stained both green and red and therefore in treated cells with damaged
mitochondria, a drop in the red signal and increase in green signal would be
expected as the stain would remain as monomers in the cytosol rather than
aggregating in mitochondria. In cells treated for 1h, there was no change
compared to respective control following NU:UB 31 nor betulinic acid
treatments (Fig. 8.8, Fig. 8.9a, Fig. 8.9b). The lack of mitochondrial damage
could have been due to too short an exposure time, however following 40IJM
NU:UB 31 treatment there appeared to be cells killed, with a lot of material
with low green and low red fluorescence (Fig. 8.8d). Treating the cells for 4h
with betulinic acid 40IJM resulted in a drop in red fluorescence compared to
control, indicating that these cells have damaged mitochondria, however the
green remained the same (Fig. 8.9c, Fig. 8.9d). Following 4h NU:UB 31
exposure (201JM and 301JM) there was rather an increase in red fluorescence
compared to control (Fig. 8.10). It might be that NU:UB 31 did not affect
mitochondria. However, since NU:UB 31 has a bright red fluorescence, it is
likely that NU:UB 31 interfered with the red MitoCapture colour which would
explain the increase in red fluorescence compared to control. This red
275
interference presented problems, but it was thought that there would be an
increase in green fluorescence as an indication of mitochondrial membrane
disruptions. This was, however, not the case in this assay, even following
treatment with betulinic acid. Without a change in green signal it was not
possible to use this stain to investigate possible mitochondrial membrane
disruptions caused by NU:UB 31. In summary, betulinic acid showed a drop in
red signal (but no change in green) and could therefore be used as a positive
control of mitochondrial disruption. NU:UB 31 was however, red like the
MitoCapture stain, and this assay was therefore not suitable for NU:UB 31 (or
other red compounds). Any conclusions whether NU:UB 31 targets
mitochondria or not could not be drawn using the MitoCapture assay.
8.3.5 LysoTracker And Hoechst Staining Of NU:UB 31 Treated
HL60 Cells
The green LysoTracker stain reveals the localisation of Iysosomes in HL60
cells. Lysosomes in untreated HL60 cells are seen in Fig. 8.11. Cells were
treated for 1h with 10IJM NU:UB 31 in Fig. 8.12 and Fig. 8.13. From this study
it seemed that the main localisation of NU:UB 31 coincided with the green
LysoTracker stain within the cells, and thus it appeared that the drug
accumulated in acidic compartments in cells, which mainly were Iysosomes.
Although a lot of the drug seemed to be taken up by Iysosomes, NU:UB 31
may also reach other organelles within the cell.
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Fig. 8.1a NU:UB 31 10IJM, viewed immed iately
Fig. 8.1b NU:UB 31 10IJM 1h
Fig. 8.1c NU:UB 31 10IJM 2h
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Fig. 8.1d NU:UB 31 10~M 4h
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Fig. 8.1e NU:UB 31 10~M 24h
Fig. 8.1a-e Time course of HL60 cells treated with NU:UB 31 for Oh (a), 1h (b), 2h (c)I 4h (d)
and 24h (e) and viewed under confocal microscope with 60x magnification, or 60x
magnification and zoomed 4 times. White represents the red NU:UB 31 fluorescence.
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Fig. 8.2a Control
Fig. 8.2c NU:UB 80 10j.JM 1h
Fig. 8.2e NU:UB 80 10j.JM 4h
Fig. 8.2b NU:UB 80 10j.JM,
viewed immed iately
Fig. 8.2d NU:UB 80 10j.JM 2h
Fig. 8.2f NU:UB 80 10j.JM 24h
Fig. 8.2a-f Time course of HL60 cells treated with NU:UB 80 for Oh (a), 1h (b), 2h (c), 4h (d)
and 24h (e) and viewed under confocal microscope with 60x magn ification . White represents
the red NU:UB 80 fluorescence.
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Fig . 8.3a Doxorubicin 10IJM, viewed immediately
Fig. 8.3b Doxorubicin 10IJM 24h
Fig. 8.3a-b Time course of HL60 cells treated with Doxorubicin for Oh (a) as well as 24h (b)
and viewed under confocal microscope at 60x magnification. 0 rat 60x magnification with 4
times zoom. White represents the red doxorubicin fluorescence .
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Fig.8.4a NU:UB 31 10IJM 1h Fig.8.4b Hoechst stain in NU:UB 31
treated cells
Fig. 8.4a-b NU:UB 31 (10IJM, 1h) treated HL60 cells viewed under confocal microscope. The same
HL60 cells, where red (a) shows NU:UB 31 localisation, and blue Hoechst stain visualises the nucleus
(b) in these cells. NU:UB 31 was notfound in the blue, Hoechst stained nucleus. These c ells were
viewed under confocal microscope at 60x magnification.
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Fig . 8.5 Confocal microscope picture of untreated HL60 cells. Hoechst stained nucleus (blue) and
MitoTracker green stained mitochondria (green). 60x magnification, zoomed 4 times
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Fig. 8.6a-d Confocal microscope pictures of 1h NU:UB 31 (10IJM) treated HL60 cells. NU:UB 31
localisation (a), Hoechst stained nucleus (b), MitoTracker green (c) and merged picture of the three
above (d). 60x magnification.
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Fig. 8.7 Confocal microscope picture of NU:UB 31 (10~M, 1h) treated HL60 cells. NU:UB 31
localisation (red), Hoechst stained nucleus (blue) and MitoTracker green stained mitochondria (green).
60x magnification, zoomed 4 times
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Fig. 8.8a-d Flow cytometer eytograms of MitoCapture stained HL60 cells. Unstained cells (a),
Stained control cells 1h (b), NU:UB 31 20IJM 1h (c), NU:UB 31 40IJM 1h (d). Treatments were
carried out for 1h, cells were washed and left to recover for 4h.
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Fig. 8.9a-d Flow cytometer eytograms of MitoCapture stained HL60 cells. MitoCapture stained
control cells 1h (a), betulinie acid 40IJM 1h (b), Stained control cells 4h (c), betulinie acid 40IJM
4h (d).
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Fig. 8.10a-c Flow cytometer cytograms of MitoCapture stained HL60 cells. MitoCapture stained
control cells 4h (a), NU:UB 31 20IJM 4h (b), NU:UB 31 30IJM 4h (c).
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Fig. 8.11 Confocal microscope picture of untreated HL60 cells. Hoechst stained nucleus (blue) and
LysoTracker green stained Iysosomes (green). 60x magnification, zoomed 4 times.
288
Fig. 8.12a-d Confocal microscope pictures of 1h NU:UB 31 (10~M) treated HL60 cells. NU:UB 31
localisation (a), Hoechst stained nucleus (b), LysoTracker green (c) and merged picture of the three
above (d). 60x magnification.
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Fig. 8.13 Confocal microscope picture of NU:UB 31 (10jJM, 1h) treated HL60 cells. NU:UB 31
localisation (red), Hoechst stained nucleus (blue) and LysoTracker green stained Iysosomes (green).
BOx magnification, zoomed 4 times.
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8.4 DISCUSSION
The confocal microscope observations and images presented in this chapter
revealed intracellular sites where NU:UB (NU:UB 31 and NU:UB 80) and
doxorubicin fluorescence was seen. All agents were rapidly taken up into
cells. When comparing the fluorescence patterns of doxorubicin and NU:UB
compounds, these differed, but the fluorescence from each agent appeared to
remain the same at the various time points. Whereas the main fluorescence
from doxorubicin was found in the nucleus, confirmed with Hoechst stain, the
NU:UB agent fluorescence was not seen in this location. Rather, for the two
NU:UB compounds, the fluorescence was observed in the cytoplasm, with the
brightest fluorescence found in small circular compartments within the
cytoplasm. The NU:UB agents had however been synthesised to interact with
their proposed targets, nuclear DNA and DNA topoisomerases. No red
fluorescence was confirmed with Hoechst stain to be within the nucleus. Thus,
in contrast to doxorubicin, the NU:UB agents did not appear to reach the
nucleus, the localisation of their intended topoisomerase targets. This would
imply that these do not target nuclear DNA and nuclear topoisomerases, and
their mechanism of action would then not be what it was designed to be.
Other explanations for the lack of fluorescence in the nuclear region include:
Firstly, when NU:UB 31 (or NU:UB 80) reaches acidic vesicles and organelles
such as Iysosomes, the compound is broken down. The bright red
fluorescence would then originate from this degraded species rather than from
the intact NU:UB 31 (or NU:UB 80). Intact NU:UB 31 would then not fluoresce
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within the cell, and may thus be located in the nuclear region where no red
fluorescence was observed. Secondly, a more feasible phenomenon, that was
observed by others is quenching. NU:UB 31 could reach the nucleus as well
as other sites within the cell. However, upon reaching and intercalating DNA
its conformation would then change so that it no longer fluoresces. Tkaczyk-
Gobis et al. (2001) studied anticancer agents (BP1, BP2 and BP3) from the
benzoperimidine family, a family supporting a flat conjugated ring system that
is likely intercalated between the base pairs of DNA. Upon adding these
fluorescent compounds to whole cells, cell nuclei or to naked DNA there was
a decrease in the fluorescence, and this quenching of the fluorescence signal
was here thought here to be due to the drug-DNA interaction. Like these
drugs, the NU:UB compounds, also consist of rings and therefore a similar
quenching mechanism may take place when NU:UB compounds interact with
DNA. However, doxorubicin is also made up of a ring system that is known to
intercalate DNA, yet the doxorubicin fluorescence was readily observed. It is
likely that doxorubicin accumulated in the nucleus at very high concentrations,
so that although quenching may occur, this did not prevent the detection of
doxorubicin fluorescence in the nucleus. Hence, NU:UB agents may not
accumulate in the nucleus at high concentrations, but low concentrations of
NU:UB compound with quenched fluorescence may still reach and affect its
nuclear target(s). However, in an earlier study by Lampidis et al. (1997) the
quenching phenomenon of a series of anthracyclines was disputed. Cell
nuclei were isolated and treated with different anthracycline analogues
(exhibiting different lipophilic, charge and drug localisation properties),
following treatment the drugs were extracted and assayed by HPLC. The
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results were compared to microscopic observations of the anthracycline
analogues and suggested that nuclear/DNA quenching did not alter the
microscopic observations of nuclear/cytoplasmic localisation. Thus, in contrast
to the finding by Tkaczyk-Gobis et al. (2001), the lack of drug fluorescence in
nucleus in the study by Lampidis et al. (1997) did not appear to be due to
DNA quenching but rather to an absence of drug in the nuclear compartment.
Furthermore, it was also suggested that positive charge, along with degree of
lipophilicity, influenced whether or not the anthracyclines were recognised by
P-gp, and anthracycline analogues that localised in the cytoplasm rather than
in the nuclear region of the cell were able to overcome MDR. Although
absolute intracellular localisation to the nucleus or cytoplasm was not likely to
occur with any of the anthracyclines they tested, a general pattern was
suggested by Lampidis et al. (1997), that, with decreased affinity for binding
DNA, anthracyclines shift in their primary localisation from nuclear to
mitochondrial to diffuse cytoplasmic localisation. Thus, as lipophilicity
increased and nuclear DNA binding properties of the studied anthracycline
analogues decreased, the analogues seemed to distribute in mitochondria
suggesting that mitochondria may pose as an anthracycline target, although
this was not the case for doxorubicin, showing no mitochondrial localisation.
Further sub-cellular localisation studies suggested that the main NU:UB 31
fluorescence was contained within the cytoplasmic Iysosomes, and possibly
other acidic vesicles and organelles such as endosomes. Although the main
fluorescence was thought to be within acidic organelles, this does not mean
that NU:UB 31 does not at all reach other cytosolic compartments such as
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mitochondria. Apart from the very bright red (possibly high concentrations of
NU:UB 31) sites, NU:UB 31 seemed to be present at somewhat lower
concentration throughout the cytosol. It may be that these levels at which
NU:UB 31 is present throughout the cytosol are sufficient to have effect on
other cytosolic targets. Possibly, the high intensity of NU:UB 31 that is seen,
in what appear to be Iysosomes is a mechanism used by the cells to exclude
the NU:UB compound. Since many drugs target nuclear DNA and/or nuclear
enzymes, distribution of drug into cytoplasmic organelles and vesicles may
decrease the toxicity of a drug as a result of less drug-target interactions.
Altered drug sequestration is often seen in resistant cells and from such
studies different patterns of drug distribution in sensitive and MDR cells have
been revealed (Hindenburgh et al. 1989). MDR cells are thought to express
certain proteins acting as efflux pumps. P-gp is an example of such a protein
associated with resistance. The increased expression of P-gp in the plasma
membrane is the most consistent change detected in MDR cells, correlating
with decreases in intracellular drug accumulation and increased drug
resistance (Larsen et al., 2000). While some of the transporters associated
with resistance are capable of transporting drugs from the plasma membrane,
others can transport drugs from the cytoplasm into vesicles, eventually
resulting in drug exclusion (efflux). In a study by Hindenburgh et al. (1989),
sensitive cells showed daunorubicin drug distribution into both the nucleus
and the cytoplasm, whereas in resistant cells the drug had a cytoplasmic,
dotted distribution, in what was possibly vesicles moving towards the plasma
membrane. Thus, it may, in part be transporter proteins related to MDR that
alter drug distribution and bring the intracellular drug concentration down.
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However, if the drug concentrations were increased to levels that exceed the
capacity of this transporter system, the intracellular drug concentrations may
become toxic to cells. Additionally, in the case of altered drug distribution of
weak lipophilic base topoisomerase inhibitors (including agents for the
anthracyclines and anthracenediones e.g. daunorubicin, doxorubicin and
mitoxantrone) a mechanism has been proposed (Larsen et al., 2000). As long
as a substantial fraction of these agents stay uncharged, as they are at
normal intracellular pH (7.2-7.6), they can freely penetrate the membranes of
cytoplasmic organelles. Once inside, for example, the acidic Iysosomes (pH
4.8-5.2), these weak bases are thought to be converted into charged
molecules that cannot escape. As a result, these drugs will be retained within
the organelle, can therefore not reach their nuclear target(s) and will instead
be excluded from the cell.
Although it is generally believed that cytotoxicity from anthracycline anti-
cancer drugs such as doxorubicin is linked to interactions with nuclear DNA
and topoisomerase II, the exact mechanism for inducing cell death and
apoptosis is yet to be completely understood. Serafino et al. (1999) suggested
that anthracycline mediated apoptosis was induced by interactions with both
nuclear as well as cytoplasmic components. In this project we investigated
NU:UB 31 accumulation in relation to mitochondria. Although NU:UB 31 to
some degree was found throughout the cytoplasm it was more likely
Iysosomes, rather than the mitochondria that supported the main fluorescence
from NU:UB 31. Mitochondria do however also contain their own DNA and
topoisomerases. Recent publications have supported the idea that for
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mitochondrial DNA metabolism such as replication, repair and transcription
there is a requirement for mitochondrial topoisomerases. Mitochondrial
topoisomerase I is further thought to be homologous to nuclear
topoisomerase I so perhaps it is not surprising therefore that mitochondrial
topoisomerase I was reported to be sensitive to camptothecin. However,
whether or not mitochondrial topoisomerase I is a target for camptothecin,
contributing to its cytotoxicity is still to be revealed (Zhang et a/., 2001; Wang
et a/., 2002). Since mitochondria contain DNA and topoisomerases, it may be
feasible that like nuclear effects, fluorescence quenching may take place
within these organelles upon NU:UB 31 interaction. The faint red NU:UB 31
fluorescence in mitochondria may thus be due to fluorescence quenching
rather than this compound not being present at high levels in the
mitochondria. Therefore, despite there being no red fluorescence observed
within nuclear DNA and faint fluorescence observed through out the cytosol
including the mitochondria, neither the nucleus nor mitochondria can be fully
excluded from being possible NU:UB agent targets. In a study by Bigioni et a/.
(2001) doxorubicin was compared to its disaccharide analogue (MEN 10755)
in the context of cellular drug uptake, localisation and induction of DNA
damage and apoptosis. It was found that higher concentrations of doxorubicin
accumulated within the nucleus than its analogue. In spite of this, the
disaccharide analogue induced more topoisomerase-mediated DNA damage
than that produced by doxorubicin. This damage was possibly achieved
through fewer but more long-lasting interactions with topoisomerase II
(increased stabilisation of the cleavable complex). Furthermore, the
doxorubicin analogue MEN 10755 appeared to accumulate in the cytoplasmic
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compartment of the cell. Based on this, and the fact that this analogue was
more effective than doxorubicin in inducing Bcl-2 phosphorylation
mitochondria were suggested as an additional target of the MEN 10755
doxorubicin analogue. Strikingly, correlations of NU:UB agents with
topoisomerase inhibitors as well as pyrimidine biosynthetic enzyme inhibitors
in the NCI database have been made. NU:UB 31,43,80 and 81 were used as
seeds to produce the LC50 comparision table that can be found in appendix 5.
In this table, Pearson correlation coefficients above 0.6 are considered to be
statistically relevant. For the NU:UB agents there are coefficients above 0.6
making correlations between NU:UB agents and topoisomerase inhibitors and
also between NU:UB agents and inhibitors of pyrimidine biosynthesis.
Interestingly, pyrimidine synthesis take place in mitochondria (Baldwin et al.,
2002) and agents that interfere with this pathway should thus target
components and enzymes participating in the mitochondrial pyrimidine
biosynthesis pathway. An agent that regularly appears in correlation with
NU:UB compounds is brequinar. Brequinar inhibits the pyrimidine
biosynthesis pathway at the dihydroorotate dehydrogenase step (step 4 in
pyrimidine biosynthesis) (McLean et al., 2001). Thus, the cytotoxicities of
NU:UB agents may partly be attributed to a common pathway to brequinar or
to other mitochondria-targeted drugs, involving inhibition of dihydroorotate
dehydrogenase or other enzymes involved in biosynthetic pathways taking
place within the mitochondria. A deeper investigation of these possibilities is
thus merited.
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Several groups have used etoposide to investigate what effect(s) this
topoisomerase drug has on mitochondria. The formation of free radicals, the
release of cytochrome c, condensed mitochondria, reduced mitochondrial
transmembrane potential, and the release of apoptogenic proteins have been
identified following etoposide treatment (Kagan et al., 1994; Chen et al., 2000;
Zhuang et al., 1998; Meng et al., 2000). It was also suggested by Custo'dio et
al. (2001) that etoposide may induce mitochondrial permeability transition
releasing mitochondrial apoptogenic factors, and their study showed the
effects of etoposide on mitochondrial permeability transition in vitro. The
authors concluded that the drug effects, as well as the side effects in normal
cells in vivo, could be explained by etoposide induced mitochondrial
permeability transition, mediating apoptotic cell death and/or ATP depletion.
The mitochondrial transmembrane potential was investigated by Facompre' et
al. (2000) using flow cytometry with cationic fluorescent probes. The
relationship between the HL60 cell cycle effects of etoposide and
mitochondrial transmembrane potential variations were studied here. This
group found that an arrest in the G2/M phase of the cells was associated with
an increase in the potential of mitochondrial membranes at low etoposide
concentrations (O.5IJM, 24h treatment). Following this there was a subsequent
decrease of mitochondrial transmembrane potential and the appearance of a
sub G1 peak indicative of apoptosis. Complete collapse of mitochondrial
transmembrane potential and extensive apoptosis was, on the other hand,
triggered by higher etoposide concentrations (~1IJM, 24h treatment). In a
study by Robertson et al. (2000), it was also stated that the concentration of
etoposide appeared to decide which apoptotic pathway(s) was induced. High
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concentrations appeared to induce cytochrome c release by mitochondrial
pathways, and low concentrations via nuclear pathways. Thus, the
topoisomerase II inhibitor etoposide appears to induce apoptosis by pathways
that vary depending on concentration. However, this mayor may not be the
case for all topoisomerase inhibitors and Facompre et al. (2000) also
suggested that topoisomerase II drugs may differ from topoisomerase I
agents in their effect on mitochondria. With regard to NU:UB 31 it may be that
this compound, like etoposide, has different nuclear/mitochondria effects
depending on concentration.
Mitochondrial disruption investigations were performed in our studies using a
MitoCapture kit and betulinic acid was used as a positive control as this agent
has been reported to directly target mitochondria. Unfortunately the
MitoCapture assay proved to be unsuitable for use when treating cells with
NU:UB 31 due to problems with overlapping fluorescence spectra. In addition
to directly targeting mitochondria, betulinic acid has also been found to have a
similar potency in wild type as it has in mutant p53-containing cell lines. This
was, however, not the case for doxorubicin, which is more cytotoxic in wild
type p53-containing cell lines. In a cell line screen containing both p53 types,
doxorubicin exerted its anti-proliferative activity in a large range of
concentrations whereas betulinic acid showed activity in a very narrow range
of doses. These observations were suggested to reflect the wild type p53-
dependent cytotoxicity of doxorubicin and the p53-independent cytotoxicity of
betulinic acid (Zuco et al., 2002). Although p53-dependent apoptotic pathways
have a role in response to DNA damage, it is not certain that wild type p53
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function is required for anthracyclines to induce apoptosis. The disaccharide
doxorubicin analogue MEN 10755 was more effective in the treatment of p53-
mutant tumours than doxorubicin, which would suggest that the analogue had
an increased ability to induce p53-independent apoptosis (Perego et a/.,
2001). The NU:UB agents showed a relatively narrow IC50 range when
screened in the NCI 60 cell line screen (Appendix 1). Also, in the NCI p53
screen, the cytotoxicity of the NU:UB compounds tested were similar in wild
type and mutant cell lines (reported in Chapter 7). From this it may be
suggested that an intact p53 pathway may not be essential for the NU:UB
agents, but that p53-independent pathways could also be important for
NU:UB cytotoxicity. In addition to the fairly narrow IC50 range of the NU:UB
agents, the MTT assay results showed that the assayed NU:UB agents also
had a very rapid effect, exerting cytotoxicity within short, 4h exposure times.
Could this rapid effect be due to a direct action on mitochondria, considering
that the MTT assay relies on functional mitochondria as a measure of
cytotoxicity? For betulinic acid the mitochondria are the main targets, for
NU:UB 31 these organelles may be implied, but no conclusions can so far be
made to confirm or deny this idea. A suitable experimental model to study
whether or not NU:UB agents affect mitochondria (interacting with
mitochondrial DNA, or requiring proper function of these organelles to exert
cytotoxicity), could be to use cells that lack mitochondrial DNA. The NU:UB
cytotoxicity in these cells could then be compared to that in their parental, wild
type counterparts. Cells devoid of mitochondrial DNA are referred to as po,
these cannot perform electron transport or oxidative phosphorylation. In a
study by Hu et a/., (2000) the cytotoxicities of rhodamine 123 and doxorubicin
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were investigated in a human osteosarcoma pO cell line and in its wild type
counterpart. It was found that doxorubicin had similar ICso values in these cell
lines, whereas rhodamine 123 had a much higher ICsovalue in the pO cell line,
containing no mitochondrial DNA. Further, less rhodamine 123 was
accumulated in the pO cells compared to wild type, whereas both cell types
accumulated similar amounts of doxorubicin. The results thus showed that
doxorubicin did not appear to target mitochondria. Rhodamine 123 did
however seem to rely on normal functioning mitochondria and maintenance of
normal mitochondrial membrane potential may play an important role in the
intracellular accumulation and subsequent cytotoxicity of this compound.
These pO cell line results were in agreement with previous findings that
rhodamine 123 localises in the mitochondria (Chen et a/., 1982), while
doxorubicin is found mainly in the nucleus (Lampidis et a/., 1997). With regard
to doxorubicin, the study by Hu et a/. (2000) further implied that doxorubicin
has a non-mitochondrial dependent mechanism of action. This suggestion
however argues against previous findings that doxorubicin in addition to
utilising nuclear DNA, also uses the mitochondrial electron transport system to
form cytotoxic superoxides and free radicals.
In summary, NU:UB 31 (and possibly other NU:UB componds) may reach its
nuclear target(s), acting as an anti-topoisomerase inhibitor, but it is also
feasible that cytosolic organelles are important for its cytotoxic actions, such
as mitochondria, considering these organelles contain mitochondrial DNA and
topoisomerases. The recent NCI comparision correlations of LCso values
further suggest that NU:UB agents as well as acting as nuclear
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topoisomerase inhibitors, may have additional mechanisms of action.
Considering the frequency of correlation with agents acting on enzymes
participating in the pyrimidine biosynthesis pathway such as dihydroorotate
dehydrogenase, mitochondrial enzymes or functions may be additional targets
of the NU:UB agents. Further investigations are warranted to deduce whether
or not NU:UB agents interact with mitochondrial components as part of their
mechanism of action. In our studies, NU:UB 31 also seemed to accumulate
within the Iysosomes and possibly other acidic vesicles and this could be due
to its weak base properties and possibly be a mechanism for the cell to efflux
the NU:UB 31 agent. Anti-topoisomerase agents with concomitant anti-
metabolite activity may represent a novel dual mechanism of cytotoxic action;
further work to elucidate whether or not these dual properties are vested in
the NU:UB series are warranted.
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CHAPTER 9
SUMMARY DISCUSSION
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9.0 SUMMARY DISCUSSION
The discovery that topoisomerases were the targets for many of the most
potent anti-cancer drugs led to a great interest in these enzymes and in the
synthesis of more of these types of drugs. The current clinically useful anti-
cancer agents doxorubicin, mitoxantrone and etoposide are examples of such
drugs acting via the type II topoisomerase enzyme. More recently the
topoisomerase I targeting camptothecin derivatives irinotecan and topotecan
have also been introduced into the clinic. However, most of the current anti-
topoisomerase drugs were, from the beginning, not specifically designed to
target topoisomerases, this has been a later discovery. Furthermore, it has
now been realised that these drugs are not clean topoisomerase inhibitors,
but that many, in addition to their anti-topoisomerase activities, also have
other activities that are unrelated to these enzymes and that in many cases
can result in dose-limiting side effects when administered to patients
(Cummings et al. 1991; Cummings and Smyth, 1993).
In addition to the non-specific toxicities induced by many currently used
therapeutics, there is also a severe problem with drug resistance that limits
the uses of today's anti-cancer drugs. Many topoisomerase inhibitors are
prone to so-called altered topoisomerase (atypical) drug resistance. This type
of resistance is modulated by alterations in the expression levels of
topoisomerase enzyme (type I or II). Studies have indicated that cells
responsive to topoisomerase I-targeted drugs have elevated levels of
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topoisomerase I, require active DNA replication, and may need a functional
apoptotic pathway (Coleman, 2001). One of the mechanisms associated with
resistance to topoisomerase I inhibitors has been reported to be decreased
activity of the topoisomerase I enzyme (Uemura, 1984; Goto, 1985).
Furthermore, it is known that when cells lose topoisomerase I activity,
topoisomerase II instead takes care of the roles of topoisomerase I in cells
(Brill, 1987). This increased importance of topoisomerase II can then make
topoisomerase I-negative cells more sensitive to topoisomerase II inhibitors
(Nitiss, 1994b; Byl, 1999). Thus, it may be possible to actively exploit the
cellular imbalance of topoisomerase I and topoisomerase II enzymes as a
rationale in chemotherapy regimens. Sequential chemotherapy targeting of
topoisomerase enzymes, modulating topoisomerase II expression levels by
topoisomerase I inhibitors might be more effective than using a
topoisomerase II inhibitor alone (Kim, 1999).
Another approach to defeat resistance due to altered topoisomerase function,
may be to invest in both topoisomerase I and topoisomerase II targeting
properties within the same molecule. Compounds that may be truly classified
as dual (or mixed) topoisomerase I and topoisomerase II inhibitors are
currently few in number. The anthracycline aclarubicin, the acridine DACA
(Fig. 9.1) and the indenoquinone TAS-103 (Fig. 9.2) are examples of recently
identified drugs in clinical trials that are thought to exhibit dual topoisomerase
inhibitory properties, although some controversy still exists over the relative
contributions of anti-topoisomerase I versus anti-topoisomerase II action.
Studies using cell free, purified enzyme cleavable complex formation assays,
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revealed that DACA and TAS-103 seemed to poison both topoisomerase I
and topoisomerase II. Despite this, in a study using the recently developed
TARDIS assay (trapped in ~garose DNA jmrnunostaininq), these agents
showed a preference for topoisomerase 110 in whole cells. For topoisomerase
I, TAS-103 only induced low levels of drug-stabilised cleavable complexes,
and DACA did not appear to form cleavable complexes with topoisomerase I.
However, although whole cell and cell free systems appeared to show
different results, whole cell assays in comparison with the purified enzyme
assays, are more complex systems, so although both DACA and TAS-103
showed the preference for topoisomerase 110 in whole cells by TARDIS assay,
the formation of low levels of topoisomerase I and 1113 cleavable complexes
may ultimately playa role in their in vivo mechanisms of cytotoxicity (Padget
et a/., 2000). Similar to the NU:UB compounds, both TAS-103 and DACA are
cationic side chain-substituted polycyclic systems that are thought to owe their
cytotoxicity to interactions with DNA. However, whereas studies of the
acridine DACA suggested that its rings intercalate DNA, and its aminoalkyl
carboxamide chain was located in the minor groove of DNA (Pastawa et a/.,
1998), TAS-103 showed a different binding mode, binding mainly to the
surface of DNA (outside binding), and only minor binding via intercalation
(Ishida and Asao, 2002).
Fig. 9.1 Chemical structure of DACA
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Fig.9.2 Chemical structure of TAS-1 03
A feature observed with DACA is that while this agent at low concentrations
acts to poison topoisomerases, at higher concentrations it mainly acts as a
catalytic inhibitor. So at high concentrations the drug binding may obstruct
topoisomerase binding sites on DNA, suppressing cleavable complex
formation and poisoning. Similar findings have also been uncovered with
some of the NU:UB compounds, where these appear to inhibit their own
cleavage reaction when used at high concentrations (self-inhibition), for
example, evident in the gel electrophoresis results of NU:UB 31 induced
stimulation of topoisomerase I-mediated DNA cleavage (Fig.3.5). In addition
to concentration-dependent effects that appeared to be able to affect the
balance between enzyme poisoning and enzyme inhibition, small changes in
the DACA structure also seemed to alter this balance as well as the bias
towards topoisomerase I and topoisomerase II interaction (Bridewell et aI.,
1999). Since the NU:UB agents, containing an anthraquinone ring system and
cationic aminoalkyl side-chains, have structural similarities to the two agents
above (TAS-103 and DACA), what has been learnt in studying TAS-103 and
DACA could therefore provide useful information in relation to the
investigations of anti-topoisomerase I and anti-topoisomerase II activity of the
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NU:UB agents. Strikingly, anthraquinone-based amino acid substituted drugs
(NU/ICRF 600,601 and 602), investigated by Meikle et al. (1995b) were also
shown to be dual inhibitors of the catalytic activity of topoisomerase I and
topoisomerase II, notably, however, these compounds contained C-terminally
free and uncharged side-chains with consequently reduced DNA-binding
capacity. In a study of DACA by Finlay et al. (1993) the sensitivity of this
compound in drug resistant cell lines was compared to other topoisomerase-
directed drugs, including amsacrine, etoposide and doxorubicin. It was shown
that DACA was different from the other topoisomerase-directed drugs,
overcoming atypical multidrug resistance in a series of Jurkat leukaemia cell
lines. Furthermore, DACA was also said to exhibit reduced susceptibility to P-
gp mediated multidrug resistance mechanisms. This lack of DACA
susceptibility to P-gp mediated multidrug resistance was further thought to be
related to the lipophilic character of the DACA structure, allowing for rapid
uptake by tumour cells exceeding the rate of P-gp mediated drug efflux. In this
study, DACA proved to be unique in comparison to the included clinical
topoisomerase II drugs in its ability to overcome two different multidrug
resistance mechanisms. Hence, in common with most classes of
chemotherapeutics, drugs that target a single topoisomerase (either type I or
II) protein are, in addition to atypical resistance, also at risk of MDR (e.g. P-gp
and MRP transporter-mediated resistance), where certain transporter
molecules are capable of excluding the drug (or several drugs) from resistant
cells. For a drug to be effective it is therefore beneficial if this agent is not a
substrate of MDR related transporters. In the study by Finlay et al. (1993)
DACA proved to be capable of circumventing P-gp mediated multidrug
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resistance. This was supported and extended in a more recent study of DACA
by Davey et a/. (1997), where DACA, in addition to avoiding P-gp mediated
MDR mechanisms, was also effective against MRP-mediated MDR. The focus
of the present study, NU:UB 31, has like DACA been shown to circumvent
atypical and P-gp mediated MDR. NU:UB 31 was demonstrated to be active
and non-cross resistant to doxorubicin in (resistant) cell lines with elevated
expression of the P-gp MDR gene product (Chapter 4).
For any cytotoxic agent to be clinically useful, its administration ultimately has
to lead to tumour cell kill, ideally with tumour cell selectivity. The NU:UB
compounds have been screened in the NCI panel of 60 human cancer cell
lines, including sub-panels of melanomas, breast cancer, lung cancer, colon
and ovary cancers using the sulforhodamine B cytotoxicity assay with 48h
endpoints. From this in vitro screen it was demonstrated that these agents
proved to be cytotoxic at this time point in a range of different cell lines.
Strikingly, some of the NU:UB compounds, for example NU:UB 31,43, 80 and
81, showed selectivity for the colon and melanoma (including metastatic
melanoma) sub-panels of the NCI 60 cell line in vitro drug screen (see
Appendix 2). It is possible that this activity is related to the NU:UB
compounds' ability to induce both topoisomerase I and topoisomerase II
induced DNA lesions that trigger apoptosis in the sensitive cell lines of these
sub-panels. Furthermore, MTT cytotoxicity assays performed within this
project using leukaemia and colon cell lines revealed that the NU:UB agents
tested had ICso values in the low IJM range even at exposure times that were
shorter than 48h. For the comparator anti-topoisomerase inhibitors, the ICso
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values were not as low at the shorter exposure times as those recorded for
the NU:UB conjugates, but were indeed lower than for the NU:UB agents at
longer exposure times. This fairly rapid effect may be as a result of increased
cellular uptake of the NU:UB compounds due to their cationic lipophilic
character, and possibly related to diminished capacity to serve as a substrate
for P-gp efflux pumps in common with N,N-dialkylaminoanthracyclines
(Lampidis et al., 1997).
It should be recognised that the relationship between cell cycle and response
to topoisomerase inhibitors is important and that topoisomerase I and
topoisomerase lIa targeted drugs require active cell proliferation. The ability of
the NU:UB conjugates to target topoisomerase II~, in addition to
topoisomerase I and topoisomerase lIa may explain their activity against solid
tumours that tend to develop large GO/G1 cell populations. Thus, NU:UB
conjugates offer the prospect of efficacy against tumours with large
proportions of both cycling and non-cycling cell populations. Although both
solid tumours and many normal tissues would be expected to have large
GO/G1 populations, solid tumour cells are more likely to have defects in cell
cycle checkpoints that prevent replication in the presence of DNA damage
caused by drug stabilised topoisomerase II~-DNA cleavable complexes
(Mincher D. J., personal communications). A topoisomerase II~-targeting
quinoxaline XK469 was recently reported for which topoisomerase I and lIa
were not significant contributors to cytotoxicity and which killed large numbers
of non-cycling cells in solid tumour models (Gao et al., 1999). Cell cycle
analyses were performed to deduce whether or not NU:UB 31 had an effect
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on the cell cycle progression, and if so, whether or not this was similar to the
cell cycle effect induced by the known anti-topoisomerase I or II inhibitors
used for comparison. Results demonstrated that whereas the known anti-
topoisomerase drugs caused a cell cycle block, NU:UB 31 did not appear to
have such effects. Although the cells were killed, being found in the sub G1
region of the cell cycle histogram (indicative of apoptotic cell death), they
seemed to be killed without cell cycle phase specificity. Thus, this further
highlighted that more than one type of topoisomerase enzyme may be
targeted, and/or that there could be mechanisms other than purely anti-
topoisomerase interactions involved following treatment with the NU:UB
compounds.
Anti-topoisomerase action is likely to induce DNA damage due to the DNA
cleaving nature of these enzymes. DNA damage is known to induce the
tumour suppressor protein p53 and this is likely to result in cell cycle arrest
and repair of the damaged DNA or in apoptotic cell death. Several anti-
topoisomerase inhibitors induce apoptotic cell kill and do so via induction of
p53. Doxorubicin is an example of an agent that was used in this project as a
positive control for the induction of p53-mediated apoptosis. Following NU:UB
treatment of human leukemia (HL60) cells, apoptotic cell death was confirmed
with morphological as well as various biochemical assays. Furthermore, p53
was rapidly induced in human colon carcinoma (HCT116) cells by NU:UB
treatment, although this induction was fairly brief and not as significant as the
maximum induction produced by doxorubicin. Down stream mediators of p53
were also investigated to confirm activation of the p53 induction pathway.
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Mdm2 levels, but not p21 levels were increased in HCT116 cells after
treatments with NU:UB compounds. The lack of p21 induction could possibly
be related to the lack of cell cycle block following NU:UB treatment. It may be
that since NU:UB compounds appeared to have a rapid mechanism of action,
apoptosis was perhaps induced via p53-dependent, as well as p53-
independent pathways and such pathways could also play a part in the
NU:UB-induced cell kill mechanism considering p53 was briefly induced but
no excessive p53 levels were maintained following NU:UB treatment. To
support this, the NCI drug screen is not purely a cytotoxicity screen, but it can
also be used as a tool to search for p53-independent candidate drugs. This
drug screen has previously shown remarkably good correlation between
functional p53 status and sensitivity of many of the DNA damaging drugs
currently used in the clinic (Makin and Hickman, 2000). Results from the NCI
p53-wild type/mutant drug screen included within this study revealed that
while the standard drugs doxorubicin and mitoxantrone were more potent in
wild type p53 containing cells, the NU:UB compounds had overall similar
(equipotent) values in the p53 wild type and p53 mutant cell lines. Thus, this
further supported the possibility that the NU:UB compounds had a p53-
independent component in their cell kill mechanism (along with, or in place of
a p53-dependent mechanism).
In another aspect of intracellular drug action, mitochondria have now been
identified as sub-cellular targets for clinically used anthracyclines. Data is
being accumulated to suggest that anthracyclines, in addition to targeting
nuclear DNA and nuclear enzymes, may also interact with mitochondria
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interfering with the functions of these organelles as part of their toxicity (Jung
and Reszka, 2001). Many of the conventional anti-cancer agents including
doxorubicin and etoposide have, however, no direct effect on mitochondria,
but may instead elicit mitochondrial membrane permeabilisation in an indirect
fashion by inducing endogeneous effectors that are involved in the control of
apoptosis. A recurrent problem when using these types of classical drugs is,
however, that the endogeneous apoptosis-induction pathways often are
compromised by alterations such as mutations of p53. One strategy to
circumvent this, and enforce cell death may be to trigger downstream events
of the common apoptotic pathway. In contrast to the conventional drugs, an
increasing number of experimental anti-cancer agents are thought to have a
direct effect on mitochondria. These types of agents may then induce
apoptosis when conventional drugs do not work due to disruptions in
endogeneous apoptosis induction pathways such as those involving p53 and
caspases (Constantini, 2000). These drugs were, however, not originally
designed to act on mitochondrial targets. Instead as these drugs were
developed and as more information on mechanisms became available, their
effects on mitochondria were revealed (Howell et a/., 2003). Betulinic acid is
an example of a novel (natural product) experimental agent with anti-tumour
activity. Fulda et at. (1998) have shown that betulinic acid induces apoptosis
via direct mitochondrial alterations in intact cells and cell free systems. When
added to isolated mitochondria, betulinic acid directly induced loss of
mitochondrial transmembrane potential in a way not affected by caspase
inhibitors. Thus, betulinic acid may induce cell death in cells with
compromised endogeneous apoptosis-induction pathways by triggering p53-
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independent apoptosis and thereby permeabilise mitochondrial membranes in
a caspase-independent fashion (Constantini et al., 2000). F16 is another
example of an agent that is thought to directly target mitochondria. F16 is a
small lipophilic cationic molecule that, due to its fluorescent properties, allows
for cellular localisation studies to be carried out. Mitochondrial
hyperpolarisation is a shared feature of many tumour cell lines and lipophilic
cations are found to accumulate in the mitochondria driven by the
electrochemical gradient. Several types of cancer cells have been described
to accumulate cationic agents to a higher level than normal cells (Fantin et al.,
2002). Accumulation studies of F16 have revealed that this molecule
accumulated in cells with a high mitochondrial membrane potential, providing
some degree of cancer cell selectively. Fantin et al. (2002) reported that F16
induced mitochondrial damage, which resulted in swelling, failure to
synthesize ATP, and release of cytochrome c, but no specific mitochondrial
target of F16 has so far been identified.
Like F16, NU:UB 31 is also a small cationic lipophilic molecule. In this study,
fluorescent NU:UB 31 and stained mitochondria were observed under the
confocal microscope using a MitoTracker probe. NU:UB 31 appeared to be
present within these organelles (as well as the Iysosomes, investigated with
LysoTracker). What outcome this had for cell survival and whether or not
NU:UB 31 had a direct or indirect effect on mitochondria is, however, at this
stage impossible to confirm. In addition, the Compare pattern of the LC50 data
from the NCI drug screen allowed more detailed information on mechanisms
of drug action to be hypothesised. Each compound pattern from this drug
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screen could be considered as a molecular fingerprint and these patterns are
being used in conjunction with molecular structural features of the tested
agents to give insight into potential target molecules and modulators
(Weinstein et al., 1997). Similarity in pattern often indicates similarity in
mechanism of action, mode of resistance, and molecular structure. By using
the NU:UB compounds as seeds in such a Compare study it was noted that,
in addition to significant similarities to topoisomerase inhibitors, NU:UB agents
also had significant similarities to several drugs thought to interact with the
components of mitochondria and thus with mitochondrial function (see
Appendix 5). This suggests that both nuclear DNA-related enzymes, as well
as mitochondrial enzymes may playa part in the ultimate cytotoxic effect that
NU:UB compounds have in vitro.
This study has thus identified topoisomerases and mitochondria, in part, as
potential targets for NU:UB agents in vitro. Further investigations will,
however, be needed to determine whether or not there are other NU:UB
interactions involved that contribute to the cytotoxicity of these compounds.
Studies are also required, if indeed mitochondria are involved, to establish
what is the mitochondrial target enzyme(s), pathway(s) or mitochondrial
function(s) that is being disrupted by the NU:UB agents. Moreover, once the
NU:UB mechanism(s) of action has been fully realised in vitro, it should be
established if this is a valid explanation for the anti-tumour activity observed in
vivo.
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CONCLUSIONS AND SUGGESTIONS FOR FURTHER WORK
The NU:UB compounds were initially synthesised and developed with the
objective of exerting cytotoxicity by selectively inhibiting topoisomerase
enzymes and by limiting other non-specific interactions that may result in
unwanted side effects. This research project aimed to investigate the cell kill
properties of selected NU:UB compounds (focusing on NU:UB 31) in an in
vitro setting, specifically to prove or disprove the working hypothesis that
NU:UB compounds have anti-topoisomerase properties that, in part,
contribute to their mechanism of cytotoxic action in vitro.
The anti-topoisomerase activity of NU:UB 31 was investigated and it was
revealed that this compound had anti-topoisomerase activity in vitro when
using both whole cell systems and purified recombinant enzyme. NU:UB 31
inhibited topoisomerase I and II mediated DNA relaxation in cell free systems.
Topoisomerase I mediated DNA relaxation was partially inhibited by NU:UB
31 at 101JM. Partial topoisomerase 110 and II~ inhibition was achieved by
NU:UB 31 concentrations of 10IJM and 151JM, with complete inhibition at
25IJM and 201JM, respectively. Notably, NU:UB 31 (optimum concentration
5IJM) stimulated topoisomerase I-mediated cleavage of supercoiled DNA in a
manner comparable to the topoisomerase I poison camptothecin. NU:UB 31
also induced drug-stabilised topoisomerase I and II (0 and ~) cleavable
complex formation in intact cells, as well as in purified enzyme assays.
Topoisomerase I-DNA cleavable complexes were stabilised in whole cells by
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100IJM NU:UB 31. Cleavable complex formation with topoisomerase lIa and
topoisomerase II~ in intact cells, was achieved by NU:UB 31 at concentrations
of 300IJM and 200IJM respectively. Thus, from these experiments it was found
that the NU:UB mechanism of action, at least in part, was topoisomerase
mediated. Furthermore, NU:UB 31 seemed to exhibit a dual action on both
topoisomerase I and II that could prove to be beneficial for circumvention of
altered topoisomerase resistance mechanisms.
The cell survival assays showed that NU:UB compounds were cytotoxic in the
low micro-molar range as early as 4h in the HL60, HCT116 and HT29 cell
lines. NU:UB 31 had 4h IC50 values in the order of 27.5IJM, 30.01JM and
33.51JM and 96h IC50 values of 3.1IJM, 2.81JM and 4.21JM in HL60, HCT116
and HT29 cells respectively. Morphological and biochemical experiments
showed that NU:UB treatment induced apoptosis. In the caspase activation
studies, 4h NU:UB 31 treatment at 20IJM resulted in approximately 15%
caspase positive cells in the (p53 negative) HL60 cell line and 40IJM NU:UB
31 resulted in approximately 30% caspase positive HCT116 cells (p53
positive). DNA fragmentation was evident (gel electrophoretic detection of
DNA laddering) in HL60 cells following 6h NU:UB 31 (at 201JM) treatment.
Furthermore over 20% of HL60 cells showed apoptotic morphology following
8h NU:UB 31 (at 201JM) treatment. Current chemotherapeutics generally
induce DNA damage and p53-mediated apoptosis. Whereas clinically used
topoisomerase inhibitors are deemed to require a functional p53 pathway,
from the observations made in this study, together with supporting data from
NCI where NU:UB agents had comparable GI50 values in p53 wild type and
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p53 mutated cell lines, it was suggested that apoptosis induced by NU:UB
compounds may partly have a p53-independent component. Moreover,
observations made in this project of the sub-cellular localisation of NU:UB 31,
and with Compare data from NCI, suggested that mitochondria may provide
an additional target for these agents. In summary, this NU:UB study has
provided further information on the mechanism of cell death induced by
NU:UB conjugates, information that hopefully will be of benefit in the future
development of novel NU:UB agents as potential anti-cancer drugs.
For future work with the NU:UB agents, it may be beneficial to extend the
study of NU:UB compound cellular localisation patterns to include more cell
types to further investigate whether or not the lack of nuclear NU:UB 31
fluorescence in HL60 cells was due to absence of NU:UB 31 in the nucleus,
or due to a fluorescence quenching phenomenon. NU:UB 31 could be added
directly to cell nuclei, or to naked DNA and its fluorescence could be
monitored to see whether it decreased as NU:UB 31 interacted with DNA
(observed with other DNA-intercalating drugs). Targeting mitochondria may
be favourable since it has been realised that mitochondria are central to
several of the apoptotic pathways, as they contain various apoptotic
mediators. Thus, mitochondrial-targeting properties may prove to be beneficial
in killing cells with defective mechanisms of inducible apoptotic pathway(s).
Therefore, a thorough investigation of the possible mitochondrial component
contribution to the NU:UB mechanism of action is warranted. To study
whether or not NU:UB agents, as well as interacting with nuclear DNA and
topoisomerases, also interact with mitochondrial DNA and topoisomerases,
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assays using mitochondrial extracts may be suitable given the presence of
topoisomerase I, type II~ topoisomerase and topoisomerase lila enzymes in
mitochondria, independent of the nuclear enzymes that may shuttle between
nucleus and the mitochondria (Zhang et al., 2001; Wang et aI., 2002; Lowet
al., 2003). Furthermore, cytotoxic investigations, comparing IC50 values
obtained using normal cells and cells devoid of functional mitochondria could
be performed. Progressing from the use of cell lines resistant to
topoisomerase I or II inhibitors for cytotoxic investigations of NU:UB agents,
use could be made of yeast systems transfected with mutated topoisomerase
enzyme, rendering the cells insensitive to the specific enzyme which should
then allow an assessment of the relative contributions of type I versus type II
interactions to cell-kill (Woo et aI., 2001; Nitiss and Nitiss, 2001). Mutated
topoisomerase I, for example, confers drug resistance to the camptothecin
poisons. These yeast cell survival assays could thus be used as a
mechanism-based screen for a panel of NU:UB agents. Equally, cancer cell
lines bearing mutated topoisomerase enzymes could be used to probe the
cytotoxic properties of compounds for dependency on catalytically functional
topoisomerases.
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NCI in vitro screen of tumour-specific cell line sensitivity to NU:UB 31
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Appendix 2. graph 1. Cytotoxicity of NU:UB 31 in the NCI colon cancer sub-panel.
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Appendix 2. graph 2. Cytotoxicity of NU:UB 31 in the NCI melanoma sub-panel.
NU:UB 31 (and close analogues) shows exceptional broad spectrum activity against both
colon and melanoma (including metastatic melanoma) not seen with comparator clinical
agents.
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MOLT 4 -552 -503 -443
SR -5.41 -497 -434
Non-Small Cell Lung Cancer ................................... ......... . ...... ........... ....... ................................ . ..•.......................... .. ..................
A5491ATCC -5 15 -468 -4.31
EKVX -500 -466 -01
HOP·62 ·524 ·470 -429
HOP-92 -5.41 .418 -04
NCI·H226 ·544 ·5.01 -445
NCI·H23 ·4.91 -4.62 ·428
NCI-H460 -532 ·414 -421
NCI-H522 ·525 -4.14 -433
ColonCancer :,r ... _._ ..__.;.~~ .._.................... _._ ............_... . ............................................ . ...................... , ..................................... . ............................................ . ..................
COLO 205 -488 -442
HCC-2998 -530 ·413 -424
HCT-116 ·547 ·490 -444
HCT-15 -540 ·487 -4.42
HT29 ·546 -491 -442
KMIZ -536 -416 -04
SW-6Z0 -540 -468 > -4.00
eNS Cancer ............................ ...... - ......... - .......................... . ....•............... -_................. ..................................... ..................
SF-268 -491 ·452 -4.13
SF·295 -5.09 -466 -428
SNB·19 ·519 -471 -4.34
SNB 15 ·523 -4.64 -401
U251 -5.03 .466 -431
Melanoma ........ .•.............. ............ .... ...... ......... ........ .... ..................
LOX IMVI ·512 -5 38 -5.04
IvlALME·3M -4.86 -455 -4.25
MI4 -5.11 -541 -5.10
SK-MEL-28 -5.66 -526 -4.66
SK·MEL·5 ·5.36 -4.82 -4.41y.h'1" UACC-257 ·5.56 -516 -4.54
...f lJACC-6Z -559 -519 -4.64
..\ OvarianCancer ............................................................. ............................................. ............................................................. ............................................. ..................
IGROVI -544 -479 -439
OYCAR-3 -5.60 -5.02 -4.43
OVCAR-4 -5.36 -475 ·4.34
OVCAR-5 -497 -464 ·431
OYCAR·8 ·5.29 -4.74 -4_34
SK-OV-3 -505 -464 -4.27
Renal Cancer ...................................................... ............................................. ..................
786-0 -522 -412 -4.35
A498 -5.06 -466 -429
ACI-I1'I -5.37 ·480 -4.40
CAKI-I ·504 -461 ·432
RXF 393 -5.32 ·467 -4.16
SNI2C ·524 -474 -4.36
TK-IO -5.03 -4.63 -4.25
UO·31 -5.47 -487 -442
PrOSli.1IC Cancer .. ...•.•.....•.•.......•. . ......••......•......... .............. - .......................
..................
PC-) -5 24 -473 -4.35
DU-145 -5.20 -461 ·4.24
Brcusr Cancer ............................. . ....................................... '0 ••••••••••••••••••••••••••••••••• ...................................
..................
MCF7 -521 -4.69 -4.26
NCI/ADR-RES -5.11 -465 -4.24
MDA-MB·231/ATCC ·5.32 ·413 .4.30
HS 578T -416 -4.26 > -4.00
MDA-MB-435 ·540 -480 -4.36
MDA-N ·4.89 ·459 -429
BT·549 -493 ·461 -4.28
T -110 ·488 -443 > -4.00
.........
MG.MID ·5 27 -419 -435
Della 0.45 062 075
Range 096 I 14 1.10
+3 +2 +1 0 -I ·2 -3 +3 +2 +1 0 -1 ·2 -3 +3 +2 +1
0 -1 ·2 -3
._---------
I
I:
I
I
I
I
I
I
I
I
I
I
~
I
I
I
I
I
I
I
I
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NSC D- 709778
o
DRUG SYNTHESIS AND CHEMISTRY BRANCH, DTP, DCTD, NCI
NSC NUMBER LIST
Dr. R. C. Harrison
Pharmaceuticals Division
British Technology Group
101 Newington Causeway
London SE1 6BU
United Kingdom
Transmittal Letter or Collection Date: 01/26/99
Supplier Compound ID: NU:UB 43
NSC Number: D709778-H
Molecular Formula: C23H25N303.C2HF302
Acquired for Testing Against: CANCER
National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results
D- 709778 -H / 1 Experiment ID: 9907MD58-36 Test Type: 08 Units: Molar
ort Date: August 5, 1999 Test Date: July 6,1999 QNS: Me:
Stain Reagent: SRB Dual-P SSPL: OB6Z
Log10 concentration
Time Mean Optical Densities Percent Growth
panel/Cell Line Zero Ctr1 -3 .0 -7.0 -6.0 -5.0 -4.0 -8.0 -7.0 -6.0 -5.0 -4.0 G150 TG1 LC50
Leukemia
CCRF-CEM 0.107 0.494 0.513 0.474 0.490 0.223 0.126 105 95 99 30 5 5.12E-06 >1.00E-04 >1. 00E-04
HL-60 (TS) 0.246 1.118 1.277 1.197 1.196 0.174 0.142 118 109 109 -29 -42 2.66E-06 6.12E-06 >1.00E-04
K-562 0.157 1. 282 1.300 1. 240 1.197 0.102 0.048 102 96 92 -35 -69 2.15E-06 5.29E-06 2.69E-05
MOLT-4 0.149 0.680 0.666 0.665 0.631 0.159 0.044 97 97 91 2 -70 2.88E-06 1.06E-05 5.21E-05
Non-Small Cell Lung Cancer
A549/ATCC 0.198 0.996 1.011 1.025 1.020 0.522 0.029 102 104 103 41 -86 7.07E-06 2.10E-05 5.22E-05
EKVX 0.630 1.403 1. 442 1.368 1. 364 1.195 0.085 105 95 95 73 -87 1.40E-05 2.87E-05 5.91E-05
HOP-62 0.199 0.510 0.558 0.546 0.517 0.320 0.041 11.6 112 102 39 -19 6.69E-06 2.13E-05 5.64E-05
HOP-92 0.394 0.932 0.948 0.935 0.921 0.809 0.084 103 101 98 11 -79 1.49E-05 3.13E-05 6.55E-05
NCI-H23 0.301 0.965 0.913 0.912 0.963 0.797 0.012 101 101 100 75 -96 1. 40E-05 2.14E-05 5.38E-05
NCI-H322M 0.427 1. 366 1. 314 1.348 1.325 0.818 0.006 101 98 96 48 -99 9.08E-06 2.12E-05 4.66E-05
NC1-H460 0.312 1.601 1.501 1.593 1.655 0.640 0.023 93 99 104 25 -93 4.88E-06 1. 64E-05 4.35E-05
NC1-H522 0.262 0.182 0.841 0.684 0.929 0.152 0.036 113 81 128 94 -86 1.16E-05 3.32E-05 6.29E-05
colon Cancer
COLO 205 0.406 1.525 1. 493 1.503 1.432 0.100 0.016 91' 98 92 -15 -96 1.11E-06 3.53E-06 1.04E-06
HCC-2998 0.360 0.698 0.687 0.688 0.611 0.098 0.006 91 91 92 -13 -98 1. 80E-06 3.62E-06 7.26E-06
HCT-116 0.254 1.511 1.585 1.511 1. 461 0.495 0.010 101 95 92 18 -96 3.10E-06 1.45E-05 3.96E-05
HCT-15 0.169 1. 243 1.191 1.256 1.220 0.167 0.024 95 101 98 -1 -86 3.04E-06 9.13E-06 3.18E-05
HT29 0.162 1.016 1.030 0.918 1. 010 0.210 0.031 102 96 99 6 -81 3.35E-06 1.16E-05 4.37E-05
KM12 0.286 1.237 1. 242 1.310 1. 263 0.697 0.047 101 108 103 43 -84 7.69E-06 2.19E-05 5.43E-05
SW-620 0.066 0.549 0.564 0.551 0.511 0.219 0.011 103 100 106 32 2 5.65E-06 >1.00E-04 >1.00E-04
eNS Cancer
SF-268 0.250 1.003 1.091 1.041 1.027 0.855 0.060 112 105 103 80 -76 1.56E-05 3.26E-05 6.82E-05
SF-295 0.454 1.212 1.251 1.196 1.242 0.797 0.060 91 91 96 42 -87 7.10E-06 2.12E-05 5.11E-05
SF-539 0.568 1.211 1.111 1.250 1. 235 0.374 0.033 94 106 104 -34 -94 2.45E-06 5.65E-06 1.83E-05
SNB-19 0.335 1.055 1.054 1.043 1.035 0.519 0.040 100 98 97 26 -88 4.56E-06 1.68E-05 4.62E-05
SNB-75 0.265 0.611 0.613 0.619 0.620 0.534 0.016 101 102 103 18 -94 1.45E-05 2.84E-05 5.54E-05
U251 0.161 0.911 0.840 0.891 0.861 0.304 -0.006 90 97 93 19 -100 3.83E-06 1. 45E-05 3.80E-05
Melanoma
LOX 1MV! 0.085 0.835 0.895 0.887 0.863 0.058 0.039 108 107 104 -32 -55 2.48E-06 5.79E-06 6.16E-05
MALME-3M 0.361 0.826 0.868 0.766 0.988 0.828 0.021 109 87 135 100 -94 1.81E-05 3.27E-05 5.91E-05
M14 0.295 1.057 1.091 1.067 1. 034 0.011 0.027 105 101 91 -76 -91 1. 81E-06 3.64E-06 7.08E-06
SK-MEL-2 0.257 0.675 0.647 0.616 0.676 0.193 0.002 93 100 100 -25 -99 2.52E-06 6.33E-06 2.11E-05
SK-MEL-28 0.267 1. 088 1.103 1.018 1. 096 0.212 0.081 102 99 101 -21 -70 2.62E-06 6.75E-06 3.96E-05
SK-MEL-5 0.428 1.801 1.788 1. 810 1.828 0.554 0.004 99 101 102 9 -99 3.63E-06 1. 21E-05 3.52E-05
UACC-257 0.554 1.144 1. 043 1.104 1.122 0.114 0.012 83 93 96 -19 -98 1. 84E-06 3.53E-06 6.80E-06
UACC-62 0.700 1.717 1.159 1.154 1.797 0.154 0.012 104 104 108 -78 -98 2.05E-06 3.80E-06 7.06E-06
Ovarian Cancer
IGROV1 0.110 0.137 0.744 0.111 0.763 .437 0.030 101 105 104 52 -73 1.04E-05 2.61E-05 6.53E-05
OVCAR-3 0.446 0.821 0.841 0.816 0.819 0.668 0.075 101 99 99 59 -83 1.16E-05 2.60E-05 5.84E-05
OVCAR-4 0.265 0.752 0.165 0.742 0.190 0.595 0.028 103 98 108 68 -90 1.30E-05 2.10E-05 5.60E-05
OVCAR-5 0.774 1. 698 1. 646 1.613 1.638 1.605 0.029 94 97 94 90 -96 1.64E-05 3.04E-05 5.64E-05
OVCAR-8 0.121 0.888 0.856 0.929 0.895 0.529 0.056 96 105 101 53 -54 1.07E-05 3.13E-05 9.15E-05
SK-OV-3 0.281 0.545 0.547 0.527 0.625 0.425 0.033 100 93 130 54 -88 1.07E-05 2.40E-05 5.39E-05
Renal Cancer
786-0 0.226 0.874 0.841 0.823 0.177 0.225 0.014 96 92 85 -1 -94 2.56E-06 9.82E-06 3.38E-05
A498 0.848 1. 426 1. 469 1. 393 1.453 1.265 0.044 101 94 105 12 -95 1. 36E-05 2.10E-05 5.39E-05
ACHN 0.231 0.867 0.891 0.888 0.894 0.500 -0.001 104 103 104 42 -100 7.37E-06 1.91E-05 4.44E-05
CAK1-1 0.454 1.044 1.107 1.136 1.073 0.811 0.014 111 115 105 61 -91 1.18E-05 2.44E-05 5.06E-05
RXF 393 0.359 0.697 0.120 0.608 0.614 0.482 0.030 101 74 93 36 -92 5.12E-06 1.92E-05 4.12E-05
SN12C 0.377 0.989 0.960 0.940 0.923 0.692 0.019 95 92 89 51 -95 1.02E-05 2.24E-05 4.92E-05
TK-10, 0.529 1.165 1.069 1.111 1.153 0.913 0.013 85 101 98 60 -98 1.16E-05 2.41E-05 5.00E-05
00-31 0.242 0.664 0.632 0.654 0.678 0.159 0.009 92 98 103 -34 -96 2.44E-06 5.63E-06 1.79E-05
Prostate Cancer
PC-3 0.189 0.673 0.638 0.661 0.657 0.339 -0.003 93 97 91 31 -100 5.14E-06 .12E-05 4.15E-05
DU-145 0.211 0.680 0.693 0.630 0.689 0.541 0.003 103 89 102 70 -99 1.32E-05 .61E-05 5.16E-05
Breast Cancer
MCF7 0.245 0.927 0.878 0.934 0.899 0 .442 0.031 93 101 96 29 -87 4.84E-06 1.77E-05 4.11E-05
NCI/ADR-RES 0.299 0.877 0.851 0.855 0.857 0 .699 0.123 96 96 96 69 -59 1.41E-05 3.46E-05 8.50E-05
MDA-MB-231/ATCC 0.322 0.858 0.812 0.830 0.852 0 .580 0.005 91 95 99 48 -98 9 ..21E-06 2.13E-05 4.61E-05
HS 578T 0.106 0.485 0.540 0.520 0.640 0 .402 0.073 115 109 141 78 -32 1.80E-05 5.15E-05 >1.00E-04
MDA-MB-435 0.279 0.964 0.987 0.969 1.016 0.211 0.016 103 101 108 -25 -94 2.73E-06 6.52E-06 2. HE-OS
MDA-N 0.352 1. 414 1. 408 1.374 1. 347 0.236 0.008 99 96 94 -33 -98 2.21E-06 5.48E-06 1.83E-05
BT-549 0.502 1. 328 1. 298 1. 299 1.272 1.124 0.009 96 96 93 75 -98 1.40E-05 2.72E-05 5.27E-05
T-47D 0.300 0.503 0.592 0.490 0.581 0.458 0.061 144 94 139 78 -80 1.51E-05 3.12E-05 6.48E-05
Test Date: July 6, 1999
;'%i~" ~ ~"~\ ... .-<""'j~1:l~~t:~~~~:Nlt:M: "'~:f:,:::::}~~~:~:~;~:i!"':)'!":::i~i~~%\:i:"'nilJ:::::::::i:!::<",,"',' " , """!!:::C3J~~,,,e
"Units: Molar ISSPL: OB6Z1Exp, ID:9907MDS8-36
Report Date: August 5, 1999
National Cancer Institute Developmental Therapeutics Program
Mean Graphs
Panel/Cell Line Log GI50 GI50 Log __TGI
Leukemia
CCRF·CEM
-5.29 > -4.00
,HL-60(TBl
-558 -5.21
K-561 -5.67
-5.28
MOLT-4
-5.54 -4.97
Non-Smull Cell Lung Cuncer ..................
A549/ATCC
-515 -4.68
EKVX
-4.85 -454
HOP-62 -5.17 -4.67
HOP-91
-483 -4.50
NCI-HD -4.85 -456
NCI-H322M -5.04 -4.67
NCI-H460
-5.31 -4.79
NCI-H522
-475 -4.48
Colon Cancer
COLO lOS
·il -575 -545HCC-1998
-5.74 -544
HCT-116
-5.43 -4.84
HCT-15
-552 -5.01
HTI9 -547 -4.94
KMI2 -5.11 -466
SW-620
-5.25 > -400
eNS Cancer .......•...•.••...
SF-168 -4.81 -4.49
SF-195 ·5.15 -467
SF-539 -5.61 -525
SNB-19 ·5.34 -4.77
SNB-75 -484 -455
U251 -542 -484
Meluuuma ..................
LOX IMVI -5.61 ·524
MALME-3M -4.74 ·449
MI4 -5.73 ·544
SK-MEL-l -5.60 -520
SK-MEL-28 -558 -517
SK-MEU -5.44 '-4.92
UACC-257 -5.74 -5.45
UACC-61 -5.69 -5.42
OvunuuCancer
IGROVI -498 -458
OVCAR-3 -4.94 -4.59
OVCAR-4 -4.89 -4.57
OVCAR-5 -4.79 -4.52
OVCAR-8 -4.97 -4.50
SK-OV-3 -497 -4.62
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-
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NSC D- 709768
o
DRUG SYNTHESIS AND CHEMISTRY BRANCH, DTP, DCTD, NCI,
NSC NUMBER LIST
Dr. R. C. Harrison
Pharmaceuticals Division
British Technology Group
101 Newington Causeway
London SE1 6BU
United Kingdom
Transmittal Letter or Collection Date: 01/26/99
Supplier Compound ID: NU:UB 73
NSC Number: D709768-U
Molecular Formula: C21H22N204.C2HF302
Acquired for Testing Against: CANCER
National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results
D- 709768 -U I I Experiment ID: 9907MD59-23 Test Type: 08 Units: Molar
6, 1999 Test Date: July 12,1999 QNS: Me:
Stain Reagent: SRB Dual-P SSPL: OB6Z
Lagl0 concentration
Time Mean Optical Densities Percent Growth
el/Cell Line Zero Ctrl -8 .0 -7.0 -6.0 -5.0 -4.0 -8.0 -7.0 -6.0 -5.0 -4 .0 GI50 TGI LC50
Leukemia
CCRF-CEM 0.300 0.738 0.718 0.750 0.695 0 .584 0.055 95 103 90 65 -82 .26E-05 2.77E-05 6 .08E-05
HL-60ITBI 0.939 2.785 2.676 2.590 2.563 2 .014 0.130 94 89 88 58 -86 .14E-05 2.53E-05 5 .62E-05
K-562 0.157 0.917 0.917 0.907 0.864 0 .602 0.233 100 99 93 58 10 .49E-05 >1.00E-04 >1 .00E-04
MOLT-4 0.423 1.352 1. 376 1. 356 1.324 1 .016 0.141 103 100 97 64 -67 .28E-05 3.08E-05 7 .45E-05
SR 1.084 2.814 2.674 2.697 2.761 1 .976 0.214 92 93 97 52 -80 .03E-05 2.46E-05 5 89E-05
n-small Cell Lung Cancer
A549/ATCC 0.272 1 .156 1.165 1 .149 1.126 0 .989 0.059 101 99 97 81 -78 .57E-05 3.23E-05 6.64E-05
E1CVX 0.307 0 .788 0.796 0 .794 0.759 o. 623 0.076 ID2 101 94 66 -75 .29E-05 2.92E-05 6.62E-05
HOP-62 0.362 0 .887 0.915 0 .901 0.894 0 .822 0.130 105 103 101 88 -64 1.77E-05 3.78E-05 8.07E-05
HOP-92 0.506 0 .777 0.778 0.760 0.794 O. 720 0.150 100 94 106 79 -70 1.57E-05 3.38E-05 7.30E-05
NCI-H226 0.788 1 .073 1. 098 1.007 1.085 O. 965 0.201 109 77 104 62 - 7 5 1. 22E-05 2.84E-05 6.61E-05
NCI-H23 0.291 0 .931 0.985 0.986 0.980 o. 894 0.026 108 108 108 94 -91 1.73E-05 3.22E-05 6.00E-05
NCI-H460 0.341 1 .964 1.968 1. 963 1.968 1 .603 0.120 100 100 100 78 -65 1.56E-05 3.51E-05 7.86E-05
NCI-H522 0.267 0 .830 0.855 0.831 0.816 O. 694 0.082 104 100 98 76 -69 1.51E-05 3.33E-05 7.36E-05
Ion Cancer
COLO 205 0 .553 1.737 1.760 1 .658 1 .752 1. 517 0.030 102 93 101 81 -95 . 51E-05 .90E-05 5 . 58E-05
HCC-2998 0 .333 0.868 0.867 0 .849 0 .897 O. 828 0.037 100 96 105 93 -89 .72E-05 .23E-05 6 .10E-05
HCT-116 0 .119 1.002 0.982 0 .963 1 .006 0 .765 0.004 98 96 101 73 -97 .37E-05 .70E-05 5 .31E-05
HCT-15 0 .084 0.536 0.519 0 .524 0 .541 0 .378 -0.015 96 97 101 65 -100 .23E-05 .48E-05 4 .98E-05
HT29 0 .381 1.766 1.774 1 .838 1 .824 1 .493 0.010 101 105 104 80 -97 .48E-05 .83E-05 5 .41E-05
KM12 0 .279 1. 183 1. 084 1 .058 1 .080 0 .845 0.065 89 86 89 63 -77 .23E-05 .81E-05 6 .42E-05
SW-620 0 .081 0.488 0.476 0 .439 0 .462 o. 362 0.055 97 88 94 69 -32 .55E 05 .82E-05 >1 .00E04
Cancer
SF-268 0 .251 .044 1 .015 1.062 1 .053 0 .928 0 .131 96 102 101 85 -48 .84E-05 4 .36E-05 >1 .00E-04
SF-295 0 .622 .959 1 .974 2.025 1 .969 1 .721 0 .089 101 105 101 82 -86 .55E-05 3. 09£-05 6 .13E-05
SNB-19 0 .387 .014 0 .975 1.002 0 _968 O. 814 0 .095 94 98 93 68 - 7 5 .34E-05 2 .98E-05 6 .65E-05
SNB-75 0 .418 .628 0 .644 0.636 0 .623 0 .547 0 .155 107 104 98 61 -63 .23E-05 3 .l1E-05 7 .87E-05
U251 0 .268 .358 1 .293 1. 276 1 .271 1 .006 0 .038 94 92 92 68 86 .30E·05 2 .76E-05 5 .83E-05
lanorna
LOX IMVI .226 .280 1 .229 1 .229 .264 .934 .081 95 95 99 67 64 .351':-05 .25E-05 7 .80E-05
MALME-3M .319 _803 0 .808 O. 797 .791 .768 .111 101 99 98 93 -65 .86E-05 .86E-05 8 ODE-OS
M14 .402 .267 1 .239 1 .310 .303 .203 .068 97 105 104 93 -83 .75E-05 .37E-05 6 48E"·05
SK-MEL-28 .220 .679 0 .677 0 .686 .679 600 .067 100 101 100 83 -70 .64E-OS .49E OS ") .44EOS
SK-MEL-5 .703 .676 ] .708 1 .616 747 .571 005 103 94 107 89 ··99 .61E-05 .97E -05 5 .48E-05
UACC-257 .615 .482 1 .498 1 .497 .510 480 117 102 102 103 100 8] .89E-05 57£ OS 6 .74E-O r)
UACC-62 .457 .630 1 .651 1 .666 .567 .328 .029 102 103 95 74 -94 .39E 05 .77E OS 5 SOE 05
arian Cancer
IGROVl .279 .021 029 0 .992 1 005 790 0 .068 101 96 98 69 - 75 .35E 05 .99E- o~) .63E-05
OVCAR-3 .534 .026 .065 1 .046 1 .024 .840 0 111 108 104 100 62 -79 .22£ 05 .75E -05 .2]E-05
OVCAR-4 .510 .249 .252 1 .269 1 . ] 78 .941 0 l3] 100 103 90 58 74 .16E 05 2. ISE 0:-) .56E-05
OVCAR-5 .596 .335 .338 1 .407 1 406 .254 0 .062 100 110 110 89 -90 .65£-05 .15E-05 .00E-05
OVCAR-8 .230 .B32 .821 0 .795 O. 792 .662 0 .077 9B 94 93 72 -67 .44E-05 .30E-05 .57E-05
SK-OV-3 356 _852 .B53 0 .B82 0 .B40 .743 0 .119 100 106 97 7B 67 .5610 -OS .46E-05 .67E-05
al Cancer
786-0 0 .429 538 1 .608 .532 .574 293 0 098 106 99 103 78 -77 .51E 05 .lBE-05 6 .68E 05
A498 0 .991 .682 1 .738 .669 641 .446 0 .014 108 9B 94 66 -99 .25E 05 .51E-05 5 .06E· 05
ACHN 0 .341 .309 1 .271 .305 .275 .B51 0 .020 96 100 96 53 -94 .04E 05 2BE-·05 5 . ODE OS
CAKI-l 0 .413 .217 1 . 171 .1 B3 .106 .B70 O. l33 94 96 B6 57 -68 .13 E -OS .B5E·05 7 .18E-05
RXF 393 0 .5B3 .220 1 .1BO .139 .139 0.927 0 .226 94 B7 B7 54 ·61 .08E 05 .94E-05 7 .99E-05
SN12C 0 .302 .001 0 . 990 _970 .033 0.827 O. 045 98 96 105 75 ··85 .43E 05 .94E-05 6 .04E,-05
TK-I0 0 .520 .310 1 .32B .389 .405 1.141 0 .080 102 110 112 79 -85 SOE-OS .03E-05 6 .13E-05
state Cancer
PC-3 .293 .904 0 .930 .931 932 .812 039 104 104 105 85 87 .60E 05 3. 12E 05 .l1E-05
DU-145 .265 . 833 o. 833 766 .B08 .610 .082 100 88 96 61 -69 .21E-05 2 .93E 05 .11E-05
east Cancer
MCF7 .316 5BO 1 .599 1 .481 1 .538 .470 05 c1 102 92 97 91 -83 .72E-05 3 .34E OS .46E-05
NCI/ADR-RLS .282 814 o. 830 o. 818 0 .814 .726 090 103 101 100 83 -68 66E-05 3 .55E 05 .60E-05
MDA-MB-231 I ATCC .391 .833 o. 813 o. 860 0 .829 .721 .074 95 106 99 75 -81 .44E-05 3 .01E OS . HE05
HS 578T 225 .899 0 910 0 _883 0 .938 .876 _148 102 98 106 97 -34 .27£ 05 5. 47E" 05 >1 .00E-04
MDA-MB-435 .297 .271 1 .246 1 217 1 .165 .971 019 97 95 89 69 -94 . HE-OS 2 .66E· 05 5 .40E-05
MDA-N 691 .314 2 .292 2 .214 2 .478 194 .012 99 94 no 93 -98 .67E-05 _06E-05 5 .59E-05
BT-549 .304 .746 0 .745 0 714 0 767 .698 .050 100 93 105 89 -84 69E-Oo .28E-05 6 .39E-OS
T-47D .433 .026 o. 970 0 .994 0 .942 B18 .210 91 95 86 65 -52 .34E-05 61E-05 9 .69E--05
Leukemia
CCRF-CEM -4.90 -456 -4.22
HL-60ITB) -494 ·4.60 -4.25
K-562 -483 .> ·4.00 > -4.00
MOLT-4 ·4.89 -451 -4.13
SR -499 -4.61 -4.23
Non-Smut! Cell LungCancer .
A5491ATCC -4.80 -4.49 -4.18
EKVX -489 -4.53 -4.18
HOP-62 -475 ·4.42 -4.09
HOP-92 -4.80 -4.47 -4.14
NCI-H226 -491 -455 -4.18
NCI-H23 -476 -4.49 -4.22
NCI-H460 -4.81 -4.45 -4.10
NCI-H522 -482 -4.48 -4.13
Colon Cancer .
COLO 205 -4.82 -454 -4.25
HCC-2998 -4.76 -4.49 -4.21
HCT-116 -4.86 ·457 -4.27
HCT-15 -491 -4.61 -4.30
HT29 -483 -4 55 -4.27
KMI2 -491 -455 -4.19
SIY-620 ·481 -432 > -4.00
C:'\IS Cunce t • .
SF·268 ·474 I -436 > -4.00
SF-295 -4.8 I .451 -421
SNB·19 -4.87 -453 -4.18
SNB-75 -4.91 ·451 -4.10
1)251 -4.89 -456 -4.23
Melunornu . .. ", .. ,... .. - .
LOX IMVI -4.87 -449 -411
.Y1ALME-3M ·473 -441 -4.10
MI4 -476 -4.47 -4.19
SK-MEL-28 -479 -446 -4.13
SK·MEL-S -4.79 -4.53 -4.26
UACC-257 -472 -4.45 -4.17
UACC-62 -486 -456 -426
OvurinnCancer ,......•.....•...................•
IGROVI -487 -452 -4.18
OVCAR-3 -491 -456 -4.21
OVCAR-4 -4.94 -456 -4.18
OVCAR-5 -478 -450 -4.22
eve AR-8 -484 -4.48 -412
SK-OV-3 -481 -4.46 -4.12
Rena!Cancer . - "'" .
786-0 -4.82 -450 -4.18
A498 -490 -460 -4.30
ACH ,N -498 -4 64 -4.30
CAKI-[ -495 -455 -414
RXF 393 -497 ·453 -4.10
SN 12C -4.84 ·4.53 -4.22
TK-IO -482 -452 -4.21
Prostate Cancer . .
PC-) -480 -451 -4.21
DU-145 -492 -453 -4.15
BreastCancer ,,~ .
MCF7 -476 -4.48 -4.19
NCIIADR-RES -478 -4.45 -4.12
MDA-MB-23IIATCC -484 -452 -4.20
HS 578T -4.64 -426 > -4.00
MDA·MB-435 -488 -458 -4.27
MDA-N -478 -4 SI -425
BT-S49 -4.77 -4.48 -4.19
T-47D -4.87 -444 -4.01
.... . .
MG_~11D -484 -450 -417
Della 015 015 0.13
Range 034 064 0.30
+3 +2 +1 0 -) -2 -.1 +3 +2 +) 0 ·1 -2·3 +3 +2 +1 0 .J .2 .3
DRUG SYNTHESIS AND CHEMISTRY BRANCH, DTP, DCTD, NCI
NSC NUMBER LIST
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HN~NH NH
2
o
o
o
Dr. R. C. Harrison
Pharmaceuticals Division
British Technology Group
101 Newington Causeway
London SE1 6BU
United Kingdom
Transmittal Letter or Collection Date: 01/26/~9
Supplier Compound ID: NU:UB 80
NSC Number: D709769-V
Molecular Formula: C23H27N303.C2HF302
Acquired for Testing Against: CANCER
NSC D- 709769
National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results
D- 709769 -vII Experiment ID: 9907MD58-32 Test Type: 08 Units: Molar
5. 1999 Test Date: July 6,1999 QNS: Me:
COMI: NU:UB 80 Stain Reagent: SRB Dual-P SSPL: OB6Z
Log10 Concentration
Time Mean Optical Densities Percent Growth
panel/Cell Line Zero Ctrl -B.O -7.0 -6.0 -5.0 -4.0 -8.0 -7.0 -6.0 -5.0 -4 .0 Gl50 Tel LC50
Leukemia
CCRF-CEM 0.107 0.456 0.417 0.425 0.435 0.059 0.013 B9 91 94 -45 -BB 2.06E-06 4.72E-06 1.2BE-05
HL-60lTBI 0.246 1.197 1.25B 1.211 1.119 0.046 0.053 106 101 92 -Bl -7B 1.74E-06 3.39E-06 6.59E-06
K-562 0.157 1. 369 1. 317 1.292 1.210 0.076 0.073 96 94 87 -52 -54 1. B4E-06 4.23E-06 9.69E-06
MOLT-4 0.149 0.640 0.615 0.67B 0.596 0.120 0.076 95 108 91 -19 -49 2.35E-06 6.67E-06 >1. 00E-04
SR 0.136 0.415 0.437 0.445 0.407 0.171 0.lB5 lOB 111 97 13 17 3.61E-06 >1.00E-04 >1.00E-04
Non-Small Cell Lung Cancer
A549/ATCC 0.198 1. 042 1.069 1.042 1.054 0.323 0.016 103 100 101 15 -92 3.92E-06 1.3BE-05 4.05E-05
EKVX 0.630 1.291 1. 300 1.272 1.2B6 1. 036 0.169 101 97 99 61 -73 1.22E-05 2.B6E-05 6.73E-05
HOP-62 0.199 0.476 0.44B 0.459 0.466 0.165 0.042 90 94 96 -17 -79 2.56E-06 7.06E-06 3.39E-05
NCl-H23 0.301 0.903 0.945 0.950 0.B76 0.632 -0.022 107 lOB 96 55 -100 1.0BE-05 2.26E-05 4.76E-05
NCl-H322M 0.427 1.290 1.257 1.162 1.2B6 0.47B 0.065 96 B5 100 6 -B5 3.3BE-06 1.16E-05 4.13E-05
NCl-H460 0.312 1. 646 1. 556 1.69B 1. 663 0.102 0.016 93 104 101 -67 -95 2.01E-06 3.99E-06 7.B9E-06
NCl-H522 0.262 0.B04 0.7B2 o.B13 0.B02 0.065 0.018 96 102 100 -75 -93 1.92E-06 3.71E-06 7.16E-06
Colon Cancer
COLO 205 0.406 1.511 1.522 1.538 1. 454 -0.005 0.015 101 102 95 -100 -96 1.70E-06 3.07E-06 5.54E-06
HCC-299B 0.360 0.772 0.698 0.775 0.754 -0.005 -0.009 B2 101 96 -100 -100 1.71E-06 3.0BE-06 5.55E-06
HCT-116 0.254 1.411 1. 583 1.682 1.536 0.304 0.073 115 123 111 4 -71 3.72E-06 1.14E-05 5.23E-05
HCT-15 0.169 1.10B 1.085 1.173 1.107 0.16B 0.010 9B 107 100 -1 -94 3.13E-06 9.80E-06 3.36E-05
HT29 0.162 0.995 1. 001 0.960 0.989 0.OB4 0.033 101 96 99 -4B -80 2.16E-06 4.71E-06 1.14E-05
KM12 0.286 1.1B6 1.190 1.206 1.137 0.305 0.073 100 102 95 2 -74 3.03E-06 1.07E-05 4.79E-05
SW-620 0.066 0.457 0.477 0.43B 0.463 0.035 -0.013 105 95 102 -4B -100 2.22E-06 4.79E-06 1.11E-05
CNS Cancer
SF-26B 0.250 1. 052 1. 065 1.088 1.039 0.651 0.070 102 105 98 50 -72 1. 00E-05 2.57E-05 6.60E-05
5F-295 0.454 1.1BB 1.189 1.lB6 1.221 0.429 0.066 100 100 104 -6 -B5 3.13E-06 B.91E-06 3.60E-05
SF-539 0.56B 1.051 1.050 1.122 1.094 0.037 0.001 100 115 109 -94 -100 1.95E-06 3.45£-06 6.09£-06
SNB-19 o. 335 1.015 1.022 1. 063 1.003 0.332 0.020 101 107 9B -1 -94 3.06E-06 9.76E-06 3.35E-05
SNB-75 0.265 0.572 0.565 0.546 0.565 0.3B7 0.057 98 91 9B 40 -79 6.66£-06 2.17£-05 5.73E-05
U251 0.161 0.972 0.90B 0.955 O.92B o.11B 0.015 92 9B 95 -27 -91 2.33E-06 6.02£-06 2.31E-05
Melanoma
MALME-3M 0.367 0.B61 0.876 0.BB4 0.920 0 .053 -0 .020 103 105 112 -B6 -100 2.06E-06 3.69£-06 6.61E-06
M14 0.295 1. 043 1. 062 1.072 1.055 O. 036 -0. 001 103 104 102 -BB -100 1.87£-06 3.44£-06 6.32E-06
SK-M£L-2 0.257 0.729 0.652 0.733 0.679 0 .05B -0.002 B4 101 90 -7B -100 1.72E-06 3.43£-06 6.83E-06
SK-M£L-2B 0.267 0.960 0.950 0.938 0.969 0.065 0.018 99 97 101 -76 -93 1.95E-06 3.74£-06 7.16£-06
SK-M£L-5 0.428 1. 65B 1. 6B8 1.6BB 1.641 -0.014 -O.OlB 102 102 99 -100 -100 1.76E-06 3.14E-06 5.60£-06
UACC-257 0.554 1.147 1.076 1.140 1.156 0.072 -0.007 BB 99 102 -B7 -100 1.BB£-06 3.45E-06 6.36E-06
UACC-62 0.700 1. 59B 1.603 1.596 1.696 0.045 -0.009 101 100 III -94 -100 1.9B£-06 3.4B£-06 6.12£-06
Ovarian Cancer
OVCAR-3 0.446 0.779 0.766 0.763 0.74B 0.307 0 .102 96 95 91 -31 -77 2.16E-06 5 .55E-06 2.56£-05
OVCAR-4 0.265 0.729 0.732 0.716 0.691 0.296 0 .112 101 97 92 7 -5B 3.10E-06 1 .27E-05 7.54E-05
OVCAR-5 0.774 1. 636 1. 656 1.560 1.616 1.299 0 .OB5 102 91 98 61 -B9 1.1BE-05 2 .55E-05 5.49£-05
5K-OV-3 0.281 0.506 0.499 0.504 0.505 0.190 0 .040 97 99 99 -32 -B6 2.37E-06 5 .6B£-06 2.13£-05
Renal Cancer
7B6-0 0.226 0.792 0.964 0.906 0.827 0 .077 0 .046 130 120 106 -66 -BO 2.12E-06 4 .13E-06 B.06£-06
A49B 0.B48 1. 398 1. 404 1. 394 1.392 1 .143 0 .011 101 99 99 54 -99 1.06£-05 2 .25£-05 4.79£-05
ACHN 0.237 0.B2B 0.B43 0.B5B 0.B4B 0 .257 -0 .015 102 105 103 3 -100 3.42E-06 1 .OBE-05 3.28E-05
CMl -1 0.454 1.077 1.109 1. 093 1.060 0 .509 0 .069 105 102 97 9 -B5 3.42E-06 1.24E-05 4.24E-05
RXF 393 0.359 0.B24 0.795 0.790 0.779 0.225 0.053 94 93 90 -37 -B5 2.07£-06 5.10E-06 1.B4£-05
SN12C 0.377 1. 016 1.120 1.091 1. 031 0.525 0.07B 116 112 102 23 -79 4.59E-06 1.6B£-05 5.18E-05
TK-10 0.529 1. 129 1. 032 1.155 1.155 0.6B6 -0.006 84 104 104 26 -100 4.95£-06 1.61£-05 4.01£-05
UO-3.1 0.242 0.694 0.626 0.693 0.7BB 0.090 0.010 85 100 121 -63 -96 2.43E-06 4.54E-06 B.50E-06
Prostate Cancer
PC-3 0.189 0.725 0.634 0.717 0.700 o.16B -0.002 B3 9B 95 -11 -100 2.66E-06 .82E-06 2.73£-05
00-145 0.211 0.776 0.794 0.744 0.798 0.447 0.002 103 94 104 42 -99 7.36E-06 .9BE-05 4.4B£-05
Breast Cancer
MCn o.245 0.BB8 0.851 0.870 0.B95 0.121 0.009 94 97 101 -51 -97 2.17E-06 4.64E-06 9.91E-06
NCII ADR-RES 0.299 0.739 0.739 0.772 0.771 0.417 0.071 100 107 107 27 -76 5.14£-06 1.82E-05 5.56£-05
MDA-MB-231/ATCC 0.322 0.937 0.B79 0.927 0.8B5 0.338 0.003 91 9B 91 3 -99 2.93£-06 1.06£-05 3.29£-05
HS 578T 0.106 0.466 0.4BO 0.475 0.4BO 0.176 0.073 104 103 104 19 -31 4.34E-06 2.41E-05 >1.00£-04
MDA-MB-435 0.279 0.952 1. 003 0.911 0.926 0.094 0.045 lOB 94 96 -66 -84 1.92E-06 3.91E-06 7.94£-06
MDA-N 0.352 1. 246 1. 405 1.37B 1.352 0.265 0.047 118 U5 112 -25 -87 2.83E-06 6.58E-06 2.55E-05
BT-549 0.502 1. 099 1.135 1.119 1.123 0.901 0.020 106 103 104 67 -96 1.27£-05 2.57£-05 5.22E-05
T-47D 0.300 0.716 0.709 0.687 0.67B 0.246 0.121 98 93 91 -18 -60 2.37E-06 6.83£-06 5.86E-05
Mean Graphs
Panel/Cell Line Log "GI50 GI50 Log u TGI TGI I Log ... LC50 LC50
Leukemia
CCRF-CEM -569 -533 -489
HL-60(TB) -5 76 -547 -5.18
~-562 -5.74 -5.37 ·5.01
MOLT-4 -5.63 -5.18 > ·4.00
SR -5.44 > -4.00 > -4.00
Non-Smull Cell Lung Cancer
A5491ATCC -5.41 -4.86 ·4.39
EKYX ·4.91 -4.54 -4.17
HOP·62 -5.59 ·5.15 -4.47
NCI·H23 ·497 ·465 -4.32
NCI·H322M -547 ·494 -4.38
NCI·H460 -570 ·5.40 ·5.10
NCI·H512 -5.72 -5.43 ·515
ColonCancer .
COLO 205 ;1 -5.77 -551 ·5.26
HCC·2998 -5.77 ·551 -5.26
HCT-116 -5.43 -4.94 ·4.28
HCT·15 -5.50 ·5.01 -4.47
HT29 ·567 -533 -4.94
KM12 -5.52 ·4.97 ·4.32
SW·620 ·5.65 -532 -495
eNS Cancer .................................•.•...•.............•.........
SF-268 -500 -459 -4.18
SF-295 ·5.50 -505 -4.44
SF·539 ·5.71 -546 -522
SNB·19 -5.51 -5.01 -4.47
SNB·75 -5.18 ·4.66 -424
U251 -5.63 ·522 ·4.64
Metunomu ..••.••••.•..••••••••.•..••..••................•.••..•.•...•.•..•..•....•••.•••••.•..••..•••..•..•..........•..••.•..•.••..•...•...•....••......•.....•.....•.•...•....•...•.•.••..•..•.....•.••.••.••••••.••.•..•...••..•••••••••••••
MALME·3M ·569 ·5.43 -5.18
MI4 ·573 -5.46 -5.20
SK·MEL-2 ·576 -546 -5.17
SK·MEL·28 ·5.71 -543 ·5.15
SK·MEL-5 ·5.75 -5.50 ·5.25
UACC-257 ·573 ·5.46 -5.20
UACC-62 ·570 -5.46 -521
Ovarian Cancer .
OYCAR·3 -5.67 ·526 ·4.59
OYCAR·4 -551 -490 ·4.12
OYCAR·5 ·493 ·4.59 -4.26
SK·OV·3 ·5.63 ·525 ·4.67
Rena Cancer
786-0 ·5.67 ·5.38 ·5.09
A498 -4.97 -465 -4.32
ACHN ·5.47 -497 ·4.48
CAKI-I - ·5.47 ·491 ·4.37
RXF 393 -5.68 -529 -4.74
SNI2C -5.34 ·4.77 ·4.29
TK-IO ·5.31 ·4.79 -4.40
UO-31 -5.61 ·534 -5.07
Prostate Cancer .
PC·3 ·5.58 ·5.11 ·4.56
DU-145 -513 -470 -4.35
Breast Cancer
MCF7 -566 ·533 -5.00
NCI/ADR-RES ·5.29 ·4.74 -4.25
MDA-MB-231IATCC -5.53 -4.97 ·448
HS 578T -536 ·4.62 > -4.00
MDA-MB-435 -5_72 ·5.41 -5.10
MDA·N ·5.55 -518 ·4.59
BT·549 ·490 ·4.59 ·4.28
T-47D ·5.63 -517 ·4.23
MG_MID -551 -5.09 ·4.66
Delta 0.26 0.42 0.60
Range 0.87 1.51 1.26
+3 +2 +1 0 ·1 ·2·3 +3 +2 +1 0 ·1 ·2.3 +3 +2 +1 0 ·1 ·2 ·3
NSC D- 709770
o
DRUG SYNTHESIS AND CHEMISTRY BRANCH, DTP, DCTD, NCI
NSC NUMBER LIST
Dr. R. C. Harrison
Pharmaceuticals Division
British Technology Group
101 Newington Causeway
London SE1 6BU
United Kingdom
Transmittal Letter or Collection Date: 01/26/99
Supplier Compound ID: NU:UB 81
NSC NUmber: D709770-W
Molecular Formula: C23H27N303.C2HF302
Acquired for Testing Against: CANCER
National Cancer Institute Developmental Therapeutics Program
In- Vitro Testing Results
D- 709770 -W I 1 Experiment II): 9907MD58-33 Test Type: 08 Units: Molar
5, 1999 Test Date: July 6,1999 QNS: Me:
COMI: NU:UB 81 Stain Reagent: SRB Dual-P SSPL: OB6Z
Log10 Concentration
Time Mean optical Densities Percent Growth
Panel/Cell Line Zero Ctr1 -8.0 -7.0 -6.0 -5.0 -4.0 -8.0 -7.0 -6.0 -5.0 -4.0 Gl50 TGl LC50
Leukemia
8'8CCRF-CEM 0 .107 0.447 0.396 0.406 0.438 0.151 0.138 85 97 13 9 3.62E-06 >1.00E-04 >1.00E-04
HL-60 (TBI 0 .246 1. 066 0.908 0.886 0.937 0.136 0.184 81 78 84 -45 -25 1.84E-06 4.50E-06 >1.00E-04
K-562 0 .157 1.250 1.248 1.257 1. 266 0.113 0.252 100 101 101 -28 9 2.49E-06 >1.00E-04
MOLT-4 0.149 0.635 0.640 0.638 0.620 0.129 0.247 101 101 97 -14 20 2.66E-06 >1.00E-04
Non-Small Cell Lung Cancer
A549/ATCC 0.198 0.999 0.980 0.988 0.966 0.387 0.060 98 99 96 24 -70 4.31E-06 1.79E-05 6.12E-05
EKVX 0.630 1.370 1. 364 1.361 1. 387 1. 086 0.157 99 99 102 62 -75 1.2lE-05 2.82E-05 6.55E-05
HOP-62 0.199 0.534 0.498 0.553 0.513 0.214 0.088 '89 106 94 4 -56 3.08E-06 1.18E-05 7.95E-05
HOP-92 0.394 0.919 0.942 0.932 0.874 0.745 0.063 104 103 91 67 -84 1.29E-05 2.77E-05 5.94E-05
NCl-H23 0.301 0.946 0.937 0.986 0.885 0.549 0.075 99 106 91 38 -75 5.98E-06 2.18E-05 6.01E-05
NCl-H322M 0.427 1.358 1.308 1.354 1. 333 0.730 0.031 95 100 97 33 -93 5.37E-06 1.82E-05 4.56E-05
NCl-H460 0.312 1.582 1.623 1. 515 1. 599 0.337 0.031 103 95 101 2 -90 3.28E-06 1. 05E-05 3.67E-05
NCl-H522 0.262 0.690 0.705 0.761 0.759 0.275 0.057 103 116 116 3 -78 3.84E-06 1. 09E-05 4.49E-05
Colon Cancer
COLO 205 0.406 1.459 1. 309 1. 335 1.360 0.010 -0.004 86 88 91 -98 -100 1. 64E-06 3.03£-06 5.58E-06
HCC-2998 0.360 0.667 0.676 0.671 0.537 0.037 0.024 103 101 58 -90 -93 1.13E-06 2.46E-06 5.38E-06
HCT-116 0.254 1. 538 1. 388 1. 508 1.465 0.463 0.123 88 98 94 16 -52 3.70E-06 1.73E-05 9.42E-05
HCT-15 0.169 1.142 1.174 1.106 1.070 0.255 0.017 103 96 93 9 -90 3.23E-06 1.23E-05 3.94E-05
HT29 0.162 0.999 0.977 0.963 0.985 0.118 0.040 97 96 98 -27 -75 2·42E-06 6.05E-06 2.96E-05
KM12 0.286 1. 218 1.125 1.191 1.159 0.324 0.084 90 97 94 4 -71 3.01£-06 1. DE-OS 5.27E-05
SW-620 0.066 0.525 0.484 0.540 0.484 0.126 0.069 91 103 91 13 1 3.35E-06 >1.00E-04 >1. 00E-04
CNS Cancer
SF-268 0.250 0.940 0.926 0.914 0.893 0.748 0.133 98 96 93 72 -47 1.54E-05 4.04E-05 >1. 00E-04
SF-295 0.454 1. 326 1.234 1. 297 1. 331 0.660 0.126 89 97 100 24 -72 4.53E-06 1.76E-05 5.85E-05
SF-539 0.568 1. 040 0.920 0.992 1.066 0.099 -0.003 75 90 105 -83 -100 1.97E-06 3.64E-06 6.70E-06
SNB-19 0.335 1.023 0.996 1. 046 0.977 0.382 0.068 96 103 93 7 -80 3.17E-06 1.20E-05 4.53E-05
SNB-75 0.265 0.600 0.541 0.589 0.602 0.437 0.089 82 97 101 51 -67 1.02E-05 2.72E-05 7.23E-05
U251 0.161 0.857 0.833 0.804 0.814 0.225 -0.001 97 92 94 9 -100 3.30E-06 1.21E-05 3.48E-05
Melanoma
LOX lMVl 0 .085 0.817 0.827 0.797 0.757 0 .009 0.034 101 97 92 -89 -60 1.70E-06 3.21E-06 6.06E-06
I1ALME-3M 0 .367 0.773 0.851 0.880 0.792 0.327 0.099 119 126 105 -11 -73 2.97E-06 8.05E-06 4.26E-05
M14 0 .295 1. 065 1. 058 1. 046 0.988 0.052 0.046 99 97 90 -83 -84 1.70E-06 3.32E-06 6.48E-06
SK-MEL-2 O. 257 0.701 0.675 0.646 0.614 0.243 0.018 94 87 80 -6 -93 2.25E-06 8.60E-06 3.21E-05
SK-MEL-2B 0 .267 1.070 1. 025 1. 070 1. 073 0.304 0.108 94 100 100 5 -60 3.36E-06 1.18E-05 7.06E-05
SK-MEL-5 0 .428 1.634 1. 483 1.530 1.408 0.023 -0.023 88 91 81 -95 -100 1.51E-06 2.90E-06 5.58E-06
UACC-257 0 .554 1.129 1.131 1.125 1.119 0.193 0.068 100 99 98 -65 -88 1.97E-06 3.99E-06 8.08E-06
UACC-62 0 .700 1.699 1. 622 1.751 1.725 0.644 0.011 92 105 103 -8 -99 2.99E-06 B.45E-06 2.91E-05
Ovarian Cancer
lGROVl .110 0.786 0.777 0.754 0.673 0.109 0 .020 99 95 83 -1 -82 2.48E-06 .75E-06 4.04E-05
OVCAR-3 0.446 0.828 0.783 0.832 0.758 0.398 0 .097 88 101 82 -11 -78 2.20E-06 7.65E-06 3.81E-05
OVCAR-4 0.265 0.816 0.757 0.792 0.807 0.408 0 .098 89 96 98 26 -63 4.66E-06 1.96E-05 7.14E-05
OVCAR-5 0.774 1.725 1. 693 1. 718 1. 680 1.500 0.042 97 99 95 76 -95 1.43E-05 2.80E-05 5.48E-05
OVCAR-8 o . 121 0.875 0.924 0.889 0.835 0.308 0.024 107 102 95 25 -81 4.36E-06 1.72E-05 5.12E-05
SK-OV-3 0.281 0.561 0.501 0.537 0.537 0.335 0.070 78 92 91 19 -75 3.74E-06 1.60E-05 5.42E-05
Renal Cancer
786-0 0 .226 0.877 0.807 0.913 0.853 0 .154 0.075 89 106 96 -32 -67 2.29E-06 5.62E-06 3.28E-05
A498 0.848 1. 443 1. 389 1. 451 1. 516 1.272 0.068 91 101 112 71 -92 1. 35E-05 2.73E-05 5.53E-05
ACHN 0.237 0.853 0.820 0.847 0.835 0.403 0.002 95 99 97 27 -99 4.70E-06 1.63E-05 4.07E-05
CAKl-l 0.454 1.154 1.008 1.126 1.048 0.630 0.047 79 96 85 25 -90 3.83E-06 1.65E-05 4.51E-05
RXF 393 0.359 0.823 0.756 0.833 0.790 0.530 0.100 85 102 93 37 -72 5.80E-06 2.17E-05 6.25E-05
SN12C 0.377 0.972 0.892 0.986 1.004 0.530 0.078 87 102 105 26 -79 4.96E-06 1.76E-05 5.25E-05
TK-I0 0.529 1.127 1.170 1.174 1.145 0.765 0.012 107 108 103 39 -98 6.81E-06 1.94E-05 4.49E-05
UO-3l 0.242 0.661 0.627 0.587 0.660 0.201 0.026 92 82 100 -17 -89 2.67E-06 7.16E-06 2.87E-05
Prostate Cancer
PC-3 .189 0.653 0.642 0.630 0.615 0.234 -0.001 98 95 92 10 -100 3.23E-06 .22E-05 .50E-05
DU-145 .211 0.787 0.716 0.787 0.768 0.438 0.038 88 100 97 39 -82 6.53E-06 .llE-05 .43E-05
Breast Cancer
MCF7 0 .245 0.911 0.869 0.821 0.786 0.249 0.057 94 86 81 1 -77 2.44E-06 .OlE-05 4.51E-05
NCl/ADR-RES 0 .299 0.889 0.908 0.860 0.873 0.518 0.085 103 95 97 37 -72 6.11E-06 2.l9E-05 6.3lE-05
MDA-MB-2311ATCC 0 .322 0.871 0.849 0.883 0.836 0.474 0.001 96 102 94 28 -100 4.59E-06 1.65E-05 4.07E-05
HS 578T 0 .106 0.465 0.413 0.426 0.451 0.241 0.097 85 89 96 38 -8 6.13E-06 6.54E-05 >1.00E-04
MDA-MB-435 0 .279 1.011 0.928 1.011 0.926 0.175 0.083 89 100 88 -37 -70 2.02E-06 5.04E-06 2.41E-05
MDA-N 0 .352 1. 370 1. 247 1. 385 1.367 0.322 0.129 88 101 100
-9 -63 2.88E-06 8.32E-06 5.67E-05
BT-549 0 .502 1.171 1.186 1.250 1.181 1.027 0.089 102 112 101 78 -82 1.50E-05 3.08E-05 6.30E-05
T-47D 0 .300 0.725 0.663 0.714 0.698 0.469 0.175 B5 98 94 40 -42 6.45E-06 3.07E-05 >1.00E-04
Leuketuiu
CCRF-CEM -544 > -4.00 > -4.00
HL-6O<TB) -5.74 -535 > -4.00
K-562 -5.60 > -4.00
MOLT·4 -5.58 > -400
Nou-Smult Ct:11 Lung Cancer _._ .... "" ............ -._ ............ . - ................................ _......................... -... - ........... . ..................
A5491ATCC -5.37 -475 -4.21
EKYX -492 -455 -4.18
HOP-62 -5.51
-493 -410
HOP-92 -4.89
-456
-423
NCI-H23 -522 -466
-422
NCI-H322M -5.27 -4.74
-4.34
NCI-H460 -548 -498 -444
NCI-H5n -542 -496
-435
(111011 CUIH;~r ................................................ _... -_... - ....................... .............................................................. ............................................. ..................
COLO 205 il -579 -552 -525HCC-2998 -595 -5.61
-5.27
HCT-116 -543 -4.76 -4.03
HCT-15 -549
-491
-440
HT29 -562 ·5.11 -453
KMI2
-551 -495 -4.28
SW-620 -547 > -400 > -4.00
eNS Cuucer
SF-268 -4.81
-4.39 > -400
SF-295 -5.34
-4.75 -4.23
SF-539
-5.71
-544 -5.17
SNB-19
-550 -4.92 -4.34
SNB-75
-499
-4.57 -4.14
U251
-548 -492 -4.46
Melunomu ............................................................. ............................................. ............................................................. ............................................. ..................
LOX !MYI
-5.77 -549 -5.22
MALME-3M
-5.53 -509 -4.37
MI4
-577
-548 -5.19
SK-MEL-2
-565
-5.07 -4.49
SK-MEL-28
-547
-493 -4.15
SK-MEL-5
-5.82
-554 -5.25
UACC-257
-5.71 -540 -5.09
UACC-62
-5.52 -5.07 -454
Ovunun Cuncer ............................................................. ............................................. ............................................................. ............................................. ...................
IGROYI
-5.61 -5.01 -4.39
OYCAR-3
-5.66 -512 ·4.42
OYCAR-4
-533 -471 -415
OYCAR-5 -4.84 -4.55 -4.26
OYCAR-8 -5.36 -4.76 -4.29
SK-OY-3
-543 .480 ·4.27
RL·1l1.11 C!.IIH.:cr ............................................. ............................................................. ............................................. ..................
786-0
-5.64 -525 -4.48
A498
-487 -4.56 -4.26
ACHN ·533 -479 -439
CAKI-I
-542 -478
-435
RXF 393 -5.24 -466 -4.20
SNI2C -5.30
-475 -4.28
TK-IO -5.17 -4.71
-4.35
UO-31 -5.57
-5.15
-4.54
Prostate Cancer ............................................................. ............................................. ............................................................. ............................................. ..................
PC-3 -5.49 -4.91
-4.46
DU-145 -5.19 -4.68
-4.27
Breast Cancer ............................................................. ............................................. ............................................................. ................_........................... ..................
MCF7 -5.61 .499
-4.35
NCIIADR-RES -5.21 -4.66
-4.20
MDA·MB·231/ATCC -5.34 -4.78
·4.39
HS 578T ·5.21 -4.18 > -4.00
MDA-MB-435 -5.69 -5.30
·4.62
MDA-N -5.54 -5.08
·4.25
BT-549 -4.82 -4.51
-4.20
T-47D -5.19 -4.51 > -4.00
MG.MID -5.42 -489
-4.38
Dt:ltll 0.53 0.72 0.89
Runge 1.13 1.61 1.27
+3 +2 +1 0 .J ·2 -3 +3 +2 +1 0 ·1 ·2 ·3 +3 +2 +1 0 ·1 -2
APPENDIX 3
Assessment of in vivo drug activity
Pure strain NMRI mice of 6-8 weeks old (B+K Universal Ltd, UK) were used for the
assessment of in vivo drug activity.
MAC 15A tumours were established from cells grown in culture. Cells were pelleted and
resuspended in 2ml of HBSS. 0.2ml of cell suspension was injected subcutaneously into the
flank of NMRI mice. Treatment of mice commenced approximately 4-5 days after cell
implantation when tumours were visible and of a measurable size (4x5mm).
NU:UB compound was dissolved in a DMSO/arachis oil (1/10) mixture and administered at
suitable concentrations of (e.g. NU:UB 31 at 100 (MTD), 67 and 33 rnqkq"), Camptothecin
was given in DMSO/oil and administered at 10 mgkg-1 (MTD). Controls were treated with
DMSO/oil. Mitoxantrone was dissolved in saline and administered at 5 mgkg-1 (MTD). All
treatments were intraperitoneal (IP).
Tumours were measured daily using calipers and the tumour volume calculated using the
formula below (Geran et al., 1972)
v=
Where a = smaller diameter and b= larger diameter
The significance of any delays in tumour growth between control and treated groups of mice
was determined by the use of the Mann-Whitney U-test using the time taken for the tumours
to double in volume (RTV2).
Geran. R. I., Greenberg, N. H, and MacDonald, M. M. (1972). Protocols for screening
chemical agents and natural products against tumours and other biological systems (third
edition). Cancer Chemotherapy Reports, 3:1-1033.
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Appendix 3, graph 1. In vivo graph of relative tumour volume versus days for NU:UB 31.
DOSE (mg/Kg) Growth delay (days) Significance % Weight loss
100 2.7 p<0.01 5.1%
67 4.3 p<0.01 2.3%
33 3.2 p<0.01 1.9%
Appendix 3, table 1. In vivo data of growth delay and weight loss relative to NU:UB 31
concentration.
MAC15A TUMOURS TREATED WITH NU:UB51
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Appendix 3, graph 2. In vivo graph of relative tumour volume versus days for NU:UB 51.
DOSE (mg/Kg) Growth delay (days) Significance % Weight loss
60 1.9 p<0.01 4.1%
40 3.5 p<0.05 3.2%
20 1.9 p<0.05 1.1%
Appendix 3, table 2. In vivo data of growth delay and weight loss relative to NU:UB 51
concentration.
MAC15A TUMOURS TREATED WITH MITOXANTRONE
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Appendix 3, graph 3. In vivo graph of relative tumour volume versus days of a single dose of
mitoxantrone (mean ±SEM, n=9).
Group Mean time Median time to Growth Significance Maximum
to RTV 2 RTV 2 (days) delay % weight
(days) (days) loss
Control 2.5 2.6 - - 10.5
Mitoxantrone 5.0 4.9 2.3 P<0.01 20
5mQ/kQ ip
Appendix 3, table 3. In vivo data of growth delay and weight loss relative to mitoxantrone
concentration.
MAC15A TUMOURS TREATED WITH CAMPTOTHECIN
10
Gl
E
:::l
'0
>
..
:::l
o
E
.a
Gl
>
..
CIl
1!
c
CIl
Gl
:::i!:
0.1
o 2 4
TIME (days)
6 8
I-e-CONTROL_=-CPT 10mg/kg I
Appendix 3, graph 4. In vivo graph of relative tumour volume versus days of a single dose of
camptothecin (mean ±SEM, n=5).
Group Mean time to Median time to Growth Significance Maximum %
RTV 2 (days) RTV 2 (days) delay weight loss
(days)
Solvent 2.9 3.5 - - -
control
(dmso/oil)
Camptotheci 4.2 4.3 0.8 ns 8.6
n 10mg/kg
Lp
Appendix 3, table 4. In vivo data of growth delay and weight loss relative to camptothecin
concentration.
Comparative in vivo data of NU:UB 31, doxorubicin and mitoxantrone
against MAC15A adenocarcinoma of the colon
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Appendix 3, graph 5. In vivo chemosensitivity against MAC15A adenocarcinoma of the
colon, comparison of NU:UB 31, doxorubicin and mitoxantrone.
The anthraquinone NU:UB 31 showed a different behaviour to the anthraquinones
mitoxantrone and doxorubicin. The latter induced a modest growth delay with no reduction in
tumour volume whereas NU:UB 31 produced significant delay in this tumour model which in
common with human clinical diseases is refractory to standard clinical agents. Thus, NU:UB
31 as well as NU:UB 51 was active in vivo in experimental colon cancer.
APPENDIX 4
Pharmacokinetics of NU:UB 31
000
0 NH~NHCO"""""""'NH2 OOCCF3
«»~ I ~
0 NU:UB31
ICso (u M)[exposure] in vitro 38 [1 h] 8 [24 h] 5 [96 h]
MAC 15A MTT assay
Stability: tl/2 [hours] in vitro > 100 h 75.1 h 25.7 h
[ plasma] [culture medium] [whole blood]
Pharmacokinetics: tl/2 plasma 2.2 hours and an AUC of 44.5 ug h ml'
[hours] [i.p, at 100mgkg'!] [Cmax = 12 I-lg ml", at 30 min]
Pharmacokinetics: t1/2 tumour 6 hours and an AUC of371 ug h g.t
[hours] [i.p, at IOOmgkg'!] [Cmax = 39.5 ug g'!, at 2h]
exT values 176.2J..lg hr ml"]] h] 82 ug hr ml' [24 h] 18.8 ug hr mr![96
h]
Appendix 4, table 1. Pharmacokinetics data of NU:UB 31
ICso values for NU:UB 31 determined against MAC15A (murine adenocarcinoma) cells using
MTT assay were 5IJM, 8IJM and 38IJM for 96h, 24h and 1h exposures respectively.
A method has been developed to detect and analyse NU:UB 31 in biological samples using
LC-MS. Assessment of the stability of NU:UB 31 in vitro gave t1/2 values of 75.1 and 25.7
hours in tissue culture medium and whole murine blood respectively at 37°C. The compound
was very stable in murine plasma with t1l2 >100 hours.
Pharmacokinetic analysis of NU:UB 31 in vivo was assessed in MAC15A tumour bearing
mice. NU:UB 31 was given i.p. at 100mgkg·1 and plasma and tumour levels monitored over
an 8 hour period. Drug concentration peaked in the plasma after 30 minutes (Cmax = 12 IJg rnl
1) with a t1l2 value of 2.2 hours and an AUC of 44.5 IJg h rnl". Peak tumour concentrations
exceeded those seen in the plasma by approximately 3-fold peaking at 2 hours (Cmax =39.5
IJg g.1) with a t1/2 of 6 hours and an AUC of 371 IJg h s" (8-fold greater than plasma).
ICso values for the compound in vitro were converted to exT values (taking into account the
stability of the drug in tissue culture medium) giving values of 18.8, 82 and 176.21Jg hr/ml for
96h, 24h and 1h exposures respectively. The concentration of NU:UB 31 measured in
MAC15A tumours in vivo therefore exceeds those of the in vitro ICso values. The
concentration of NU:UB 31 in tumours and the long half life may go some way to explaining
the good anti-tumour activity seen against MAC15A tumours.
APPENDIX 5
(Tj-topoisomerase inhibitor, (M)-Inhlbltor of mitochondrial enzyme(s)
Compare Correlation LCso
NU:UB 31
Chemical Name N Pearson Corr. Coeff.
Bleomycin 60 0.509
cvctooentenvt cytosine (M) 60 0.507
Brequinar (DUP785) (M) 60 0.486
Phosphotrienin 60 0.473
N-N-dibenzyldaunomycin (T) 60 0.472
Anguidine 60 0.469
CCNU 60 0.452
Methyl CCNU 60 0.451
Topotecan (T) 60 0.439
D-tetrandrine 60 0.433
Amonafide (T) 60 0.424
NU:UB 43
Aclacinomycin A (T) 57 0.663
Mitramycin 58 0.659
Deoxydoxorubicin (T) 58 0.653
5-Azacytidine 58 0.645
Cvternbena 58 0.619
Anguidine 58 0.612
Bactobolin 58 0.607
Pancratiaststin (M) 58 0.604
Daunomycin (T) 58 0.598
Brequinar (DUP785) (M) 58 0.590
Thalicarpine 58 0.583
NU:UB 80
Aclacinomycin A (T) 57 0.630
Anquidine 58 0.625
Thalicarpine 58 0.623
Pancratiastatin (M) 58 0.622
Mitomycin C 58 0.620
Adriamycin (T) 58 0.618
Triethylenemelamine 58 0.615
Daunomycin (T) 58 0.614
Mitramycin 58 0.610
Amonafide (T) 58 0.606
Actinomycin D (T) 58 0.602
NU:UB 81
Brequinar (DUP785) (M) 58 0.720
Anguidine 58 0.669
Bactobolin 58 0.663
5-Azacytidine 58 0.658
Pancratiaststin (M) 58 0.650
Phyllanthoside 58 0.644
Amonafide (T) 58 0.641
Thalicarpine 58 0.635
Aclacinomycin A (T) 57 0.632
Deoxydoxoribicin (T) 58 0.609
Cvternbena 58 0.609
..
